# PROTEIN-PROTEIN INTERACTIONS Between *Shigella flexneri* polypeptides And Mammalian Polypeptides

## **PRIORITY**

[0001] This application claims priority on the basis of United States Provisional Application No. 60/261,130, filed January 12, 2001, the contents of which are hereby incorporated by reference.

# BACKGROUND OF THE INVENTION

[0002] Most biological processes involve specific protein-protein interactions. Protein-protein interactions enable two or more proteins to associate. A large number of non-covalent bonds form between the proteins when two protein surfaces are precisely matched. These bonds account for the specificity of recognition. Thus, protein-protein interactions are involved, for example, in the assembly of enzyme subunits, in antibody-antigen recognition, in the formation of biochemical complexes, in the correct folding of proteins, in the metabolism of proteins, in the transport of proteins, in the localization of proteins, in protein turnover, in first translation modifications, in the core structures of viruses and in signal transduction.

[0003] General methodologies to identify interacting proteins or to study these interactions have been developed. Among these methods are the two-hybrid system originally developed by Fields and co-workers and described, for example, in U.S. Patent Nos. 5,283,173, 5,468,614 and 5,667,973, which are hereby incorporated by reference.

[0004] The earliest and simplest two-hybrid system, which acted as basis for development of other versions, is an *in vivo* assay between two specifically constructed proteins. The first protein, known in the art as the "bait protein" is a chimeric protein which binds to a site on DNA upstream of a reporter gene by means of a DNA-binding domain or BD. Commonly, the binding domain is the DNA-binding domain from either Gal4 or native *E. coli* LexA and the sites placed upstream of the reporter are Gal4 binding sites or LexA operators, respectively.

[0005] The second protein is also a chimeric protein known as the "prey" in the art. This second chimeric protein carries an activation domain or AD. This activation domain is typically derived from Gal4, from VP16 or from B42.

[0006] Besides the two hybrid systems, other improved systems have been developed to detected protein-protein interactions. For example, a two-hybrid plus one system was developed that allows the use of two proteins as bait to screen available cDNA libraries to detect a third partner. This method permits the detection between proteins that are part of a larger protein complex such as the RNA polymerase II holoenzyme and the TFIIH or TFIID complexes. Therefore, this method, in general, permits the detection of ternary complex

formation as well as inhibitors preventing the interaction between the two previously defined fused proteins.

[0007] Another advantage of the two-hybrid plus one system is that it allows or prevents the formation of the transcriptional activator since the third partner can be expressed from a conditional promoter such as the methionine-repressed Met25 promoter which is positively regulated in medium lacking methionine. The presence of the methionine-regulated promoter provides an excellent control to evaluate the activation or inhibition properties of the third partner due to its "on" and "off" switch for the formation of the transcriptional activator. The three-hybrid method is described, for example in Tirode et al., *The Journal of Biological Chemistry*, **272**, No. 37 pp. 22995-22999 (1997). incorporated herein by reference.

[0008] Besides the two and two-hybrid plus one systems, yet another variant is that described in Vidal et al, *Proc. Natl. Sci. 93* pgs. 10315-10320 called the reverse two- and one-hybrid systems where a collection of molecules can be screened that inhibit a specific protein-protein or protein/DNA interactions, respectively.

[0009] A summary of the available methodologies for detecting protein-protein interactions is described in Vidal and Legrain, *Nucleic Acids Research* Vol. 27, No. 4 pgs.919-929 (1999) and Legrain and Selig, FEBS Letters 480 pgs. 32-36 (2000) which references are incorporated herein by reference.

[0010] However, the above conventionally used approaches and especially the commonly used two-hybrid methods have their drawbacks. For example, it is known in the art that, more often than not, false positives and false negatives exist in the screening method. In fact, a doctrine has been developed in this field for interpreting the results and in common practice an additional technique such as co-immunoprecipitation or gradient sedimentation of the putative interactors from the appropriate cell or tissue type are generally performed. The methods used for interpreting the results are described by Brent and Finley, Jr. in *Ann. Rev. Genet., 31 pgs. 663-704 (1997)*. Thus, the data interpretation is very questionable using the conventional systems.

[0011] One method to overcome the difficulties encountered with the methods in the prior art is described in WO 99/42612, incorporated herein by reference. This method is similar to the two-hybrid system described in the prior art in that it also uses bait and prey polypeptides. However, the difference with this method is that a step of mating at least one first haploid recombinant yeast cell containing the prey polypeptide to be assayed with a second haploid recombinant yeast cell containing the bait polynucleotide is performed. Of course the person skilled in the art would appreciate that either the first recombinant yeast cell or the second recombinant yeast cell also contains at least one detectable reporter gene that is activated by a polypeptide including a transcriptional activation domain.

[0012] The method described in WO 99/42612 permits the screening of more prey polynucleotides with a given bait polynucleotide in a single step than in the prior art systems due to the cell to cell mating strategy between haploid yeast cells. Furthermore, this method is more thorough and reproducible, as well as sensitive. Thus, the presence of false negatives and/or false positives is extremely minimal as compared to the conventional prior art methods.

[0013] The genus *Shigella* includes four species (major serogroups): *S. dysenteriae* (Grp. A), *S. flexneri* (Grp. B), *S. boydii* (Grp. C) and *S. sonnei* (Grp. D) as classified in Bergey's Manual for Systematic Bacteriology (N. R. Krieg, ed., pp. 423-427 (1984)). The genera *Shigella* and *Escherichia* are phylogenetically closely related. Brenner and others have suggested that the two are more correctly considered sibling species based on DNA/DNA reassociation studies (D. J. Brenner et al., International J. Systematic Bacteriology, 23:1-7 (1973)). These studies showed that *Shigella* species are on average 80-89% related to *E. coli* at the DNA level. Also, the degree of relatedness between *Shigella* species is on average 80-89%.

[0014] The genus *Shigella* is pathogenic in humans; it causes bacillary dysentery at levels of infection of 10 to 100 organisms.

[0015] Shigellosis or bacillary dysentery is a disease that is endemic throughout the world. The disease presents a particularly serious public health problem in tropical regions and developing countries where *Shigella dysenteriae* and *S. flexneri* predominate. In industrialized countries, the principal etiologic agent is *S. sonnei* although sporadic cases of shigellosis are encountered due to *S. flexneri*, *S. boydii* and certain entero-invasive *Escherichia coli*.

[0016] The primary step in the pathogenesis of bacillary dysentery is invasion of the human colonic mucosa by *Shigella* (Labrec, E. H., H. Schneider, T. J. Magnani, and S. B. Formal. 1964. Epithelial cell penetration as an essential step in the pathogenesis of bacillary dysentery. J. Bacteriol. 88:1503). Mucosal invasion encompasses several steps which include penetration of the bacteria into epithelial cells, intracellular multiplication, killing of host cells, and final spreading to adjacent cells and to connective tissue (Formal, S. B., T. L. Hale, and P. J. Sansonetti. 1983. Invasive enteric pathogens. Rev. Infect. Dis. 5:S702, Rout, W. R., S. B. Formal, R. A. Giannella, and G. J. Dammin. 1975. The pathophysiology of Shigella diarrhea in the Rhesus monkey; intestinal transport, morphology and bacteriological studies. Gastroenterology 68:270, Takeuchi, A., H. Spring, E. H. LaBrec, and S. B. Formal. 1965. Experimental acute colitis in the Rhesus monkey following peroral infection with Shigella flexneri. Am. J. Pathol. 52:503, Takeuchi, A. 1967. Electron microscope studies of experimental Salmonella infection. I. Penetration into cells of the intestinal epithelium by Salmonella typhimurium. Am. J. Pathol. 47:1011). The overall process which is usually

limited to the mucosal surface leads to a strong inflammatory reaction which is responsible for abscesses and ulcerations (Labrec, E. H., H. Schneider, T. J. Magnani, and S. B. Formal. 1964. Epithelial cell penetration as an essential step in the pathogenesis of bacillary dysentery. J. Bacteriol. 88:1503., Rout, W. R., S. B. Formal, R. A. Giannella, and G. J. Dammin. 1975. The pathophysiology of Shigella diarrhea in the Rhesus monkey; intestinal transport, morphology and bacteriological studies. Gastroenterology 68:270, Takeuchi, A., H. Spring, E. H. LaBrec, and S. B. Formal. 1965. Experimental acute colitis in the Rhesus monkey following peroral infection with Shigella flexneri. Am. J. Pathol. 52:503).

[0017] Even though dysentery is characteristic of shigellosis, it may be preceded by watery diarrhea. Diarrhea appears to be the result of disturbances in colonic reabsorption and increased jejunal secretion whereas dysentery is a purely colonic process (Kinsey, M. D., S. B. Formal, G. J. Dammin, and R. A. Giannella. 1976. Fluid and electrolyte transport in Rhesus monkeys challenged intraceacally with Shigella flexneri 2a. Infect. Immun. 14:368). These include toxic megacolon, leukemoid reactions and hemolytic-uremic syndrome ("HUS"). The latter is a major cause of mortality from shigellosis in developing areas (Gianantonio, C., H. Vitacco, F. Mendilaharzu, A. Rutty, and J. Mendilaharzu. 1964. The hemolytic-uremic syndrome. J. Pediatr. 64:478, Koster, F., J. Levin, L. Walker, K. S. K. Tung, R. H. Gilman, M. M. Rajaman, M. A. Majid, S. Islam, and R. C. Williams Jr. 1977. Hemolyticuremic syndrome after shigellosis. Relation to endotoxin and circulating immune complexes. N. Engl. J. Med. 298:927).

[0018] The role of Shiga-toxin produced at high level by S. dysenteriae 1 (Conradi, H., 1903. Ueber loshlishe, durch aseptische Autolyse, erhaltene Giftstoffe von Ruhr--un Typhus bazillen. Dtsch. Med. Wochenschr. 29:26) and Shiga-like toxins ("SLT") produced at low level by S. flexneri and S. sonnei (Keusch, G. T., and M. Jacewicz. 1977. The pathogenesis of Shigella diarrhea. VI. Toxin and antitoxin in Shigella flexneri and Shigella sonnei infections in humans. J. Infect. Dis. 135:552) in the four major stages of shigellosis (i.e., invasion of individual epithelial cells, tissue invasion, diarrhea and systemic symptoms) is not well understood. For review see O'Brien and Holmes (O'Brien, A. D., and R. K. Holmes. 1987. Shiga and Shiga-like toxins. Microbiol. Rev. 51:206). Plasmids of 180-220 kilobases ("kb") are essential in all Shigella species for invasion of individual epithelial cells (Rout, W. R., S. B. Formal, R. A. Giannella, and G. J. Dammin. 1975. The pathophysiology of Shigella diarrhea in the Rhesus monkey; intestinal transport, morphology and bacteriological studies. Gastroenterology 68:270, Sansonetti, P. J., D. J. Kopecko, and S. B. Formal. 1981. Shigella sonnei plasmids: evidence that a large plasmid is necessary for virulence. Infect. Immun. 34:75, Sansonetti, P. J., T. L. Hale, G. I. Dammin, C. Kapper, H. H. Collins Jr., and S. B. Formal. 1983. Alterations in the pathogenesis of Escherichia coli K12 after transfer of plasmids and chromosomal genes from Shigella flexneri. Infect. Immun. 39:1392). This

includes entry, intracellular multiplication and early killing of host cells (Clerc, P., A. Ryter, J. Mounier, and P. J. Sansonetti. 1987. Plasmid-mediated early killing of eucaryotic cells by Shigella flexneri as studied by infection of J774 macrophages. Infect. Immun. 55:521, Clerc, P., and P. J. Sansonetti. 1987. Entry of *Shigella flexneri* into HeLa cells: Evidence for directed phagocytosis involving actin polymerization and myosin accumulation. Infect. Immun. 55:2681). The role of Shiga-toxin and SLT at this stage is unclear.

[0019] Recent evidence indicates that Shiga-toxin is cytotoxic for primary cultures of human colonic cells (Moyer, M. P., P. S. Dixon, S. W. Rothman, and J. E. Brown. 1987. Cytotoxicity of Shiga toxin for human colonic and ileal epithelial cells. Infect. Immun. 55:1533). Tissue invasion requires additional chromosomally encoded products among which are smooth lipopolysaccharides ("LPS") (Sansonetti, P. J., T. L. Hale, G. I. Dammin, C. Kapper, H. H. Collins Jr., and S. B. Formal. 1983. Alterations in the pathogenesis of Escherichia coli K12 after transfer of plasmids and chromosomal genes from Shigella flexneri. Infect. Immun. 39:1392), the non-characterized product of the Kcp locus, and aerobactin. A region of the S. flexneri chromosome necessary for fluid production in rabbit ileal loops has been localized to the rha-mt1 regions and near the lysine decarboxylase locus (Sansonetti, P. J., T. L. Hale, G. I. Dammin, C. Kapper, H. H. Collins Jr., and S. B. Formal. 1983. Alterations in the pathogenesis of Escherichia coli K12 after transfer of plasmids and chromosomal genes from Shigella flexneri. Infect. Immun. 39:1392). However, no evidence has been adduced to show that the ability to cause fluid accumulation is due to the SLT of S. flexneri. Thus, the role of Shiga-toxin in causing the systemic complications of shigellosis is still hypothetical. However, Shiga-toxin can mediate vascular damage since capillary lesions observed in HUS resemble those observed in cerebral vessels of animals injected with this toxin (Bridgewater, F. A. I., R. S. Morgan, K. E. K. Rowson, and G. P. Wright. 1955. the neurotoxin of Shigella shigae. Morphological and functional lesions produced in the central nervous system of rabbits. Br. J. Exp. Pathol. 36: 447, Cavanagh, J. B., J. G. Howard, and J. L. Whitby. 1956. The neurotoxin of Shigella shigae. A comparative study of the effects produced in various laboratory animals. Br. J. Exp. Med. 37:272).

[0020] As described before, the genera of *Shigella* and *Escherichia* are phylogenetically closely related. Furthermore, the pathogenesis of enteroinvasive *E. coli* is very similar to that of *Shigella*. In both, dysentery results from invasion of the colonic epithelial cells followed by intracellular multiplication which leads to bloody, mucous discharge with scanty diarrhea.

[0021] Pathogenic *E. coli* serotypes are collectively referred to as Enterovirulent *E. coli* (EVEC) (J. R. Lupski, et al., J. Infectious Diseases, 157:1120-1123 (1988); M. M. Levine, J. Infectious Diseases, 155:377-389 (1987); M. A. Karmali, Clinical Microbiology Reviews, 2:15-38 (1989)). This group includes at least 5 subclasses of *E. coli*, each having a

characteristic pathogenesis pathway resulting in diarrheal disease. The subclasses include Enterotoxigenic *E. coli* (ETEC), Verotoxin-Producing *E. coli* (VTEC), Enteropathogenic *E. coli* (EPEC), Enteroadherent E. coli (EAEC) and Enteroinvasive E. coli (EIEC). The VTEC include Enterohemorrhagic *E. coli* (EHEC) since these produce verotoxins.

[0022] Thus, detection of *Shigella* and EIEC is important in various medical contexts. For example, the presence of either *Shigella* or EIEC in stool samples is indicative of gastroenteritis, and the ability to screen for their presence is useful in treating and controlling that disease. Detection of *Shigella* or EIEC in any possible transmission vehicle such as food is also important to avoid spread of gastroenteritis.

[0023] That is why there is a great need to construct Protein Interaction Map between Shigella polypeptides and human polypeptides in order to understand mechanisms of Shigella pathogenesis and to identify drug target to treat Shigella associated diseases and Shigella detection means.

#### SUMMARY OF THE PRESENT INVENTION

[0024] Thus, it is an object of the present invention to identify protein-protein interactions between *Shigella* polypeptides and mammalian, preferably human, polypeptides.

[0025] It is another object of the present invention to identify protein-protein interactions between *Shigella* polypeptides and mammalian, preferably human, polypeptides for the development of more effective and better targeted therapeutic applications.

[0026] It is yet another object of the present invention to identify complexes of polypeptides or polynucleotides encoding the polypeptides and fragments of the polypeptides of *Shigella* genus and polypeptides and fragments of the polypeptides of mammals, preferably human.

[0027] It is yet another object of the present invention to identify antibodies to these complexes of polypeptides or polynucleotides encoding the polypeptides and fragments of the polypeptides of *Shigella* genus and mammals, preferably human, including polyclonal, as well as monoclonal antibodies that are used for detection.

[0028] It is still another object of the present invention to identify selected interacting domains of the polypeptides, called SID® polypeptides.

[0029] It is still another object of the present invention to identify selected interacting domains of the polynucleotides, called SID® polynucleotides.

[0030] It is another object of the present invention to generate protein-protein interactions maps called PIM®s.

[0031] It is yet another object of the present invention to provide a method for screening drugs for agents which modulate the interaction of proteins and pharmaceutical compositions that are capable of modulating the protein-protein interactions between *Shigella* polypeptides and mammalian, preferably human, polypeptides.

- [0032] It is another object to administer the nucleic acids of the present invention via gene therapy.
- [0033] It is yet another object of the present invention to provide protein chips or protein microarrays.
- [0034] It is yet another object of he present invention to provide a report in, for example paper, electronic and/or digital forms, concerning the protein-protein interactions, the modulating compounds and the like as well as a PIM®.
- [0035] Thus the present invention, in one aspect thereof, relates to a protein complex between a *Shigella* polypeptide and a mammalian polypeptide. In another embodiment, the Shigella and the mammalian polypeptides are polypeptides set forth on columns 1 and 3 respectively of Table II.
- [0036] Furthermore, the present invention provides SID® polynucleotides and SID® polypeptides of Table III, as well as a PIM® between *Shigella* polypeptides and mammalian, preferably human, polypeptides.
- [0037] The present invention also provides antibodies to the protein-protein complexes between *Shigella* polypeptides and mammal, preferably human, polypeptides.
- [0038] In another embodiment the present invention provides a method for screening drugs for agents that modulate the protein-protein interactions and pharmaceutical compositions that are capable of modulating protein-protein interactions.
- [0039] In another embodiment the present invention provides protein chips or protein microarrays.
- [0040] In yet another embodiment the present invention provides a report in, for example, paper, electronic and/or digital forms.

# BRIEF DESCRIPTION OF THE DRAWINGS

- [0041] Fig. 1 is a schematic representation of the pB1 plasmid.
- [0042] Fig. 2 is a schematic representation of the pB5 plasmid.
- [0043] Fig. 3 is a schematic representation of the pB6 plasmid.
- [0044] Fig. 4 is a schematic representation of the pB13 plasmid.
- [0045] Fig. 5 is a schematic representation of the pB14 plasmid.
- [0046] Fig. 6 is a schematic representation of the pB20 plasmid.
- [0047] Fig. 7 is a schematic representation of the pP1 plasmid.
- [0048] Fig. 8 is a schematic representation of the pP2 plasmid.
- [0049] Fig. 9 is a schematic representation of the pP3 plasmid.
- [0050] Fig. 10 is a schematic representation of the pP6 plasmid.
- [0051] Fig. 11 is a schematic representation of the pP7 plasmid.
- [0052] Fig. 12 is a schematic representation of vectors expressing the T25 fragment.
- [0053] Fig. 13 is a schematic representation of vectors expressing the T18 fragment.

[0054] Fig. 14 is a schematic representation of various vectors of pCmAHL1, pT25 and pT18.

[0055] Fig. 15 is a schematic representation of identification of SID®. In this figure the "Full-length prey protein" is the Open Reading Frame (ORF) or coding sequence (CDS) where the identified prey polypeptides are included. The Selected Interaction Domain (SID®) is determined by the commonly shared polypeptide domain of every selected prey fragment.

[0056] Fig. 16 is a protein map (PIM®).

## DETAILED DESCRIPTION OF THE INVENTION

[0057] As used herein the terms "polynucleotides", "nucleic acids" and "oligonucleotides" are used interchangeably and include, but are not limited to RNA, DNA, RNA/DNA sequences of more than one nucleotide in either single chain or duplex form. The polynucleotide sequences of the present invention may be prepared from any known method including, but not limited to, any synthetic method, any recombinant method, any *ex vivo* generation method and the like, as well as combinations thereof.

[0058] The term "polypeptide" means herein a polymer of amino acids having no specific length. Thus, peptides, oligopeptides and proteins are included in the definition of "polypeptide" and these terms are used interchangeably throughout the specification, as well as in the claims. The term "polypeptide" does not exclude post-translational modifications such as polypeptides having covalent attachment of glycosyl groups, aceteyl groups, phosphate groups, lipid groups and the like. Also encompassed by this definition of "polypeptide" are homologs thereof.

[0059] By the term "homologs" is meant structurally similar genes contained within a given species, orthologs are functionally equivalent genes from a given species or strain, as determined for example, in a standard complementation assay. Thus, a polypeptide of interest can be used not only as a model for identifying similiar genes in given strains, but also to identify homologs and orthologs of the polypeptide of interest in other species. The orthologs, for example, can also be identified in a conventional complementation assay. In addition or alternatively, such orthologs can be expected to exist in bacteria (or other kind of cells) in the same branch of the phylogenic tree, as set forth, for example, at <a href="http://ftp.cme.msu.edu/pub/rdp/SSU-rRNA/SSU/Prok.phylo">ftp://ftp.cme.msu.edu/pub/rdp/SSU-rRNA/SSU/Prok.phylo</a>.

[0060] As used herein the term "prey polynucleotide" means a chimeric polynucleotide encoding a polypeptide comprising (i) a specific domain; and (ii) a polypeptide that is to be tested for interaction with a bait polypeptide. The specific domain is preferably a transcriptional activating domain.

[0061] As used herein, a "bait polynucleotide" is a chimeric polynucleotide encoding a chimeric polypeptide comprising (i) a complementary domain; and (ii) a polypeptide that is to

be tested for interaction with at least one prey polypeptide. The complementary domain is preferably a DNA-binding domain that recognizes a binding site that is further detected and is contained in the host organism.

[0062] As used herein "complementary domain" is meant a functional constitution of the activity when bait and prey are interacting; for example, enzymatic activity.

[0063] As used herein "specific domain" is meant a functional interacting activation domain that may work through different mechanisms by interacting directly or indirectly through intermediary proteins with RNA polymerase II or III-associated proteins in the vicinity of the transcription start site.

[0064] As used herein the term "complementary" means that, for example, each base of a first polynucleotide is paired with the complementary base of a second polynucleotide whose orientation is reversed. The complementary bases are A and T (or A and U) or C and G.

[0065] The term "sequence identity" refers to the identity between two peptides or between two nucleic acids. Identity between sequences can be determined by comparing a position in each of the sequences which may be aligned for the purposes of comparison. When a position in the compared sequences is occupied by the same base or amino acid, then the sequences are identical at that position. A degree of sequence identity between nucleic acid sequences is a function of the number of identical nucleotides at positions shared by these sequences. A degree of identity between amino acid sequences is a function of the number of identical amino acid sequences that are shared between these sequences. Since two polypeptides may each (i) comprise a sequence (i.e., a portion of a complete polynucleotide sequence) that is similar between two polynucleotides, and (ii) may further comprise a sequence that is divergent between two polynucleotides, sequence identity comparisons between two or more polynucleotides over a "comparison window" refers to the conceptual segment of at least 20 contiguous nucleotide positions wherein a polynucleotide sequence may be compared to a reference nucleotide sequence of at least 20 contiguous nucleotides and wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) of 20 percent or less compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences.

[0066] To determine the percent identity of two amino acids sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison. For example, gaps can be introduced in the sequence of a first amino acid sequence or a first nucleic acid sequence for optimal alignment with the second amino acid sequence or second nucleic acid sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied

by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecules are identical at that position.

[0067] The percent identity between the two sequences is a function of the number of identical positions shared by the sequences. Hence % identity = number of identical positions / total number of overlapping positions X 100.

[0068] In this comparison the sequences can be the same length or may be different in length. Optimal alignment of sequences for determining a comparison window may be conducted by the local homology algorithm of Smith and Waterman (*J. Theor. Biol.*, 91 (2) pgs. 370-380 (1981), by the homology alignment algorithm of Needleman and Wunsch, *J. Miol. Biol.*, 48(3) pgs. 443-453 (1972), by the search for similarity via the method of Pearson and Lipman, *PNAS*, *USA*, 85(5) pgs. 2444-2448 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetic Computer Group, 575, Science Drive, Madison, Wisconsin) or by inspection.

[0069] The best alignment (i.e., resulting in the highest percentage of identity over the comparison window) generated by the various methods is selected.

[0070] The term "sequence identity" means that two polynucleotide sequences are identical (i.e., on a nucleotide by nucleotide basis) over the window of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size) and multiplying the result by 100 to yield the percentage of sequence identity. The same process can be applied to polypeptide sequences.

[0071] The percentage of sequence identity of a nucleic acid sequence or an amino acid sequence can also be calculated using BLAST software (Version 2.06 of September 1998) with the default or user defined parameter.

[0072] The term "sequence similarity" means that amino acids can be modified while retaining the same function. It is known that amino acids are classified according to the nature of their side groups and some amino acids such as the basic amino acids can be interchanged for one another while their basic function is maintained.

[0073] The term "isolated" as used herein means that a biological material such as a nucleic acid or protein has been removed from its original environment in which it is naturally present. For example, a polynucleotide present in a plant, mammal or animal is present in its natural state and is not considered to be isolated. The same polynucleotide separated

from the adjacent nucleic acid sequences in which it is naturally inserted in the genome of the plant or animal is considered as being "isolated."

[0074] The term "isolated" is not meant to exclude artificial or synthetic mixtures with other compounds, or the presence of impurities which do not interfere with the biological activity and which may be present, for example, due to incomplete purification, addition of stabilizers or mixtures with pharmaceutically acceptable excipients and the like.

[0075] "Isolated polypeptide" or "isolated protein" as used herein means a polypeptide or protein which is substantially free of those compounds that are normally associated with the polypeptide or protein in a naturally state such as other proteins or polypeptides, nucleic acids, carbohydrates, lipids and the like.

[0076] The term "purified" as used herein means at least one order of magnitude of purification is achieved, preferably two or three orders of magnitude, most preferably four or five orders of magnitude of purification of the starting material or of the natural material. Thus, the term "purified" as utilized herein does not mean that the material is 100% purified and thus excludes any other material.

[0077] The term "variants" when referring to, for example, polynucleotides encoding a polypeptide variant of a given reference polypeptide are polynucleotides that differ from the reference polypeptide but generally maintain their functional characteristics of the reference polypeptide. A variant of a polynucleotide may be a naturally occurring allelic variant or it may be a variant that is known naturally not to occur. Such non-naturally occurring variants of the reference polynucleotide can be made by, for example, mutagenesis techniques, including those mutagenesis techniques that are applied to polynucleotides, cells or organisms.

[0078] Generally, differences are limited so that the nucleotide sequences of the reference and variant are closely similar overall and, in many regions identical.

[0079] Variants of polynucleotides according to the present invention include, but are not limited to, nucleotide sequences which are at least 95% identical after alignment to the reference polynucleotide encoding the reference polypeptide. These variants can also have 96%, 97%, 98% and 99.999% sequence identity to the reference polynucleotide.

[0080] Nucleotide changes present in a variant polynucleotide may be silent, which means that these changes do not alter the amino acid sequences encoded by the reference polynucleotide.

[0081] Substitutions, additions and/or deletions can involve one or more nucleic acids. Alterations can produce conservative or non-conservative amino acid substitutions, deletions and/or additions.

[0082] Variants of a prey or a SID® polypeptide encoded by a variant polynucleotide can possess a higher affinity of binding and/or a higher specificity of binding to its protein or

polypeptide counterpart, against which it has been initially selected. In another context, variants can also loose their ability to bind to their protein or polypeptide counterpart.

[0083] By "anabolic pathway" is meant a reaction or series of reactions in a metabolic pathway that synthesize complex molecules from simpler ones, usually requiring the input of energy. An anabolic pathway is the opposite of a catabolic pathway.

[0084] As used herein, a "catabolic pathway" is a series of reactions in a metabolic pathway that break down complex compounds into simpler ones, usually releasing energy in the process. A catabolic pathway is the opposite of an anabolic pathway.

[0085] As used herein, "drug metabolism" is meant the study of how drugs are processed and broken down by the body. Drug metabolism can involve the study of enzymes that break down drugs, the study of how different drugs interact within the body and how diet and other ingested compounds affect the way the body processes drugs.

[0086] As used herein, "metabolism" means the sum of all of the enzyme-catalyzed reactions in living cells that transform organic molecules.

[0087] By "secondary metabolism" is meant pathways producing specialized metabolic products that are not found in every cell.

[0088] As used herein, "SID®" means a Selected Interacting Domain and is identified as follows: for each bait polypeptide screened, selected prey polypeptides are compared. Overlapping fragments in the same ORF or CDS define the selected interacting domain.

[0089] As used herein the term "PIM®" means a protein-protein interaction map. This map is obtained from data acquired from a number of separate screens using different bait polypeptides and is designed to map out all of the interactions between the polypeptides.

[0090] The term "affinity of binding", as used herein, can be defined as the affinity constant Ka when a given SID® polypeptide of the present invention which binds to a polypeptide and is the following mathematical relationship:

[0091] [SID®/polypeptide complex]

[0092] Ka = -----

[0093] [free SID®] [free polypeptide]

[0094] wherein [free SID®], [free polypeptide] and [SID®/polypeptide complex] consist of the concentrations at equilibrium respectively of the free SID® polypeptide, of the free polypeptide onto which the SID® polypeptide binds and of the complex formed between SID® polypeptide and the polypeptide onto which said SID® polypeptide specifically binds.

[0095] The affinity of a SID® polypeptide of the present invention or a variant thereof for its polypeptide counterpart can be assessed, for example, on a Biacore™ apparatus marketed by Amersham Pharmacia Biotech Company such as described by Szabo et al *Curr* 

Opin Struct Biol 5 pgs. 699-705 (1995) and by Edwards and Leartherbarrow, Anal. Biochem 246 pgs. 1-6 (1997).

[0096] As used herein the phrase "at least the same affinity" with respect to the binding affinity between a SID® polypeptide of the present invention to another polypeptide means that the Ka is identical or can be at least two-fold, at least three-fold or at least five fold greater than the Ka value of reference.

[0097] As used herein, the term "modulating compound" means a compound that inhibits or stimulates or can act on another protein which can inhibit or stimulate the protein-protein interaction of a complex of two polypeptides or the protein-protein interaction of two polypeptides.

[0098] More specifically, the present invention comprises complexes of polypeptides or polynucleotides encoding the polypeptides composed of a bait polypeptide, or a bait polynucleotide encoding a bait polypeptide and a prey polypeptide or a prey polynucleotide encoding a prey polypeptide. The prey polypeptide or prey polynucleotide encoding the prey polypeptide is capable of interacting with a bait polypeptide of interest in various hybrid systems.

[0099] As described in the Background of the present invention there are various methods known in the art to identify prey polypeptides that interact with bait polypeptides of interest. These methods, include, but are not limited to, generic two-hybrid systems as described by Fields et al in *Nature*, 340:245-246 (1989) and more specifically in U.S. Patent Nos. 5,283,173, 5,468,614 and 5,667,973, which are hereby incorporated by reference; the reverse two-hybrid system described by Vidal et al, *supra*; the two plus one hybrid method described, for example, in Tirode et al, *supra*; the yeast forward and reverse 'n'-hybrid systems as described in Vidal and Legrain, *supra*; the method described in WO 99/42612; those methods described in Legrain et al *FEBS Letters* 480 pgs. 32-36 (2000) and the like.

[0100] The present invention is not limited to the type of method utilized to detect protein-protein interactions and therefore any method known in the art and variants thereof can be used. It is however better to use the method described in WO 99/42612 or WO 00/66722, both references incorporated herein by reference due to the methods' sensitivity, reproducibility and reliability.

[0101] Protein-protein interactions can also be detected using complementation assays such as those described by Pelletier et al. at <a href="http://www.abrf.org/JBT/Articles/JBT0012/jbt0012.html">http://www.abrf.org/JBT/Articles/JBT0012/jbt0012.html</a>, WO 00/07038 and WO98/34120.

[0102] Although the above methods are described for applications in the yeast system, the present invention is not limited to detecting protein-protein interactions using yeast, but also includes similar methods that can be used in detecting protein-protein interactions in, for example, mammalian systems as described, for example in Takacs et al., *Proc. Natl. Acad.* 

Sci., USA, **90** (21):10375-79 (1993) and Vasavada et al., Proc. Natl. Acad. Sci., USA, 88 (23):10686-90 (1991), as well as a bacterial two-hybrid system as described in Karimova et al (1998), WO99/28746, WO 00/66722 and Legrain et al FEBS Letters, **480** pgs. 32-36 (2000).

[0103] The above-described methods are limited to the use of yeast, mammalian cells and *Escherichia coli* cells, the present invention is not limited in this manner. Consequently, mammalian and typically human cells, as well as bacterial, yeast, fungus, insect, nematode and plant cells are encompassed by the present invention and may be transfected by the nucleic acid or recombinant vector as defined herein.

[0104] Examples of suitable cells include, but are not limited to, VERO cells, HELA cells such as ATCC No. CCL2, CHO cell lines such as ATCC No. CCL61, COS cells such as COS-7 cells and ATCC No. CRL 1650 cells, W138, BHK, HepG2, 3T3 such as ATCC No. CRL6361, A549, PC12, K562 cells, 293 cells, Sf9 cells such as ATCC No. CRL1711 and Cv1 cells such as ATCC No. CCL70.

[0105] Other suitable cells that can be used in the present invention include, but are not limited to, prokaryotic host cells strains such as *Escherichia coli*, (e.g., strain DH5- $\alpha$ ), *Bacillus subtilis*, *Salmonella typhimurium*, or strains of the genera of *Pseudomonas*, *Streptomyce*s and *Staphylococcus*.

[0106] Further suitable cells that can be used in the present invention include yeast cells such as those of *Saccharomyces* such as *Saccharomyces cerevisiae*.

[0107] The bait polynucleotide, as well as the prey polynucleotide can be prepared according to the methods known in the art such as those described above in the publications and patents reciting the known method *per se*.

[0108] The bait polynucleotide of the present invention is obtained from *Shigella flexneri* (see Table I). The prey polynucleotide is obtained form a human placenta cDNA or variants thereof and fragments from the genome or transcriptome of human placenta ranging from about 12 to about 5,000, or about 12 to about 10,000 or from about 12 to about 20,000. The prey polynucleotide is then selected, sequenced and identified.

[0109] A human placenta cDNA prey library is prepared from global human placenta and constructed in the specially designed prey vector pP6 as shown in Figure 10 after ligation of suitable linkers such that every cDNA fragment insert is fused to a nucleotide sequence in the vector that encodes the transcription activation domain of a reporter gene. Any transcription activation domain can be used in the present invention. Examples include, but are not limited to, Gal4,YP16, B42, His and the like. Toxic reporter genes, such as CAT<sup>R</sup>, CYH2, CYH1, URA3, bacterial and fungi toxins and the like can be used in reverse two-hybrid systems.

[0110] The polypeptides encoded by the nucleotide inserts of the human placenta cDNA prey library thus prepared are termed "prey polypeptides" in the context of the presently described selection method of the prey polynucleotides.

[0111] The bait polynucleotide can be inserted in bait plasmid pB6 or pB20 as illustrated in Figure 3 or 6 respectively. The bait polynucleotide insert is fused to a polynucleotide encoding the binding domain of, for example, the Gal4 DNA binding domain and the shuttle expression vector is used to transform cells. The bait polynucleotides used in the present invention are describes in Table I. As stated above, any cells can be utilized in transforming the bait and prey polynucleotides of the present invention including mammalian cells, bacterial cells, yeast cells, insect cells and the like.

[0112] In an embodiment, the present invention identifies protein-protein interactions in yeast. In using known methods a prey positive clone is identified containing a vector which comprises a nucleic acid insert encoding a prey polypeptide which binds to a bait polypeptide of interest. The method in which protein-protein interactions are identified comprises the following steps:

[0113] mating at least one first haploid recombinant yeast cell clone from a recombinant yeast cell clone library that has been transformed with a plasmid containing the prey polynucleotide to be assayed with a second haploid recombinant yeast cell clone transformed with a plasmid containing a bait polynucleotide encoding for the bait polypeptide;

- [0114] cultivating diploid cell clones obtained in step i) on a selective medium; and
- [0115] selecting recombinant cell clones which grow on the selective medium.
- [0116] This method may further comprise the step of:
- [0117] iv) characterizing the prey polynucleotide contained in each recombinant cell clone which is selected in step iii).
- [0118] In yet another embodiment of the present invention, in lieu of yeast, Escherichia coli is used in a bacterial two-hybrid system, which encompasses a similar principle to that described above for yeast, but does not involve mating for characterizing the prey polynucleotide.
- [0119] In yet another embodiment of the present invention, mammalian cells and a method similar to that described above for yeast for characterizing the prey polynucleotide are used.
- [0120] By performing the yeast, bacterial or mammalian two-hybrid system it is possible to identify for one particular bait an interacting prey polypeptide. The prey polypeptide that has been selected by testing the library of preys in a screen using the two-hybrid, two plus one hybrid methods and the like, encodes the polypeptide interacting with the protein of interest.

[0121] The present invention is also directed, in a general aspect, to a complex of polypeptides, polynucleotides encoding the polypeptides composed of a bait polypeptide or bait polynucleotide encoding the bait polypeptide and a prey polypeptide or prey polynucleotide encoding the prey polypeptide capable of interacting with the bait polypeptide of interest. These complexes are identified in Table II, as the bait amino acid sequences and the prey amino acid sequences, as well as the bait and prey nucleic acid sequences.

[0122] In another aspect, the present invention relates to a complex of polynucleotides consisting of a first polynucleotide, or a fragment thereof, encoding a prey polypeptide that interacts with a bait polypeptide and a second polynucleotide or a fragment thereof. This fragment has at least 12 consecutive nucleotides, but can have between 12 and 5,000 consecutive nucleotides, or between 12 and 10,000 consecutive nucleotides or between 12 and 20,000 consecutive nucleotides.

[0123] The polypeptides of column 1 and 3 from Table II according to the present invention and the complexes of these two polypeptides also form part of the present invention. More specifically, the polypeptides of SEQ ID NOS. 1 to 7 are part of the present invention and their complexes with the polypeptides of Column 3, Table II.

[0124] In yet another embodiment, the present invention relates to an isolated complex of at least two polypeptides encoded by two polynucleotides wherein said two polypeptides are associated in the complex by affinity binding and are depicted in columns 1 and 3 of Table II.

[0125] In yet another embodiment, the present invention relates to an isolated complex comprising at least a polypeptide as described in column 1 of Table II and a polypeptide as described in column 3 of Table II. The present invention is not limited to these polypeptide complexes alone but also includes the isolated complex of the two polypeptides in which fragments and/or homologous polypeptides exhibiting at least 95% sequence identity, as well as from 96% sequence identity to 99.999% sequence identity.

[0126] Also encompassed in another embodiment of the present invention is an isolated complex in which SID® of the prey polypeptides encoded by SEQ ID Nos. 15 to 215 in Table III form the isolated complex.

[0127] Besides the isolated complexes described above, nucleic acids coding for a Selected Interacting Domain (SID®) polypeptide or a variant thereof or any of the nucleic acids set forth in Table III can be inserted into an expression vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. Such transcription elements include a regulatory region and a promoter. Thus, the nucleic acid which may encode a marker compound of the present invention is operably linked to a promoter in the expression vector. The expression vector may also include a replication origin.

[0128] A wide variety of host/expression vector combinations are employed in expressing the nucleic acids of the present invention. Useful expression vectors that can be used include, for example, segments of chromosomal, non-chromosomal and synthetic DNA sequences. Suitable vectors include, but are not limited to, derivatives of SV40 and pcDNA and known bacterial plasmids such as col EI, pCR1, pBR322, pMal-C2, pET, pGEX as described by Smith et al [need cite 1988], pMB9 and derivatives thereof, plasmids such as RP4, phage DNAs such as the numerous derivatives of phage I such as NM989, as well as other phage DNA such as M13 and filamentous single stranded phage DNA; yeast plasmids such as the 2 micron plasmid or derivatives of the 2m plasmid, as well as centomeric and integrative yeast shuttle vectors; vectors useful in eukaryotic cells such as vectors useful in insect or mammalian cells; vectors derived from combinations of plasmids and phage DNAs, such as plasmids that have been modified to employ phage DNA or the expression control sequences; and the like.

[0129] For example in a baculovirus expression system, both non-fusion transfer vectors, such as, but not limited to pVL941 (*Bam*HI cloning site Summers, pVL1393 (*Bam*HI, *Sma*I, *Xba*I, *Eco*RI, *Not*I, *Xma*III, *Bg*III and *Pst*I cloning sites; Invitrogen) pVL1392 (*Bg*III, *Pst*I, *Not*I, *Xma*III, *Eco*RI, *XbaI*I, *Sma*I and *Bam*HI cloning site; Summers and Invitrogen) and pBlue *Bac*III (*Bam*HI, *Bg*III, *Pst*I, *Nco*I and *Hind*III cloning site, with blue/white recombinant screening, Invitrogen), and fusion transfer vectors such as, but not limited to, pAc700(*Bam*HI and *Kpn*I cloning sites, in which the *Bam*HI recognition site begins with the initiation codon; Summers), pAc701 and pAc70-2 (same as pAc700, with different reading frames), pAc360 (*Bam*HI cloning site 36 base pairs downstream of a polyhedrin initiation codon; Invitrogen (195)) and pBlueBacHisA, B, C (three different reading frames with *Bam*HI, *Bg*III, *Pst*I, *Nco*I and *Hind*III cloning site, an N-terminal peptide for ProBond purification and blue/white recombinant screening of plaques; Invitrogen (220) can be used.

[0130] Mammalian expression vectors contemplated for use in the invention include vectors with inducible promoters, such as the dihydrofolate reductase promoters, any expression vector with a DHFR expression cassette or a DHFR/methotrexate co-amplification vector such as pED (*Pst*I, *SaI*I, SbaI, SmaI and *Eco*RI cloning sites, with the vector expressing both the cloned gene and DHFR; Kaufman, 1991). Alternatively a glutamine synthetase/methionine sulfoximine co-amplification vector, such as pEE14 (*Hind*III, *XbaI*I, *Sma*I, *Sba*I, *Eco*RI and *BcI*I cloning sites in which the vector expresses glutamine synthetase and the cloned gene; Celltech). A vector that directs episomal expression under the control of the Epstein Barr Virus (EBV) or nuclear antigen (EBNA) can be used such as pREP4 (*Bam*HI, *Sf*II, *Xho*I, *Not*I, *Nhe*I, *Hind*III, *Nhe*I, *Pvu*II and *Kpn*I cloning sites, constitutive RSV-LTR promoter, hygromycin selectable marker; Invitrogen) pCEP4 (*Bam*HI, *Sf*II, *Xho*I, *Not*I, *Nhe*I, *Pvu*II and *Kpn*I cloning sites, constitutive hCMV

immediate early gene promoter, hygromycin selectable marker; Invitrogen), pMEP4 (*Kpn*I, *Pvu*I, *Nhe*I, *Hind*III, *Not*I, *Xho*I, *Sfi*I, *Bam*HI cloning sites, inducible methallothionein IIa gene promoter, hygromycin selectable marker, Invitrogen), pREP8 (*Bam*HI, *Xho*I, *Not*I, *Hind*III, *Nhe*I and *Kpn*I cloning sites, RSV-LTR promoter, histidinol selectable marker; Invitrogen), pREP9 (*Kpn*I, *Nhe*I, *Hind*III, *Not*I, *Xho*I, *Sfi*I, *Bam*HI cloning sites, RSV-LTR promoter, G418 selectable marker; Invitrogen), and pEBVHis (RSV-LTR promoter, hygromycin selectable marker, N-terminal peptide purifiable via ProBond resin and cleaved by enterokinase; Invitrogen).

[0131] Selectable mammalian expression vectors for use in the invention include, but are not limited to, pRc/CMV (*Hind*III, *Bst*XI, *Not*I, *Sba*I and *Apa*I cloning sites, G418 selection, Invitrogen), pRc/RSV (*Hind*II, *Spe*I, *Bst*XI, *Not*I, *Xba*I cloning sites, G418 selection, Invitrogen) and the like. Vaccinia virus mammalian expression vectors (see, for example Kaufman 1991 that can be used in the present invention include, but are not limited to, pSC11 (*Sma*I cloning site, TK- and β-gal selection), pMJ601 (*SaI*I, *Sma*I, *AfI*I, *Nar*I, *Bsp*MII, *Bam*HI, *Apa*I, *Nhe*I, *Sac*II, *Kpn*I and *Hind*III cloning sites; TK- and β-gal selection), pTKgptF1S (*Eco*RI, *Pst*I, *SaI*II, *Acc*I, *Hind*II, *Sba*I, *Bam*HI and *Hpa* cloning sites, TK or XPRT selection) and the like.

[0132] Yeast expression systems that can also be used in the present include, but are not limited to, the non-fusion pYES2 vector (*Xbal*, *Sphl*, *Shol*, *Notl*, *GstXI*, *EcoRI*, *BstXI*, *BamHI*, *SacI*, *KpnI* and *HindIII* cloning sites, Invitrogen), the fusion pYESHisA, B, C (*XbalI*, *SphI*, *Shol*, *Notl*, *BstXI*, *EcoRI*, *BamHI*, *SacI*, *KpnI* and *HindIII* cloning sites, N-terminal peptide purified with ProBond resin and cleaved with enterokinase; Invitrogen), pRS vectors and the like.

[0133] Consequently, mammalian and typically human cells, as well as bacterial, yeast, fungi, insect, nematode and plant cells an used in the present invention and may be transfected by the nucleic acid or recombinant vector as defined herein.

[0134] Examples of suitable cells include, but are not limited to, VERO cells, HELA cells such as ATCC No. CCL2, CHO cell lines such as ATCC No. CCL61, COS cells such as COS-7 cells and ATCC No. CRL 1650 cells, W138, BHK, HepG2, 3T3 such as ATCC No. CRL6361, A549, PC12, K562 cells, 293 cells, Sf9 cells such as ATCC No. CRL1711 and Cv1 cells such as ATCC No. CCL70.

[0135] Other suitable cells that can be used in the present invention include, but are not limited to, prokaryotic host cells strains such as *Escherichia coli*, (e.g., strain DH5- $\alpha$ ), *Bacillus subtilis*, *Salmonella typhimurium*, or strains of the genera of *Pseudomonas*, *Streptomyce*s and *Staphylococcus*.

[0136] Further suitable cells that can be used in the present invention include yeast cells such as those of *Saccharomyces* such as *Saccharomyces cerevisiae*.

- [0137] Besides the specific isolated complexes, as described above, the present invention relates to and also encompasses SID® polynucleotides. As explained above, for each bait polypeptide, several prey polypeptides may be identified by comparing and selecting the intersection of every isolated fragment that are included in the same polypeptide. Thus the SID® polynucleotides of the present invention are represented by the shared nucleic acid sequences of SEQ ID Nos. 15 to 215 encoding the SID® polypeptides of SEQ ID Nos. 216 to 416 in columns 5 and 7 of Table III, respectively.
- [0138] The present invention is not limited to the SID® sequences as described in the above paragraph, but also includes fragments of these sequences having at least 12 consecutive nucleic acids, between 12 and 5,000 consecutive nucleic acids and between 12 and 10,000 consecutive nucleic acids and between 12 and 20,000 consecutive nucleic acids, as well as variants thereof. The fragments or variants of the SID® sequences possess at least the same affinity of binding to its protein or polypeptide counterpart, against which it has been initially selected. Moreover this variant and/or fragments of the SID® sequences alternatively can have between 95% and 99.999% sequence identity to its protein or polypeptide counterpart.
- [0139] According to the present invention the variants can be created by known mutagenesis techniques either *in vitro* or *in vivo*. Such a variant can be created such that it has altered binding characteristics with respect to the target protein and more specifically that the variant binds the target sequence with either higher or lower affinity.
- [0140] Polynucleotides that are complementary to the above sequences which include the polynucleotides of the SID®'s, their fragments, variants and those that have specific sequence identity are also included in the present invention.
- [0141] The polynucleotide encoding the SID® polypeptide, fragment or variant thereof can also be inserted into recombinant vectors which are described in detail above.
- [0142] The present invention also relates to a composition comprising the above-mentioned recombinant vectors containing the SID® polypeptides in Table III, fragments or variants thereof, as well as recombinant host cells transformed by the vectors. The recombinant host cells that can be used in the present invention were discussed in greater detail above.
- [0143] The compositions comprising the recombinant vectors can contain physiological acceptable carriers such as diluents, adjuvants, excipients and any vehicle in which this composition can be delivered therapeutically and can include, but is are not limited to sterile liquids such as water and oils.
- [0144] In yet another embodiment, the present invention relates to a method of selecting modulating compounds, as well as the modulating molecules or compounds themselves which may be used in a pharmaceutical composition. These modulating compounds may

act as a cofactor, as an inhibitor, as antibodies, as tags, as a competitive inhibitor, as an activator or alternatively have agonistic or antagonistic activity on the protein-protein interactions.

- [0145] The activity of the modulating compound does not necessarily, for example, have to be 100% activation or inhibition. Indeed, even partial activation or inhibition can be achieved that is of pharmaceutical interest.
- [0146] The modulating compound can be selected according to a method which comprises:
- [0147] cultivating a recombinant host cell with a modulating compound on a selective medium and a reporter gene the expression of which is toxic for said recombinant host cell wherein said recombinant host cell is transformed with two vectors:
- [0148] wherein said first vector comprises a polynucleotide encoding a first hybrid polypeptide having a DNA binding domain;
- [0149] wherein said second vector comprises a polynucleotide encoding a second hybrid polypeptide having a transcriptional activating domain that activates said toxic reporter gene when the first and second hybrid polypeptides interact;
- [0150] selecting said modulating compound which inhibits or permits the growth of said recombinant host cell.
- [0151] Thus, the present invention relates to a modulating compound that inhibits the protein-protein interactions between *Shigella flexneri* polypeptide and human placenta polypeptide of columns 1 and 3 of Table II, respectively. The present invention also relates to a modulating compound that activates the protein-protein interactions between *Shigella flexneri* polypeptide and human placenta polypeptide of columns 1 and 3 of Table II, respectively.
- [0152] In yet another embodiment, the present invention relates to a method of selecting a modulating compound, which modulating compound inhibits the interaction between *Shigella flexneri* polypeptide and human placenta polypeptide of columns 1 and 3 of Table II, respectively. This method comprises:
- (a) cultivating a recombinant host cell with a modulating compound on a selective medium and a reporter gene the expression of which is toxic for said recombinant host cell wherein said recombinant host cell is transformed with two vectors:
- (i) wherein said first vector comprises a polynucleotide encoding a first hybrid polypeptide having a first domain of an enzyme;
- (ii) wherein said second vector comprises a polynucleotide encoding a second hybrid polypeptide having an enzymatic transcriptional activating domain that activates said toxic reporter gene when the first and second hybrid polypeptides interact;

- (b) selecting said modulating compound which inhibits or permits the growth of said recombinant host cell.
- [0153] In the two methods described above any toxic reporter gene can be utilized including those reporter genes that can be used for negative selection including the URA3 gene, the CYH1 gene, the CYH2 gene and the like.
- [0154] In yet another embodiment, the present invention provides a kit for screening a modulating compound. This kit comprises a recombinant host cell which comprises a reporter gene the expression of which is toxic for the recombinant host cell. The host cell is transformed with two vectors. The first vector comprises a polynucleotide encoding a first hybrid polypeptide having a DNA binding domain; and a second vector comprises a polynucleotide encoding a second hybrid polypeptide having a transcriptional activating domain that activates said toxic reporter gene when the first and second hybrid polypeptides interact.
- [0155] In yet another embodiment a kit is provided for screening a modulating compound by providing a recombinant host cell, as described in the paragraph above, but instead of a DNA binding domain, the first vector comprises a first hybrid polypeptide containing a first domain of a protein. The second vector comprises a second polypeptide containing a second part of a complementary domain of a protein that activates the toxic reporter gene when the first and second hybrid polypeptides interact.
- [0156] In the selection methods described above, the activating domain can be p42 Gal 4, YP16 (HSV) and the DNA-binding domain can be derived from Gal4 or Lex A. The protein or enzyme can be adenylate cyclase, guanylate cyclase, DHFR and the like.
- [0157] Examples of modulating compounds are set forth in Table III.
- [0158] In yet another embodiment, the present invention relates to a pharmaceutical composition comprising the modulating compounds for preventing or treating bacillary dysentery in a human or animal, most preferably in a mammal.
- [0159] This pharmaceutical composition comprises a pharmaceutically acceptable amount of the modulating compound. The pharmaceutically acceptable amount can be estimated from cell culture assays. For example, a dose can be formulated in animal models to achieve a circulating concentration range that includes or encompasses a concentration point or range having the desired effect in an *in vitro* system. This information can thus be used to accurately determine the doses in other mammals, including humans and animals.
- [0160] The therapeutically effective dose refers to that amount of the compound that results in amelioration of symptoms in a patient. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or in experimental animals. For example, the LD50 (the dose lethal to 50% of the population) as

well as the ED50 (the dose therapeutically effective in 50% of the population) can be determined using methods known in the art. The dose ratio between toxic and therapeutic effects is the therapeutic index which can be expressed as the ratio between LD 50 and ED50 compounds that exhibit high therapeutic indexes.

- [0161] The data obtained from the cell culture and animal studies can be used in formulating a range of dosage of such compounds which lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
- [0162] The pharmaceutical composition can be administered via any route such as locally, orally, systemically, intravenously, intramuscularly, mucosally, using a patch and can be encapsulated in liposomes, microparticles, microcapsules, and the like. The pharmaceutical composition can be embedded in liposomes or even encapsulated.
- [0163] Any pharmaceutically acceptable carrier or adjuvant can be used in the pharmaceutical composition. The modulating compound will be preferably in a soluble form combined with a pharmaceutically acceptable carrier. The techniques for formulating and administering these compounds can be found in "Remington's Pharmaceutical Sciences" Mack Publication Co., Easton, PA, latest edition.
- [0164] The mode of administration optimum dosages and galenic forms can be determined by the criteria known in the art taken into account the seriousness of the general condition of the mammal, the tolerance of the treatment and the side effects.
- [0165] The present invention also relates to a method of treating or preventing bacillary dysentery in a human or mammal in need of such treatment. This method comprises administering to a mammal in need of such treatment a pharmaceutically effective amount of a modulating compound which binds to a targeted Shigella protein. In a preferred embodiment, the modulating compound is a polynucleotide which may be placed under the control of a regulatory sequence which is functional in the mammal or human.
- [0166] In yet another embodiment, the present invention relates to a pharmaceutical composition comprising a SID® polypeptide, a fragment or variant thereof. The SID® polypeptide, fragment or variant thereof can be used in a pharmaceutical composition provided that it is endowed with highly specific binding properties to a bait polypeptide of interest.

- [0167] The original properties of the SID® polypeptide or variants thereof interfere with the naturally occurring interaction between a first protein and a second protein within the cells of the organism. Thus, the SID® polypeptide binds specifically to either the first polypeptide or the second polypeptide.
- [0168] Therefore, the SID® polypeptides of the present invention or variants thereof interfere with protein-protein interactions between *Shigella* or *Escherichia* polypeptides or between a mammal polypeptide.
- [0169] Thus, the present invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable amount of a SID® polypeptide or variant thereof, provided that the variant has the above-mentioned two characteristics; i.e., that it is endowed with highly specific binding properties to a bait polypeptide of interest and is devoid of biological activity of the naturally occurring protein.
- [0170] In yet another embodiment, the present invention relates to a pharmaceutical composition comprising a pharmaceutically effective amount of a polynucleotide encoding a SID® polypeptide or a variant thereof wherein the polynucleotide is placed under the control of an appropriate regulatory sequence. Appropriate regulatory sequences that are used are polynucleotide sequences derived from promoter elements and the like.
- [0171] Polynucleotides that can be used in the pharmaceutical composition of the present invention include the nucleotide sequences of SID®s of SEQ ID Nos. 15 to 215.
- [0172] Besides the SID® polypeptides and polynucleotides, the pharmaceutical composition of the present invention can also include a recombinant expression vector comprising the polynucleotide encoding the SID® polypeptide, fragment or variant thereof.
- [0173] The above described pharmaceutical compositions can be administered by any route such as orally, systemically, intravenously, intramuscularly, intradermally, mucosally, encapsulated, using a patch and the like. Any pharmaceutically acceptable carrier or adjuvant can be used in this pharmaceutical composition.
- [0174] The SID® polypeptides as active ingredients will be preferably in a soluble form combined with a pharmaceutically acceptable carrier. The techniques for formulating and administering these compounds can be found in "Remington's Pharmaceutical Sciences" supra.
- [0175] The amount of pharmaceutically acceptable SID® polypeptides can be determined as described above for the modulating compounds using cell culture and animal models.
- [0176] Such compounds can be used in a pharmaceutical composition to treat or prevent bacillary dysentery.
- [0177] Thus, the present invention also relates to a method of preventing or treating bacillary dysentery in a mammal said method comprising the steps of administering to a

mammal in need of such treatment a pharmaceutically effective amount of a recombinant expression vector comprising a polynucleotide encoding a SID® polypeptide which binds to a either to a *Shigella flexneri* protein or to a human placenta protein involved in a protein-protein interaction between a *Shigella flexneri* protein and an human placenta protein. More specifically, the present invention relates to a method of preventing or treating bacillary dysentery in a mammal said method comprising the steps of administering to a mammal in need of such treatment a pharmaceutically effective amount of:

- (1) a SID® polypeptide of SEQ ID Nos. 216 to 416 or a variant thereof which binds to a targeted *Shigella flexneri* protein or human placenta protein; or
- (2) a SID® polynucleotide encoding a SID® polypeptide of SEQ ID Nos. 15 to 215 or a variant or a fragment thereof wherein said polynucleotide is placed under the control of a regulatory sequence which is functional in said mammal; or
- (3) a recombinant expression vector comprising a polynucleotide encoding a SID® polypeptide which binds either to a *Shigella flexneri* protein or to a human placenta protein involved in a protein-protein interaction between a *Shigella flexneri* protein and an human placenta protein.
- [0178] In another embodiment the present invention nucleic acids comprising a sequence of SEQ ID Nos. 15 to 215 which encodes the protein of sequence SEQ ID Nos. 216 to 416 and/or functional derivatives thereof are administered to modulate complex (from Table II) function by way of gene therapy. Any of the methodologies relating to gene therapy available within the art may be used in the practice of the present invention such as those described by Goldspiel et al *Clin. Pharm.* 12 pgs. 488-505 (1993).
- [0179] Delivery of the therapeutic nucleic acid into a patient may be direct *in vivo* gene therapy (i.e., the patient is directly exposed to the nucleic acid or nucleic acid-containing vector) or indirect *ex vivo* gene therapy (i.e., cells are first transformed with the nucleic acid in vitro and then transplanted into the patient).
- [0180] For example for *in vivo* gene therapy, an expression vector containing the nucleic acid is administered in such a manner that it becomes intracellular; i.e., by infection using a defective or attenuated retroviral or other viral vectors as described, for example in U.S. Patent 4,980,286 or by Robbins et al, Pharmacol. *Ther.*, **80** No. 1 pgs. 35-47 (1998).
- [0181] The various retroviral vectors that are known in the art are such as those described in Miller et al, *Meth. Enzymol.* 217 pgs. 581-599 (1993) which have been modified to delete those retroviral sequences which are not required for packaging of the viral genome and subsequent integration into host cell DNA. Also adenoviral vectors can be used which are advantageous due to their ability to infect non-dividing cells and such high-capacity adenoviral vectors are described in Kochanek, *Human Gene Therapy*, 10, pgs. 2451-2459 (1999). Chimeric viral vectors that can be used are those described by Reynolds

et al, *Molecular Medecine Today*, pgs. 25 –31 (1999). Hybrid vectors can also be used and are described by Jacoby et al, *Gene Therapy*, **4**, pgs. 1282-1283 (1997).

[0182] Direct injection of naked DNA or through the use of microparticle bombardment (e.g., Gene Gun®; Biolistic, Dupont). or by coating it with lipids can also be used in gene therapy. Cell-surface receptors/transfecting agents or through encapsulation in liposomes, microparticles or microcapsules or by administering the nucleic acid in linkage to a peptide which is known to enter the nucleus or by administering it in linkage to a ligand predisposed to receptor-mediated endocytosis ( See, Wu & Wu, J. Biol. Chem., 262 pgs. 4429-4432 ( 1987)) can be used to target cell types which specifically express the receptors of interest.

[0183] In another embodiment a nucleic acid ligand compound may be produced in which the ligand comprises a fusogenic viral peptide designed so as to disrupt endosomes, thus allowing the nucleic acid to avoid subsequent lysosomal degradation. The nucleic acid may be targeted *in vivo* for cell specific endocytosis and expression by targeting a specific receptor such as that described in WO92/06180, WO93/14188 and WO 93/20221. Alternatively the nucleic acid may be introduced intracellularly and incorporated within the host cell genome for expression by homologous recombination. See, Zijlstra et al, *Nature*, **342**, pgs. 435-428 (1989).

[0184] In ex vivo gene a gene is transferred into cells in vitro using tissue culture and the cells are delivered to the patient by various methods such as injecting subcutaneously, application of the cells into a skin graft and the intravenous injection of recombinant blood cells such as hematopoietic stem or progenitor cells.

[0185] Cells into which a nucleic acid can be introduced for the purposes of gene therapy include, for example, epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes and blood cells. The blood cells that can be used include, for example, T-lymphocytes, B-lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryotcytes, granulocytes, hematopoietic cells or progenitor cells and the like.

[0186] In yet another embodiment the present invention relates to protein chips or protein microarrays. It is well known in the art that microarrays can contain more than 10,000 spots of a protein that can be robotically deposited on a surface of a glass slide or nylon filter. The proteins attach covalently to the slide surface, yet retain their ability to interact with other proteins or small molecules in solution. In some instances the protein samples can be made to adhere to glass slides by coating the slides with an aldehydecontaining reagent that attaches to primary amines. A process for creating microarrays is described, for example by MacBeath and Schreiber in *Science*, Volume 289, Number 5485, pgs, 1760-1763 (2000) or Service, *Science*, Vol, 289, Number 5485 pg. 1673 (2000). An

apparatus for controlling, dispensing and measuring small quantities of fluid is described, for example, in U.S. Patent No. 6,112,605.

[0187] The present invention also provides a record of protein-protein interactions, PIM®'s, SID®'s and any data encompassed in the following Tables. It will be appreciated that this record can be provided in paper or electronic or digital form.

[0188] In order to fully illustrate the present invention and advantages thereof, the following specific examples are given, it being understood that the same are intended only as illustrative and in no way limitative.

#### **EXAMPLES**

EXAMPLE 1: Preparation of a collection of random-primed cDNA fragments

1.A. Collection preparation and transformation in Escherichia coli

1.A.1. Random-primed cDNA fragment preparation

[0189] For the human placenta mRNA sample, random-primed cDNA was prepared from 5  $\mu$ g of polyA+ mRNA using a TimeSaver cDNA Synthesis Kit (Amersham Pharmacia Biotech) and with 5  $\mu$ g of random N9-mers according to the manufacturer's instructions. Following phenolic extraction, the cDNA was precipitated and resuspended in water. The resuspended cDNA was phosphorylated by incubating in the presence of T4 DNA Kinase (Biolabs) and ATP for 30 minutes at 37°C. The resulting phosphorylated cDNA was then purified over a separation column (Chromaspin TE 400, Clontech), according to the manufacturer's protocol.

1.A.2. Ligation of linkers to blunt-ended cDNA

Oligonucleotide HGX931 (5' end phosphorylated) 1 μg/μl and HGX932 1μg/μl.

Sequence of the oligo HGX931: 5'-GGGCCACGAA-3' (SEQ ID NO. 417)

Sequence of the oligo HGX932: 5'-TTCGTGGCCCCTG-3' (SEQ ID NO. 418)

[0190] Linkers were preincubated (5 minutes at 95°C, 10 minutes at 68°C, 15 minutes at 42°C) then cooled down at room temperature and ligated with cDNA fragments at 16°C overnight.

[0191] Linkers were removed on a separation column (Chromaspin TE 400, Clontech), according to the manufacturer's protocol.

1.A.3. Vector preparation

[0192] Plasmid pP6 (see Figure 10) was prepared by replacing the *SpellXhol* fragment of pGAD3S2X with the double-stranded oligonucleotide:

[0193] The pP6 vector was successively digested with *Sfi*1 and *Bam*HI restriction enzymes (Biolabs) for 1 hour at 37°C, extracted, precipitated and resuspended in water. Digested plasmid vector backbones were purified on a separation column (Chromaspin TE 400, Clontech), according to the manufacturer's protocol.

1.A.4. Ligation between vector and insert of cDNA

[0194] The prepared vector was ligated overnight at 15°C with the blunt-ended cDNA described in section 2 using T4 DNA ligase (Biolabs). The DNA was then precipitated and resuspended in water.

1.A.5. Library transformation in Escherichia coli

[0195] The DNA from section 1.A.4 was transformed into Electromax DH10B electrocompetent cells (Gibco BRL) with a Cell Porator apparatus (Gibco BRL). 1 ml SOC medium was added and the transformed cells were incubated at 37°C for 1 hour. 9 mls of SOC medium per tube was added and the cells were plated on LB+ampicillin medium. The colonies were scraped with liquid LB medium, aliquoted and frozen at -80°C.

[0196] The obtained collection of recombinant cell clones is named HGXBPLARP1.

1.B. Collection transformation in Saccharomyces cerevisiae

[0197] The Saccharomyces cerevisiae strain (Y187 (MAT $\alpha$  Gal4 $\Delta$  Gal80 $\Delta$  ade2-101, his3, leu2-3, -112, trp1-901, ura3-52 URA3::UASGAL1-LacZ Met)) was transformed with the cDNA library.

[0198] The plasmid DNA contained in E. coli were extracted (Qiagen) from aliquoted E. coli frozen cells (1.A.5.). Saccharomyces cerevisiae yeast Y187 in YPGlu were grown.

[0199] Yeast transformation was performed according to standard protocol (Giest et al. Yeast, 11, 355-360, 1995) using yeast carrier DNA (Clontech). This experiment leads to  $10^4$  to  $5 \times 10^4$  cells/µg DNA.  $2 \times 10^4$  cells were spread on DO-Leu medium per plate. The cells were aliquoted into vials containing 1 ml of cells and frozen at -80°C.

[0200] The obtained collection of recombinant cell clones is named HGXYPLARP1 (placenta).

1.C. Construction of bait plasmids

[0201] For fusions of the bait protein (listed in Table II) to the DNA-binding domain of the GAL4 protein of *S. cerevisiae*, bait fragments were cloned into plasmid pB6. For fusions of the bait protein to the DNA-binding domain of the LexA protein of *E. coli*, bait fragments were cloned into plasmid pB20.

[0202] Plasmid pB6 (see Figure 3) was prepared by replacing the Nco1/Sal1 polylinker fragment of pAS $\Delta\Delta$  with the double-stranded DNA fragment:

5'

[0203] Plasmid pB20 (see Figure 6) was prepared by replacing the *EcoRIPstI* polylinker fragment of pLex10 with the double-stranded DNA fragment:

5'

3'

[0204] The amplification of the bait ORF was obtained by PCR using the Pfu proof-reading *Taq* polymerase (Stratagene), 10 pmol of each specific amplification primer and 200 ng of plasmid DNA as template.

[0205] The PCR program was set up as follows:

[0206] The amplification was checked by agarose gel electrophoresis.

[0207] The PCR fragments were purified with Qiaquick column (Qiagen) according to the manufacturer's protocol.

[0208] Purified PCR fragments were digested with adequate restriction enzymes. The PCR fragments were purified with Qiaquick column (Qiagen) according to the manufacturer's protocol.

[0209] The digested PCR fragments were ligated into an adequately digested and dephosphorylated bait vector (pB6 or pB20) according to standard protocol (Sambrook *et al.*) and were transformed into competent bacterial cells. The cells were grown, the DNA extracted and the plasmid was sequenced.

Example 2: Screening the collection with the two-hybrid in yeast system

2.A. The mating protocol

[0210] The mating two-hybrid in yeast system (as described by Legrain et al., Nature Genetics, vol. 16, 277-282 (1997), Toward a functional analysis of the yeast genome through

exhaustive two-hybrid screens) was used for its advantages but one could also screen the cDNA collection in classical two-hybrid system as described in Fields et al. or in a yeast reverse two-hybrid system.

[0211] The mating procedure allows a direct selection on selective plates because the two fusion proteins are already produced in the parental cells. No replica plating is required.

[0212] This protocol was written for the use of the library transformed into the Y187 strain.

[0213] For bait proteins fused to the DNA-binding domain of GAL4, bait-encoding plasmids were first transformed into *S. cerevisiae* (CG1945 strain (MATa Gal4-542 Gal180-538 ade2-101 his3∆200, leu2-3,112, trp1-901, ura3-52, lys2-801, URA3::GAL4 17mers (X3)-CyC1TATA-LacZ, LYS2::GAL1UAS-GAL1TATA-HIS3 CYH<sup>R</sup>)) according to step 1.B. and spread on DO-Trp medium.

[0214] For bait proteins fused to the DNA-binding domain of LexA, bait-encoding plasmids were first transformed into *S. cerevisiae* (L40∆gal4 strain (MATa ade2, trp1-901, leu2 3,112, lys2-801, his3∆200, LYS2::(lexAop)<sub>4</sub>-HIS3, ura3-52::URA3 (lexAop)<sub>8</sub>-LacZ, GAL4::Kan<sup>R</sup>)) according to step 1.B. and spread on DO-Trp medium.

Day 1, morning: preculture

[0215] The cells carrying the bait plasmid obtained at step 1.C. were precultured in 20 ml DO-Trp medium and grown at 30°C with vigorous agitation.

Day 1, late afternoon: culture

[0216] The  $OD_{600nm}$  of the DO-Trp pre-culture of cells carrying the bait plasmid pre-culture was measured. The  $OD_{600nm}$  must lie between 0.1 and 0.5 in order to correspond to a linear measurement.50 ml DO-Trp at  $OD_{600nm}$  0.006/ml was inoculated and grown overnight at 30°C with vigorous agitation.

Day 2: mating

medium and plates

1 YPGlu 15cm plate

50 ml tube with 13 ml DO-Leu-Trp-His

100 ml flask with 5 ml of YPGlu

8 DO-Leu-Trp-His plates

2 DO-Leu plates

2 DO-Trp plates

2 DO-Leu-Trp plates

[0217] The OD<sub>600nm</sub> of the DO-Trp culture was measured. It should be around 1.

[0218] For the mating, twice as many bait cells as library cells were used. To get a good mating efficiency, one must collect the cells at 10<sup>8</sup> cells per cm<sup>2</sup>.

[0219] The amount of bait culture (in ml) that makes up 50 OD<sub>600nm</sub> units for the mating with the prey library was estimated.

[0220] A vial containing the HGXYCDNA1 library was thawed slowly on ice. 1.0ml of the vial was added to 5 ml YPGlu. Those cells were recovered at 30°C, under gentle agitation for 10 minutes.

#### Mating

[0221] The 50 OD<sub>600nm</sub> units of bait culture was placed into a 50 ml falcon tube.

[0222] The HGXYCDNA1 library culture was added to the bait culture, then centrifuged, the supernatant discarded and resuspended in 1.6ml YPGlu medium.

[0223] The cells were distributed onto two 15cm YPGlu plates with glass beads. The cells were spread by shaking the plates. The plate cells-up at 30°C for 4h30min were incubated.

#### Collection of mated cells

[0224] The plates were washed and rinsed with 6ml and 7ml respectively of DO-Leu-Trp-His. Two parallel serial ten-fold dilutions were performed in 500µl DO-Leu-Trp-His up to 1/10,000. 50µl of each 1/10000 dilution was spread onto DO-Leu and DO-trp plates and 50µl of each 1/1000 dilution onto DO-Leu-Trp plates. 22.4ml of collected cells were spread in 400µl aliquots on DO-Leu-Trp-His+Tet plates.

#### Day 4

[0225] Clones that were able to grow on DO-Leu-Trp-His+Tetracyclin were then selected. This medium allows one to isolate diploid clones presenting an interaction.

[0226] The His+ colonies were counted on control plates.

[0227] The number of His+ cell clones will define which protocol is to be processed:

[0228] Upon 60.10<sup>6</sup> Trp+Leu+ colonies:

- if the number His+ cell clones <285 : then use the process luminometry protocol on all colonies
- if the number of His+ cell clones > 285 and <5000: then process via overlay and then luminometry protocols on blue colonies (2.B and 2.C).
- if number of His+ cell clones >5000 : repeat screen using DO-Leu-Trp-His+Tetracyclin plates containing 3-aminotriazol.

# 2.B. The X-Gal overlay assay

[0229] The X-Gal overlay assay was performed directly on the selective medium plates after scoring the number of His<sup>+</sup> colonies.

#### Materials

[0230] A waterbath was set up. The water temperature should be 50°C.

0.5 M Na<sub>2</sub>HPO<sub>4</sub> pH 7.5.

1.2% Bacto-agar.

2% X-Gal in DMF.

Overlay mixture: 0.25 M Na<sub>2</sub>HPO<sub>4</sub> pH7.5, 0.5% agar, 0.1% SDS, 7% DMF (LABOSI), 0.04% X-Gal (ICN). For each plate, 10 ml overlay mixture are needed.

DO-Leu-Trp-His plates.

Sterile toothpicks.

Experiment

[0231] The temperature of the overlay mix should be between 45°C and 50°C. The overlay-mix was poured over the plates in portions of 10 ml. When the top layer was settled, they were collected. The plates were incubated overlay-up at 30°C and the time was noted. Blue colonies were checked for regularly. If no blue colony appeared, overnight incubation was performed. Using a pen the number of positives was marked. The positives colonies were streaked on fresh DO-Leu-Trp-His plates with a sterile toothpick.

2.C. The luminometry assay

[0232] His+ colonies were grown overnight at 30°C in microtiter plates containing DO-Leu-Trp-His+Tetracyclin medium with shaking. The day after, the overnight culture was diluted 15 times into a new microtiter plate containing the same medium and was incubated for 5 hours at 30°C with shaking. The samples were diluted 5 times and read  $OD_{600nm}$ . The samples were diluted again to obtain between 10,000 and 75,000 yeast cells/well in 100  $\mu$ l final volume.

[0233] Per well, 76  $\mu$ l of One Step Yeast Lysis Buffer (Tropix) was added, 20  $\mu$ l SapphireII Enhancer (Tropix), 4  $\mu$ l Galacton Star (Tropix) and incubated 40 minutes at 30°C. The  $\beta$ -Gal read-out (L) was measured using a Luminometer (Trilux, Wallach). The value of (OD<sub>600nm</sub> x L) was calculated and interacting preys having the highest values were selected.

[0234] At this step of the protocol, diploid cell clones presenting interaction were isolated. The next step was now to identify polypeptides involved in the selected interactions.

Example 3: Identification of positive clones

3.A. PCR on yeast colonies

Introduction

[0235] PCR amplification of fragments of plasmid DNA directly on yeast colonies is a quick and efficient procedure to identify sequences cloned into this plasmid. It is directly derived from

[0236] a published protocol (Wang H. et al., *Analytical Biochemistry*, **237**, 145-146, (1996)). However, it is not a standardized protocol and it varies from strain to strain and it is dependent of experimental conditions (number of cells, *Taq* polymerase source, etc). This protocol should be optimized to specific local conditions.

Materials

[0237] For 1 well, PCR mix composition was :

32.5 µl water,

5 μl 10X PCR buffer (Pharmacia),

1 μl dNTP 10 mM,

0.5 μl Taq polymerase (5u/μl) (Pharmacia),

0.5 μl oligonucleotide ABS1 10 pmole/μl: 5'-GCGTTTGGAATCACTACAGG-3',(SEQ ID NO. 424)

 $0.5~\mu l$  oligonucleotide ABS2 10 pmole/ $\mu l$ : 5'-CACGATGCACGTTGAAGTG-3'.(SEQ ID NO. 425)

1 N NaOH.

#### Experiment

[0238] The positive colonies were grown overnight at 30°C on a 96 well cell culture cluster (Costar), containing 150  $\mu$ l DO-Leu-Trp-His+Tetracyclin with shaking. The culture was resuspended and 100  $\mu$ l was transferred immediately on a Thermowell 96 (Costar) and centrifuged for 5 minutes at 4,000 rpm at room temperature. The supernatant was removed. 5  $\mu$ l NaOH was added to each well and shaken for 1 minute.

[0239] The Thermowell was placed in the thermocycler (GeneAmp 9700, Perkin Elmer) for 5 minutes at 99.9°C and then 10 minutes at 4°C. In each well, the PCR mix was added and shaken well.

[0240] The PCR program was set up as followed:

94°C	3 minutes	
94°C	30 seconds	
53°C	1 minute 30 seconds	x 35 cycles
72°C	3 minutes	
72°C	5 minutes	
15°C	∞	

[0241] The quality, the quantity and the length of the PCR fragment was checked on an agarose gel. The length of the cloned fragment was the estimated length of the PCR fragment minus 300 base pairs that corresponded to the amplified flanking plasmid sequences.

[0242] 3.B. Plasmids rescue from yeast by electroporation Introduction

[0243] The previous protocol of PCR on yeast cell may not be successful, in such a case, plasmids from yeast by electroporation can be rescued. This experiment allows the recovery of prey plasmids from yeast cells by transformation of *E. coli* with a yeast cellular extract. The prey plasmid can then be amplified and the cloned fragment can be sequenced. Materials

# [0244] Plasmid rescue

Glass beads 425-600  $\mu m$  (Sigma)Phenol/chloroform (1/1) premixed with isoamyl alcohol (Amresco)

Extraction buffer: 2% Triton X100, 1% SDS, 100 mM NaCl, 10 mM TrisHCl pH 8.0, 1 mM EDTA pH 8.0.

Mix ethanol/NH $_4$ Ac : 6 volumes ethanol with 7.5 M NH $_4$  Acetate, 70% Ethanol and yeast cells in patches on plates.

Electroporation

SOC medium

M9 medium

Selective plates: M9-Leu+Ampicillin

2 mm electroporation cuvettes (Eurogentech)

Experiment

Plasmid rescue

[0245] The cell patch on DO-Leu-Trp-His was prepared with the cell culture of section 2.C. The cell of each patch was scraped into an Eppendorf tube, 300  $\mu$ l of glass beads was added in each tube, then, 200  $\mu$ l extraction buffer and 200  $\mu$ l phenol:chloroform:isoamyl alcohol (25:24:1) was added.

[0246] The tubes were centrifuged for 10 minutes at 15,000 rpm.

[0247] 180  $\mu$ l supernatant was transferred to a sterile Eppendorf tube and 500  $\mu$ l each of ethanol/NH<sub>4</sub>Ac was added and the tubes were vortexed. The tubes were centrifuged for 15 minutes at 15,000 rpm at 4°C. The pellet was washed with 200  $\mu$ l 70% ethanol and the ethanol was removed and the pellet was dried. The pellet was resuspended in 10  $\mu$ l water. Extracts were stored at -20°C.

Electroporation

Materials:

[0248] Electrocompetent MC1066 cells prepared according to standard protocols (Sambrook et al. *supra*).

1  $\mu l$  of yeast plasmid DNA-extract was added to a pre-chilled Eppendorf tube, and kept on ice.

1  $\mu$ l plasmid yeast DNA-extract sample was mixed and 20  $\mu$ l electrocompetent cells was added and transferred in a cold electroporation cuvette. Set the Biorad electroporator on 200 ohms resistance, 25  $\mu$ F capacity; 2.5 kV. Place the cuvette in the cuvette holder and electroporate.

1 ml of SOC was added into the cuvette and the cell-mix was transferred into a sterile Eppendorf tube. The cells were recovered for 30 minutes at 37°C, then spun down for

1 minute at 4,000 x g and the supernatant was poured off. About 100  $\mu$ l medium was kept and used to resuspend the cells and spread them on selective plates (e.g., M9-Leu plates). The plates were then incubated for 36 hours at 37°C.

[0249] One colony was grown and the plasmids were extracted. Check for the presence and size of the insert through enzymatic digestion and agarose gel electrophoresis. The insert was then sequenced.

Example 4: Protein-protein interaction

[0250] For each bait, the previous protocol leads to the identification of prey polynucleotide sequences. Using a suitable software program (e.g., Blastwun, available on the Internet site of the University of Washington : <a href="http://bioweb.pasteur.fr/seqanal/interfaces/blastwu.html">http://bioweb.pasteur.fr/seqanal/interfaces/blastwu.html</a>) the identity of the mRNA transcript that is encoded by the prey fragment may be determined and whether the fusion protein encoded is in the same open reading frame of translation as the predicted protein or not.

[0251] Alternatively, prey nucleotide sequences can be compared with one another and those which share identity over a significant region (60nt) can be grouped together to form a contiguous sequence (Contig) whose identity can be ascertained in the same manner as for individual prey fragments described above.

Example 5: Identification of SID®

[0252] By comparing and selecting the intersection of all isolated fragments that are included in the same polypeptide, one can define the Selected Interacting Domain (SID®) as illustrated in Figure 15. The SID® is illustrated in Table III .

Example 6: Identification of PIM®

[0253] The PIM® is then constructed using methods known in the art as exemplified in Figure 16.

Example 7: Making of polyclonal and monoclonal antibodies

[0254] The protein-protein complex of columns 1 and 3 of Table II was injected into mice and polyclonal and monoclonal antibodies were made following the procedure set forth in Sambrook et al. (*supra*).

[0255] More specifically, mice are immunized with an immunogen comprising Table II complexes conjugated to keyhole limpet hemocyanin using glutaraldehyde or EDC as is well known in the art. The complexes can also be stabilized by crosslinking as described in WO 00/37483. The immunogen is then mixed with an adjuvant. Each mouse receives four injections of 10 ug to 100 ug of immunogen, and after the fourth injection, blood samples are taken from the mice to determine if the serum contains antibodies to the immunogen. Serum titer is determined by ELISA or RIA. Mice with sera indicating the presence of antibody to the immunogen are selected for hybridoma production.

[0256] Spleens are removed from immune mice and single-cell suspension is prepared (Harlow et al 1988). Cell fusions are performed essentially as described by Kohler et al (1976). Briefly, P365.3 myeloma cells (ATTC Rockville, Md) or NS-1 myeloma cells are fused with spleen cells using polyethylene glycol as described by Harlow et al (1989). Cells are plated at a density of 2 x 10<sup>5</sup> cells/well in 96-well tissue culture plates. Individual wells are examined for growth and the supernatants of wells with growth are tested for the presence of the complex-specific antibodies by ELISA or RIA using one of the proteins set forth in Table II as a target protein. Cells in positive wells are expanded and subcloned to establish and confirm monoclonality.

[0257] Clones with the desired specificities are expanded and grown as ascites in mice or in a hollow fiber system to produce sufficient quantities of antibodies for characterization and assay development. Antibodies are tested for binding to one of the proteins in Table II, to determine which are specific for the Table II complexes as opposed to those that bind to the individual proteins. More specifically, antibodies are tested for binding to bait polypeptide of column 1 of Table II alone or to prey polypeptide of column 3 of Table II alone, to determine which are specific for the protein-protein complex of columns 1 and 3 of Table II as opposed to those that bind to the individual proteins.

[0258] Monoclonal antibodies against each of the complexes set forth in columns 1 and 3 of Table II are prepared in a similar manner by mixing specified proteins together, immunizing an animal, fusing spleen cells with myeloma cells and isolating clones which produce antibodies specific for he protein complex, but not for individual proteins.

Example 8: Modulating compounds/PIM screening

[0259] Each specific protein-protein complex of columns 1 and 3 of Table II may be used to screen for modulating compounds.

[0260] One appropriate construction for this modulating compound screening may be:

- bait polynucleotide inserted in pB6 or pB20;- prey polynucleotide inserted in pP6;
- transformation of these two vectors in a permeable yeast cell;
- growth of the transformed yeast cell on medium containing compound to be tested;
- and observation of the growth of the yeast cells.
- [0261] The following results obtained from these Examples, as well as the teachings in the specification are set forth in the Tables below.
- [0262] While the invention has been described in terms of the various preferred embodiments, the skilled artisan will appreciate that various modifications, substitutions, omissions and changes may be made without departing from the scope thereof. Accordingly, it is intended that the present invention be limited by the scope of the following claims, including equivalents thereof.

[0263] All patent and non-patent publications cited in this specification, including the websites set forth onpages 8, 13 and 33, are indicative of the level of skill of those skilled in the art to which this invention pertains. All these publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated herein by reference.

Nucleic Amin Position o- s acid acid ID No. [1-888] 8 No.					O. Villing and codact
acid No. No. 11-888] 8 No. No. 11-711] 9	3; Nucieic aciu sequerice	2	Vucleic Position	Amin o-	
8 8 8 9 9 9 1 1 1 1 1 1 1 1 1 1 1 1 1 1			"	acid ID No.	
9	ATGGTGTTAG	+	1-888]	8	MNLDGVRPYCRIVNKKNESIS
9 0 1 1 4 3 4 1 1 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SCACATATAATA	AAAAGGGTAAAAATTCATCATGTACTCACCCAAAAGCAGCAIIG			VFLGEKGFCDSNDVLSIMGQQ
AAAAGGCAAAACAGTAAATGATGATGATGACGATACTGAT GAAAGCGAAAACAGTAAACGATACTGAT GAAAGCGAAAACAGTAAACGATACTGAT TTCCAAGAATGAAACAGTAAACGATACGAT	GAGAGAAAGG	FTTTTGTGATAGCAATGATGTTTTAAAAATGAAAAAGTAAAAATGAAAAATTTTAAAAAA			<b>IPRVFKNKMLYDYVFKNEKSK</b>
AAAAAGCGAAAATAAAAACGTAAACGATACTGAT GCACGGTAGTCCTGGTTCTCAATTAGGCCTT TTTCAAGAATGACGTTCTCATCAATTGTG CTGATAAAGTGCCCTTTTTTAAGGAAAATTTTAACAATGC CTGATAAAGTGGCTCCTAAAAATTTTAACAATGC CTGTGCCTTTTTTTAAGGAAAAATATCGGCT GAGTCATTGAGTGATGGTCTAAAAATATCGGCT GAGTCATTGAGTGATGGTCTAAAAATATCGGCT AAAAAAAAAA	TTTAAGAACAAG	GGCTACCACAGAGTGAACCAATAGTAATAAATAATGATGATGAC			NDFLKMAESWLPQSEPIVINN
GCACGGTAGTCCIGGILCICALCAAITAGACCII TITCAAGAATGAAAGACTGTGGTATTCTAAATGTG CTGATAAAGTGAAAGAATTTTAACAATGC CTGATAAAGGGAAAAAGAATTTTACCGGCT CTCTGCCTTTTTTTAAGGAAAAAGAATCTTGCT GAGTCATTGAGTGATGGTCTAAAAATTTCGTTCAACTTCAA GACTCATCACACACAAAAAGAATTTATTAATAAAGGCAGC GGATATAGCACAAAAAATACGGTTAATAGGCAGC GGATATAGGAGAATTTGTTTTCTTTCAT GTAAATACGGGGAATTTTATTAATAAGGCAAAT TAATAAGGAGTTATAAAATTTGTTTTGT	GCTGCTGCTTAT				DDDALNAAATESVARANINI V NDTDEKEYNKVYILGHGSPGS
[1-7-1] 9 11-1434] 10	TATAATAAGGTTT				HOLGLGSELIDVQTIISRMKDC
7	CTTATTGATGTA	CAAACAAICAIIICAAGAAIGAAAGAGACIGIGGCTTTTAACAATGC			GILNVKDIRFTSCGSADKVAPK
[1-7-1] 9 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	CGTIIIACIICAI	GCGGCTCTTTTTTTAAGGAAAAAATCTTTTGCT			NFNNAPAESLSCILNSLPFFKE
[1-711] 9 [1-714] 9 [1-1434] 10 [1-1434] 1	TANA A A A CA	GAAAACGATGAGTCATTGAGTGATGGTCTAAAAATATCCGGCT		_	KESLLEQIKKHLENDESLSDG
[1-711] 9 N N [1-1434] 10 H	ATGGAGTTCACT	ATGGTCAAGAGCTTTTTCCCTACTCACATTATCGTTCAACTTCAA			KISGYHGYGVHYGQELFFIS VDSTSIPANDEHTVKBSSOK
[1-711] 9 N	ATCCGGAGCATA	CAGTAAAAAGAAGCTCTCAGAAAAAAGACTTTTATTATTATAAAAA		_	TEIINKELD*YKIFNL*
[1-1434] 10	AGTATAAAATTTT	-	[4-711]	σ	MSINNYGLHPANNKNMHLIIGS
A [1-1434] 10	AATAACTATGGAT		- - -	>	NTANENKGMKNNIINVTNTAIS
A [1-1434] 10	AATGAAAATAAAG	GAAI GAAAAA AATATAGTGTGTTTCTTTCAGAAAATTGGCCA			HAINEEKSGGGYSGVSFRKLA
A [1-1434] 10	SANGAAGAAAA	CAGAGAAGAATAAAGGAGTATAACCGCCATAATTTGTTTTCAT			KIQNISIPTKNNKEYNRHNLFS
[1-1434] 10	ATGGAAATGCCC	ATGCAGCGCGTAAATACAGTGAATCGCTGTTGGCAGCCGAAAT			LIWHGNADAAKKYSESLLAA BIYTTIY EVI AABNNAGESAI
[1-1434] 10	AGGAAAAACTAG/	AAGTTCTTGCAGCACGAAATAATGCTGGGGAATCTGCTTTGTTCA			AL DEGHSAAIQAYGDFIKTFDL
A [1-1434] 10	AAGAAGGTCATT	CCGCTGCGATTCAAGCTTATGGAGAIIIIAIIAAAACIIIIGAII			SPKETIKLLDVRDNEGLPGLFL
A A	AAGAAACGATTA	AACTATIGGAIGIAAGAGAIAATGAGAGAITAOAAGAGAGATATAAATATGCCATCATAGTG			AAGKGNIEAMMAYINICHHSGI
AACAGA [1-1434] 10   1 AGATGA ACAGAG ACCATCA ATCTGA	AGGGAAAGGGA	A L A L CARGO LA LA RATA CARACA GACATOTT TATATATATATA			KLTEIADRLNNNEQDMFNIISD
AACAGA [1-1434] 10 AGATGA ACAGAG ACCATCA ATCTGA	CI I ACAGAAA I AG	TTTAAAGTGCTAAATAGCTGCAAAGAATTGCACTTAG			KIQELF*VC*IAAKNCI*
	TCACAGAGACTO	A A CT CAGCAATACCCAATGCAATATAGATTCTATGGATAACAGA			MNISETLNSANTQCNIDSMDN
4	TTGTTTCCAAAA	STGACATCAGTGCGAAACGCTGCACAACAAACTATGCCAGATGA		_	DEKNLKDSANIIKDFFRKTIAA
	AAAAGATAGTGC	;AAATATTATTAAAGAIIICIIIAGGAAAACIAIAGCAATGCAAT			OSYSRMFSQGSNFKSLNIAID
	AATGTTCTCIC	AAGGCICIAACIIIAAAIGIIIAAAIGIIAAAAAAGATTATCGAAGCATTATATATCTGA			APSDAKASFKAIEHLDRLSKHY
	GACGCI AAAGCCI CAI II AAGGCI AI I GAC AATAAGGGAAAAACTTCATCCTCTTTTTGC/	GACGCI AAAGCCI CAIII AAGGCIAII CAGCAGGGGGGGGGG			ISEIREKLHPLSAEELNLLSLIIN SDLIFRHQSNSDLSDKILNIKSF

		AATAAAATTCAGTCTGAAGGAATATGCACAAAACGAAACACATACGCTGATGATATAAAAAAAA	<u> </u>	NKIOSEGIC I KKN I YADDIKKIA NHDFVFFGVEISNHOKKHPLN	
		GCTAATCATGACIIIGIGIIIIIIGGCGIIGAAATGCGTATATCATTGATCATGAGACTCTCCATATGGA ACAAAACATCACACTGTTGATTTTGGTGCGTATATCATTATTAAATGAATG	<u> </u>	TKHHTVDFGANAYIIDHDSPY GYMTLTDHFDNAIPPVFYHEH	
		TATATGACATTAACCGATCACTTTGATAATGCIAIICCACCIGIIIIIACCAIGAGCACCACCACACATTTTCAGAGGATTAAATAAAGAAGTTAGTCGATACGTACATGGAAGTAAAGGAATT		OSFLDKFSEVNKEVSRYVHGS	
		ATAGATGTACCAATATTCAATACTAAAGATATGAAGTTAGGGCTCGGATTATACCTGATTGACTTT	X []	KGIIDVPIFN I KDIVIKLGLGL YLI DFIRKSEDQSFKEFCYGKNLA	
		ATTAGAAAAAGTGAAGGCCAAAGCTTCAAGGAGIIIIGCIAIGGAAAAAAIOIIGCCCCIGIGCA	1 [1]	PVDLDRIINFVFQPEYHIPRMV	
		TCTGGATAGAATCATAAACIIIIGIIIIICAGCCAGAGIACCATAIACAGAGGCTGTTACAGCATCTAATTACG	(0)	STENFKKVKIREISLEEAVTAS	
-		AAAACTICAAAAAAGIIAAGAIIAAGAAAAAAAAAATIGCTCTCCAGGCTCTTTTTTTTTGGTTACTA		NYEEINKQVTNKKIALQALFLSI	
		AAGAAAAGAGGATGTCGCCTTATATATATTATCTAATTTTGAGATAACTAGACAAGATGTTATTTC		TNQKEDVALYILSNFELLKQDVI SIKHELVDIEVLLSAHNSSCKV	
				LEYFINKGLVDVNTKFKKTNSG	
		TGAGTATTTTATCAATAAGGGATTGGTTGATGTAACACAAAGTTAAAAAACTATTATTGAAATATGG		<b>DCMLDNAIKYENAEMIKLLLKY</b>	
		TTGTATGTTGGATAACGCAAIAAAAIAIGAGAAIGCAGAAATIGATATGATAT		GATSDNKYI*SKLNIV*	
9		IGCAACA  CIGACAA AAA AAA AAAA AAAAAAAAAAAAAAAAAA	F	MNITTLTNSISTSSFSPNNTNG	_
Snigelia	4	TCATCAACCGAAACAGTTAATTCTGATATAAAAACAACGACCAGTTCTCATCCTGTAAGTTCCCTT	,, <sub>[</sub>	SSIELVNSDIKI I ISSUFVSSE TMI NDTI HNIBTTNOA! KKELS	
		ACTATECTCAACGACACCCTTCATAATATCAGAACAACAAATCAGGCATTAAAGAAAG		OKTLTKTSLEEIALHSSQISMD	
		ACAAAAAACGTTGACTAAAAACATCGCTAGAAGAAAIAGCAIIACAIICAICICAGAIIAGCAIIAGAAAAAGACG	_	VNKSAQLLDILSRNEYPINKDA	
		ATGTAAATAAATCCGCTCAACTALIGGATALIOCAGGAAACGAATGAATGAATGAATGAATGATGTCAAT		RELLHSAPKEAELDGDQMISH	
		CAAGAGAGATIALIACAIIOAGCCCCAACACACACACATGATATTAATGAACAGTATATAT	<u>-</u> -	RELWAKIANSINDINEGYLKVY	
		AGAGATGCGTTAGTTCATATACTCAAATGTATCAAGATTTTAGCGCTGTTCTTTCCAGTCTTGCC		EHAVSSYTQMYQDFSAVLSSL ACWISDGGNDGNSVKI OVNS	
		GGCTGGATCTCTCCCGGAGGTAACGACGGAAACTCCGTGAAATTACAAGTCAACTCGCTIAAAA	<u> </u>	AGWIST GGINDGING TILL GOTTE	
		AGGCATTGGAAGAACTCAAGGAAAAATATAAAGATAAACCGCIAIAICCAGCAAAIAAIAGIII		NTVSQEQANKWLTELGGTIGK	Y
		AGTCAGGAACAAGCAAATAAATGGCIIACAGAAIIAGGIGGAAAAAIGGGAAAAAAAAAA		VSQKNGGYVVSINMTPIDNML	
		AAACGGGGGATATGTGTTGTGTTGTAAATATGCAAAATATCAGGCATGGAATGCCGGATT		KSLDNLGGNGEVVLDNAKYQ	
		CTCTGCCGAAGATGAAAAATGATCTTCAAACTTTAGTTCAAAAATACAGTAATGCCAA		AWNAGFSAEDE I MKNNLQ I L VOKYSNANSIFDNI VKVLSSTI	
		TAGTATTTTTGATAATTTAGTAAAGGTTTTGAGTAGTACAATAAGCICAIGIACAGAIACAGAIAA		SSCTDTDKLFLHF*GA	
	L	ACTITITICTCCALLICIGAGGIGCG	12	MLOKOFCNKLLLDTNKENVME	Ш (
Shigella	ဂ	AIGIIGCAAAACCAAACCAAGCCAGACTTTATATACAGATATATCCACAAAACAAAC		IONTKPTOTLY I DISTRUTUSS	Λ.
pac		GAAACACAAAAATCACAAAAATTATCAGCAGATTGCAGCGCATATTCCACTTAATGTCGGTAAAAAT		SELOKSON (QQIAALIILENVO KNDVI TTTI NDDOLI KLSEQV	
		CCCGTATTAACAACCACATTAAATGATCAACTTTTAAAGTIAICAGAGGGGGGIICAGGAGAAGAAGAAGAAAAAAAAAA		QHDSEIIARLTDKKMKDLSEM	
		TCAGAAATCATTGCTCGCCTTACTGACAAAAGATGATGATGCTGTTTCTTTAGTGTA TACTCCAGAGAACACTCTGGATATTTCCAGTGTA		SHTLTPENTLDISSLSSNAVSLI	
		GOCGTTCTACTTTCTGCTCTCCGCACTGCAGAAACTAAATTGGGCTCTCAATTGTCATTGATTG		LIAFDATKSAAENIVROGLAAL	
		GTTCGATGCTACAAAAICAGCIGCAGAAAAAIIGIIIQAAAAAAAAIIGAAAAAAAAAA			

		TO THE SECOND SE		SSSITGAVTOVGITGIGAKKTH	Γ
		AGCALLACIGGAGCAGLCACACAGLAGGLAGGLACGCTTGCCACTGCCACTGCTCAATCTCTTGAAAAAGA		SGISDQKGALRKNLATAQSLE	
		GCTTGCAGGTTCTAAATTAGGGTTAAATAAACAAATAGATACAAATATACAAATATCACCTCACCACAAACTAA		KELAGSKLGLNKQIDTNITSPQ	_
		CTCTAGGAAAATTTTTAGGTAAAAATAAACTGGCGCCAGATAATATATAT		TNSSTKFLGKNKLAPDNISLST	_
		TAAAACTTCTCTTAGTTCTCCCGATATTTCTTTGCAGGATAAAATTGACACCCAGAGAAGTTA		EHKTSLSSPDISLQDKIDTQRR	~
		CGAGCTCAATACCCTTTCTGCGCAGCAAAACATTGGCCGTGCAACATGGAAACATCA		TYELNTLSAQQKQNIGRATME	
		GCCGTTGCTGGTAATATATCCACATCAGGAGGGCGTTATGCATCTGCTTGAAGAAGAAGAACA		TSAVAGNISTSGGRYASALEE	
		AACTAATCAGGCCAGCAGTAAACAAGCAGGGAAGCATCCCAAGTATCTAAAGAAGCATC		<b>EEQLISQASSKQAEEASQVSK</b>	
		CCAAGCGACAAATCAATTAATACAAAAATTATTGAATAATTGACAGCATCAACCAATCAAAGAA		EASQATNQLIQKLLNIIDSINQS	"
				KNSAASQIAGNIRA*	1
Shinella	Œ	CCCAAAATTCTTTTATAACACTATTTCCGGTACAT [1-1022]	13	MLPINNNFSLPQNSFYNTISGT	
ina Ho a	>	AT CONTRACT TITL CAGGAT A A A TIGG GA A A A A GO GA GO GO CO CO CO GO		YADYFSAWDKWEKQALPGEE	111
25.5		TGAGGCTGTCTCCCGACTTAAAGAATGTCTTATCAATAATTCCGATGAACTTCGACTGGACCGTT		RDEAVSRLKECLINNSDELRL	
		TABATCTGTCCTCGCTGCCTGACACTTACCAGCTCAGATAACGCTGCTCAATGTATCATATAATC		DRLNLSSLPDNLPAQITLLNVS	
		AATTAACTAACCTACCTGAACTGCCTGTTACGCTAAAAAATTATTCCGCCAGCAATAATTAT		YNQLTNLPELPVTLKKLYSASN	
		CAGAATTGCCCGTGCTACCTCCTGCGCTGGAGTCACTTCAGGTACAACACACAATGAGCTGGAAAA		KLSELPVLPPALESLQVQHNE	
		CCTGCCAGCTTTACCCGATTCGTTATTGACTATGAATATCAGCTATAACGAAATAGTCTCCTTACC		LENLPALPDSLLTMNISYNEIV	
		ATCRETECTA A GENERAL TO THE A SA TOTO A GOOD A TOTO A TOTO A CONTRACT A SA A TOTO A CONTRACT A		SLPSLPQALKNLRATRNFLTEL	
		TTTTTGAGGGAAATAATCCCGTTGTCAGAGAGTATTTTTTTT		PAFSEGNNPVVREYFFDRNQI	_
		CEGAAAGCATTCTTAATCTGAGGAATGATGTTCAATACATATAGTGATAGCATATAGTCATCTCCC		SHIPESILNLRNECSIHISDNPL	
		ATGCTCTGCAAGCCCTGCAAAGATTAACCTCTTCGCCGGACTACCACGGCCCACGGATTTACTT		SSHALQALQRLTSSPDYHGPR	Υ_
				IYFSMSDGQQNTLHRPLADAV	_
		GTTCCCGGAAACAAACAATCTGATGTATCACAGATATGGCATGCTTTTGAACATGAAGAGCATG		TAWFPENKQSDVSQIWHAFE	
	_	CCAACACACTTTCCGCGTTCCTTGACCGCCTTTCCGATACCGTCTCTGCACGCAATACCTCCGG		HEEHANTFSAFLDRLSDTVSA	
		ATTOCATE A CAGA CAGA CAGA CAGA CAGA A A A A A A		RNTSGFREQVAAWLEKLSAS	
		ATTOCCIONATECTO TO T		<b>AELRQQSFAVAADATESCEDR</b>	œ
Shinella	7	ATGABABATAACATCTACCATTATTCAAACACCTTTTCCATTTGAGAATAATAATTCTCATGCTGGCA [1-612]	14	MKITSTIIQTPFPFENNNSHAGI	<del></del>
SnG		TAGTAACGGAGCCCATTCTCGGTAAGTTAATAGGTCAGGGGTCGACAGCAGAAATCTTTGAAGA		VTEPILGKLIGGGSTAEIFEDV	
5		TGTGATTGATTCATCTGCTTTGTATAAAAGTATGATCTTATTGGCAACCAGTACAATGAGTTCT		NDSSALYKKYDLIGNQYNEILE	111
		GGAAATGGCTTGGCAAGAATCTGAGCTTTTTAATGCTTTTTATGGCGATGAAGCATCCGTTGTTA		MAWQESELFNAFYGDEASVVI	=
				QYGGDVYLRMLRVPGTPLSDI	_
		TGATACAGCTGATATCCCTGATATATAGAGAGCCTTTATCTACAGTTGATATGTAAATTGAATGA		DTADIPDNIESLYLQLICKLNEL	,
		GTTGAGTATAATCCATTACGATCTTAATACAGGTAATATGCTGTATGATAAAGAAAG		SIIHYDLNTGNMLYDKESESLF	11
		ATTCCCAATAGATTTTCGCAATATTTATGCTGAATATTACGCTGCAACCAAAAAAAGATAAAAGATA		PIDFRNIYAEYYAATKKDKEIIU	
		TATCGACCGACGATTACAAATGCGTACAAATGATTTTTTATTCGTTATTAAACAGGAAATATTTATA		KALOMKI NDFYSLENKKYL" I	
		GACGTATTTGTTGATGCTATAA		Y L L IVIL "	
	:				

Table II : Bait-prey interactions

1: Bait name 2: Bait nuc

2: Bait nucleic 3: Prey name

ospB         accepted of the propertion of the properties of the prope	
ospB         1         prey67804 (1)           ospB         1         prey67806           ospB         1         prey67810 (1)           ospB         1         prey67810 (1)           ospB         1         prey67661 (1)           ospB         1         prey67675 (2)           ospB         1         prey67575 (2)           ospB         1         prey6763 (1)           ospB         1         prey6783 (1)           ospB         1         prey6784 (1)           ospB         1         prey6785 (1)           ospD1         2         prey6765 (1)           ospD1         2         prey6765 (1)           ospD1         2         prey6765 (1)           ospD1         2         prey6765 (2)           ospD1         2         prey6765 (1)           ospD1         2         prey6765 (1)           ospD1         2         prey6765 (1)           ospD1         2         prey6767 (1)           ospD1         2         prey6767 (1)           ospD1         2         prey6768 (1)           ospD1         2         prey6768 (1)           ospD1         2	EDC91851) hhypothetical proteinXP_041083  FBXO3 FBX3 DKFZp564B092 FBA) hFBXO3  ONO NRB54 NMT55 P54NRB) hNONO  CAPN2 CANPL2 CANPML) hCAPN2  LMO4; prey34731) hLMO4  ZIN; prey33142) hZIN  (LOC136773) hsimilar to 3-HYDROXYISOBUTYRATE DEHYDROGENASE, NR (HIBADH) (H.sapiens)  MGC4126) hMGC4126  LOC90706) hhypothetical proteinXP_033663  LMO2 RBTNL1 RHOM2 TTG2 RBTN2; prey12714) hLMO2 hTTG-2a/RBTN-2a  WYO9A) hMYO9A
ospB         1         prey67806           ospB         1         prey5237 (N           ospB         1         prey5737 (N           ospB         1         prey67810 (N           ospB         1         prey67873 (N           ospB         1         prey67637 (N           ospD1         2         prey67651 prey67651 prey67653 (N           ospD1         2         prey67657 prey67651 prey67657 (N           ospD1         2         prey67657 prey67657 (N           ospD1         2         prey67657 prey67657 (N           ospD1         2         prey67657 (N           ospD1         2         prey67657 (N           ospD1         2         prey67658 (N           ospD1         2         prey67658 (N           ospD1         2         prey67667 (N           ospD1         2         prey67667 (N	FBXO3 FBX3 DKFZp564B092 FBA) hFBXO3 ONO NRB54 NMT55 P54NRB) hNONO CAPN2 CANPL2 CANPML) hCAPN2 LMO4; prey34731) hLMO4 ZIN; prey33142) hZIN (LOC136773) hsimilar to 3-HYDROXYISOBUTYRATE DEHYDROGENASE, NR (HIBADH) (H.sapiens) MGC4126) hMGC4126 -OC90706) hhypothetical proteinXP_033663 LMO2 RBTNL1 RHOM2 TTG2 RBTN2; prey12714) hLMO2 hTTG-2a/RBTN-2a WYO9A) hMYO9A
ospB         1         prey67810 ()           ospB         1         prey5237 (N)           ospB         1         prey67661 (           ospB         1         prey67575           ospB         1         prey67575           ospB         1         prey67637 (           ospB         1         prey67836 (           ospD1         2         prey67853 (           ospD1         2         prey67651 prey	FBXO3 FBX3 DKFZp564B092 FBA) hFBXO3 ONO NRB54 NMT55 P54NRB) hNONO CAPN2 CANPL2 CANPML) hCAPN2 LMO4; prey34731) hLMO4 ZIN; prey33142) hZIN (LOC136773) hsimilar to 3-HYDROXYISOBUTYRATE DEHYDROGENASE, OR (HIBADH) (H.sapiens) MGC4126) hMGC4126 LOC90706) hhypothetical proteinXP_033663 LMO2 RBTNL1 RHOM2 TTG2 RBTN2; prey12714) hLMO2 hTTG-2a/RBTN-2a WYO9A) hMYO9A
ospB         1         prey5237 (N           ospB         1         prey34730 (           ospB         1         prey34730 (           ospB         1         prey67575           ospB         1         prey67637 (           ospB         1         prey67637 (           ospB         1         prey67836 (           ospB         1         prey67836 (           ospB         1         prey67844           ospB         1         prey67843 (F)           ospB         1         prey67853 (F)           ospD1         2         prey67853 p           ospD1         2         prey67651 p           ospD1         2         prey67657 p           ospD1         2         prey67650 p           ospD1         2         prey67650 p<	ONO NRB54 NMT55 P54NRB) hNONO CAPN2 CANPL2 CANPML) hCAPN2 LMO4; prey34731) hLMO4 ZIN; prey33142) hZIN (LOC136773) hsimilar to 3-HYDROXYISOBUTYRATE DEHYDROGENASE, OR (HIBADH) (H.sapiens) NGC4126) hMGC4126 LOC90706) hhypothetical proteinXP_033663 LMO2 RBTNL1 RHOM2 TTG2 RBTN2; prey12714) hLMO2 hTTG-2a/RBTN-2a WYO9A) hMYO9A
ospB         1         prey67661 (           ospB         1         prey34730 (           ospB         1         prey33141 (           ospB         1         prey67575           ospB         1         prey67637 (           ospB         1         prey67836 (           ospB         1         prey67844           ospB         1         prey67847           ospD1         2         prey67651 p           ospD1         2         prey67651 p           ospD1         2         prey67657 (           ospD1         2         prey67657 (           ospD1         2         prey67657 (           ospD1         2         prey6767 ( <t< th=""><td>YDROGENASE, RBTN-2a</td></t<>	YDROGENASE, RBTN-2a
ospB         1         prev34730 (           ospB         1         prey67575           ospB         1         prey67637 (           ospB         1         prey67637 (           ospB         1         prey67637 (           ospB         1         prey67836 (           ospB         1         prey67836 (           ospB         1         prey67836 (           ospB         1         prey67844           ospB         1         prey67836 (           ospB         1         prey67845 (           ospD1         2         prey67851 prey67851 prey67857 (           ospD1         2         prey67857 prey67857 (           ospD1         2         prey67858 (           ospD1         2         prey67858 (           ospD1         2         prey6783160 (           ospD1         2         prey6783160 (           ospD1         2         prey6783160 (           ospD1 <td< th=""><th>YDROGENASE,</th></td<>	YDROGENASE,
ospB         1         prey33141 (           ospB         1         prey67575           ospB         1         prey67608 (           ospB         1         prey67637 (           ospB         1         prey67837 (           ospB         1         prey67836 (           ospB         1         prey67836 (           ospB         1         prey6784 (           ospB         1         prey6785 (           ospD1         2         prey6765 (           ospD1         2         prey6767 (           ospD1         2         prey6767 (           ospD1         2         prey6767 (           ospD1         2         prey6767 (           ospD1         2         prey6768 (           ospD1         2         prey67620 (           ospD1         2         prey67620 (           ospD1         2         prey67620 ( <th>YDROGENASE,</th>	YDROGENASE,
ospB         1         prey67575           ospB         1         prey67637 (           ospB         1         prey67637 (           ospB         1         prey67836 (           ospB         1         prey67836 (           ospB         1         prey67836 (           ospB         1         prey6784 (           ospB         1         prey6785 (           ospD1         2         prey6765 prey6765 (           ospD1         2         prey6765 prey6765 (           ospD1         2         prey6767 (           ospD1         2         prey6767 (           ospD1         2         prey6767 (           ospD1         2         prey6767 (           ospD1         2         prey6762 (           ospD1         2         prey6762 (           ospD1         2         prey6762 (           ospD1         2         prey6762	YDROGENASE,
ospB         1         prey67608 (1)           ospB         1         prey67637 (2)           ospB         1         prey67637 (3)           ospB         1         prey67836 (1)           ospB         1         prey67844           ospB         1         prey67863           ospB         1         prey67863           ospD1         2         prey67651 prey67651 prey67651 prey67651 prey67651 prey67651 prey67651 prey67657 (1)           ospD1         2         prey67657 prey67657 (1)           ospD1         2         prey67657 (1)           ospD1         2         prey67578 (1)           ospD1         2         prey67578 (1)           ospD1         2         prey6758 (1)           ospD1         2         prey6758 (1)           ospD1         2         prey6758 (1)           ospD1         2         prey67623 (1)	prey67608 (MGC4126) hMGC4126 prey67607 (LOC90706) hMpothetical proteinXP_033663 prey12713 (LMO2 RBTNL1 RHOM2 TTG2 RBTN2; prey12714) hLMO2 hTTG-2a/RBTN-2a prey67836 (MYO9A) hMYO9A
ospB         1         prey67637 (1)           ospB         1         prey12713 (1)           ospB         1         prey67836 (1)           ospB         1         prey67844           ospB         1         prey67843 (1)           ospB         1         prey67843 (1)           ospB         1         prey66272 (1)           ospD1         2         prey67651 prey67651 prey67651 prey67651 prey67657 (1)           ospD1         2         prey67657 (1)	prey67637 (LOC90706) hhypothetical proteinXP_033663 prey12713 (LMO2 RBTNL1 RHOM2 TTG2 RBTN2; prey12714) hLMO2 hTTG-2a/RBTN-2a prey67836 (MYO9A) hMYO9A
ospB         1         preyf713 (PAPG7836 (PAPG7830 (PAPG7836 (PAPG78 (PA	prey12713 (LMO2 RBTNL1 RHOM2 TTG2 RBTN2; prey12714) hLMO2 hTTG-2a/RBTN-2a prey67836 (MYO9A) hMYO9A
ospB         1         prey67836 (RA           ospB         1         prey67844           ospB         1         prey67853           ospB         1         prey67853           ospD1         2         prey67851 prey67851 prey67651 prey67657 (cospD1         2         prey67657 prey67657 prey67657 prey67667 (cospD1           ospD1         2         prey67657 prey67667 (cospD1         2         prey67657 (cospD1           ospD1         2         prey67578 (cospD1         2         prey67650 (cospD1           ospD1         2         prey67667 (cospD1         2           ospD1         2         prey67623 (cospD1         2	prey67836 (MYO9A) hMYO9A
ospB         1         preyf700 (RA           ospB         1         preyf7844           ospB         1         preyf7844           ospB         1         preyf7853           ospD1         2         preyf06272 (F           ospD1         2         preyf0551 p           ospD1         2         preyf0551 p           ospD1         2         preyf0557 h           ospD1         2         preyf0557 h           ospD1         2         preyf07657 h           ospD1         2         preyf0767 (I           ospD1         2         preyf0767 (I           ospD1         2         preyf0767 (I           ospD1         2         preyf0762 (I	
ospB         1         prey67844           ospB         1         prey67853           ospD1         2         prey700 (RA ospD1           ospD1         2         prey700 (RA ospD1           ospD1         2         prey67651 prey67653 prey67651 prey67652 prey6	prey700 (RANBP9 RANBPM RANBP9-PENDING; prey701) hRANBP9 hRanBPM
ospB         1         prey67853           ospB         1         prey66272 (F           ospD1         2         prey700 (RA           ospD1         2         prey67651 p           ospD1         2         prey67651 p           ospD1         2         prey67657 h           ospD1         2         prey67657 h           ospD1         2         prey67657 h           ospD1         2         prey67504 (I           ospD1         2         prey67578 (I           ospD1         2         prey67580 (I           ospD1         2         prey67580 (I           ospD1         2         prey67580 (I           ospD1         2         prey67623 (I           ospD1         2         prey67623 (I           ospD1         2         prey67623 (I           ospD1         2         prey67623 (I	prey67844
ospB         1         prey66272 (F           ospD1         2         prey700 (RA           ospD1         2         prey67651 p           ospD1         2         prey67653 p           ospD1         2         prey67657 p           ospD1         2         prey67657 p           ospD1         2         prey67657 p           ospD1         2         prey67501 (l           ospD1         2         prey67501 (l           ospD1         2         prey67578 (l           ospD1         2         prey67580 (l           ospD1         2         prey67580 (l           ospD1         2         prey67580 (l           ospD1         2         prey675623 (l           ospD1         2         prey67623 (l           ospD1         2         prey67623 (l           ospD1         2         prey67623 (l	prey67853
ospD1         2         prey700 (RA ospD1           ospD1         2         prey67651 prey67651 prey67651 prey67651 prey67653 prey67653 prey67657 prey67667 (Ray ospD1           ospD1         2         prey67657 prey67667 (Ray ospD1           ospD1         2         prey67657 prey67501 (Lay ospD1           ospD1         2         prey67678 (Lay ospD1           ospD1         2         prey67678 (Lay ospD1           ospD1         2         prey67650 (Kay ospD1           ospD1         2         prey67657 (Ray ospD1           ospD1         2         prey67623 (Lay ospD1           ospD1         2         prey67623 (Lay ospD1           ospD1         2         prey67623 (Lay ospD1	prey66272 (FLJ20254) hFLJ20254
ospD1         2         prey2492 (FI           ospD1         2         prey67651 p           ospD1         2         prey67653 p           ospD1         2         prey67657 (I           ospD1         2         prey67657 (I           ospD1         2         prey67657 (I           ospD1         2         prey67678 (I           ospD1         2         prey67678 (I           ospD1         2         prey6768 (I           ospD1         2         prey6767 (I           ospD1         2         prey67627 (I           ospD1         2         prey67623 (I           ospD1         2         prey67623 (I           ospD1         2         prey67623 (I	prey700 (RANBP9 RANBPM RANBP9-PENDING; prey701) hRANBP9 hRanBPM
ospD1         2         prey67651 p           ospD1         2         prey67653 p           ospD1         2         prey67667 (f           ospD1         2         prey67657 h           ospD1         2         prey67501 (f           ospD1         2         prey67578 (f           ospD1         2         prey67578 (f           ospD1         2         prey6758 (f           ospD1         2         prey67427 (f           ospD1         2         prey67427 (f           ospD1         2         prey67623 (f           ospD1         2         prey67623 (f           ospD1         2         prey67623 (f	prey2492 (FLJ11026; prey2493) hFLJ11026
ospD1         2         prey67653 p           ospD1         2         prey67667 (f           ospD1         2         prey67557 h           ospD1         2         prey67501 (f           ospD1         2         prey67578 (f           ospD1         2         prey67578 (f           ospD1         2         prey6758 (f           ospD1         2         prey50427 (f           ospD1         2         prey67623 (f           ospD1         2         prey67623 (f           ospD1         2         prey67623 (f           ospD1         2         prey67623 (f	prey67651 putative homolog of prey064241 - Mouse
ospD1         2         prey67667 (f           ospD1         2         prey67657 h           ospD1         2         prey67501 (l           ospD1         2         prey67578 (l           ospD1         2         prey67578 (l           ospD1         2         prey6758 (l           ospD1         2         prey50427 (l           ospD1         2         prey67627 (l           ospD1         2         prey67623 (l           ospD1         2         prey67623 (l           ospD1         2         prey67623 (l	prey67653 putative homolog of prey067652 -
ospD1         2         prey67657 h           ospD1         2         prey67501 (l           ospD1         2         prey67578 (l           ospD1         2         prey67578 (l           ospD1         2         prey67580 (l           ospD1         2         prey67620 (l           ospD1         2         prey60427 (l           ospD1         2         prey67623 (l           ospD1         2         prey67623 (l           ospD1         2         prey67623 (l	prey67667 (PACSIN2) hPACSIN2
ospD1         2         prey67501 (I           ospD1         2         prey67578 (I           ospD1         2         prey67578 (I           ospD1         2         prey67580 (I           ospD1         2         prey67580 (I           ospD1         2         prey50427 (I           ospD1         2         prey67623 (I           ospD1         2         prey67623 (I	prey67657 hUnknown (protein forMGC:16824)
ospD1         2         prey67678 (I           ospD1         2         prey67578 (I           ospD1         2         prey67580 (I           ospD1         2         prey3160 (KI           ospD1         2         prey50427 (I           ospD1         2         prey67623 (I           ospD1         2         prey67623 (I           ospD1         2         prey67623 (I	prey67501 (LOC51667) hLOC51667
ospD1         2         prey67578 (I           ospD1         2         prey67580 (I           ospD1         2         prey3160 (KI           ospD1         2         prey60427 (I           ospD1         2         prey67623 (I           ospD1         2         prey67623 (I	prey67678 (LOC90410) hhypothetical proteinXP_031534
ospD1         2         prey67580 (I           ospD1         2         prey3160 (KI           ospD1         2         prey50427 (I           ospD1         2         prey63765 (I           ospD1         2         prey67623 (I	
ospD1         2         prev3160 (Kl)           ospD1         2         prev50427 (l)           ospD1         2         prev63765 (l)           ospD1         2         prev67623 (l)           ospD1         2         prev67623 (l)	prey67580 (DKFZp586l021) hDKFZp586l021
ospD1         2         prey50427 (l           ospD1         2         prey63765 (l           ospD1         2         prey67623 (l           ospD1         2         prey67623 (l	prey3160 (KIF5B UKHC KNS KNS1 U-KHC KINH; prey3161) hKIF5B hkinesin heavychain
ospD1         2         prey63765 (loss)           ospD1         2         prey67623 (loss)	prey50427 (KIAA0419; prey50428) hKIAA0419
ospD1 2 prey67623 (l	prey63765 (LIM; prey63767) hLIM
1) 3 Portional 1	prey67623 (LDB2 CLIM1) hLDB2
n) crc/faid	
ospD1 2 prey67601 (v	prey67601 (ATIP1 KIAA1288 DKFZp586D1519 FLJ14295) hATIP1
ospD1 2 prey53735 (7	prey53735 (TLN1 TLN KIAA1027) hTLN1
Shigella ospD1 2 prey67630	prey67630

prev12665 (CREBL1 CREB-RP G13; prey12666) hCREBL1 hG13	prey67631 (FLJ21742) hFLJ21742	prey20143 (SYNCOILIN; prey20144) hSYNCOILIN		prey67642 (ALDH3B2 ALDH3B2-PENDING ALDH8) hALDH3B2	prey67648 (PON2) hPON2	prey67266	prey67267	prey50590 (TID1; prey48229) hTID1	prey9822	prey67268			prey700 (RANBP9 RANBPM RANBP9-PENDING; prey701) hRANBP9 hRanBPM	prey3486 (PM5; prey3487) hPM5 hpM5	prey14801 (KIAA0321) hKIAA0321	prey67279	prey67280	prey49194 (KIAA0211; prey49195) hKIAA0211		prey19931 (HEF1 CAS-L) hHEF1	prey67290	prey67291	prey67294	prey67296		prey4637 (TAF2A BA2R CCG1 CCGS NSCL2 TAFII250; prey4638; prey4639) h1AF2A	prey67316	prey67318	IMMT P8	prey67328 (TSC22) hTSC22	prey37430 (WASL N-WASP; prey37432) hWASL hN-WASP	prey67351	prey67353		prey4411 (ZNF147 EFP TRIM25 Z147) hZNF147	prey2686 (VRP AD3; prey2687) hVRP
0	2	2	2	2	2	က	က	8	3	3	က	3	8	က	က	3	3	က	3	က	3	3	က	3	က	က	က	3	က	3	က	3	က	3	3	3
Shidella osnD1	1	1		1	1			1	1	l	1			ļ	1	ŀ		1			1		1	1	1	i				1	1	1	1	i	1	1

osbC1         3         prey67371           osbC1         3         prey67381           osbC1         3         prey67390           osbC1         3         prey67300           osbC1         3         prey67405           osbC1         3         prey67405           prey67405         prey67405         prey67405           ospC1         3         prey67405           prey67406         prey67405         prey67405           ospC1         3         prey67406           ospC1         3         prey67406           ospC1         3         prey67406           ospC1         3         prey67406           ospC1         4         prey674003           ospC1         4         prey674003           ospC1         4         prey67502           paD         4         prey675039         (IVIM: prey122) hWM hwimentin           paD         4         prey67504         prey67504	prey67368 (LOC92609) hhypothetical proteinXP_053074	3	Shigella ospC1
ospC1         3         prey4006 (KIAA0141; prey4006; prey4407) hKIAA0141           ospC1         3         prey67380           ospC1         3         prey67380           ospC1         3         prey67380           ospC1         3         prey2108 (prey210; prey2107; prey2102; prey2103)           ospC1         3         prey2108 (prey210; prey2104; prey2107; prey2102; prey2103)           ospC1         3         prey67403           prey67403         prey67403           prey67403         prey67403           prey67403         prey67403           prey67403         prey67403           prey67403         prey67403           prey67403         prey67403           prey67404         prey67403           prey67403         prey67604           prey67603         prey67604           prey67604         prey67604           prey676063         prey67604           prey676064         prey67606           prey676066         prey67669           prey676066         prey67669           prey67606         prey67669           prey67606         prey67669           prey67606         prey67669           prey67606         prey676	_	က	ł
ospC1         3         prey87380           ospC1         3         prey2108; prey2107; prey2107; prey2102; prey2103           ospC1         3         prey2108 (prey2104; prey2107; prey2102; prey2103)           subunit 5(Arabidopsis) hsimilar to COP9 (constitutive photomorphogenic, Arabidopsis, hon prey67403         prey67406         prey67406         prey67407; prey2106; prey2107; prey2102; prey2109; prey2109; prey67403           ospC1         3         prey67405         prey67405         prey67405         prey67405         prey67406         prey67506         prey67506 </td <td>prey4005 (KIAA0141; prey4006; prey8649; prey44107) hKIAA0141</td> <td>က</td> <td>ł</td>	prey4005 (KIAA0141; prey4006; prey8649; prey44107) hKIAA0141	က	ł
ospC1         3         prey3296 (FHOS; prey3297) hFHOS           ospC1         3         prey3208 (FHOS; prey3104; prey2102; prey2103)           subunit Schabidopsis, horingtor         Arabidopsis, hon           ospC1         3         prey67403           paD         prey67403         prey67403           ospC1         3         prey67403           prey6702         prey6703         prey6704           paD         prey6703         prey6703           paD         prey6703         prey60028           paD         prey60028         prey60028           paD         prey60029         prey60029           paD         prey60029         prey60029           paD         prey60029         prey6000         prey6000           paD         prey6000         prey6000         prey6000         prey6000           paD         prey6000         prey6000         prey6000         prey6000         prey6000 <th< td=""><td>prey67380</td><td>က</td><td>J</td></th<>	prey67380	က	J
ospC1         3         preyZ108 (preyZ101; preyZ104; preyZ107; preyZ102; preyZ103)           subuinf 5(Arabidopsis)         hismilar to COP9 (constitutive photomorphogenic, Arabidopsis, Inamilar to COP9 (constitutive photomorphogenic, Arabidopsis, Inamilar to COP9 (constitutive photomorphogenic, Arabidopsis, Inamilar to COP9)           ospC1         3         prey67403           ospC1         3         prey67403           prey67403         4         prey67403           prey67403         4         prey67563 (PRSC1) hPRSC1           pabD         4         prey67567 (NIM; prey9122) hVIM hvimentin           pabD         4         prey67567 (NIM; prey9122) hVIM hvimentin           pabD         4         prey67567 (NIM; prey9122) hVIM hvimentin           pabD         4         prey67569 (PLCB3) hPLCB3           pabD         4         prey67567 (NIM; prey9122) hVIM hvimentin           pabD         4         prey67569 (LRS KIAA0070; prey65697) hKARS hILSy1 HRANSy1 hRANS hILSy1 HRANSy1 hRANS           pabD         4         prey67694 (INDO IDO; prey65697) hKARS hILSy1 HRANS           pac         prey67594 (INDO IDO; prey65697) hKARS hI	prey3296 (FHOS; prey3297) hFHOS	က	ł .
subunit 5(Arabidopsis)           ospC1         3         prey67403         ospC1         orey67405         ospC2         ospC1         ospC2	prey2108 (prey2101; prey2104; prey2107; prey2102; prey2103) hSimilar to COP9 (constitutive photomorphogenic),	3	1
New Parison of the Control of the	hogenic, Arabidopsis, homolog) subunit 5 (I		
ospC1         3         prey67403           ospC1         3         prey67405           ospC1         3         prey67406           ospC1         3         prey67563 (P           paD         4         prey67563 (P           paD         4         prey67571           paD         4         prey67574           paD         4         prey67574           paD         4         prey67574           paC         5         prey67527           paC         5         prey67527           paC         5	INCOPSS Insimilar to COP9 (constitutive photomorphogenic, Arabidopsis, nomolog) subunit 5 (H.sapiens) INCOPSS Insimilar to COP9 (constitutive photomorphogenic, Arabidopsis, homolog) subunit 5 (H.sapiens)	-	
ospC1         3         prey67405           ospC1         3         prey50029           ipaD         4         prey5185 h-           ipaD         4         prey5185 h-           ipaD         4         prey5185 h-           ipaD         4         prey5390 (T           ipaD         4         prey67571           ipaD         4         prey67572           ipaD         4         prey67572           ipaD         4         prey67574           ipaC         5         prey67514           ipaC         5         prey67514           ipaC         5         prey67514           ipaC         5         prey6751           ipaC         5         prey6752           ipaC         5         prey6752           ipaC         5         prey527 (CLT           ipaC         5         prey527 (CLT           ipaC         5         prey527 (CLT           ipaC </td <td>prey67403</td> <td>8</td> <td>1</td>	prey67403	8	1
ospC1         3         prey14400 (pl           ospC1         3         prey50029           ipaD         4         prey5185 (PC           ipaD         4         prey5185 (PC           ipaD         4         prey5390 (TC           ipaD         4         prey67571           ipaD         4         prey67571           ipaD         4         prey67572           ipaD         4         prey67574           ipaD         4         prey6888 (INI           ipaD         4         prey685696 (INI           ipaD         4         prey67574           ipaD         4         prey67574           ipaC         5         prey67574           ipaC         5         prey67514           ipaC         5         prey67514           ipaC         5         prey4458 (RF           ipaC         5         prey4527 (CLT           ipaC         5         prey527 (CLT </td <td>prey67405</td> <td>က</td> <td>)</td>	prey67405	က	)
ospC1         3         prey50029           paD         4         prey67563 (P           paD         4         prey2109 (CC           paD         4         prey2185 hP           paD         4         prey67571           paD         4         prey67572           paD         4         prey67571           paD         4         prey67574           paD         4         prey65696 (K           paD         4         prey65694 (INI           paD         4         prey67574           paD         4         prey67574           paC         5         prey67574           paC         5         prey67574           paC         5         prey67574           paC         5         prey67514           paC         5         prey4458 (RF           paC         5         prey4527 (CLT           paC         5         prey527 (CLT           pac </td <td>prey14400 (prey14399; prey14401) hprotein phosphatase 5, catalyticsubunit hPPP5C hPPP5C</td> <td>က</td> <td>ı</td>	prey14400 (prey14399; prey14401) hprotein phosphatase 5, catalyticsubunit hPPP5C hPPP5C	က	ı
pad         4         prey67563 (P           pad         4         prey2109 (CC           pad         4         prey53990 (T           pad         4         prey67571           pad         4         prey67571           pad         4         prey67572           pad         4         prey67571           pad         4         prey65696 (K           pad         4         prey65694 (INI           pad         4         prey67574           pad         4         prey67574           pad         4         prey67574           pac         5         prey67574           pac         5         prey67574           pac         5         prey67574           pac         5         prey4458 (RF           pac         5         prey4527 (CLT           pac         5         prey527 (CLT           pac         5         prey527 (CLT           pac         5         prey53735 (T           pac         5         prey53735 (T           pac         5         prey53735 (T           pac         5         prey53735 (T           pac	prey50029	က	
pad         4         prey2109 (CC           pad         4         prey53990 (T           pad         4         prey53990 (T           pad         4         prey67571           pad         4         prey67571           pad         4         prey65696 (K           pad         4         prey65696 (K           pad         4         prey65694 (INI           pad         4         prey65694 (INI           pad         4         prey67574           pad         4         prey67574           pad         5         prey67574           pac         5         prey67574           pac         5         prey67574           pac         5         prey4458 (RF           pac         5         prey458 (RF           pac         5         prey67527           pac         5         prey67527           pac         5         prey67527           pac         5         prey67527           pac         5         prey67527 (CLT           pac         5         prey67527 (CLT           pac         5         prey67527 (CLT	prey67563 (PRSC1) hPRSC1	4	i
paD         4         prey25185 hr           paD         4         prey53990 (T           paD         4         prey67571           paD         4         prey65696 (K           paD         4         prey65696 (K           paD         4         prey65696 (K           paD         4         prey66696 (K           paD         4         prey667674           paD         4         prey67574           paC         5         prey4458 (RF           paC         5         prey4458 (RF           paC         5         prey67522           paC         5         prey67527 (CLT           paC         5         prey67527 (CLT           paC         5         prey5277 (CLT           paC         5         prey5277 (CLT           paC         5         prey53735 (T           pac         5         prey53735 (T	prey2109 (COPS5 JAB1 SGN5 MOV-34; prey2110) hCOPS5 h38 kDa Mov34homolog	4	1
paD         4         prey53990 (T           paD         4         prey9120 (VIII           paD         4         prey67571           paD         4         prey67572           paD         4         prey6889 (PL           paD         4         prey6889 (PL           paD         4         prey6694 (INI           paD         4         prey67574           paC         5         prey67574           paC         5         prey67514           paC         5         prey67514           paC         5         prey67514           paC         5         prey67509 (PL           paC         5         prey4458 (RF           paC         5         prey4552 (CLT           paC         5         prey67522           paC         5         prey527 (CLT           paC         5         prey527 (CLT           paC         5         prey53735 (T           paC         5         prey53735 (T           paC         5         prey53735 (T           pac         5         prey53735 (T           pac         6         prey53735 (T	prey25185 hHSPC272	4	
paD         4         prey9120 (VIII)           paD         4         prey67571           paD         4         prey6556 (K           paD         4         prey65696 (K           paD         4         prey65696 (K           paD         4         prey65700 (RAN           paD         4         prey2694 (INI           paD         4         prey53735 (T           paC         5         prey67574           paC         5         prey67574           paC         5         prey67509 (F           paC         5         prey67514           paC         5         prey67527           paC         5         prey67527           paC         5         prey5277 (CLT           paC         5         prey53735 (T           paC         5         prey53735 (T           paC         5         prey53735 (T           pac         5         prey53735 (T	prey53990 (TNFRSF1A CD120a TNF-R TNF-R-I TNF-R55 TNFAR TNFR60 TNFR1 p55-R p55) hTNFRSF1A	4	1
paD         4         prey67571           paD         4         prey65596 (K           paD         4         prey65696 (K           paD         4         prey8889 (PL           paD         4         prey2694 (INI           paD         4         prey53735 (T           paC         5         prey67574           paC         5         prey67574           paC         5         prey67514           paC         5         prey67527           paC         5         prey67527           paC         5         prey527 (CLT           paC         5         prey53735 (T           paC         5         prey53735 (T           paC         5         prey53735 (T           pac         5         prey53735 (T           pac         6         prey53735 (T           pac	prey9120 (VIM; prey9122) hVIM hvimentin	4	ļ
paD         4         prey67572           paD         4         prey65696 (K           paD         4         prey8889 (PL           paD         4         prey700 (RAN           paD         4         prey2694 (INI           paD         4         prey53735 (T           paC         5         prey67574           paC         5         prey67514           paC         5         prey67514           paC         5         prey4458 (RF           paC         5         prey4458 (RF           paC         5         prey4527 (CLT           paC         5         prey527 (CLT           paC         5         prey527 (CLT           paC         5         prey53735 (T           pac         6         prey53735 (T           pac         6         prey53735 (T <tr< td=""><td>prey67571</td><td>4</td><td>) )</td></tr<>	prey67571	4	) )
paD         4         prey65696 (K           paD         4         prey8889 (PL           paD         4         prey700 (RAN           paD         4         prey2694 (INI           paD         4         prey53735 (T           paC         5         prey67574           paC         5         prey67514           paC         5         prey67514           paC         5         prey4458 (RF           paC         5         prey4458 (RF           paC         5         prey4527 (CLT           paC         5         prey527 (CLT           paC         5         prey527 (CLT           paC         5         prey53735 (T           pac         6         prey5736 (L           pac         6         prey573735 (T           pac         6         prey57746 (L <td>prey67572</td> <td>4</td> <td>1</td>	prey67572	4	1
ipaD         4         prey8889 (PL           ipaD         4         prey700 (RAN           ipaD         4         prey5694 (INI           ipaD         4         prey57574           ipaC         5         prey67574           ipaC         5         prey67514           ipaC         5         prey4458 (RF           ipaC         5         prey4458 (RF           ipaC         5         prey4458 (RF           ipaC         5         prey527 (CLT           ipaC         5         prey527 (CLT           ipaC         5         prey53735 (T	prey65696 (KARS KIAA0070; prey65697) hKARS hLysyl tRNASynthetase	4	
paD         4         prey700 (RAN pad prey2694 (INI pad	prey8889 (PLCB3) hPLCB3	4	
paD         4         prey2694 (INI paD prey53735 (Tree pad	JBP9 RANBPM RANBP9-PENDING; pr	4	ı
paD         4         prey53735 (T           paD         4         prey67574           paC         5         prey67509 (P           paC         5         prey67514           paC         5         prey67514           paC         5         prey4458 (RF           paC         5         prey4458 (RF           paC         5         prey67522           paC         5         prey527 (CLT           paC         5         prey527 (CLT           paC         5         prey53735 (T           paC         6         prey53736 (T	NDO IDO; prey2696; prey2693) hINDO	4	l
paD         4         prey67574           paC         5         prey67514           paC         5         prey67514           paC         5         prey4458 (RL paC)           paC         5         prey4458 (RL paC)           paC         5         prey67522           paC         5         prey67522           paC         5         prey527 (CL)           paC         5         prey53735 (T		4	
paC         5         prey67509 (P           paC         5         prey67514           paC         5         prey2926 (FL           paC         5         prey4458 (RF           paC         5         prey67522           paC         5         prey67522           paC         5         prey527 (CLT           paC         5         prey53735 (T           ipaC         5         prey53735 (T           ipaC         5         prey53735 (T           ipaC         5         prey53735 (T           ipaC         5         prey53735 (T	prey67574	4	
ipaC         5         prey67514           ipaC         5         prey2926 (FL)           ipaC         5         prey4458 (RF)           ipaC         5         prey67522           ipaC         5         prey527 (CLT)           ipaC         5         prey527 (CLT)           ipaC         5         prey53735 (TCT)           ipaC         6         prey53736 (TCT)	prey67509 (POLR2A RPOL2 POLR2 POLRA HRPB220 hSRPB1 RPO2 RpIILS RPBh1 RPB1) hPOLR2A	5	
ipaC         5         prey2926 (FL)           ipaC         5         prey4458 (RF)           ipaC         5         prey4458 (RF)           ipaC         5         prey5752           ipaC         5         prey527 (CL)           ipaC         5         prey53735 (TCL)           ipaC         5         prey53736 (TCL)	prey67514	5	
paC         5         prey4458 (RF)           paC         5         prey4458 (RF)           ipaC         5         prey527 (CL)           ipaC         5         prey527 (CL)           ipaC         5         prey53735 (T)           ipaC         5         prey53735 (T)           ipaC         5         prey53735 (T)	FLJ23153; prey2927) hFLJ23153	5	
ipaC         5         prey4458 (RF           ipaC         5         prey527 (CLT           ipaC         5         prey527 (CLT           ipaC         5         prey53735 (TLT	hRRBP1	5	ļ.
ipaC         5         prey522           ipaC         5         prey527 (CLT)           ipaC         5         prey53735 (TI)           ipaC         5         prey53735 (TI)           ipaC         5         prey53735 (TI)           ipaC         5         prey53735 (TI)	RRBP1 ES130 ES/130; prey4459) hRRBP1	5	
ipaC         5         prey527 (CL1           ipaC         5         prey53735 (T           ipaC         5         prey53735 (T           ipaC         5         prey53735 (T           ipaC         5         prey53736 (T	prey67522	5	1
ipaC         5         prey53735 (T           ipaC         5         prey53735 (T           ipaC         5         prey67546 (L	Ļ	2	ı
ipaC         5         prey53735 (T           ipaC         5         prey67546 (L		5	
ipaC 5 prey67546 (L	prey53735 (TLN1 TLN KIAA1027) hTLN1	5	
	prey67546 (LOC128116) hsimilar to phosphodiesterase 4D interacting protein (myomegalin) (H.sapiens)	5	1
ipaC 5 prey4671 (KI/	prey4671 (KIAA0454) hKIAA0454	5	1 1

prev67550 (LOC92689) hhypothetical proteinXP_046663	prey8889 (PLCB3) hPLCB3	prey11375 (HSPBP1; prey11376) hHSPBP1 hHsp70 binding proteinHspBP1	prey67473 (GALE) hGALE	prey8929 (KIAA0728 FLJ21489) hKIAA0728	prey3488 (ACF7 ABP620 KIAA1251 KIAA0465) hACF/	prey3514 (SNX1; prey3515) hSNX1	prey5814 (USP9X DFFRX) hUSP9X	prey5814 (USP9X DFFRX) hUSP9X	prey67479		prey67481 (GDBR1 GBDR1) hGDBK1	prey67488 (LOC126257) hsimilar to putative (H.sapiens)	prey51967 (UBQLN1 DSK2 PLIC-1 DA41 XDRP1) 110004LN1	prey67491 (KIAA1007 AD-005) hKIAA1007	prey323 (CSH1 CSMT CSA PL; prey324; prey325) ncan1	prey67495	prey67506 (LOC126083) hdynamin2	AP SAP1 GLBA; prey5664) hPSAP	prey1135 (PSMD1 P112 S1; prey1136) hPSMD1 hproteasonne subunity i 12	prey67465 (COL4A2 FLJ22259) hCOL4A2	prey28880 (KPNA4; prey28881) hKPNA4 hQIP1	prey3599 (TRIP12 KIAA0045; prey3600) h1HIP12 hKIAA0045	prey67717	≨		prey2530 harrestin, beta1	prey67731 (LOC126896) hsimilar to Gene 33/Mig-6 (H.Sapiens)	prey7155 (CSH2 CSB) hCSH2	prey1687 (DCTN1) hDCTN1	10618	prey2694 (INDO IDO; prey2696; prey2693) hINDO niNDO	prey67740	prey67703 (PPP2R4 PTPA) hPPP2H4	prey67741	prey67742 (FLJ20313) hFLJ20313	prey67339 (MMP19 RASI-1 MMP18) niviniP19
L.	o rc	2	22	2	22	2	5	2	22	5	5	2	5	5	5	5	22	5	ហ	5	2	2	9	9	9	9	9	9	9	9	9	9	9	9	9	9
Jewi cllowido	1	1	1		ı				1	1	1	1	l l	l		1	1		1		Ļ		1	1	1	1	1		Į.	1	1	1		i	1	1 '

- [	The second secon	
Shigella ipaH9.8	9	prey67337 (MMP19 HASI-1 MMP18) nWMP19
Shigella ipaH9.8	9	prey67746 (FBXO25 FBX25) nFBXO25
Shigella ipaH9.8	9	prey54430 (PSG4 PSG9) hPSG4
	9	prey67749
	9	
ì	9	
1	9	
	9	prey66739 (EIF2B1 EIF2B EIF-2B) hEIF2B1
1	9	
Shigella ipaH9.8	9	
!	9	prey3337 (LMNA LMN1 EMD2 FPL LFP LDP1 FPLD CMD1A; prey14196) hLMNA
ı	9	prey67774 (LOC119758) hsimilar to REGULATOR OF PRESYNAPTIC ACTIVITY AEX-3 (H.sapiens)
1	9	prey67776
Shigella ipaH9.8	9	
	9	prey67781 putative homolog of prey046760 - Mouse Fmnl
-	9	prey2109 (COPS5 JAB1 SGN5 MOV-34; prey2110) hCOPS5 h38 kDa Mov34homolog
Shigella ipaH9.8	9	prey4060 (KIAA0155; prey4061; prey4062) hKIAA0155
	9	prey49284 (SLC7A8 LAT2) hSLC7A8
Shigella ipaH9.8	9	prey67686
	9	
ĺ	9	
Shiqella ipaH9.8	9	prey67695 (ATP6N1B RDRTA2 RTA1C VPP2 RTADR) hATP6N1B
	9	prey67336 (MMP19 RASI-1 MMP18) hMMP19
1	9	
	9	prey6586 (FLNA ABPX ABP-280 FLN FLN1 NHBP; prey6587) hFLNA
	9	prey56789 (ALDH4 P5CDH; prey56791) hALDH4 hP5CDh
	9	prey67711
i	9	prey2118 (RNF2 dinG Bap-1; prey2119) hRNF2 hring finger proteinBAP-1
	9	X15 HRH2 DBP1; prey3597) hDDX15 hATP-dependent RNA helicase#46
Shigella ipaH9.8	9	prey666 (RANBP16 KIAA0745; prey667; prey665; prey9721) hHANBP16 nHAN binding protein to invalue to
- 1	7	MEN 2017 (RTRD FI 190386: prev.3920: prev.3921; prev.3922; prev.3919) hBTBD2
	7	previous 200 (7 NET 80: previous projects) projects proje
- 1	_	previous (z.iv. 104) previous
		preyz109 (COPSS JAB1 SGINS MOV-34, PIEYZ110) 11001 SS 1100 NDB 110
	7	prey54201 (UBEZU3 UBCH5C; prey54Z0Z) nUBEZU3 nUBCH3C
Shigella ospG	7	prey1922 (DLS1 DL1S; prey1923) nDLS1 nE2A
Shigella ospG	7	prey67418 (UBE2L3 UBCH7) hUBE2L3

Shigella ospG		prey67314 (UBEZL6 UBCH8 RIG-B) nUBEZL6
Shinella ospG	7	prey67435 hUnknown (protein forMGC:3432)
Shinella OspG	7	prey67443 (FLJ11807) hFLJ11807
Shipella OspG	7	prey67317 (KIAA1485) hKIAA1485
Shinella ospē		prey67393 (UBE2D2 UBCH5B UBC4) hUBE2D2
Shigella ospG	7	prey700 (RANBP9 RANBPM RANBP9-PENDING; prey701) hRANBP9 hRanBPM
Shigella ospG	7	prey67411 (UBE2E3 UBCH9) hUBE2E3
Shiqella ospG	7	prey67423
Shiqella ospG	7	prey67298
Shigella ospG	7	prey67464
Shiqella ospG	7	prey67320
Shigella ospG	7	prey67321
Shigella ospG	7	prey35777 (PSG2 PSGGB; prey35778) hPSG2 hPSG1
Shidella ospG	7	prey67327 (AKAP13 HT31 BRX) hAKAP13
Shidella ospG		prey412 (RPN2; prey413) hRPN2 hsignalpeptide
Shigella ospG	7	prey50598 (PEX10 NALD; prey50599) hPEX10 hperoxisome assembly proteinPEX10
Shigella ospG	7	prey67364
Shigella ospG		prey67367
Shigella ospG	7	prey67369
Shidella ospG	7	prey67372 (CD63 MLA1 ME491) hCD63
Shiqella ospG	7	prey67379
Shigella ospG	7	prey67381 (LOC131541) hhypothetical proteinXP_059524

Span Span Span Span Span Span Span Span		gb AB008515 AB008515 Homo sapiens mRNA for RanBPM, complete cds. gb AC005091 AC005091 Homo sapiens BAC clone CTA-318C11 from 7p14-p15, complete sequence. gb AF117888 AF117888 Homo sapiens myosin-IXa mRNA, complete cds.
ospB ospB	-	gb AF141347 AF141347 Holino sapiens F-box protein FBX3 mRNA, partial cds.
OspB	-	gb AF177198 AF177198 Homo sapiens talin mRNA, complete cds.
ospB	-	gb AF212940 AF212940 Homo sapiens zinedin (ZIN) mRNA, complete cds.
ospB	-	gb AF257211 AF257211 Homo sapiens LMO2b splice variant (LMO2) mHNA, complete cds.
gdso	<del></del>	gb AJ005897 HSA005897 Homo sapiens mRNA for JM5 protein, complete CD3 (clotte invace 3555), EEVECTO 1557 Street Berlin) and LLNLc110G0913Q7 (RZPD Berlin)).
ospB	-	gb/AK024239/AK024239 Homo sapiens cDNA FLJ14177 fis, clone NT2RP2003161.
gdso	-	of DNA sequence from clone 141H5 on chromosome Agzz. 1-z3. Contains ctor type C domains. Contains ESTs, STSs and GSSs, complete sequence to the complete sequence of the complete sequence.
gdso	-	gb/AL122043 HSM801240 Homo sapiens mRNA; cDNA DKFZp566G1424 (from clone DKFZp500G 1424).
ospB	-	gb AL442166 HSMX1A Homo sapiens chromosome 21 from 5 PACs and 5 Cosmids map 21qzz.z,Dz15349-wn1; segment 1/z, complete sequence.
Baso	-	gb/AP002026/AP002026 Homo sapiens genomic DNA, chromosome 4q22-q24, clone:429K21, complete sequence.
ospB	-	gb D21260 HUMORFEA Human mRNA for KIAA0034 gene, complete cds.
OSDB	-	gb L14599 HUMPSFHOMO Human mRNA, complete cds.
gdso	-	piens dbpB-like protein mRNA, complete cds.
ospB	-	gb M23254 HUMCANP Human Ca2-activated neutral protease large subunit (CANP) mRNA, complete cus.
ospB	1	
gdso	1	gb X61118 HSTTG2 Human TTG-2 mRNA for a cysteine rich protein with Lilw mouli.
ospD1	2	gb AB007879 AB007879 Homo sapiens KIAA0419 mKNA, complete cus.
ospD1	2	gb AB008515 AB008515 Homo sapiens mRNA for HanBPIM, complete cus.
ospD1	2	gb AB016485 AB016485 Homo sapiens mRNA for LIM homeobox protein colactor (CLIM-Z), complete cust
ospD1	2	gb AB028956 AB028956 Homo sapiens mRNA for KIAA1033 protein, partial cds.
ospD1	2	gb AB033114 AB033114 Homo sapiens mRNA for KIAA1288 protein, partial cus.
ospD1	2	gb AC003108 HUAC003108 Human Chromosome 16 BAC clone CIT987 SN-327024, contiplete sequence:
ospD1	2	gb AC008764 AC008764 Homo sapiens chromosome 19 clone CTD-3222DT9, COTIPIETE Sequence:
ospD1	2	
ospD1	2	gb AF006466 AF006466 Mus musculus lymphocyte specific formin related process (1.17) min why complete days
ospD1	2	gb AF061258 AF061258 Homo sapiens LiM protein miniva, complete cus.

ipaC	C L	gb/AB020335/AB020335 Homo sapiens Pancreas-specific TSA305 mRNA , complete cds.
ipaC	0 0	gb/AB029290/AB029290 Homo sapiens mRNA for actin binding protein ABP620, complete cds.
ipaC	5	gb AB046026 AB046026 Macaca fascicularis brain cDNA, clone: QccE-16688.
ipaC	5	gb AC003991 AC003991 Human BAC clone CTB-167B5 from 7q21, complete sequence.
ipaC	2	gb AC005578 AC005578 Homo sapiens chromosome 19, cosmid F20887, complete sequence.
ipaC	2	gb AF006751 AF006751 Homo sapiens ES/130 mRNA, complete cds.
ipaC	2	gb AF006751 AF006751 Homo sapiens ES/130 mRNA, complete cds.
ipaC	5	gb AF006751 AF006751 Homo sapiens ES/130 mRNA, complete cds.
ipaC	5	gb AF006751 AF006751 Homo sapiens ES/130 mRNA, complete cds.
ipaC	2	gb AF100153 AF100153 Homo sapiens connector enhancer of KSR-like protein CNK1 mHNA, complete cds.
ipaC	2	gb AF176069 AF176069 Homo sapiens ubiquilin mRNA, complete cds.
ipaC	5	gb AF176069 AF176069 Homo sapiens ubiquilin mRNA, complete cds.
ipaC	5	gb AF176796 AF176796 Homo sapiens putative glialblastoma cell differentiation-related protein (GDDB1) mBNA complete cds.
ipaC	5	gb AF176796 AF176796 Homo sapiens putative glialblastoma cell differentiation-relation (GDDD1) Illinia, complete des
ipaC	5	gb AF176796 AF176796 Homo sapiens putative glialblastoma cell differentiation-related protein (GBDR1) mRINA, complete cus.
ipaC	5	gb AF177198 AF177198 Homo sapiens talin mRNA, complete cds.
ipaC	5	gb AF177198 AF177198 Homo sapiens talin mRNA, complete cds.
ipaC	5	gb AF187859 AF187859 Homo sapiens Hsp70 binding protein HspBP2 mRNA, complete cds.
ipaC	2	gb AF189009 AF189009 Homo sapiens ubiquitin-like product Chap1/Dsk2 mHNA, complete cds.
ipaC	5	gb AK000982 AK000982 Homo sapiens cDNA FLJ10120 fis, clone HEMBA1002863.
ipaC	2	gb D21260 HUMORFEA Human mRNA for KIAA0034 gene, complete cds.
ipaC	5	gb D28476 HUMKG1C Human mRNA for KIAA0045 gene, complete cds.
ipaC	5	gb D44466 D44466 Homo sapiens mRNA for proteasome subunit p112, complete cds.
ipaC	5	
ipaC	2	gb J00118 HUMPLB Human placental lactogen hormone (PL-4) mRNA, complete cds.
ipaC	2	gb J04164 HUM927A Human interferon-inducible protein 9-27 mRNA, complete cds.
ipaC	5	gb L36983 HUMDNM Homo sapiens dynamin (DNM) mRNA, complete cds.
ipaC	2	gb L41498 HUMPTI1B Homo sapiens longation factor 1-alpha 1 (PTI-1) mRNA, complete cds.
ipaC	2	gb L41668 HUMGALE Homo sapiens UDP-galactose-4-epimerase (GALE) mHNA, complete cds.
ipaC	5	gb M24766 HUMCOL4A2P Human (clone pHAIV2-12) alpha-2 collagen type IV (COL4A2) mHINA, 3 end.
ipaC	5	gb M81355 HUMSPHINO Homo sapiens sphingolipid activator proteins 1 and 2 processed mutant minny, complete cus.
ipaC	2	gb U02389 HSU02389 Human hLON ATP-dependent protease mHNA, nuclear gene erroduing mitocholibrial protein, comprete cost
ipaC	5	gb U53225 HSU53225 Human sorting nexin 1 (SNX1) mHNA, complete cds.

		This is a second of the second
ipaC	2	gb X05610 HSC4AZ Human mHNA for type IV collageri alpira (z) crain.
ipaC	5	gb X63564 HSRPIILS H.sapiens mRNA for RNA polymerase II largest subunit.
ipaC	5	gb X98296 HSUBIQHYD H.sapiens mRNA for ubiquitin hydrolase.
ipaC	5	gb Z26649 HSPPLCB3 H.sapiens mRNA for phospholipase C-b3.
ipaH9.8	9	dbj AB001636.1 AB001636 Homo sapiens mRNA for ATP-dependent RNA helicase #46, complete cds
ipaH9.8	9	dbj AB002333.1 AB002333 Human mRNA for KIAA0335 gene, complete cds
ipaH9.8	9	dbj AB008515.1 AB008515 Homo sapiens mRNA for RanBPM, complete cds
ipaH9.8	9	dbj AB023187.1 AB023187 Homo sapiens mRNA for KIAA0970 protein, complete cds
ipaH9.8	9	dbj AB033043.1 AB033043 Homo sapiens mRNA for KIAA1217 protein, partial cds
ipaH9.8	9	dbjjAK001451.1 AK001451 Homo sapiens cDNA FLJ10589 fis, clone NT2RP2004389, weakly similar to PROBABLE MITOCHONDHIAL
		403 RIBOSOWAL FINO EIN 391 NECONOCIO
ipaH9.8	9	
ipaH9.8	9	mRNA for KIAAU155 gene, complete cds
ipaH9.8	9	emb AL034405.16 HS537K23 Human DNA sequence from clone RP4-537K23 on chromosome Aq25-26.1, complete sequence
		- 1
ipaH9.8	9	emb AL034417.14 HS215D11 Human DNA sequence from clone 215D11 on chromosome 1p36.12-36.33 Contains a gene for a niva-
		binding protein regulatory subunit, a gene similar to rat gene 33, a pseudogene similar to FLA-A, EO 13, OOS and OPC
		islands, complete sequence [Homo saple
ipaH9.8	9	emb AL050313.6 HSBK754D9 Human DNA sequence from clone CTA-754D9 on chromosome 22 Contains GSSs, complete sequence
ipaH9.8	9	$\sim$
ipaH9.8	9	emb AL137068.10 AL137068 Human DNA sequence from clone RP11-165P4 on chromosome 9q34.11-34.13, complete sequence
		[Homo sapiens]
ipaH9.8	9	emb X53416.1 HSABP280 Human mRNA for actin-binding protein (filamin) (ABP-280)
ipaH9.8	9	emb X73478.1 HSPTPAA H.sapiens hPTPA mRNA
ipaH9.8	9	emb X74801.1 HSHUMAPC H.sapiens Cctg mRNA for chaperonin
ipaH9.8	9	
ipaH9.8	9	gb AC005392.1 AC005392 Homo sapiens chromosome 19, CIT-HSP BAC 490g23 (BC338531), complete sequence
ipaH9.8	9	gb AC005833.1 AC005833 Homo sapiens 12p13.3 BAC RPCI11-234B24 (Roswell Park Cancer Institute Human BAC LIDIALY)
	!	complete sequence
ipaH9.8	9	gb AC005881.3 AC005881 citb_79_e_16, complete sequence [Homo sapiens]
ipaH9.8	9	gb AC020663.1 AC020663 Homo sapiens chromosome 16 clone HPCI-11_12/120, complete sequence
ipaH9.8	9	gb AF006466.1 AF006466 Mus musculus lymphocyte specific formin related protein (Fr1) minny, complete cus
ipaH9.8	9	gb AF010404.1 AF010404 Homo sapiens ALR mRNA, complete cds

ipaH9.8	9	gb AF064729.1 AF064729 Homo sapiens RAN binding protein 16 mRNA, complete cds
ipaH9.8	9	gb AF084940.1 AF084940 Homo sapiens beta-arrestin 1B mHNA, complete cds
ipaH9.8	9	gb AF135159.1 AF135159 Homo sapiens GMP reductase mRNA, complete cds
ipaH9.8	9	gb AF139184.1 AF139184 Homo sapiens Sec31 protein mRNA, complete cds
ipaH9.8	9	gb AF141327.1 AF141327 Homo sapiens ring finger protein BAP-1 mRNA, complete cds
ipaH9.8	9	gb AF171669.1 AF171669 Homo sapiens glycoprotein-associated amino acid transporter LAT2 (LAT2) mRNA, complete cds
ipaH9.8	9	gb AF174605.1 AF174605 Homo sapiens F-box protein Fbx25 (FBX25) mRNA, partial cds
ipaH9.8	9	gb AF207661.1 AF207661 Homo sapiens sodium bicarbonate cotransporter-like protein mRNA, partial cds
іраН9.8	9	gb AF245517.1 AF245517 Homo sapiens vacuolar proton pump 116 kDa accessory subunit (ATP6N1B) mRNA, complete cds,
ipaH9.8	9	gb AF249874.1 AF249874 Homo sapiens vacuolar proton pump 116 kDa accessory subunit gene, exon 3 and 5' untranslated region,
ipaH9.8	9	gb J00118.1 HUMPLB Human placental lactogen hormone (PL-4) mHNA, complete cas
ipaH9.8	9	gb L14283.1 HUMPROKINC Human protein kinase C zeta mRNA, complete cds
ipaH9.8	9	gb L25286.1 HUMCOLXVA1 Homo sapiens alpha-1 type XV collagen mRNA, complete cds
ipaH9.8	9	
ipaH9.8	9	gb M21616.1 HUMPDGFR Human platelet-derived growth factor (PDGF) receptor mRNA, complete cds
ipaH9.8	9	gb M32053.1 HUMH19 Human H19 RNA gene, complete cds
ipaH9.8	9	gb M34455.1 HUMIGIIDO Human interferon-gamma-inducible indoleamine 2,3-dioxygenase (IDO) mHNA, complete cds
ipaH9.8	9	gb M94890.1 HUMPSBG11 Human pregnancy-specific beta-1-glycoprotein 11 (PSG11) mRNA, complete cds
ipaH9.8	9	gb M98478.1 HUMTGH1A Human transglutaminase mRNA, complete cds
ipaH9.8	9	gb U24267.1 HSU24267 Human pyrroline-5-carboxylate dehydrogenase (P5CDh) mRNA, short form, complete cds
ipaH9.8	9	gb U37791.1 HSU37791 Homo sapiens clone rasi-1 matrix metalloproteinase RASI-1 mRNA, complete cds
ipaH9.8	9	gb U38431.1 HSU38431 Human clone rasi-6 matrix metalloproteinase RASI-1 mRNA, splice variant, complete cds
ipaH9.8	9	gb U65928.1 HSU65928 Human Jun activation domain binding protein mRNA, complete cds
ipaH9.8	9	ref[NM_014285.1] Homo sapiens homolog of Yeast RRP4 (ribosomal RNA processing 4), 3'-5'-exoribonuclease (RRP4), mRNA
ipaH9.8	9	refINM_017762.1 Homo sapiens hypothetical protein FLJ20313 (FLJ20313), mRNA
ipaH9.8	9	ref[NM_018155.1] Homo sapiens hypothetical protein FLJ10618 (FLJ10618), mRNA
ospG	7	gb/AB008515/AB008515 Homo sapiens mRNA for RanBPM, complete cds.
ospG	7	gb AB013818 AB013818 Homo sapiens PEX10 mRNA for peroxisome biogenesis factor (peroxin) 10, complete cds.
osbg	7	gb/AB033054/AB033054 Homo sapiens mRNA for KIAA1228 protein, partial cds.
osbg	7	gb/AB033054/AB033054 Homo sapiens mRNA for KIAA1228 protein, partial cds.
osbG	7	gb AB040918 AB040918 Homo sapiens mRNA for KIAA1485 protein, partial cds.
osbG	7	gb AC005281 AC005281 Homo sapiens PAC clone RP4-722F20 from 7q31.1-q31.3, complete sequence.

Table II	Table III : SID®	_				T. OID amine and openioned
1: Bait name	2: Bait	3: Prey name	4:	5: SID nucleic acid sequence	6: SIU	7: SID ammo-acid sequence
	nucleic acid	•	SID		acid ID	
	SEQ ID No.		eic acid ID		ò	
			S S		216	FSHDSSFLCASSDKGTVHI
Shigella	-	prey44074	15		2	FALKDTRLNRRSALARVGK
adeo				GCGTGGGCAAGGTGGGCCTATGATTGGGCAGTACGTGGACTCTCAGTGGA		VGPMIGQYVDSQWSLASF TVPAESACICAFGRNTSKN
				GCCTGGCGAGCTTCCAGGGACGTCAGTCAGTCAGCTTGCCATCTGCGTAGATGG		VNSVIAICVDGTFHKYVFTP
				GACCTTCCACAAATATGTCTTCACTCCTGATGGAAACTGCAACAGAGAGGCT		DGNCNREAFUV YLDICUUU DF*
Shinella	-	prev67804	16		217	TSKSCEYNGTTYQHGELFV
ospB	-			GTTCGTAGCTGAAGGGCTCTTTCAGAATCGGCAACCCAATCAAT		SEGUL GINACOLINACIO COSCIONO COSCIONO CONTRA SEGUINA SEG
				TGCAGCTGTTCGGAGGGAAACG1G1A11G1GG1C1CAAAGAC11GCCCGAAATTCTATTCCAGATTCTGTTGCAGATTCCTGCTGCTGCGGGTATGCAG		PVSVPDSCCRVCRGDGEL
				AACCIGIGCOI   CCCAGIO   COACATO   COACATO   COACATO   CAACATO   CAACATO		SWEHSDGDIFRQPANREA
				CCTGCCAACAGAAGCAAGACATTCTTACCACCGCTCTCACTATGATCCTC		RHSYHRSHYDPPPSRQAG
				CACCAAGCCGACAGGCTGGAGGTCTGTCCCGCTTTCCTGGGGGCCAGAGTC		GLSRFPGARSHRGALMUS
				ACCGGGGGAGCTCTTATGGATTCCCAGCAAGCATCAGGAACCA   G   GCAAA		OCCASO INCIDITION IN IC
				TGTCATCAATAACAAACACAAGCA!GGACAAGIGIGIGIGIGIGIGIGIGIGIGIGIGIGIGIGI		NI BAFGIVECVLCTCNVTK
				ACCTATTCTCATGGCGAGICCIGGCACCCAAACCICCGGGCAIIIGGCAIIG		QECKKIHCPNRYPCKYPQK
				GGAGTGTGTGTACTACTGTACTGCAAAAAAAAAAAAAAA		IDGKCCKVCPGKKAKELPG
				TECTECAAGGTGTGCCAGGTAAAAAAGCAAAAAAGAACTTCCAGGCCAAAGCT		QSFDNKGYFCGEETMPVY
				TTGACAATAAAGGCTACTTCTGCGGGGAAGAAACGATGCCTGTGTATGAGTC		ESVFMEDGETTRKIALETE
				TGTATTCATGGAGGATGGGGAGACAACCAGAAAAATAGCACTGGAGACTGA		TYPQVEVEVW ITAKGILQT
				GAGACCACCTCAGGTAGAGGTCCACGTTTGGACIAIICGAAAGGGCATTCTC		TRTTL SQWKIFTEGEAQISG
				CAGCACTTCCALALIGAGAAGALCICCAAGAGALGIIIGAGGAAGATGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAG		MCSSRVCRTELEDLVKVLY
				ACTICAAGO GGIGACCAGAACAGO CAGAGO CAGAGO CAGAGO AGAACAGA		LERSEKGHC*
				GCTTGAAGATTTAGTCAAGGTTTTGTACCTGGAGAGATCTGAAAAGGGCCAC		
				TGTTAG	218	XXI XXTSI VXI PGXTGCXV
Shigella	-	prey67806	17	NCTNCCCTGNGCGNGACCAGCCIGGINANCIIACCNGGANCCACNGGAIGI NGTGTANCTGTGCTCTGCGCTTGCCATGATGACTTNTGGGAGCTGCANCCG	0 7	XVLCACHDDXWELXPSRX
adso				TCGCGTTTNTGNNNCGTNGTTGGTGNCNGGCCTCCNTANGNTGTGNNACGA		XXVVGXXPPXXVXHHLXFA

				CAGAGAAGCTGGTTATAAAAAACCAGCAATTTCACAAGGAACGAGAGCAGCC ACCCAGATTTGCACAGCCTGGCTCCTTTGAGTATGAATATGCCATGCGCTGG AAGGCACTCATTGAGATGGAGAAGCAGCAGCAGGACCAAGTGGACCGCAAC ATCAAGGAGGC	QPGSFEYAMRWKALIE MEKQQDQVDRNIKE
Shigella ospB	<b></b>	prey67661	50	· · ·	GDFCIRVFSEKKADYQAVD DEIEANLEEFDISEDDIDDG VRRLFAQLAGEDAEISAFEL QTILRRVLAKRQDIKSDGFS IETCKIMVDMLDSDGSGKL GLKEFYILWTKIQKYQKIYR EIDVDRSGTMNSYEMRKAL EEAGFKMPCQLHQVIVARF ADDQLIIDFDNFVRCLVRLE TLFKIFKQLDPENTGTIELDL ISWLCFSVL*
Shigella ospB	<del></del>	prey34730	5	ATGGTGAATCCGGGCAGCTCGCAGCCGCCCGGTGACGGCCGGC	MVNPGSSSQPPV1AGSL SWKRCAGCGGKIADRFLLY AMDSYWHSRCLKCSCCQA QLGDIGTSCYTKSGMILCR NDYIRLFGNSGACSACGQS IPASELVMRAQGNVYHLKC FTCSTCRNRLVPGDRFHYI NGSLFCEHDRPTALINGHL NSLQSNP
Shigella ospB	-	prey33141	22	CCTGAGCCTGCCGGGGATCCTGCACTTTATCCAGCAGGTGGGCGCGCTT 223 CGAAGCCGAGAAAGCCCGCTGGGAGGCCGAGCGCCCGAGTTACAGGCTC AGGTGGCCTTCCTTCAGGGAGAGAGAAAGGGCCAGGAGATCTAAAGACGG ACCTGGTGCGCGGGATCAAGAGGGAAAGGGCCAGAGAATCTAAAGACGG CCAAATATCATAAACTGAAGTTTGGGACAGAGTATGCGCTGAAGCAGGAAAGGG ACCAGATGTGTCAGAACTTTCCAATGGCCCCGTGGAATCGGTCACCCT AGCAGATGTGTGGTGTG	LSLPGILHFIQHEWARFEAE KARWEAERAELQAQVAFL QGERKGQENLKTDLVRRIK MLEYALKQERAKYHKLKFG TDLNQGEKKADVSEQVSN GPVESVTLENSPLVWKEG RQLLRQYLE
Shigella ospB	<del>-</del>	prey67575	23	ATGGCAGCCTCCTTACGGCTCCTCGGAGCTGCCTCCGGTCTCCGGTACTGG 224 AGCCGGCGGCGGCCGGCCGGCAGCTTTGCAGCGGTGTGTTCTAG GTCAGTGGCTTCAAAGACTCCAGTTGGATTCATTGGACTGGGCAACATGGG GAATCCAATGGCAAAAAATCTCATGAAACATGGCTATCATTATTATG ATGTCTCCTGATGCCTGCAAAAGATTTCAAGATTCAAGGTGAACAGGTAGT	MAASLRILGAASGLRYWS RRLRPAAGSFAAVCSRSVA SKTPVGFIGLGNMGNPMAK NLMKHGYPLIIYDVFPDACK EFQDAGEQVVSSPADVAE

			ATCTTCCCCAGCAGATGTTGCTGAAAAGCTGACAGAATTATTACAATGCTGC	KADRIITMLPTSINAIEAYSG
	•		CCACCAGTATCAATGCAATAGAAGCTTATTCCGGAGCAAATGGGATTCTAAA	ANGILKKVKKGSLLIDSSTID
			AAAAGTGAAGAAGGGCTCATTATTAATAGATTCCAGCACTATTGATCCTGCAG	PAVSKELAKEVEKMGAVFM
				MVGGVEDEFAAAGELLGG
				MGSNVYCGAVGTGQAAK
			TGCATGGGCTCCAACGTGGTGTACTGTGGAGCTGTTGGGACTGGGCAGGCG	ICNNMLLAISMIGTAEAMNL
			GCAAAGATCTGCAACAACATGCTGTTAGCTATTAGTATGGATTGGAACTGCTGA	GIRLGLDPKLLAKILNMSSG
			AGCTATGAATCTTGGAATCAGGTTAGGGCTTGACCCAAAACTACTGGCTAAA	RCWSSDTYNPVPGVMDGV
			ATCCTAAATATGAGCTCAGGACGGTGTTGGTCAAGTGACACTTATAATCCTGT	PSANNYQGGFGTTLMAKD
			ACCTGGAGTGATGGCGTTCCCTCGGCTAATAACTATCAGGGTGGATTT	LGLAQDSATSTKSPILLGSL
			GGAACAACACTCATGGCTAAGGATCTGGGATTGGCACAAGACTCTGCTACCA	AHQIYRMMCAKGYSKKDF
			GCACAAAGAGGGCTACTCAAAGAAGACTTCTCATCCGTGTTCCAGTTC	) 
			CTACGAGAGGAGACCTTCTGA	
Shigella 1	prey67608	24	100	AEEEEAEVRQPKGPDPDSL
ospB			ACAGCCTTAGTTCACAGTTTATGGCGTATATTGAACAGCGGCGAATCTCAT	SSOFMAYIEORKISHEGSP
			GAGGGTTCACCAGTAAAGCCAGTAGCCATTAGGGAAGIIICAAAAAACAGAAG	VKFVAIREFUKI EDMIKKYL
			ATATGAGAAGATACTTACATCAAAACAGGGTTCCAGCTGAGCCATCTTCCCT	HONRVPAEPSSLLSLSASH
			CCTGTCACTATCAGCAAGTCACAATCAGCTGTCACACACA	NOLSHIDLELHORREOLVE
			CATCAGAGAAGGGAGCAGTTAGTAGAGCGCACTCGGAGAGAGA	RTRREAQLAALQYEEEKIR
			GCTGCCCTGCAGTATGAGGAGGAGAAAATAAGGACCAAGGAGCAGATCCAGAGA	TKOIGHDAVLDFVKGKASG
			GATGCTGTCCTGGACTTTGTCAAACAAAAGCATCACAAAGTCCACAAAAAC	SPOKOHPLLDGVDGECPF
			AGCACCCGCTCCTAGATGCCGTAGATGGTGAGTGCCCCTTCCCATCCAGAA	PSRRSQHTDDSALCMSLS
			GGTCTCAGCACACTGATGATAGTGCCTTGTGCATGTCGCTGTCAGGGTTGAA	GLNQVGCAATLPHSSAFTP
			TCAAGTGGGCTGTGCTACCCTGCCTCATTCTTCTGCCTTCACGCCTCTT	LKSDDRPNALLSSPATETV
			AAGAGTGATGACAGACCTAATGCTCTATTAAGTTCACCTGCAACAGAAACAG	HHSPAYSFPAAIQHNQPQH
			TTCATCATTCCCCTGCATATTCTTTTCCTGCTGCTATCCAGAGAAAICAGCCT	ı.
Shinella 1	prev67637	25	ATGATACTACAGGAGTTACCAGATTTGGAGGAGCTCTTCCTGTGCCTTAATG 226	MILQELPDLEELFLCLNDYE
OspB	500	ì	ACTATGAAACAGTGTCTTGTCCTTCTATTTGCTGTCATTCTCTTAAGCTACTAC	TVSCPSICCHSLKLLHITDN
)			ATATAACAGACAATAACCTCCAAGACTGGACTGAAATACGAAAGTTAGGAGTT	NLQDWTEIRKLGVMFPSLD
			ATGTTTCCTTCACTGGATACCCTCGTCCTGGCCAACAATCATTTGAATGCTAT	TLVLANNHLNAIEEPDDSLA
			TGAGGAGCCTGATGATTCATTGGCCAGGTTGTTTCCTAATCTTCGATCCATCA	RLFPNLASISCHKSGLQSW
			GCCTCCACAAGTCAGGTTTGCAGTCCTGGGAAGACATTGATAAACTAAATTC	EDIDKLNSFPKLEEVRLLGI
			ATTTCCCAAACTGGAAGAGGGGATTGTTAGGAATTCCTCTTCTGCAGCCAT	PLLQPY I LEEKKLVIAKLY
			ATACCACCGAGGAGGGAAGGAAATTGGTAATAGCCAGATTGCCATCAGTTTC	SVSKLNGSVVIDGEREDSE
			CAAACIIAA  GGCAGCGIIGIIACIGAIGGIGAACGAGAAGAIIO GAGAGA   TTTTTATTOCTTACTAGGIGGIIGIIACIGACACGAAGAAGAGAAGAGA	HEI ITKYGKLEPLAEVDLRP
			THE TANK TO BE THE TANK THE THE TANK TH	

			CACTAAATATGGGAAGTTGGAGCCTTTGGCAGAAGTGGAC SAGCAGTGCAAAAGTAGAAGTCCACTTTAACGATCAGGTGG ATTCGTCTGGACCAAACAGTGGCAGAACTAAAGAAACAGTT ACAATTACC	QSSAKVEVHFNDQVEEMSI RLDQTVAELKKQLKTLVQL
97 97	prey12713	56	AGTGGATGAGGTGCTGCAGATCCCCCATCGCTGACATGCGGCGGCTG  CCAGCAGAACATCGGGGACCGCTACTTCCTGAAGGCCATCGACCAGTACTG  CCAGCAGAGGACTGCTGAGCTGCGACCTTCTGTGGCTGCGGCTGGGTGAGG  TGGGCGGCGCCTCTACTACAAACTGGGCCGGAAGCTCTGCCGGAGAGAC  TATCTCAGGCTTTTTGGGCAAGACGGTCTCTGCGCATCCTGTGACAGCGGA  TTCGTGCCTATGAGAAGCGGTGAAAGACAAAGTGTATCACTGGA  ATGTTTCAAGTGCGCCCCTGTCAGAAGCATTCTGTGTATCACCTGGA  ATGTTTCAAGTGCGCCCCTGTCAGAAGCATTCTGTGTATCACGATAC  CTCCTCATCAACTGGGAACATGCGAACAGGAACAGTAC  AGATCAATGGGATGATATAG	VDEVLQIPPSLLTCGGCQQ NIGDRYFLKAIDQYWHEDC LSCDLCGCRLGEVGRRLYY KLGRKLCRRDYLRLFGQD GLCASCDKRIRAYEMTMRV KDKVYHLECFKCAACQKHF CVGDRYLLINSDIVCEQDIY EWTKINGMI*
<u>C</u>	prey67836	27	1 (5. 4 ()	LKTAGKSEPSSKLRKQLKK QQDSLDVVDSSVSSLCLSN TASSHGTRKLFQIYSKSPFY RAASGNEALGMEGPLGQT KFLEDKPQFISRGTFNPEK GKQKLKNVKNSPQKTKETP EGTVMSGRRKTVDPDCTS NQQ
ā.	prey700	58	L (5 (5	MGIGLSAQGVNMNRLPGW DKHSYGYHGDDGHSFCSS GTGQPYGPTFTTGDVIGCC VNLINNTCFYTKNGHSLGIA FTDLPPNLYPTVGLQTPGE VVDANFGQHPFVFDIEDYM REWRTKIQAQIDRFPIGDR EGEWQTMIQKMVSSYLVH HGYCATAEAFARSTDQTVL EELASIKNRQRIQKLVLAGR MGEAIETTQQLYPSLLE
	prey67844	58	TTCCATACAGGAACCCCATCTGAAGGTCACCAACATCAAAGACCAAAGGTAG ATAAATCCACGAAGTTGAGGAAAAACCAGTGCAAAAAGGCTGAGAATTCCAA AAACCAGAAAGGCTCTTCTCCTCCAAAGGATCAAAACTCCTCGCCAGCAAGG GAACAAAACCAGATGAGAATGAGTTTGATGAATTTGACAGAAGTAGGCTTCA GAAGGTGGGTAATAACAAGTAAGCTAAAGGAGCATGTTCTAACCCAATGCAA GGAAGTTAAGAACCTTGAAAAAAGGTTATG	FHTGTPSEGHQHQRPKVD KSTKLRKNQCKKAENSKN QKGSSPPKDQNSSPAREQ NQMENEFDELTEVGFRRW VITSKLKEHVLTQCKEVKNL EKRL

Shigolla	<u>-</u>	prov.67853	20	POCCETAGACAGAGAGAGACCTCACCTCAGGAGAGCATAGGAAGTACCA   231	AVDGEGAGI TSEAWKYOV
ospB	-		3	TCGAGAGGACCGTTTTCCTCTTTCCAGTCGGCTGCGGTTG	TSHREDRFPLSSRLRLALK
_				GCACTGAAGAATCTTGGTGCTGACAGACACAGAGCAGGGTCTCTCGTGGAA	NLGADRHRAGSLVEQELS
				CAGGAGTTGTCTGGTCTGTTCAGTTTGATGAGTGGCAGAAAATGAGACGATG	GLFSLMSGRK*DDGKCVC
				_	GPXFXCXGX
Shigella	·	prey66272	3	ATGTGGGCCCTGGGICAAGCAGGIIIIGCCAACCICACCGAGGGACIGAAA 232	MWALGQAGFANLIEGLKV
ospB				GTGTGGCTGGGGATCATGCTGCCTGTGCTGGGCATCAAGICICIGICICCC	WLGIMLPVLGIKSLSPFAII Y
				TTTGCCATCACATACCTGGATCGGCTGCTCCTGATGCATCCCAACCTTACCA	LDRLLLMHPNLTKGFGMIG
				AGGCCTTCGGCATGATTGGCCCCAAGGACTTCTTCCCACTTCTGGACTTTGC	PKDFFPLLDFAYMPNNSLT
				CTATATGCCGAACAACTCCCTGACACCCAGCCTGCAGGAGCAGCTGTGTCA	PSLQEQLCQLYPRLKVLAF
				GCTCTACCCCGACTGAAAGTGCTGGCATTTGGAGCAAAGCCGGATTCCAC	GAKPDSTLHTYFPSFLSRA
				CCTGCATACCTACTTCCCTTTTCCTGTCCAGAGCCACCCCTAGCTGTCCC	TPSCPPEMKKELLSSLTEC
				CCTGAGATGAAGAAGAGCTCCTGAGCAGCCTGACTGAGTGCCTGACGGTG	LTVDPLSASVWRQLYPKHL
				GACCCCCTCAGTGCCAGCGTCTGGAGGCAGCTGTACCCTAAGCACCTGTCA	SQSSLLLEHLLSSWEQIPKK
				CAGTCCAGCCTTCTGCTGGAGCACTTGCTCAGCTCCTGGGAGCAGATTCCC	VQKSLQETIQSLKLTNQELL
				AAGAAGGTACAGAAGTCTTTGCAAGAAACCATTCAGTCCCTCAAGCTTACCA	RKGSSNNQDVVTCDMACK
				ACCAGGAGCTGCTGAGGAAGGGTAGCAGTAACAACCAGGATGTCGTCACCT	GLLQQVQGPRLPWTRLLLL
				GTGACATGGCCTGCAAGGGCCTGTTGCAGCAGGTTCAGGGTCCTCGGCTGC	LLVFAVGFLCHDLRSHSSF
				CCTGGACGCGGCTCCTCTTGCTGCTGGTCTTCGCTGTAGGCTTCCTGT	QASLTGRLLRSSGFLPASQ
				GCCATGACCTCCGGTCACACAGCTCCTTCCAGGCCTCCCTTACTGGCCGGT	QACAKLYSYSLQGYSWLG
				TGCTTCGATCATCTGGCTTCTTACCTGCTAGCCAACAAGCGTGTGCCAAGCT	ETLPLWGSHLLTVVRPSLQ
				CTACTCCTACAGTCTGCAAGGCTACAGCTGGCTGGGGGAGACACTGCCGCT	LAWAHTNATVSFLSAHCAS
				CTGGGGGCTCCCACCTGCTCACCGTGGTGCGGCCCAGCTTGCAGCTGGCCT	HLAWFGDSLTSLSQRLQIQ
				GGGCTCACACCAATGCCACAGTCAGCTTCCTTTCTGCCCACTGTGCCTCTCA	LPDSVNQLLRYLRELPLLFH
				CCTTGCGTGGTTTGGTGACAGTCTCACCAGTCTCTCTCAGAGGCTACAGATC	QNVLLPLWHLLLEALAWAQ
				CAGCTCCCCGATTCCGTGAATCAGCTACTCCGCTATCTGAGAGAGCTGCCC	EHCHEACRGEVTWDCMKT
				CTGCTTTTCCACCAGAATGTGCTGCTGCCACTGTGGCACCTCTTGCTTG	QLSEAVHWTWLCLQDITVA
				CCCTGGCCTGGGCCCAGGAGCACTGCCATGAGGCATGCAGAGGTGAGGTG	FLDWALALISQQ*
				ACCTGGGACTGCATGAAGACACAGCTCAGTGAGGCTGTCCACTGGACCTGG	
	•			CTTTGCCTACAGGACATTACAGTGGCTTTCTTGGACTGGGCACTTGCCCTGA	
				AG	
Shigella	0	prey700	32		MGIGLSAQGVNMNRLPGW
ospD1				GGGATAAGCATTCATATGGTTACCATGGGGATGATGGACATTCGTTTGTTCT	DKHSYGYHGDDGHSFCSS
				TCTGGAACTGGACAACCTTATGGACCAACTTTCACTACTGGTGATGTCATTG	GTGQPYGPTFTTGDVIGCC
				GCTGTTGTGTTAATCTTATCAACAATACCTGCTTTTACACCAAGAATGGACAT	VNLINNTCFYTKNGHSLGIA
				AGTTTAGGTATTGCTTTCACTGACCTACCGCCAAATTTGTATCCTACTGTGGG	FTDLPPNLYPTVGLQTPGE
				GCTTCAAACACCCAGGAGAAGTGGTCGATGCCAATTTTGGGCAACATCCTTTC	VVDANFGQHPFVFDIEDYM
				GTGTTTGATATAGAAGACTATATGCGGGAGTGGAGCAACCAAAATCCAGGCAC	REWRITKIQAQIDREPIGDR
				AGA I AGA I CGA I I I CCI A I CGGAGA I CGAGAGAGAGAGA	EGEWQ I MICHINIASSILVE

				ACAAAAAAATGGTTTCATCTTATTTAGTCCACCATGGGTACTGTGCCACAGCAG	HGYCATAE
Shigella ospD1	α	prey2492	88	AAGCCTAAAGAGGCTAACAAGAAGAGGGCAGCCTGGCCTA AAAGGCGGTCTCAGTACAACAAGAAGAGAGCAGCCTCGGCCTA AAAGGCGGTCTCAGTACATTCTTCGAAACAGGAAAAGTAGAGGATCCTCTCAGCC ATCAAAACTGGAAGATGCAAGTAATACTGCAGACACTT CAAAAGGGTCGGAAAGACAGGCAATTCCACTAAATATTGCA ATTTCAAAAGGGTGGAAAGAAGGTTTCTTTCAACTTTCAAAATATTGAA ATATTCAAAAGGGTGAATTTATTCTTTTCATTCAACTTTAAAAAGGTTT AACACTTTATGGGAAAACGGTTAAAGAATTTATGCTG AAACAAGGGTGAACAAGGTTACATAAGAAATTGCTT AACCCATCAACTTGACAAAACGTTTAAATGATTATGCTG AAACAAGAGGTTGAAAAAGGTTAAAAGAATTGCTT AACCCAGGCCTGGACAAGAAGGTTACATAAGAAAAGGTTT AACCCAGGCCTTGGAACAAGAAGGTTAAAAGAAAGATTGTAAAAGAAGATTGTAAAAGAACAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAG	TNLKRQANKKSEGSLAYVK GGLSTFFEAQDALSAIHQK LEADGTEKVEGSMTQKLEN VLNRASNTADTLFQEVLGR KDKADSTRNALNVLQRFKF LFNLPLNIERNIQKGDYDVV INDYEKAKSLFGKTEVQVF KKYYAEVETRIEALRELLLD KLLETPSTLHDQKRYIRYLS DLHASGDPAWQCIGAQHK WILQLMHSCKEGYVKDLKG NPGLHSPMLDLDNDTRPSV LGHLSQTASLKRGSSFQSG RDDTWRYKTPHRVAFVEK LTKLVLSQLPNFWKLWISY VNGSLFSETAEKSGQIERS KNVRQRGWEVKCELSGQWL AHAIQTYRLTHESLTALEIP NDLLQTIQDLILDLRVRCVM ATLQHTAEEIKRLAEKEDWI VDNEGLTSLPCQFEQCIVC SLQSLKGVLECKPGEASVF QQPKTQEEVCQLSINIMQV FIYCLEQLSTKPDADIDTTH LSVDVSSPDLFGSIHEDFSL TSEQR
Shigella ospD1	2	prey67651	34	CAGTATAAGAAGGCCTTAGAGAATGAAATGAGGAGAAATCTGGCACAC 235 CAGGAGCTGATAAAGCAGAAAAAAGATATAAGTATACAGTTAAGCTCANCCC AGTCTCGTTGTACTTCTAGAGAAGCAACTAGAATATACAAAGAATGGTT CTCAACGTAGGAGCGAGAAAGAACATGATCCTAGAACAACAGGCCCAGCTT CAGAGGGAAAAAGAAAAG	QYKKALENETNEEKSGTPG ADKAEKRYKYTVKLXPVSL YSSREATRIYKENGSQRRS EKRT*S*NNRPSFRGKKNKI R*SCMQNLKSLMSXKKSVS DLQQLX

Shigella	2	prey67653	35	CCCTGAAATCTGCAAAATGGCTGATAATTTGGATGAATTTATTGAAGAGCAAA   236	PEICKMADNLDEFIEEQKAR
ospD1				AAGCCAGATTGGCCGAAGACAAAGCAGAGTTGGAAAGTGATCCACCTTACAT	LAEDKAELESDPPYMEMK   GKLSAKLSENSKILISMAKE
				ATCTCTATGGCTAAGGAAAACATACCACCAAATAGTCAACAGACCAGGGGTT	NIPPNSQQTRGSLGIDYGL
				CCTTAGGAATTGATTATGGATTAAGTTTACCACTTGGAGAAGACTATGAACGG   AAGAAACATAAATTAAAAGAAGAATTGCG	SLPLGEDYERKKHKLKEEL
Shigella	2	prev67667	36	CGACCAGGGCACACCCCAGTACATGGAGAACATGGAGCAGGTGTTTGAGCA 237	DOGTPOYMENMEQVFEQC
ospD1		•		GTGCCAGCAGTTCGAGGAGAAACGCCTTCGCTTCTTCCGGGAGGTTCTGCT	QQFEEKRLRFFREVLLEVQ
L D				GGAGGTTCAGAAGCACCTAAACCTGTCCAATGTGGCTGGTTACAAAGCCATT	KHLNLSNVAGYKAIYHDLE
				TACCATGACCTGGAGCAGCATCAGAGCAGCTGATGCAGTGGAGGACCTG	QSIRAADAVEDLRWFRANH
				AGGTGGTTCCGAGCCAATCACGGGCCAGGCCATGGCCATGAACTGGCCGCA	GPGMAMNWPQFEEWSAD
				GTTTGAGGAGTGGTCCGCAGACCTGATTCGAACCCTCAGCCGGAGAGAAA	LIRTLSRREKKKATDGFTLT
				GAAGAAGGCCACTGACGGCTTCACCCTGACGGGCATCAACCAGACAGGCGA	GINQTGDQFLPSKPSS
				T	
Shigella	2	prey67657	37	CCCGCCTGCCATGGACTGGATCTTCCAGTGCATCTCCTACCATGCCCCGGA 238	PPAMDWIFQCISYHAPEAL
ospD1				GGCTCTGCTGACCGAGATGATGGAAAGGTGTAAGAAACTAGGAAACAATGC	LI EMMERCKKLGNNALLLN
				CTTGCTGTTGAATTCTGTGATGTCTGCCTTCCGGGCTGAGTTCATCGCCACA	SVMSAFRAEFIALRSMUFIG
				AGGTCTATGGATTTCATTGGCATGATTAAAGAGTGTGATGAATCTGGTTTCCC	MIKECDESGFPKHLLFRSL
			-	CAAGCATCTTCTTTTCGATCACTGGGATTAAACTTGGCCTTGGCTGATCCTC	GLNLALADPPESDRLQILNE
_				CTGAGAGTGACCGACTTCAGATTCTCAACGAAGCTTGGAAAGTCATCACTAA	AWKVITKLKNPODYINCAE
				GCTGAAGAACCCACAGGACTACATTAATTGTGCCGAAGTGTGGGTGG	VWVEYTCKHFTKREVNTVL
				ACCTGCAAGCATTTCACGAAACGAGAGGTGAATACCGTTTTGGCCAGATGTCA	ADVIKHMI PDKAFEDSYPQ
				TCAAGCACATGACTCCAGATCGTGCATTTGAAGATTCCTACCCCCAGCTTCA	LQLIIKKVIAHFHIJFSVLFSV
				GTTAATAATAAGAAAGTTATTGCCCACTTCCATGACIICICCAGIICIIIICIC	
				AGTGGAAAAATTTCTGCCGTTTCTGGACATGTTCTGGAAAAGAAGAGTGTGTGG	CKCIMDAFIRAGGEFIND
				GTGGAGGTTTGCAAATGCATCATGGACGCCTTTATCAAGCATCAACAAGAGC	
-			8	CCACCAAGGACC	EBI ECI ECI DDAFKKI NI A
Shigella	N_	prey6/501	30		OKCEKNOVGENDORIVEN
ospD1					
				CCACALAAAAGGAAAAIIGIGGGAAAAGAAAAGGIACIGIIIOIAAGAAGAAAAAAAAAA	BNYHSGNDVEAVEY NRH
				I ACT I CAAGGGAT CCGAAACTAT GGAAAT GGAAGGGGAT G	MOOCHWOOL INCOME
			_	AGTATCTTAACAGGCACGTCAGCICIIIAAAGAGCIAIAIAIIGAICCAICAA	VSSEKSTEIMGKW I ICCSW
				AAGTGGACAATTTGTTGCAGTTGGGGGTTTACTGCCCAGGAAGCACCGGCTTG	GLLPRANTICIONALO DE LA COMUNICACIÓN DE LA CASTALISTA DE LA COMUNICACIÓN DE LA CASTALISTA DE
	-			GCCTGAGGGCGTGTGGGAACGIGGAICAIGCGGCCACICAIAIIACCA	DHAATHIINRREELAQIRNE
		•		ACCGCAGAGGAACI GGCCCCAAI AAGGAAGGAAAAAAAAAA	
				GACGCCGCCTCGAGAACATCAGGTTTCTGAAAGGGATGGGCTACTCCACGC	HISA
				TOACATACOACACTTACOACACTTACAC	THE THE THE THE THE THE
Shigella	Ω_	prey67678	66	GAACAAGCTGAGGGTGTTGTGGACCCAGAGGTTACCCAGCAGACCATAGAGCT   240  GAAGGAAGAGAGTGCAAAGACTTTGTGGACAAAATTGGCCAGTTTCAGAAAATA	CKDFVDKIGQFQKIVGGLIE
2000					

and the second s			GTTGGTGGTTTAATTGAGCTTGTTGATCAACTTGCAAAAGAAGCAGAAAATGA	LVDQLAKEAENEKMKAIGA
			AAAGATGAAGGCCATCGGTGCTCGGAACTTGCTAATTGTATAGCAAAGCAG AGAGAAGCTCAACAGCAGCAACTTCAAGCCCTAATAGCAGAAAAGAAAATGC	ALIAEKKMOLERYRVEYEA
		<u> </u>	AGCTAGAAAGGTATCGGGTTGAATATGAAGCTTTGTGTAAAGGTAGAAGCAGA ACAAAATGAATTTATTGACCAATTTATTTTCAGAAATGA	LCKVEAEQNEFIDQFIFQK*
Shigella 2	prey67578	40	ATGGCGGTGGAGACTCTGTCCCCGGACTGGGGAGTTTGACCGCGTTGACGAC 241	MAVETLSPDWEFDRVDDG SQKIHAEVQLKNYGKFLEE
-			TGAGGAGTATACCTCTCAACTGAGAATTGAGGACGCTCTGGATGACTCA	YTSQLRRIEDALDDSIGDV
			ATTGGAGATGTTTGGGATTTCAATCTTGATCCTATAGCATTAAAGCTTTTGCC	WDFNLDPIALKLLPYEQSSL
			TTATGAACAGTCCTCTCTTTTGGAACTCATAAAGACTGAAAACAAGGTCTTAA	LELIKTENKVLNKVITVYAAL
			ACAAAGICATCACIGIIIA GC GCACIIIGIIGIGAAA CAAGAAAIIAAAAI    atgaggctgaaactaaattttacaatggtctcttttatatggagagagggct	FYGEGATDASMVEGDCOI
			ACAGATGCCAGCATGGTGGAAGGTGGTTGCCAAATTCAAATGGGGAGATTTA	QMGRFISFLQELSCFVTRC
			TTTCATTCTTACAGGAACTGTCTTGCTTTGTTACGAGGTGCTATGAAGTGGTG	YEVVMNVVHQLAALYISNKI
			ATGAACGTAGTCCACCAGTTGGCTGCCCTCTATATCAGTAACAAGATTGCAC	APKIIETTGVHFQTMYEHLG
			CCAAAATTATAGAGACAACTGGAGTTCATTTTCAGACTATGTATG	ELLTVLLTLDEIIDNHITLKD
			GGAGAACTGCTAACAGTTTTGCTCACCCTGGATGAAATTATTGATAATCATAT	HWTMYKRLLKSVHHNPSK
			CACACTGAAAGACCACTGGACTATGTACAAAGGTTACTGAAATCTGTCCAT	FGIQEEKLKPFEKFLLKLEG
			CACAATCCTTCAAAATTTGGAATTCAGGAAGAAAAATTAAAGCCATTTGAAAA	QLLDGMIFQACIEQQFDSL
			GTTCTTGCTGAAGCTAGAAGGGCAATTACTGGATGGAATGATATTCCAGGCC	NGGVSVSKNSTFAEEFAHS
			TGTATAGAACAACAATTTGATTCTCTCAATGGAGGAGTATCTGTGTCAAAAAA	IRSIFANVEAKLGEPSEIDQ
			TAGTACTTTTGCTGAGGAATTTGCACATAGTATTCGGTCAAIIIIIGCAAAIG	RDK YVGICGLEVLHFQIFKI
	-		TAGAAGCCAAACTTGGAGAACCTTCTGAAATTGACCAGAGAGACAAGTAIGI	IDKKFYKSLLD
			TGGAATTTGTGGACTCTTTGTATTGCACTTTCAGATTTTTCGAACTATTGATAA	
			$\dashv$	
Shigella 2	prey67580	4	GCACTCCCCGCCGCTCCGACTCCGCCATCTCTGTCCGCTCCCTGCACTCAG   242	TPRRSDSAISVRSLHSESS
ospD1			AGI CCAGCATGI CTCTGCGCT CCACATTCTCGTGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGA	VEAEOPSVKI CCOI CCSVE
			AGCCGGGAGCGCGTCTTCAAAGACCCCGTGATCACGCGTGTGGGCACA	KDPVITTCGHTFCRRCALK
			CGTTCTGTAGGAGATGCGCCTTGAAGTCAGAGAGTGTCCCGTGGACAACG	SEKCPVDNVKLTVVVNNIA
			TCAAACTGACCGTGGTGAACAACATCGCGGTGGCCGAGCAGATCGGGG	VAEQIGELFIHCRHGCRVA
			AGCTCTTCATCCACTGCCGGCACGGCTGCCGGGTAGCGGGCAGCGGGAAG	GSGKPPIFEVDPRGCPFTIK
			CCCCCCATCTTTGAGGTGGCCCCGAGGGTGCCCCTTCACCATCAAGCTC	LSARKDHEGSCDYRPVRC
			AGCGCCCGGAAGGACCACGAGGGCAGCTGTGACTACAGGCCTGTGCGGTG	PNNPSCPPLLRMNLEAHLK
			TCCCAACAACCCCAGCTGCCCCCCCGCTGCTCAGGATGAACCTGGAGGCCCA	ECEHIKCPHSKYGCI FIGN
			CCTCAAGGAGTGCGAGCACATCAAATGCCCCCACTCCAAGTACGGGTGCAC	QUI YEI HLEI ORFEGLNET
			GTTCATCGGGAACCAGGACACTTACGAGACCCACCTGGAGACTTGCCGCTT	LQQI DDRFHEMHVALAQK
			CGAGGGCCTGAAGGAGTTTCTGCAGGACGGATGACCGCTTCCTCCCTGAT	DQEIAFLASIMICGALSERID
			GCACG   GGC   C   GGC   C   GCG   C	

		The state of the s		GCTGGGAAAGCTCTCGGAGAAGATCGACC	
Shigella 2	2	prey3160	42	CAGAAAACTTGAAGTTTGGAAGAGACAGGTAAGACAAAGAACTTCAGACTTTAC	RKLHELTVMQDRREQARQ DLKGLEETVAKELQTLHNL
-				ACAACCTGCGCAAACTCTTGTTCAGGACCTG	RKLFVQDL
Shigella 2 ospD1	2	prey50427	43	ATGGAGGAGTATGAGAAGTTCTGTGAAAAAGTCTTGCCAGAATACAAGAAG   244   CATCACTATCCACAGAGGTTTTCTCCCTGCTCAGTCTGAAAGTATCTCACTT	MEEYEKFCEKSLARIQEAS LSTESFLPAQSESISLIRFH
				ATTCGCTTTCATGGAGTGGCTATCCTTTCTCCCACTGCTTAACATTGAGAAAAG	GVAILSPLLNIEKRKEMQQE
				CAGGTTAACAGGAAGAAAGCTTTACTGACTCGTGTCCAGGAGATTCTTGACA	LTRVQEILDNVQVRKAPNA
				ATGTTCAGGTTAGAAAAGCACCTAATGCCAGTGATTTTGATCAGTGGGAGAT	SDFDQWEMETVYSNSEVR
				GGAAACAGTTTACTCTAATTCAGAAGTCAGAAACTTGAATGTTCCTGCTACAT	NENVPATEPNSFPSHTEHS
				TTCCAAATAGCTITCCAAGCCATAGGAACACTCTACTGCAGCAAAGCTTGAT AAGATAGCTGGGATTTTGCCATTGGATAATGAGGACCAATGTAAAACTGATG	AANLUNIAGILF LUNEUGC   KTDGIDLARDSEGFNSPKQ
				GAATAGACTTAGCTAGAGATTCAGAAGGATTTAATTCTCCGAAGCAATGTGAT	CDSSNISHVENEAFPKTSS
				AGTTCCAATATTAGTCATGTAGAAATGAAGCTTTTCCAAAGACCTCTTCAGC	ATPOETLISDGPFSVNEQQ
				AACCCCACAAGAAACTCTTATTCTGATGGTCCCTTCTCAGTAAATGAACAAC	DLPLLAEVIPDPYVMSLQNL
				AGGATCTACCACTTTTGGCAGAGTCATCCCAGATCCCTATGTAATGAGTCTT	MKKSKEYIEHEQSHASLHG
				CAGAATCTGATGAAAAAGTCAAAGGAATATATAGAAAGAGAACAATCTAGAC	SMNRIVNESHLDKEHDAVE
				GCAGTCTGAGAGGTAGTATGAACAGAATTGTTAATGAGAGTCATTTAGACAA	VADCVKEKGQLTGKHCVS
				AGAACATGATGCTGTTGAAGTGGCTGACTGTTGTAAAAGAGAAAGGGCCAGTTG	VIPDKPSLNKSNVLLQGAST
					QASSMSMPVLASFSKVDIPI
				AAATGTTCTTCTCCAAGGTGCTTCCACTCAAGCAAGCAGCATGAGTATGCCA	RTGHPTVLESNSDFKVIPII
				GTTTTAGCTAGCTTTTCGAAAGTGGACATACCTATACGAACTGGCCATCCCA	VTENNVIKSLTGSYAKLPSP
				CTGTTCTAGAGTCTAATTCTGATTTTAAAGTTATTCCCACTATTGTTACCGAAA	EPSMSPKMHRRR
				ATAATGTTATCAAAAGTCTTACAGGTTCATATGCCAAATTACCTAGTCCAGAG	
a	2	prey63765	44	GGACAGCCCAACCTCTGGCAGACCAGGGGTTACCAGCCTCACAACTGCAGC 245	DSPTSGRPGVTSLTTAAAF
ospD1		-		TGCCTTCAAGCCTG1 AGGA1 CCAC1 GGCG1 CA1 CAAG1 CACCAAGC1 GGCAA	KPVGSIGVIKSPSWQRFN
				CGGCCAAACCAAGGAGI ACCI I CCAC I GGAAGAA I CI CAAACAGCGCI ACI I	APANSAI GOTOPSDODTI V
			_	ACTOAGGACACATTAGTGCAAAGAGCTGAGCATTCCAGCAGGGAAAC	OBAEHIPAGKRTPMCAHC
			_	GAACTCCGATGTGCGCCCATTGTAACCAGGTCATCAGAGGACCATTCTTAGT	NQVIRGPFLVALGKSWHPE
				GGCACTGGGGAAATCTTGGCACCCAGAAGAATTCAACTGCGCTCACTGCAA	EFNCAHCKNTMAYIGFVEE
				AAATACAATGGCCTACATTGGATTTGTAGAGGAGAAAGGAGCCCTGTATTGT	KGALYCELCYEKFFAPECG
				GAGCTGTGCTATGAGAAATTCTTTGCCCCTGAATGTGGTCGATGCCAAAGGA	RCQRKILGEVINALKQTWH
				AGATCCTTGGAGAAGTCATCAATGCGTTGAAACAAACTTGGCATGTTTCCTGT	VSCFVCVACGKPIRNNVFH
				TTTGTGTGTGTAGCCTGTGGAAAGCCCATTCGGAACAATGTTTTCACTTGGA	LEDGEPYCEIDYYALFGII
					CHGCEFPIEAGDMFLEALG
				GCCATGGATGTGGAATTTCCCATAGAAGCTGGTGACATGTTCCTGGAAGCTCT	I WHD I OF VOOLOEL

		Control of the Contro		TOTALOTOTOTOTOTOTOTOTOTOTOTOTOTOTOTOTOTO	OT IVI IVIO IGNOVINO I
				GGGCTACACCTGGCATGACACTTGTATGCTCAGTGTGTGT	GGG TTORNONTLONGATO
Shigella ospD1	N	prey67623	45	ACATGGTACAGCCAGAGTACCGAATCTAT CTCGCACAGAGGATAGTGACAGATCTAT CTCGCACAGAGGATAGTGACACCTCTGG AGCGATACACTATCGGCAGCACCTCTTC AGCGATACACTATCGGCAGCACCTCTTC TGAAGGAGGGTGACCGACCTTATTACA ATACACACTCATCCATCATTTACCAAGGT TTGGAGTTCACCTTTGATGATCTCATGAGA TAGACAATACCGAGAGTTAGTCCCGAGAA AGAACTTCACCTTTGATGATCTCAGGTTG AGAACTTCACCTCAGGTTAGTCCCAAGGT ACAAACTTCACCTCAGGATCAGCTGTCCAA ACAAACTTCACCTCAACTACCTCAGGTTG AGAACTTCACCTCAACTACCTCAGGTTG AACCCACAAGGCCAACACAAAACTTACA AACCCACAAGGCAACAAAAACTTACA AACCCACAAGGCAACAAAAACTTACA	FYRRHTPYMVQPEYRIYEM NKRLQSRTEDSDNLWWDA FATEFFEDDATLTLSFCLED GPKRYTIGRTLIPRYFSTVF EGGVTDLYYILKHSKESYH NSSITVDCDQCTMVTQHGK PMFTKVCTEGRLILEFTFDD LMRIKTWHFTIRQYRELVP RSILAMHAQDPQVLDQLSK NITRMGLTNFTLNYLRLCVI LEPMQELMSRHKTYNLSPR DCLKTCLFQKWQRMVAPP AEPTRQP
Shigella ospD1	a	prey7315	46	0.0	MLDRDVGPTPMYPPTYLEP GIGRHTPYGNQTDYRIFEL NKRLQNWTEECDNLWWD AFTTEFFEDDAMLTITFCLE DGPKRYTIGRTLIPRYFRSI FEGGATELYYVLKHPKEAF HSNFVSLDCDQGSMVTQH GKPMFTQVCVEGRLYLEF MFDDMMRIKTWHFSIRQH RELIPRSILAMHAQDPQML DQLSKNITRCGLSNSTLNYL S
Shigella ospD1	Q	prey67601	47	AGTCACTGCTTCAACCACCTGTGAGAAATTAGAAAAAGCCAGGAATGAGTTA 248 CAAACAGTGTATGAAGCATTCGTCCAGCAGCACCAGGCTGAAAAACAGAAC CAAACAGTGTTTAAAGAGTTTTACACCAGGGAGTATGAAAAACAGAAC GAGAGAATCGGCTTAAAGAGAGAGTTTTACACCAGGGAGTATGAAAAGCTTCGGGA CACTTACATTGAAGAAGCAGAGAAGTACAAAATGCAATTGCAAGAGCAGTTT GACAACTTAAATGCTGCGCATGAAACCTCTAAGTTGGAAATTGAAGCTAGC ACTCAGAGAAAATGCTGAAAAAGAAGCCTTTCAGA AATTAAGAAAAGGCCATGAAAAAGAAAAG	VTASTICEKLEKAHNELQI VYEAFVQQHQAEKTEREN RLKEFYTREYEKLRDTYIEE AEKYKMQLQEQFDNLNAA HETSKLEIEASHSEKLELLK KAYEASLSEIKKGHEIEKKS LEDLLSEKQESLEKQINDLK SENDALNEKLKSEEQKRRA

					REKANLKNPQIMYLEQELE SLKAVLEIKNEKLHQQDIKL MKMEKLVDNNTALVDKLKR FQQENEELKARMDKHMAIS RQLSTEQAVLQESLEKESK VNKRLSMENEELLWKLHN GDLCSPKRSPTSSAIPLQS PRNSGSFPSPSISPR*
Shigella ospD1	N	prey53735	48	CTCGCTTCCTCCTAGCACTGGGACATTTCAAGAGGCCGGTTGAAT GAAGCTGCTCCTCAGCCACAGAACTCGTGCAGCCGGTTGAAT GAAGCTGCTGCTGGGCTGAATCAGGCAGCCACAGAACTGGTGCAGGCCTCT CGGGGAACCCTCAGGCTCGAGCCTCAGGCCATTTGGACAGGA CTTCAGCACCTTCCTGGAAGCTGGTGGAGATGGCAGGCCAGGCTCCCAGG CCAGGAGCCCAAGTTGTTGCAACAGGCCATGTC TTCAAGCAAACTTCTTCTGGTTGCCAAGGCCTGTCCAGGACCCTGCTGC CCTAACCTCAACATCAGCTGCACCAGCAGGCACTCTCCTGAAGA TTCAACCTCAACATCAGTTGCAGCAGCAGCACTCTCTGGAAAC ATCAATCAGCTCATCATTTGGAGACGGTCCGGGAACTCTTGGTAA TGGAGAACTCAATGGAGACGGTCCAGCAGGCACTGCAGAAG TGTGATAACGCCAATTTGGAGACGGTCCAGGACAGTTAA TGGAGAACTCAATGGAGAGCGGTCCAGCAGCATTTGCACAGCCTCAAA TGGAGAACTCAATGGAGAGCGGTCCAGCAGCTTTTGCACAGCCTCAAA TGGAGAACTCAATGGAGAGCGGTCCAGGACTTTGCAAA TGGAGAACTCAATGGAGAGCAGCATTTGCATATCTGGTTGG ACAGTTTGTGCCCAAACCAGGCAGCTGCAAACGC ACAGAACCTGCAAACCAGGCAAGCAACAGCCCCACAGGCTTCTGCCCAAA GGCACTTTGTGCCCAAACCAGCCAGGTTCTGCACCATTGTGGC ACAGTTTGCCCTTGCAAACCAGCTGTCAACCCTCTGCAGGCTTCTACCAACCCTTCAACCCACACCCTTCAACCCACACCCTTCAACCCACACCTTCAACCCACACCCTTCAACCCACACACACCCTTCAACCCTTCAACCCTTCAACACCCCTTCAACCCTTCAACCCTTCAACACCCTTCAACCCTTCAACCCTTCAACCCTTCAACCCTTCAACCCTTCAACCCTTCAACCCTTCAACCTTCAACACCCTTCAACCTTCAACACCCCTTCAACCTTCAACCCTTCAACCCTTCAACCTTCAACCTTCAACCCTTCAACCTTCAACCCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTTCAACACCCTTCAACCAACTTCAACCAACTCCAACTCTCAACCAACTCCAACACCAACACCAACACCAACACCAACACCAACACCAACAC	SLPPSTGTFGEAGSRLNEA AAGLNQAATELVQASRGTP QDLARASGRFGQDFSTFLE AGVEMAGQAPSQEDRAQV VSNLKGISMSSSKLLLAAKA LSTDPAAPNLKSQLAAAAR AVTDSINQLITMCTQQAPG QKECDNALRELETVRELLE NPVQPINDMSYFGCLDSVM ENSKVLGEAMTGISQNAKN GNLPEFGDAISTASKALCG FTEAAAQAAYLVGVSDPNS QAGQGLVEPTQFARANQ VLSAATIVAKHTSALCNSCR LASARTTNPTAKRQFVQSA KEVANSTANLVKTIKALDGA KEVANSTANLVKTIKALDGA FTEENRAQCRAATAPLLEA VDNLSAFASNPEFSSIPAQI SPEGRAAMEPIVIS
Shigella ospD1	2	prey67630	49	GAGGACCTGCAGCCCCCGGCCCCTGTCGCCCCTTCACCAACAGCCTC 250 GCTCGCTCTGCGCGCCAGTCTGTGCTCCGGTATAGCACTCTCCCTGGGCCGC AGGGCCCTGAAGAACTCCCGCCTAGTGAGCCAGAAGGATGACGTCCACGTC TGTATCCTTTGTCTCAGAGCCATCATGAACTATCAGTACGGATTCAACCTGGT CATGTCCCACCCCCATGCTGTCATGAGCTTTGCATAGCAAGAG AATCCAAAGGCCATGTCTTAGAGCTTCTGGCAN	EDLQPPSALSAPFTNSLAR SARQSVLRYSTLPGRRALK NSRLVSQKDDVHVCILCLR AIMNYQYGFNLVMSHPHAV NEIALSLNNKNPRTKALVLE LLA

Shigella	2	prey12665	20	GAAGCGGCACGAGCGAATGATCAAGAACCGGGAGTCAGCCTGCCAGTCCC 251	KRHERMIKNRESACOSRR KKKFYI OGI FARI OAVI AD
i aden				TACTGGCTGACAACCAGCAGCTCCGCCGAGAGAATGCTGCCCTCCGGCGGC	NQQLRRENAALRRRLEALL
				GGCTGGAGGCCCTGCTGGCTGAAAACAGCGAGCTCAAGTTAGGGTCTGGAA	AENSELKLGSGNRKVVCIM
				ACAGGAAGGTGGTCTGCATCATGGTCTTCCTTCTTCATTGCCTTCAACTTT	VFLLFIAFNFGPVSISEPPSA
				GGACCTGTCAGCATCAGTGAGCCTCCTTCAGCTCCCATCTCTCGGATGA	PISPRMNKGEPOPRRHLLG
				ACAAGGGGAGCCTCAACCCCGGAGACACTTGCTGGGGTTCTCGAGGCAAG	PSEQEPVQGVEPLQGSSQ
				AGCCAGTTCAGGGAGTTGAACCTCTCCAGGGGTCCTCCCAGGGCCCTAAGG	GPKEPUPSPI DUPSPSNLI
				AGCCCCAGCCCAGCCCCACAGACCAGGCCCAGIIICAGCAACCIGACAGCCI	AFFGGAKELLLKULDULFL
					SSUCKHFINKI ESLKLADEL
		-		TCTCCTCTGATTGCCGGCACTTCAACCGCACTGAGGTCCCTGAGGCTTGA	SGW VCHCHGRRNIPCHA
				CGAGTTGAGTGGCTGGGTCCAGCGCCACCAGAGAGGCCGGAGGAAGATCC	QERQKSQPRKKSPPVKAV
				CTCAGAGGGCCCAGGAGAGACAGAAGTCTCAGCCACGGAAGAAGTCACCTC	1.
Shinella	٥	prev67631	5.	TGAGAGCGAGGTCTCGGAGCATCTCAGTGCCAGCTCGGCTTCTGCCATCCA 252	ESEVSEHLSASSASAIQQD
OspD1	J			GCAGGACAGCATTCCAGCATGCAGCCACCATCTGAAGCCCCCATGGTGAA	STSSMQPPSEAPMVNTVS
1 1 0				CACAGTCAGCTCAGCTTATTCGGAGGATTTTGAAAACTCTCCAAGTCTGACA	SAYSEDFENSPSLTASEPT
				GCATCTGAGCCAACCGCCCATTCCAAGGAGTCTCTTGACAGAACACTGGAC	AHSKESLDRTLDALSESSS
				GCTTTGTCTGAATCCTCTTCAAGTGTGAAGACAGACCTTCCACAAACAGCCG	SVKTDLPQTAESRKKSGRH
				AGTCTAGGAAAAAGTCGGGCAGGCACGTGACAAGAGTGCTTGTGAAGGACA	VTRVLVKDTAVQTPDPAFT
				CAGCTGTGCAGACGCCAGATCCTGCCTTCACCTACGAGTGGACCAAGGTGG	YEWTKVASMAAMGPALGG
				CCAGCATGGCAGCCATGGGGCCTGCCCTGGGAGGCGCCTACGTGGACCCG	AYVDPTPIANHVISADAIEAL
				ACACCCATCGCCAATCATGTTATCAGTGCAGATGCAATAGAAGCCCTGACCG	TAYSPAVLALHDVLKQQLS
				CTTACAGCCCGGCCGTGCTGGCACTCCATGATGTGCTGAAGCAGCAGCTGA	LTQQFIQASRHLHASLLRSL
-				GCCTGACGCAGCAGTTCATCCAGGCCAGCCGGCACCTGCACGCCTCCCTC	DADSFHYHTLEEAKEYIRC
				TGCGCTCCCTGGACGCGGACTCCTTCCACTACCACACCCTGGAGGAAGCCA	HRPAPLTMEDALEEVNKEL
				AAGAGTACATTAGGTGCCACAGACCTGCCCCACTGACCATGGAGGATGCCC	*
	,		5	GGAGGAGG GAACAAGGAGC G GA	MAESPON EFEVEROFI BI
Shigella	N	preyzu143	25	A   GGCAGAGAGCGCCGCCAGGACC   GGAGGAGGAG   A   GAGCC   CAG     CC   G   233   CCCCTACTAGAGAAAAAAAAAACTGGAACCAAAAGCTTGGAAGAAAAAAAA	I FRKFAGTKAI OBTOAFIO
osbo				GCTGAGATCCAGGAAATGAAGGAGGCTCTGAGACCCCTGCAAGCAGGAGGCC	EMKEALRPLQAEARQLRLQ
				CGGCAGCTCCGCCTGCAAAACAGGAACCTGGAGGACCAGATCGCACTTGTG	NRNLEDQIALVRQKRDEEV
				AGGCAAAAACGAGATGAAGAGGTGCAGCAGTACAGGGAACAGCTGGAGGAA	QQYREQLEEMEERQRQLR
				ATGGAAGAACGCCAGAGGCAGTTAAGAAATGGGGTGCAACTCCAGCAACAG	NGVQLQQQKNKEMEQLRL
				AAGAACAAAGAGATGGAACAGCTAAGGCTCAGTCTTGCTGAAGAGCTCTCTA	SLAEELSTYKAMLLPKSLE
				CTTATAAGGCTATGCTACTACCCAAGAGCCTGGAACAGGCTGATGCTCCCAC	QADAPTSQAGGMETQSQG
					AV*
Shigella	2	prey1418	23	CTGGGTCATCCCAGATCCCGAAGAGGAACCAGAGCGCAAGCGAAAGAAGG 254	WVIPDPEEEPERKRKKGPA PKMLGHELCRVCGDKASG
1000					

				AAGGCCTCCGGCTTCCACTACAACGTGCTCAGCTGCGAAGGCTGCAAGGGC TTCTTCCGGCGCAGTGTGGTGGGGCCAGGCGCTATGCCTGCC	FHYNVLSCEGCKGFFRRSV VRGGARRYACRGGGTCQ MDAFMRRKCQQCRLRKCK EAGMREQCVLSEEQIRKKK IRKQQQQESQSQSQSPVG PQGSSSSASGPGASPGGS PQGSSSSASGPGASPGGS EAGSQGSGEGEGVQLTAA QELMIQQLVAAQLQCNKRS
a	8	prey67642	54	TCCGACCAGCCAAAGTCACGCCCTGGCCCAGACCCCCAGTC CCGAGATGCCCGCCAGCCATTGCCCACTTCACGGAGCTGGCCATCAT CTCAGTCCAGGAGATCGTGGACTTCGCTAAGCAAGTGCCTGGTTTCCTGCA GCTGGGCCGGGAGGACCAGATCGCCTCCTGAAGGCATCCACTATCGAGAT CATGCTGCTAGAGACAGCCAGGCGCCTCCTGAAGGCATCCACTATCGAGAT ATGAAGGATGAACCACGGCCAACAACCTGTTCATGAAGCTGGACTCT ATGAAGGATGAACCACGGTCCACAACCTGTTCATGAAGCTTGGACTCGGTCT 255	RDARQQRFAHFTELAIISVQ EIVDFAKQVPGFLQLGRED QIALLKASTIEIMLLETARRY NHE MKDEPRSTNLFMKLDSVFI
ospD1				1 0	WKEPFGLVLIIAPWNYPLNL TLVLLVGTLPAGNCVVLKP SEISQGTEKVLAEVLPQYLD QSCFAVVLGGPQETGQLLE HKLDYIFFTGSPRVGKIVMT AATKHLTPVTLEL
Shigella ospD1	2	prey67648	55	(5 4 .)	LGIALALLGERLLALRNRLK ASREVESVDLPHCHLIKGIE AGSEDIDILPNGLAFFSVGL KFPGLHSFAPDKPGGILMM DLKEEKPRARELRISRGFD LASFNPHGISTFIDNDD
Shigella ospC1	င	prey67266	26		XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
Shigella ospC1	ဇ	prey67267	22	TACTATTTACTGGATGTCTCAGTAGGCATAGTTTAGAGATACGTTGTGTGCAA 258 TAGACATATAAATGATTTGTTTACATTACTCCATATAAATGATTTGTTTAA TGTCTTGGAAATTATTTTATGTCTTATGGTTGCTGATTCTGTTGCCATCNGATT ACTACGATAAANAAGATCTGNGNCTANNGANGGGNCTTNTTTGAACTGNTNC	YYLLDVSVGIV*RYVVCNKH INDLFTLLHINDLFV*CLGNY FMSYGC*FCCHXITTIXKIXX XXXXXFELXLXXXXGXXCX

	60 20 80 80 81	GGGTGCAGCGTCT 260 MADLDSPPKLSGVQQPSE TCCGCTGAGCTCTGCGG TTACGAACGCCTCTGCGG TCTTTTGGAACAGCAAAA TCTTTGGAACAGCAAAA TCTTGGGTCCTTACCTGCA AGATTATGAGCCAGGAA AGATTATGAGCAGGCTG AAGATTTGCAAATTGCTGCA AAGATTATGAGCTGCA AAGATTATGAGCTCAA AGAAGTTTGCCATTGC AAGATTGCCATTGC AAGATTGCAAATGC AAGATAGTGCATTGC AAGATTGCATTGC
TNNGGCNTNGGNTNGGGNGCNTNTGTNTNGNCNNNGTTGTTGNGNNNANGGCOGNGNNCGGNGNCNGTTGATTNNCAGGTNTGGNNNNGNTGGNGGCNCNTGGCNCCTNGCATNTN	GTTTGATCAGCCTCAGGAATACTTCATGAGTTTGACATTCAATCAA	ATGGCGGACCTTGATTCGCCTCCGAAGCTGTCAGGGGTGCAGCCGTCT GAGGGGGTGGAGGTGGCCGCTGCTCCGAAATCTCCGCTGAGCTCATTCG CTCCCTGACAGAGGTGGCCGCTGGTGTATACGAACGGCTCTGCGG CGAGGAGAAGTGGTGAGAGCTGGATGCTCTTTTGGAACAGCAAA CGAGGAGAAGTGGTCAACTCTCCACCGAATGGTCCTAATCTGCAGAA CACCATTGAGGGAGTTCCAACGCTGGCTGGAATGATCACCTGCAGAA CCTGGCTGAGAATGTGCAAAGCAGCTGGCTGGAATGATCTGCAGAA ACCTGGCTGAGAATGTGCCAACGCTGGCTGGAATTATGACCTGCAGAA CCGCCTCTATCAGGCCATTCAGGCTGGCTGGAATTATGACCTGCAGAA CCGCCCTTATCATCAGACTGCTTTGAGGAGGTGAATTTGCCAGAG CCGCCCTTTTGAGGGGGGGAGCATGATTGATGCCAACCTGAAATTGCTGCA GGAAGCTGAGCAACGTCTCAAAGCCATTGTGGCAGAGATTTGCCATTGC CCCCAAGGAAGGTGATTTGCCCCAGGTGGAGAGATTTTGCCATTGC CACCAAGGAAGTTTGCCCCAGGTGGAGAGATTTTGCCATTGC CACCAAGGAAGTTTGCCCCAGGTGGAGAGTTCTCGCAAGCTTTGCAAGGTGGCAGAGAGTTTTCCCAAGGAGAATTGCCTTTTGCAAGGTGGAGAACCTTTTTCCAAGGTGGAGAACTTTTCCCAAGGTGGAGAACTTTTTCCAAGGTGGAGAACTTTTTCCAAGATCTTTTTTTT
	28	<u>ම</u>
	prey50590	prey9822
	m	м
	Shigella ospC1	Shigella ospC1

				TACCACCAGCAGTTCCGGCATGTTCAGAACAACCTGATGAGAAATTCTACAA	YLRFLKKRISSDFEVGDSM
				CAGAAAAA   CGAACCAAGAGAAC   GGACCCCA   CC   GAC   GAGG   CACCC   GATGAACGCCGCAGTGAGCTATACTTACGTTCCTCAAGAAGAGAGATTAGC	CLLSCTMQELIGLYVTMEE
				TCTGATTTTGAGGTGGGAGACTCCATGGCCTCAGAGGAAGTAAAGCAAGAG	YFMRETVNKAVALDTYEKG
				CACCAGAAGTGTCTGGACAAACTCCTCAATAACTGCCTTTTGAGCTGTACCA	QLTSSMVDDVFYIVKKCIGR
				TGCAGGAGCTAATTGGCTTATATGTTACCATGGAGGAGTACTTCATGAGGGA	ALSSSSIDCLCAMINLATTE
				GACTGTCAATAAGGCTGTGGCTCTGGACACCTATGAGAAGGGCCAGCTGAC	LESDFRDVLCNKLRMGFPA
				ATCCAGCATGGTGGATGATGTCTTCTACATTGTTAAGAAGTGCATTGGGCGG	TTFQDIQRGVTSAVNIMHS
				GCTCTGTCCAGCTCCAGCATTGACTGTCTCTGTGCCATGATCAACCTCGCCA	SLQQGKFDTKGIESTDEAK
				CCACAGAGCTGGAGTCTGACTTCAGGGATGTTCTGTGTAATAAGCTGCGGAT	MSFLVTLNNVEVCSENISTL
				GGGCTTTCCTGCCACCACCTTCCAGGACATCCAGCGCGGGGGTGACAAGTGC	KKTLESDCTKLFSQGIGGE
				CGTGAACATCATGCACAGCAGCCTCCAGCAAGGCAAATTTGACACAAAAGGC	QAQAKFDGCLSDLAAVSNK
				ATCGAGAGTACTGACGAGGCGAAGATGTCCTTCCTGGTGACTCTGAACAAC	FRDLLQEGLTELNSIAIKPO
				GTGGAAGTCTGCAGTGAAAACATCTCCACTCTGAAGAAGACACTGGAGAGTG	VOPWINSFFSVSHNIEEEEF
				ACTGCACCAAGCTCTTCAGCCAGGGCATTGGAGGGGGAGCAGGCCCAGGCC	NDYEANDPWVQQFILNLEQ
				AAGTTTGACGGCTGCCTTTCTGACTTGGCCGCCGTGTCCAACAAATTCCGAG	QMAEFKASLSPVIYDSLTGL
				ACCTCTTGCAGGAAGGGCTGACGGAGCTCAACAGCACAGCCATCAAGCCAC	MTSLVAVELEKVVLKSTFN
				AGGTGCAGCCTTGGATCAACAGCTTTTTCTCCGTCTCCCACACATCGAGGA	RLGGLQFDKELRSLIAYLTT
				GGAAGAATTCAATGACTATGAGGCCAACGACCCTTGGGTACAACAGTTCATC	VTTWTIRDKFARLSQMATIL
				CTTAACCTGGAGCAGCAAATGGCAGAGTTCAAGGCCAGCCTGTCCCCGGTC	NLERVTEILDYWGPNSGPL
				ATCTACGACAGCCTAACCGGCCTCATGACTAGCCTTGTTGCCGTCGAGTTGG	TWRLTPAEVRQVLALRIDF
				AGAAAGTGGTGCTGAAATCCACCTTTAACCGGCTGGGTGGTCTGCAGTTTGA	RSEDIKRLRL*
	<u>.</u>			CAAGGAGCTGAGGTCGCTCATTGCCTACCTTACCACGGTGACCACGTGGAC	
			_	CATCCGAGACAAGTTTGCCCGGCTCTCCCAGATGGCCACCATCCTCAATCTG	
				GAGCGGGTGACCGAGATCCTCGATTACTGGGGACCCAATTCCGGCCCATTG	
				ACGTGGCGCCTCACCCCTGCTGAAGTGCGCCCAGGTGCTGGCCCTGCGGAT	
				$\rightarrow$	
Shigella	က	prey67268	09	CCGTGTCTTGGCTGGCTCATTTATCAGGGTTGTC111C1C111G1C111GAC1 261	PCLGWLIYGGCLSLCL LGY
ospC1				AGGCTATTTTACTACTCTATAGAGA	LICH R RTV TSALICM IITV
				GAIGIAAAIAAIICCIGIICAIAAAACIGCAAAIIAIAAICAIIGAAIGAA	VI DVOTHI *MOESISVI TINIV
				All AlgGCCCI GIAGACAII CAAGAGIIII GCCAGII I GCACCCIII GCACCCIII I GCACCIII I GCACCIII I GCACCIII I GCACCCIII I GCACCCIII I GCACCCIII I GCACCCIII I GCACCIII I G	
				TGTGTTTTAGCATCTCTTATCTGACTATAAATGTGCTGCTTTTGATTTATCTTA	LLLIYLINHLS
Shigella	3	prey67270	61	NCNGGTGNGTGNAGANGGAGTNNANCTNTGCCACTGCATGNTGTTTTGCTC 262	XGXXRXSXXXPLHXVLLHX
ospC1				AGGCANGATNNAIGAIGCIIGACIIIIAIGAAGIICCANNAIICAAAIGAAIN	PSPCXXCTCSXGIXXIXXI
				TEATGON FACOL TOCOCOL GLANTING FIGUROS FOLLOS CONGCIONS FACOL TO TOTAL SALVEN TO TATAL SALVEN	XXIRXXXTLXLSLXLPSCH*
			_	NTANTTACCCTCATGCCATTGANNAATCTGTCNTTCTCATTNATGATCCCNTA	XICXSHX*SXXXXPXIS
		-		NNNNCTGNCCANNGATCTCTC	

		0		NEI OKKAEHOVGEDGELI K
Shigella 3	prey6/2/1	Z 20	GCAGGAGCIGCAGAAGAAGACACTATACCACACACACAGAAAAAAGATATAA AAAAAAAAAA	IKLGHYATOLONTYDRCPM
osbo			CCGCTGCCCCATGGAGCTGGTCCGCTGCATCCGCCATATATTGTACAATGAA	ELVRCIRHILYNEORLVREA
-				NNGSSPAGSLADAMSQKH
			GCTGATGCCATGTCCCAGAAACACCTCCAGATCAACCAGACGTTTGAGGAG	LQINQTFEELRLVTQDTENE
			CTGCGACTGGTCACGCAGGACACAGAGAATGAGTTAAAAAAGCTGCAGCAG	LKKLQQTQEYFIIQYQESLR
			ACTCAGGAGTACTTCATCATCCAGTACCAGGAGAGCCTGAGGATCCAAGCTC	IQAQFGPLAQLSPQERLSR
			AGTTTGGCCCGCTGGCCCAGCTGAGCCCCCAGGAGCGTCTGAGCCGGGAG	ETALQQKQVSLEAWLQRE
			ACGGCCCTCCAGCAGAAGCAGGTGTCTCTGGAGGCCTGGTTGCAGCGTGA	AQTLQQYRVELPEKHQKTL
			GGCACAGACACTGCAGCAGTACCGCGTGGAGCTGCCCGAGAAGCACCAGA	QLLRKQQTIILDDELIQWKR
			AGACCCTGCAGCTGCTGCGGAAGCAGCAGACCATCATCCTGGATGACGAGC	RQQLAGNGGPPEGSLDVL
			TGATCCAGTGGAAGCGGCGGCAGCTGGCCGGGAACGGCGGGCCCCC	QSWCEKLAEIIWQNRQQIR
			CGAGGGCAGCCTGGACGTGCTACAGTCCTGGTGTGAGAAGTTGGCGGAGAT	RAEHLCQQLPIPGPVEEML
			CATCTGGCAGAACCGGCAGCAGATCCGCAGGGCTGAGCACCTCTGCCAGCA	AEVNATITDIISALVTSTFIIE
			GCTGCCCATCCCCGGCCCAGTGGAGGAGATGCTGGCCGAGGTCAACGCCA	KQPPQVLKTQTKFAATVRL
			CCATCACGGACATTATCTCAGCCCTGGTGACCAGCACGTTCATCATTGAGAA	LVGGKLNVHMNPPQVKATII
			GCAGCCTCCTCAGGTCCTGAAGACCCAGACCAAGTTTGCAGCCACTGTGCG	SEQQAKSLLKNENTRNDYS
			CCTGCTGGTGGGCGGGAAGCTGAACGTGCACATGAACCCCCCCAGGTGA	GEILNNCCVMEYHQATGTL
			AGGCCACCATCATCAGGAGCAGCAGGCCAAGTCTCTGCTCAAGAACGAGA	SAHFRNMSLKRIKRSDRRG
		_	ACACCCGCAATGATTACAGTGGCGAGATCTTGAACAACTGCTGCGTCATGGA	AESVTEEKFTILFESQFSVG
			GTACCACCAAGCCACAGGCACCCTTAGTGCCCACTTCAGGAATATGTCCCTG	GNELVFQVKTLSLPVVVIVH
-		·	AAACGAATTAAGAGGTCAGACCGTCGTGGGGCAGAGTCGGTGACAGAAGAA	GSQDNNATATVLWDNAFA
			AAATTTACAATCCTGTTTGAATCCCAGTTCAGTGTTGGTGGAAATGAGCTGGT	EPGRVPFAVPDKVLWPQL
			TTTTCAAGTCAAGACCCTGTCCCTGCCAGTGGTGGTGATCGTTCATGGCAGC	CEALNMKFKAEVQSNRGLT
			CAGGACAACAATGCGACGGCCACTGTTCTCTGGGACAATGCTTTTGCAGAG	KENLVFLAQKLFNNSSSHL
			CCTGGCAGGGTGCCATTTGCCGTGCCTGACAAAGTGCTGTGGCCACAGCTG	EDYSGLSVSWSQFNRENL
			TGTGAGGCGCTCAACATGAAATTCAAGGCCGAAGTGCAGAGCAACCGGGGC	PGRNYTFWQWFDGVMEVL
			CTGACCAAGGAGAACCTCGTGTTCCTGGCGCAGAAACTGTTCAACAACAGCA	KKHLKPHWNDGAILGFVNK
			GCAGCCACCTGGAGGACTACAGTGGCCTGTCTGTGTCCTGGTCCCAGTTCA	QQAHDLLINKPDGTFLLRFS
			ACAGGGAGAATTTACCAGGACGGAATTACACTTTCTGGCAATGGTTTGACGG	DSEIGGITIAWKFDSQERMF
			TGTGATGGAAGTGTTAAAAAAACATCTCAAGCCTCATTGGAATGATGGGGCC	WNLMPFTTRDFSIRSLADR
			ATTTTGGGGTTTGTAAACAAGCAACAGGCCCATGACCTACTGATTAACAAGC	LGDLNYLIYVFPDRPKDEVY
			CAGATGGGACCTTCCTCCTGAGATTCAGTGACTCAGAAATTGGCGGCATCAC	SKYYTPVPCESATAKAVDG
			CATTGCTTGGAAGTTTGATTCTCAGGAAAGAATGTTTTGGAATCTGATGCCTT	YVKPQIKQVVPEFVNASAD
			TTACCACCAGAGACTTCTCCATCAGGTCCCTAGCCGACCGCTTGGGAGACTT	AGGGSATYMDQAPSPAVC
	·		GAATTACCTTATCTACGTGTTTCCTGATCGGCCAAAAGATGAAGTATACTCCA	PQAHYNMYPQNPDSVLDT
			AATACTACACACCAGTTCCCTGCGAGTCTGCTACTGCTAAAGCTGTTGATGG	DGDFDLEDTMDVARRVEE
			ATACGTGAAGCCACAGATCAAGCAAGTGGTCCCTGAGTTTGTGAACGCATCT	LLGRPMDSQWIPHAQS"
			GCAGA I GCCGGGGGGGGGGGGGGGGGGGGGGGGGGGGG	

				AGCTGTGTGTCCCCAGGCTCACTATAACATGTACCCACAGAACCCTGACTCA GTCCTTGACACCGATGGGACTTCGATCTGGAGGACACAATGGACGTAGCG CGGCGTGTGGAGGACTCCTGGGCCGGCCAATGGACAGTCAGT	
Shigella ospC1	ო	prey700	8	TCTTTCTGCTCAAGGTGTGAACATGAATAGACTACCAGGTT  CCATATGGTTACCATGGGGATGATGGACTTCCTTTTGTTCT  ACAACCTTATGGACCAACTTTCACTACTGGTGATGTCATTG  AATCTTATCAACAATACCTGCTTTTACACCAAGAATGGACAT  GCTTTCACTGACCAATTCCTGCTTTTGGGCAACATCCTTTC  GAAGACTATGGGGAGTGGAGAACCAAAATCCAGGCAC  GAAGACTATTGGGGATGGAGAACCAAAATCCAGGCAC  TTCATCTTATTAGTCCACCATGGGTACTGTGCCACAGCAG  TACATCTACAGAAATTGGTATTAGGAAAAGGAAATGGGAGAA  ACACAACAGTTATAGCACAGTTTACTTGAAAGAAATCCTAA  AACACAACAGTTATAGCAGGTTTACTTGAAAGAAATCCTAA  AACACAACAGTTATAGCAGGTTTACTTGAAAGAAATCCTAA  AACACAACAGTTATAGCAGGTTTACTTGAAAGAAATCCTAA  AACACAACAGTTATAGCAGGTATTAGGAAGAATGGTGAACGTTA  AACACCAACAGTTATAGCAAGTTTACTTGAAAGAAATCCTAA  AACACCAACAGTTATAGCAAGTTTACTTGAAAGAAATCCTAA  AACACCAACAGTTATAGGAAGTTTACTTGAAAGAAATCCTAA  AACACCAACAGTTATAGAAATAACTCCAACAATTATTACAACAGTTAAAAGCACCAATTATTACAATTAGAAATAACTTCACCAGAACTAAACAGT  AACACCAGTCAACAATGAAAAAAGCACAATGGT  AACACCAGTCAACAATGAAAAAAACACTCAAAACAGT  AACACCAATGGAAATTGGAAAAAAAAAA	MGIGLSAQGVNMNRLPGW DKHSYGYHGDDGHSFCSS GTGQPYGPTFTTGDVIGCC VNLINNTCFYTKNGHSLGIA FTDLPPNLYPTVGLQTPGE VVDANFGQHPFVFDIEDYM REWRTKIQAQIDRFPIGDR EGEWQTMIQKMVSSYLVH HGYCATAEAFARSTDQTVL EELASIKNRQRIQKLVLAGR MGEAIETTQQLYPSLLERN PNLLFTLKVRQFIEMVNGT DSEVRCLGGRSPKSQDSY PVSPRPFSSPSMSPSHGM NIHNLASGKGSTAHFSGFE SCSNGVISNKAHQSYCHSN KHQSSNLNVPELNSINMSR SQQVNNFTSNDVDMETDH YSNGVGETSSNGFLNGSS KHDHEMEDCDTEMEVDSS QLRRQLCGGSQAAIERMIH FGRELQAMSEQLRRDCGK NTANKKMLKDAFSLLAYSD PWNSPVGNQLDPIQREPV CSALNSAILETHNLPKQPPL ALAMGQATQCLGLMARSGI GSCAFATVEDYLH*
Shigella ospC1	က	prey3486	64	GATCGAGATCCATGGGAAGGCAGGCCTGTTTTTAGAAGGCCAGATCCACCC 265 III CGAGTTGGAAGGATTGTCATCAGTGAAAAGGGGGCAAGTTCACC GCTGATCACAGTCTTTACTGATGACAAAGGTGCCTACAGTGTTGGCCCCTG CACAGTGACCTGGAGTACACGGTGACCTCACAGAGGGGCTATGTTCTG ACTGCGGTGGAAGGAGCTCGGAGACTTCAAGGCCTATGCCCTGGCAGGC ACTGCGGTGGAAGGAACCATCGGAGACTTCAAGGCCTATGCCCTGGCAGGC ACTGCGGTGGAAGGAACCATCGGAGACTTCAAGGCCCTTGGCAGGC	IEIHGKAGLFLEGQIHPELE GVEIVISEKGASSPLITVFTD DKGAYSVGPLHSDLEYTVT SQKEGYVLTAVEGTIGDFK AYALAGVSFEIKAEDDQPL PGVLLSLSGGLFRSNLLTQ

				DNIGII TESNI SPGOVVEKP
			TTATCCCTGAGCGGTGGCCTG111CG11CCAACC1C11GACCCAGGACACG	MMKEFRFEPSSOMIEVOE
<del></del>			GATGAAGGAGTTCCGGTTTGAGCCATCCTCACAGATGATCGAGGTGCAGGA	GQNLKITITGYRTAYSCYGT
				VSSLNGEPEQGVAMEAVG
			CTATGGCACAGTGTCTTCCTTAAACGGAGAGCCCGAACAAGGGGTTGCCAT	QNDCSIYGEDTVTDEEGKF
			GGAAGCGGTGGGCCAGAACGACTGCAGCATTTACGGAGAAGACACCGTGAC	RLRGLLPGCVYHVQLKAEG
			AGACGAAGAGGCAAGTTCAGATTACGTGGATTGCTGCCGGGATGTGTA	NDHIERALPHHRVIEVGNN
			CCACGTTCAGCTCAAGGCAGAAGGCAACGACCACATTGAGCGGGCGCTCCC	DIDDVNIIVFRQINQFDLSG
			CCACCATAGGGTGATTGAGGTTGGGAATAATGACATCGATGATGTAAACATC	NVITSSEYLPTLWVKLYKSE
			ATAGITITICCGGCAGATTAATCAATTTGATTTAAGTGGAAATGTGATCACTTC	NLDNPIQTVSLGQSLFFHFP
			CTCTGAATACCTTCCTACATTATGGGTCAAGCTTTACAAAAGCGAAAACCTCG	PLLRDGENYWLLDS1LPR
			ACAATCCAATCCAGACAGTTTCCCTTGGCCAGTCCCTGTTCTTCCCCC	SQYDYILPQVSFIAVGYHK
			CCACTGCTCAGAGACGGCGAGAACTATGTTGTGCTTCTGGGACTCCACACTCC	HI ILIFINFI RALPEQUIAGO
			CCAGATCCCAGTATGACTACATCTTGCCTCAAGTTTCTTTC	SYIALPLILLVLLAGYNHUK
			CTACCATAAACACACCACCTTGATTTTAATCCCACGAGGAAGCTGCCTGAA	LIPLLLULI SHLUGVRALGU
			CAGGACATCGCACAAGGATCCTACATTGCCCTGCCATTGACGCTGGTTC	AASDNSGPEDAKHQAKKQ
			TGCTGGCCGGTTACAACCATGACAAGCTCATTCCTTTGCTGCTGCTGCAGTTGAC	
		_	AAGCCGGCTACAGGGAGTCCGCGCGCTCGGCCAGGCAGCCICIGACAAIA	
			GCGGCCCAGAAGATGCAAAGAGACAAGCCAAGAAACAGAAGACAAGGCGGA	
			_	O HODIAI DVI SEAFFESI
Shigella 3	prey14801	65		LGLHSPIALDVLSEAFEEST
ospC1			GAATCCTTGGTGGCCAGAGAIIGGICCCGGGCCCIICAGCICAAGIG	VANDW SHACKET EV TOTAL
•			TACGGGCGAGATGTGGACGATTTGAGCAGCAIAAAGGAIGCAGICCIGAGC	VDDLSSIKDAVLSCAVATU
-		_	TGTGCTGTGGCATATGACAAAGAAGGTTGGCAATACCTGTTTCCCGTGAAGG	KEGWQYLFPVKDASLKSKL
			ATGCATCTCTGAGAAGTCGGCTGGCCCTACAGTTTGTGGACAGGTGGCCCC	ALQFVDRW PLESCLEILAY
	-		TGGAGTCATGCCTGGAGATTCTGGCCTACTGCATTTCAGACACGGCTGTCCA	CISDTAVQEGLKCELQRKL
			AGAAGGACTAAAGTGTGAGCTACAGAGGAAGCTGGCGGAGCTGCAGGTGTA	AELQVYQKILGLQSPPVWC
			TCAGAAGATTCTGGGTTTGCAGTCTCCCCCAGTGTGTGTG	DWQTLRSCCVEDPSTVMN
			CTTGAGGAGCTGTTGTGTTGAGGACCCATCAACTGTCATGAACATGATTCTA	MILEAGEYELCEEWGCLYP
			GAAGCACAGGAGTATGAACTGTGTGAAGAGTGGGGCTGCCTGTACCCCATT	IPREHLISLHOKHLLHLLER
	-		CCAAGAGAACATTTAATCAGCCTTCATCAAAAGCATCTTCTCCACCTTCTAGA	RDHDKALQLLRRIPDPTMC
			AAGAAGAGATCATGACAAGGCTCTGCAACTCCTGCGAAGAATCCCTGACCCC	LEVTEQSLDQHTSLATSHF
			ACCATGTGCCTTGAAGTGACAGAGCAATCCCTCGACCAGCACACTAGCTTGG	LANYLTTHFYGQLTAVRHR
			CCACTTCTCACTTCTTGGCCAACTACCTCACCACCCACTTCTATGGACAACTG	EIQALYVGSKILLTLPEQHR
			ACTGCTGTCCGACACCGTGAAATCCAGGCGCTGTATGTGGGATCCAAGATTC	ASYSHLSSNPLFMLEQLLM
			TGCTGACCCTGCCTGAGCAGCACCGGGCCAGCTATTCCCACTTGTCCTAA	NMKVDWATVAVQTLQQLL
			CCCCCTGTTCATGCTGGAGCAGCTGCTTATGAACATGAAGGTGGATTGGGC	VGQEIGFTMDEVDSLLSRY
			CACTGTGGCTGTGCAGACTCTCCAGCAGCTGCTTGGACAGGAGATTGG	AEKALDFPYPQREKRSDSV
-			CTTCACTATGGACGAGGTGGACTCACTGCTTTCCAGATACGCAGAGAAAGCC	IHLQEIVHQAADPE I LPRSP

	CTGGACTTTCCATACCCTCAGAGGAGAACGATCAGATTCTGTGATTCACC	SAEFSPAAPPGISSINGFOL
	I CCAAGAAATTGT CCACCAGGC GCAGAT CCCGAGACCC CCCTACATTCCCCCCAGTATCTCCCCCCAGTATCCCCCCCC	PPARHQWVPDETESICMV
	CTARTCTARGGGAAAGGAGTTTCCCACCAACCCAGGCCTCACAGGAATTTGT	CCREHFTMFNRRHHCRRC
	GCCCCCAGCCCCCTGCCAGGCACCAGTGGGTACCGGATGAGACTG	GRLVCSSCSTKKMVVEGC
	AGAGTATCTGCATGGTCTGCAGGGAGCACTTCACCATGTTTAACAGGCG	RENPARVCDQCYSYCNKD
	TCATCATTGTCGCCGCTGTGGCCGGCTAGTGTGCAGCTCCTGCTCCACTAA	VPEEPSEKPEALDSSKSES
	GAAAATGGTGGTTGAAGGCTGCAGAGAACCCTGCTCGTGTGTGT	PPYSFVVRVPKADEVEWIL
	GTGCTATAGTTACTGCAACAAAGATGTACCAGAGGAGCCTTCAGAAAAACCA	DLKEEENELVRSEFYYEQA
	GAAGCTCTAGACAGCTCCAAGAGTGAAAGCCCTCCATACTCGTTTGTGGTGA	PSASLCIAILNLHRDSIACG
-	GAGTCCCCAAAGCAGATGAGGTGGAATGGATTTTGGATCTCAAAGAGGAGG	HOLIEHCCRLSKGLINPEV
_	AAAATGAGCTGGTGCGGAGTGAATTTTACTATGAGCAGGCCCCCAGCGCCT	DAGLLTDIMKOLLFSAKMM
	CCTTGTGCATTGCCATCCTGAATCTGCACCGGGACAGCATTGCCTGTGGTCA	FVKAGQSQDLALCDSYISK
	CCAGCTGATTGAGCACTGCTGCAGGCTCTCCAAGGGCCTCACCAACCCAGA	VDVLNILVAAAYRHVPSLD
	GGTGGATGCCGGGCTGCTCACGGACATCATGAAGCAGCTGCTGTTCAGCGC	QILQPAAVTRLRNQLLEAEY
	CAAGATGATGTTCGTCAAAGCCGGCCAGAGCCAAGACTTGGCTCTTTGTGAC	YQLGVEVSTKTGLDTTGA
	AGCTACATCAGCAAGGTAGATGTGCTGAATATTTTAGTTGCTGCTGCCTATC	WHAWGMACLKAGNLTAAR
	GCCACGTGCCATCTTTGGATCAGATCTTGCAGCCAGCTGCAGTAACCAGGCT	EKFSRCLKPPFDLNQLNHG
	AAGGAACCAGCTTTTGGAAGCCGAGTACTACCAACTGGGCGTTGAGGTCTC	SRLVQDVVEYLESTVRPFV
	CACAAAGACTGGGCTTGATACCACCGGGGCGTGGCATGCTTGGGGCATGGC	SLQDDDYFATLRELEATLR
	CTGCCTCAAAGCCGGGAACCTCACTGCTGCACGGGAGAAGTTCAGTCGCTG	TQSLSLAVIPEGKIMNNTYY
	TCTGAAGCCCCCATTTGACCTCAATCAGCTGAATCATGGCTCAAGGCTGGTG	QECLFYLHNYSTNLAIISFY
	CAGGATGTGGGTTGAGTACCTAGAGTCCACAGTGAGGCCCTTTGTATCCTTGC	VRHSCLREALLHLLNKESP
	AAGATGACGATTACTTTGCCACCCTGAGGGAACTGGAAGCTACCCTTCGGAC	PEVFIEGIFQPSYKSGKLHT
	GCAGAGCCTTTCTCTGGCAGTGATTCCTGAAGGGAAAATCATGAACAACACC	LENLLESIDPTLESWGKYLI
	TACTACCAGGAATGCCTCTTCTACCTGCACAACTATAGCACCAACCTGGCCA	AACQHLQKKNYYHILYELQ
	TCATCAGCTTCTACGTGAGGCACAGCTGCCTGCGGGAAGCTCTTCTGCACCT	QFMKDQVRAAMTCIRFFSH
	TCTCAACAAGAGAGTCCTCCAGAAGTTTTTATAGAAGGCATTTTCCAACCAA	KAKSYTELGEKLSWLLKAK
	GCTATAAAAGTGGGAAGCTACACACTTTGGAGAACTTGCTAGAATCCATTGA	DHLKIYLQETSRSSGRKKT
	TCCAACCTTGGAGAGCTGGGGAAAGTACTTGATTGCTGCCTGC	TFFRKKMTAADVSRHMNIL
	CAGAAGAAGTACTACCACATTCTGTATGAGCTGCAGCAGTTTATGAAGG	QLQMEVTRFLHRCESAGT
	ACCAAGTTCGGGCCGCCATGACCTGTATTCGGTTCTTCAGTCACAAAGCAAA	SQITTLPLPTLFGNNHMKM
	GTCATATACAGAACTGGGAGAGAAGCTCTCATGGCTACTTAAGGCCAAGGAC	DVACKVMLGGKNVEDGFGI
	CACCTGAAGATCTACCTCCAAGAAACATCCCGCAGCTCTGGAAGGAA	AFRVLQDFQLDAAMTYCRA
	CCACATTCTTCAGAAAGAAGATGACTGCAGCTGATGTGTCAAGGCACATGAA	ARQLVEKEKYSEIQQLLKC
	CACACTTCAGCTGCAGATGGAAGTGACCAGGTTCTTGCATCGGTGCGAAAGT	VSESGMAAKSDGDTILLNC
 	GCTGGGACCTCTCAAATCACCACTTTGCCTCTGCCAACCCTGTTTGGAAATA	LEAFKRIPPQELEGLIQAIHN
	ACCACATGAAAATGGATGTTGCCTGCAAGGTCATGCTGGGAGGGA	DDNKVRAYLICCKLRSAYLI
	AGAAGATGGTTTTGGAATTGCTTTCCGTGTTCTGCAGGACTTCCAGCTGGAT	AVKQEHSRA I ALVQQVQQ

	267	Z68	CAGCAG CAGCATT CCACATT CCACATT CCACATT CCACATT CCACATT CCACATT CCACATT CCACATT CSKTLLFFNKCSLLRHARD HKSKGLVMQCSQLLVKPIS ADQMFVSAPVNSTAPAAPA TCTCCC ALPLYPDPVRLIRYSIKCLE CHKQMRDYMVLAAHFQRT TEETEGLTCQVCQMLLPNQ CCAGAC CCAGAC CCACATC CCACATC CCACATC CCACCATC CCACATC CCACCATC CCACCATC CCACCATC CCACCATC CCACCATC CCACCATC CCACCC EMVFNKRHIQQHFYQNVS CCACCC EMVFNKRHIQQHFYQNVS CCACCC EMVFNKRHIQQHFYQNVS CCACCC EMVFNKRHIQQHFYQNVS CCACCC EMVFNKRHIQQHFYQNVS CCACCC CCACC CCACCC CCACC CCACCC CCACCC CCACCC CCACCC CCACCC CCACCC CCACCC CCACCC CCACCC
GCTGCCATGACCTACTGCAGAGCTGCCCGCCAGTTGGTGGAGAAAGAGAAAGACATACTGCCATGATGTGTGTG	CTCCCTCTCTGCCTGGCTGGCTTTCTGTAAATAATTATTTGTGTCATAGCTTA CAGCTTTTTAAACATTTTCACTTTTATTTTCATTTTAATTTTCACACCCGGCCCC GAAAAGTGTTTTTCCACTTTACAAATTAAGATGCAGAAGCTCAGCAATANNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN	AATTTCCACCTCCCAAGGGAAGTTTATGTATTTTTCTAGGCCCTTTTCTATGT CTTTACATCTCTGTCTCACACACACACGTATACACACACA	CAACCCGTGCCCTCTATGCGCCAAATCTCAGCCCGCCTGCGGACAGCAG GATCCACGTGCCGCCTGTATGCGCCAAGTGTGGAGAGTGTGGAGACGCAT TGCCTTAGAGAAGAGCCAGTGCTGCTGCCTGGAGTGTGGAGACGCAT TGCCTTAGAGAAGAGCCTGTGCTGCTGCTGCGGGGGGGCTCACAT TGAGGTACTGTGCACCCCTGTGCTCCAAGAGCGGGCTCTTCTTCAACAGAGTGC AGCCTGCTCCGGCACCCGTGACCACAGAGCAAGGTCATCGTGTGAAGTTCCCAGCCTTCTTCCAACAGAGGGCTCATCTTCCCAACAGTGCCAATGTTCGTGTGAACTCCCGGCACCCCTTCACCCCTTCACCCTTCCCGGAATGTTCGTGCAACAGTGCCCCTTCTCCCAACAGTGCCAACAGTGCCAACAGTGCCAACAGTGCCAACAGTGCCAACAGTGCCAACAGTGCCAACAGTGCCACACTTCTGCCAGACCCCCCCC
	99	29	89
	prey67279	prey67280	prey49194
	<b>г</b>	က	m
	Shigella ospC1	Shigella ospC1	Shigella ospC1

man, and a second					OF! MOHWETHEVERNIVD
	-			SIGNACAL I CAGCAGCAL I I I I I ACCAGAAL GI CAGCAAGACG	
					TESTINE GOOD TO SELECT TO
				SCAACACGTCAAGAGCACCCACGGTGTTCCCCCGAAATGTG	VP   EPPA   SVAARSSSLFS
					GRWGRFEAHRRVEARPRL
					RNTGWTCQECQEWVPDR
				TTCTGGCCGCTGGGGTAGGCCTGAAGCCCACCGCAGGGT	ESYVSHMKKSHGRTLKRY
				CGCGGCTGAGGAACACTGGCTGGACCTGCCAGGAGTGCC	PCRACEASFHTPNSLRKHI
				CAGATCGGGAGAGCTACGTGTCCCACATGAAAAAAGAGCC	RNNHDTVKKFYTCGYCTE
				TTGAAGCGGTACCCATGCCGGCAGTGTGAACAGTCCTTCC	DSPSFPRPSLLESHISLMH
	_		-		GIRNPDLSQTSKVKPPGGH
					SPQVNHLKRPVSGVGDAP
					GTSNGATVSSTKRHKSLFQ
				ACGTCCAAAGTGAAACCTCCGGGTGGACATTCCCCTCAG	CAKCSFATDSGLEFOSHIP
				AAAAGACCAGTCAGTGGAGTGGGGGACGCTCCAGGCACC	QHQVDSSTAQCLLCGLCYT
					SASSLSRHLFIVHKVRDQE
				AGTITTGCCACAGACTCGGGGCTCGAGTTTCAGAGCCACA	EEEEEEAAAEMAVEVAEP
					EEGSGEEVPMETRENGLE
					ECAGEPLSADPEARRLLGP
					APEDDGGHNDHSQPQASQ
				GTGGCAGAGCCAGAGGAGGCTCCGGGGAGGAGGTGCC	DQDSHTLSPQV*
-				CATGGAGACTAGAGAATGGACTGGAAGAATGTGCCGGTGAGCCTTTGTC	
				AGCTGACCCAGAGGCGAGGAGATTGCTGGGCCCCGGCCCCTGAGGACGATG	
				GTGGCCACAATGATCACAGTCAACCACAGGCCTCTCAGGACCAGGACAGGC	
				-	
Shinella	m	prev67287	69	CTGTTCTTTTAAGTTTGTCTTTGAGTTGG 270	EHSSSLVMLFF*VCL*VGKV
Singuis Singuis	<b>)</b>		!		DLFGLA*GLNVSSSLGLLILS
2				TCAGTCCTTCCTGGCTATGTGGCATCATGTCTTTAAAGCAG	PSWLCGIMSLKQGE*SINIL
					RRNILPTYVFYSSFF*ALSR
				STTTTGAGCCCTTTCTAGAAAGAGTAATGCTCTAGCCTTCAA	KSNALAFNQK*KVY
				AGTCTATG	
Shigella	က	prey19931	2	STTTCTAGAAATGCCCAGCTGTTCAAGCGCTCT 271	VHQVTDLSRNAQLFKRSLL
ospC1		·			EMATF*
Shigella	က	prey67290	7	A 272	GGVGMGR**XXXLLVXIQC
ospC1					GALA AALA I ANIFFASTLS
				TNTTGTCTTCTGTGGGAGANGGCIGCININIIIIIANNGN	V V CGHALLAFLAALLAIFAIS
					HISAXLXLY FINIXAXLAXXX
				TTTATGANATANNTGCTTNTAANCNTNTANAATCTGATTAATATTTATNNACTT	VLINIYXLXLHIXXIF
				AIAGANNAIAICIII	EEC VVVT*XNIVAIVVVIII I HI
Shigella	က	prey67291	72	TTTGAAGGGNICNIANNAACATAGGANAATGTGGCTATAGTTTGGAACCTNC 273	EGAAAI AIVAIVVIILEI II

	274	275	276	AGTGACAGGAA 277 QKDDKEPQPVKKIVIGID SCAACTTCTACG SCTGGGAAGTG VPEEEIKKLSRWEVIDVVRT CTGGAGGGG STGAGCATCAAG SAACAAGGTTCT CAGCTGAAGAT CAGCTAATGTT CACTAATGTT CACTAATGTT CAGCTAATGTT CACTAATGTT
TACATATTTGTTGAATGGCTTTGACANACTTGCTGATAGTGATATGAACATTA NNGTCCAAGCTGAGGTGTCTCAAATGGAGATGAGGAACTTGTTGGGAACT GAAGNACAGGTGACTCTTGTTATGTTTTANCCAAGACCACTGTCNTCATTTTG CCTNTGCCCTANANATTNTGGAACTTTNACNTTGAGANANATGATNCANGAT CTTGGNNGANGANNTANNTAANNGNNNTATATTNN	GCACAAGCCGTCATACCATACCAGGCAGTAAAAATTTACTCCTTAGTTTTCTT CTANAAATAGATTAAGTCTGTGATCCATTTTGGGTTAATTTTTCTGTGATGTAT ACTATTGTTTGAGGTTAATTTTTTTCTAGTTTTTAAAATTTTCATCCAGTTGTTCC AGCNTCNCTTGTTGAGAAAATTGTTNTTCCCATTAANATTACTTTGGATACCT NGNGTGANGNNTATATGNGGNCTATANNGTGTNGNGNAACNCGACGCTGCG CAGNGTGANTANCGTCGTAAGNNANGTGTNGNANAGNGCCGNGAGA	AGAGTGGGGATGGGCTGGGCCTCTGTTCGTCCGTCCGACCCCCCTCATGTG TGCTGCCCCAAACCTCGCCGCTCCCTAGTTTGGTATTCTGTGTCCGGCCTGG GGTAGTAGCTGGACACCAGACTCCAGTTTGGGCTCCAGTTCCCGACTTTTCG CCTCCTCTGGGTCTGTCCTGGGGTCAGTAATTAACCCGGGTCCAGGGGTG TCGTCTTTTCCCTCCAGGGTGGGGCCTGCCTGTACATGCCAGGGGTTTTTC GCAGGGCTTTTCATCCANATTTGCTTCAGGG	CCTCCTCCAACACACACGTGCACAGTGTCTGCCCAATGCCTACTTTTTT TTTTAAANGAAANTTTNANTTNGNAANTANAANNNGGNTAAAANGNCNTNNNC NTNTANCCTTTTNNNGTTTTTTTTTNNTTTTTTTTTTNGNTAANNNANNN	AGCAGAAGGATGATAAAGAACCGCAGCCAGTGAAGAAGACAGTGACAGGAA CAGATGCAGACCTTCGTCGCCGTTCCCTGAAAAATGCCAAGCAACTTCTACG TAAATTTGGTGTGCCTGAGGAAGATTAAAAAGTTGTCCCGCTGGGAAGTG ATTGATGTGGTGCCTGAGGAAGATTAAAAAGGCTCGTTCTGGAGGGG CCCATGAGTAAATTTGCCCATGTCAACAGAACAG
TACA NNG GAAA CCTI	73 GCA CTAI ACT, AGC NGN CAG	74 AGA 1GC GGT CCT 1CG GCA	75 CCT TTT NTN TTTP AAA	76 AGC CAGG CAGG CAGG CAGG ATTA ATTA AGD AGD AGA AAA AAA CTGC CTGC CTGC CTGC CTGC CT
	prey67294	prey67296	prey67299	prey4637
	Ю	ဇ	ю	<sub>හ</sub>
ospC1	Shigella ospC1	Shigella ospC1	Shigella ospC1	Shigella ospC1

					NKFCPLYYO I NAPPSNPVA
					MI EEQEEELEKI VIRIVUNE
		-			ELIKVEGIKIVLGKOLIESAD
					EVRRKSLVLKFPKQQLPPK
				ATTGTCTTGGGGAAACAGCTAATTGAGAGTGCGGATGAGG	KKRRVGTTVHCDYLNRPH
				CTCTGGTTCTCAAGTTTCCTAAACAGCAGCTTCCTCCAAAG	KSIHRRRTDPMVTLSSILESI
				AGTTGGAACCACTGTTCACTGTGACTATTTGAATAGACCTC	NDMRDLPNTYPFHTPVNA
		-		ACCGGCGCGCACAGACCCTATGGTGACGCTGTCGTCCA	KVVKDYYKIITRPMDLQTLR
					ENVRKRLYPSREEFREHLE
					LIVKNSATYNGPKHSLTQIS
					QSMLDLCDEKLKEKEDKLA
				()	RLEKAINPLLDDDDDQVAFSF
				GCCAAAACACTCATTGACTCAGATCTCTCAATCCATGCTG	ILDNIVTQKMMAVPDSWPF
					HHPVNKKFVPDYYKVIVNP
				ACCCCTTGCTGGATGATGACCAAGTGGCGTTTTCTTT	MDLETIRKNISKHKYQSRES
					FLDDVNLILANSVKYNGPES
				CCAGTTAATAAGAAATTTGTTCCAGATTATTACAAAGTGATT	QYTKTAQEIVNVCYQTLTE
					YDEHLTQLEKDICTAKEAAL
					EEAELESLDPMTPGPYTPQ
					PPDLYDTNTSLSMSRDASV
					FQDESNMSVLDIPSATPEK
					QVTQEGEDGDGDLADEEE
					GTVQQPQASVLYEDLLMSE
		-		TTGTATGATACCAACACATCCCTCAGTATGTCTCGAGATGCCTCTGTATTTCA	GEDDEEDAGSDEEGDNPF
				AGATGAGAGCAATATGTCTGTCTTGGATATTCCCAGTGCCACTCCAGAAAAG	SAIQLSESGSDSDVGSGGI
				CAGGTAACACAGGAAGGTGAAGATGGAGATGGTGATCTTGCAGATGAAGAG	RPKQPRMLQENTRMDMEN
				GAAGGAACTGTACAACAGCCTCAAGCCAGTGTCCTGTATGAGGATTTGCTTA	EESMMSYEGDGGEASHGL
				TGTCTGAAGGAGAAGATGATGAGGAAGATGCTGGGAGTGATGAAGAAGGAG	EDSNISYGSYEEPDPKSNT
				ACAATCCTTTCTCTGCTATCCAGCTGAGTGAAAGTGGAAGTGACTCTGATGT	QDTSFSSIGGYEVSEEEED
				GGGATCTGGTGGAATAAGACCCAAACAACCCCGCATGCTTCAGGAGAACAC	<b>EEEEEQRSGPSVLSQVHLS</b>
			-	TGGAAAATGAAGAAAGCATGATGTCCTATGAGGGAGACGG	EDEEDSEDFHSIAGDSDLD
				<u> </u>	SDE*
				GAGGAGCCTGATCCCAAGTCGAACACCCCAAGACACAAGCTTCAGCAGCATC	
				GGTGGGTATGAGGTATCAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG	
				GCGCTCTGGGCCGAGCGTACTAAGCCAGGTCCACCTGTCAGAGGACGAGG	
				AGGACAGTGAGGATTTCCACTCCATTGCTGGGGACAGTGACTTGGACTCTGA	
					10 H
Shigella	က	prey67316	77	CCACTCTACTCCACAAGGCTCATTCTAACTTCCCCCCTTGCT111G1AAC1   2/8	PLYSTRLILTSPLAYL LFSL RVRPQLSLSTTYLSIYYTCS
Odeo					

				TO A CONTINUE OF TAXABLE A CONTINUE A CONTIN	EKITEKOIVVI EVOVNIOESI
					VLQYPVKRLSSKIA*VSSFS
				TTCCAAAATTGCTTAGGTCAGCTCCTTCTCCATGCAACTCTTTCAGTGAGGCTGNATCATGTAATATTGTAGAT	MQLFQ*GXIMRL*YC*
Shigella ospC1	က	prey67318	78	ı>	PPHLTLVFF*RGPLLLSLRL MIAKTTKDTIVTGQPWNLVL GNGGI *EVTHKKBI KGPKC
			,	GGAATTTGGTCTTGGGAAATGGAGGCCTGTAGTTTGTAACCCATAAGAAGAG ACTGAAGGGGCCTAAGTGCAGATGAGAATCCCTGGTGATAGAACAGACAAG	R*ESLVIEQTRTGDQCQ*FV
				AACTGGAGATCAATGCCAATAGTTTGTGATGAACGTCTTGGGGTTCCTGTGT GATCAACCTGTTGGGATTTCTGTATT	MNVLGFLCDQPVGISV
Shigella	က	prey7144	79	GGAAGCCAGAAAAGCCCACCAACTCTGGCTTTCAGTGGAGGCATTAAAGTAC 280 AGCATGAAGACCTCATCTGCAGAAACACCTACTATCCCGCTGGGTAGTGCAG	EARKAHQLWLSVEALKYS MKTSSAETPTIPLGSAVEAI
- ) ) )				TTGAGGCCATCAAAGCCAACTGTTCTGATAATGAATTCACCCAAGCTTTAACC	KANCSDNEFTQALTAAIPP
		_		GCAGCTATCCCTCCAGAGTCCCTGACCCGTGGGGTGTACAGTGAAGAGACC	ESLTRGVYSEETLRARFYA
	_ =			CTTAGAGCCCGTTTCTATGCTGTTCAAAAACTGGCCCGAAGGGTAGCAAIGA	VOKLARHVAMIDE I KNSLY
				CTGCTCCTATTCCCACCTCAGCAACTGAAGCCGCCCCCAGAGCTCTGCCT	PPPELCPEDINTFKLLSYAS
				GAGGATATAAACACATTTAAATTACTGTCATATGCTTCCTATTGCATTGAGCAT	YCIEHGDLELAAKFVNQLK
				GGTGATCTGGAGCTAGCAGCAAAGTTTGTCAATCAGCTGAAGGGGGGAATCC	GESRRVAQDWLKEARMIL
				AGACGAGTGGCACAGGACTGGCTGAAGGAAGCCCGAA  GACCC  AGAAACG    AAACACATAGTGGAAATCCTGACGATATGCCAGCGCGGTAGGAATAGGAA	ETRUTOELTAYASAVGIGTT QVQPE*
				CCACTCAGGTGCAGAGTGA	
Shigella	က	prey67328	8	ATGAAATCCCAATGGTGTAGACCAGTGGCGATGGATCTAGGAGTTTACCAAC 281	MKSQWCRPVAMDLGVYQL
ospC1	)			TGAGACATTTTCAATTTCTTGTCATCCTTGCTGGGGACTGAAAACGCT	RHFSISFLSSLLGTENASVR
-				TCTGTGAGACTTGATAATAGCTCCTCTGGTGCAAGTGTGGTAGCTATTGACA	LDNSSSGASVVAIDNKIEGA
	-			ACAAAATCGAGCAAGCTATGGATCTAGTGAAAAGCCATTTGATGTATGCGGT	MDLVKSHLMYAVREEVEVL
				CAGAGAAGAAGTGGAGGTCCTCAAAGAGCAAATCAAAGAACTAATAGAGAAA	KEQIKELIEKNSÖLEGENNL
				AATTCCCAGCTGGAGCAGGAGAACAATCTGCTGAAGACACTGGCCAGTCCT	CRILASPECLACETOBOAC
				GAGCAGCT   GCCCAGT   TCAGGCCCAGCT GCAGAACT GGCTGCCCAGCAGCAGCAGCAACTAGCA	PASQGSGPTA*
				GGGCTCAGGACCAACCGCATAG	
Shigella	က	prey37430	81	GTGGGAACAAGAGCTATACAATAACTTTGTATATAATAGTCCTAGAGGATATT 282	WEGELYNNFVYNSPRGYF
ospC1				TTCATACCI   I GCI GGAGA   ACTI GI CAAG   I GCI CI I AATTI GGCCAATGAA   GAAGAAAGAAAAATTTCGAAAAGCAGTTACAGACCTTTTGGGCCGTCGAC	AKKFRKAVTDLLGRRQRKS
				AAAGGAAATCTGAGAAAAGACGAGATCCCCCAAATGGTCCTAATCTACCCAT	EKRRDPPNGPNLPMATVDI
				GGCTACAGTTGATATAAAAATCCAGAAATCACAACAAATAGATTTTATGGTC	KNPEITTNRFYGPQVNNISH
				CACAAGTCAACATCTCCCATACCAAAGAAAGAAGAAGGAAAAGCTAA	TKEKKKGKAKKKRLTKGDI
				AAAGAAGATTAACCAAGGGAGATATAGGAACACCAAGCAATTTCCAGCAC	GTPSNFQHIGHVGWUPINI GSDI NNI DPFI KNI FDMCG
				Al lagacata and the second contract and second seco	מסטבון ווייין

	GCCTTGCTGTGCAGAGAGGTGGCACCTTCCAGATGGGGGGGTAGCAGCAGC	PSGSNVDTLLRLRGRLLLD HEALSCLLVLLFVDEPKLNT
-		SRLHRVLRNLCYHAQTRH
	GATGAGCCAAAGCTCAATACTAGCCGTCTACACCGAGTACTGAGAAATCTCT	WVIRSLLSILQRSSESELCIE
	GCTACCATGCCCAGACCCGCCACTGGGTCATCCGCAGTCTGCTCTCCATCTT	TPKLTTSEEKGKKSSKSCG
	GCAGCGCAGCAGTGAGAGTGAGCTATGCATTGAAACACCCCAAACTCACTACA	SSSHENBPLDLLHKMESKS
	AGTGAGGAAAAGGGCAAAAAGTCGAGCAAGAGCTGTGGGTCAAGTAGCCAT	SNQLSWLSVSMDAALGCR
	GAGAACCGTCCCCTGGACCTGCTACACAAGATGGAGTCAAAGAGCTCCAAC	TNIFQIQRSGGRKHTEKHA
	CAGCTTTCCTGGCTCTCAGTATCCATGGATGCAGCCCTAGGCTGCAGGACTA	SGGSTVHIHPQAAPVVCRH
	ATATTTCAGATCCAGCGTTCAGGGGGGGGGTAAACATACCGAGAAGCATGC	VLDTLIQLAKVFPSHFTQQR
	AAGCGGTGGCTCCACCGTCCACATCCCCAAGCTGCTCCTGTTGTCTG	TKETNCESDRERGNKACS
	CAGACACGTTTTGGATACACTCATTCAATTGGCCAAGGTATTTCCCAGCCACT	PCSSQSSSGICTDFWDLL
	TCACACAGCAGCGGACCAAAGAACAAACTGTGAGAGTGATCGGGAAAGGG	VKLDNMNVSRKGKNSVKS
	GCAATAAGGCCTGTAGCCCATGCTCCTCACAGTCCTCCAGCAGTGGCATTTG	VPVSAGGEGETSPYSLEAS
	CACAGACTTCTGGGACTTATTGGTAAAACTGGACAACATGAATGTCAGCCGG	PLGQLMNMLSHPVIRRSSL
	AAAGGCAAGAACTCCGTGAAGTCAGTGCCAGTGAGCGCTGGCGGTGAGGG	LTEKLLRLLSLISIALPENKV
	GGAAACCTCTCCATACAGCCTCGAGGCCTCTCCACTGGGGCAGCTCATGAA	SEAQANSGSGASSTTTATS
	CATGTTGTCACCCCAGTCATCCGCCGGAGCTCTCTTAACTGAGAAACTC	TTSTTTTAASTTPTTAP
	CTCAGACTCCTTTCTCTCATTCTCAATTGCTCTCCCAGAAAACAAGGTGTCAGA	TPVTSAPALVAATAISTIVVA
	⋖	ASTTVTTPTTATTTVSISPT
	AACCACATCTACCACCACCACTGCCGCCTCCACCACGCCCACACCCCC	TKGSKSPAKVSDGGSSST
	TACTGCACCCACCCTGTCACTTCTGCTCCAGCCCTGGTTGCTGCCACGGCT	DFKMVSSGLTENQLQLSVE
	ATTTCCACCATTGTCGTAGCTGCTTCGACCACAGTGACTACCCCCACGACTG	VLTSHSCSEEGLEDAANVL
	CTACCACTACTGTTTCAATTTCTCCCACTACTAAGGGCAGCAAATCTCCAGCG	LQLSRGDSGTRDTVLKLLL
	AAGGTGAGTGATGGGGGCAGCAGCAGTACAGACTTTAAGATGGTGTCCTCT	NGARHLGYTLCKQIGTLLA
	GGCCTCACTGAAAACCAGCTACAGCTCTCTGTAGAGGTGTTGACATCCCACT	ELREYNLEQQRRAQCETLS
	CTTGTTCTGAGGAAGGCTTAGAGGATGCAGCCAACGTACTACTGCAGCTCTC	PDGLPEEQPQTTKLKGKM
-	CCGGGGGGGACTCTGGGACCCGGGACACTGTTCTCAAGCTGCTACTGAATGG	QSRFDMAENVVIVASQKRP
	AGCCCGCCATCTGGGTTATACCCTTTGTAAACAAATAGGTACCCTGCTGGCC	LGGRELQLPSMSMLTSKTS
	GAGCTGCGGGAATACAACCTCGAGCAGCAGCGGCGAGCCCAATGTGAAACC	TQKFFLRVLQVIIQLRDDTR
	CTCTCTCCTGATGGCCTGCCTGAGGAGCAGCCACAGAGCCACCAAGCTGAAG	RANKKAKQTGRLGSSGLG
	GGCAAAATGCAGAGCAGGTTTGACATGGCTGAGAATGTGGTAATTGTGGCAT	SASSIQAAVRQLEAEADAII
_	CTCAGAAGCGACCTTTGGGTGGCCGGGAGCTCCAGCTGCCTTCTATGTCCA	QMVREGQRARRQQQAAT
	TGTTGACATCCAAGACATCTACCCAGAAGTTCTTCTTGAGGGTACTACAGGT	SESSOSEASVRREESPMD
	CATCATCCAGCTCCGGGACGACACGCGCCGGGCTAACAAGAAAGCCAAGCA	VDQPSPSAQDTQSIASDGT
	GACAGGCAGGCTAGGTTCCTCCGGTTTAGGCTCAGCTAGCAGCATCCAGGC	PQGEKEKEERPPELPLLSE
	AGCTGTTCGGCAGCTGAGGCTGATGCCATTATACAAATGGTACG	QLSLDELWDMLGECLKELE
		ESHDQHAVLVLQPAVEAFF
	GCCAGTCAGAGGCGTCTGTCCGGAGGGAGGAATCACCCATGGATGTGGAC	LVHAIERESKPPVRDIRES

					CLAHIKDEPPPLSPAPL I PA
			<u> </u>		I PSSLDPFFSHEPSSMHIS
			<u>ن</u> 		SSLPPDTQKFLRFAETHRT
			_		VLNQILRQSTTHLADGPFA
				TTCTTTCTGGTCCATGCCACAGAGCGGGAGAGCAAGCCTC	VLVDYIRVLDFDVKRKYFR
			<i>,</i> _		GELERLDEGLRKEDMAVH
				CTGCCCCTTAACCCCAGGCCATCCTCCTCCTTGACCC	VRRDHVFEDSYRELHRKSP
					EEMKNRLYIVFEGEEGQDA
				STECTE CONTROL OF THE CAGA CAGA CAGA CAGA CAGA CAGA CAGA CAG	GGLLREWYMIISREMFNPM
				A PACTOCA CONTROLLA MARCHA TO CONTINUE AND A CONTIN	YALFRTSPGDRVTYTINPSS
				TTO ET BETT CONTROLL AND TO	HCNPNHLSYFKFVGRIVAK
					AVYDNRI I ECYFTRSFYKHI
			_		GKSVRYTDMESEDYHFY
_					OGI VYI I ENDVSTLGYDLT
					ESTEVOEFGVCEVRDLKPN
					GANILVTEENKKEYVHLVC
					OMBMTGAIBKOLAAFLEGE
				TOO A CONTINUE TO TOO CONTINUE TO	VEIIPKBI ISIETEOFI FI I IS
	-				CI ETILIDI KONTEVEKO
					ALF HOLDDLANNI ETTINT &
			_		SINDICION FWHALHOFUCA
			_		DRAKFLOFVIGTSKVPLOG
					FAALEGMNGIQKFQIHRDD
					RSTDRLPSAHTCFNQLDLP
					AYESFEKSATCYCWLSRSA
			_	(5	LKALGWPNKALPNSVGFFL
			_		PLLDLGRGELKKEPERNCQ
				BAATACCACAAGTACCAGTCCAACTCTATTCAGATCCAGTG	KPINEIHQLTVCVPAAPSSP
					AHTCSSSHSLPAACFLTFS
					PLSMPSMIPTPCVLKRQ*
				AAGGCATGAATGGCATTCAGAAGTTTCAGATCCATCGAGATGACAGGTCCAC	
				AGATCGCCTGCCTTCAGCTCACACATGTTTTAATCAGCTGGATCTGCCTGC	
				TATGAGAGCTTTGAGAAGTCCGCCACATGCTACTGTTGGCTATCCAGGAGTG	
				•	
			•		
				AAGAAATTGTCAAAAACCAATAAATGAAATCCACCAACTCACCGTGTGTGT	
				CAGCTGCCCCATCTTCCCCAGCGCATACCTGTTCCTCTTCTCATTCTCCCC	
				CGCCGCCTGTTTCCTCACCTTCTCTCCCTTTCCATGCCGTCCATGATCCCC	
				TTTAAAAAGGCAGTAG	
Shipollo	c	prev////11	85	CCCAGCACAATCGGCTGCGGGAATTTTCTGCCCCGAGCA 286	RKCSQHNRLREFFCPEHS
מווממוומ	2	picytti			

				FCICHICI VEHKTCSPASI S
ospC1				QASADLEATLRHKLTVMYS
				QINGASRALDDVRNRQQD
				VRMTANRKVEQLQQEYTE
				MKALLDASETTSTRKIKEEE
				KRVNSKFDTIYQILLKKKSEI
				QTLKEEIEQSLTKRDEFEFL
-				EKASKLRGISTKPVYIPEVE
			TGGAGAAAGCATCAAAACTGCGAGGAATCTCAACAAAGCCAGTCTACATCCC	LNHKLIKGIHQSTIDLKNELK
			CGAGGTGGAACTGAACCACAAGCTGATAAAAGGCATCCACCAGAGCACCAT	QCIGRLQELTPSSGDPGEH
			AGACCTCAAAAACGAGCTGAAGCAGTGCATCGGGCGGCTCCAGGAGCTCAC	DPASTHKSTRPVKKVSKEE
			CCCCAGTTCAGGTGACCCTGGAGAGCATGACCCAGCGTCCACACACA	KKSKKPPPVPALPSKLPTF
			CACACGCCCTGTGAAGAAGGTCTCCAAAGAGGAAAAGAAATCCAAGAAACCT	GAPEQLVDLKQAGLEAAAK
			CCCCCTGTCCCTGCCTTACCCAGCAAGCTTCCCACGTTTGGAGCCCCGGAA	ATSSHPNSTSLKAKVLETFL
			CAGTTAGTGGATTTAAAACAAGCTGGCTTGGAGGCTGCAGCCAAAGCCACCA	AKSRPELLEYYIKVILDYNI
			GCTCACATCCGAACTCAACATCTCTCAAGGCCAAGGTGCTGGAGACCTTCCT	AHNKVALSECYTVASVAEM
			GGCCAAGTCCAGACCTGAGCTCCTGGAGTATTACATTAAAGTCATCCTGGAC	PONYRPHPORFTYCSOVL
			TACAACACCGCCCACAACAAGTGGCTCTGTCAGAGTGCTATACAGTAGCTT	GLHCYKKGIHYWEVELOKN
			CTGTGGCTGAGATGCCTCAGAACTACCGGCCGCATCCCCAGAGGTTCACAT	NFCGVGICYGSMNRQGPE
			ACTGCTCTCAGGTGCTGGGCCTGCTGCTACAAGAAGGGGATCCACTACT	SRLGRNSASWCVEWFNIK
			GGGAGGTGGAGCTGCAGAAGAACAACTTCTGTGGGGTAGGCATCTGCTACG	ISAWHNNVEKTLPSTKATH
			GAAGCATGAACCGGCAGGGCCCAGAAAGCAGGCTCGGCCGCAACAGCGCC	VGVLLNCDHGFVIFFAVAD
			TCCTGGTGCGTGGAGTGGTTCAACACCAAGATCTCTGCCTGGCACAATAACG	KVHLMYKFRVDFTEALYPA
				FWVFSAGATLSICSPK*
		_	ACTGTGACCACGGCTTTGTCATCTTCTCGCTGTTGCCGACAAGGTCCACCT	
			GATGTATAAGTTCAGGGTGGACTTTACTGAGGCTTTGTACCCGGCTTTCTGG	
			$\overline{}$	
Shigella 3	prey2686	98	ATGGAGCAGCTGGCCGACGTGACGCTGCGAAGGCTGCTGGATAATGAGGTC 287	MEQLADVTLRRLLDNEVFD
ospC1	•		TTTGACCTCGACCCGGATCTGCAGGAGCCGAGCCAGATCACCAAGAGGGAC	LDPDLQEPSQIIKHDLEAK
-			CTGGAAGCCAGAGCACAGAATGAGTTCTTCCGGGCTTTCTTCTGGGTTGCGA	ACMEFFRAFFRENCE
-			GGAAGGAGAAGCTGCACGCGGTTGTGGACTGTTCGCTCTGGACGCCG11CA	AVVDCSLW   PFSHCH   AG
			GTCGCTGTCACCGCGGGGCGGATGTTCGCCTCTGACAGCTACATCTGCT	RMFASDSYICFASHEDGCC
			TTGCCAGCAGAGAAGATGGCTGCTGTAAGATCATCCTGCCACTCAGAGAGG	KIILPLAEVVSIEKMED I SLL
			TGGTGAGCATCGAGAAGATGGAGGACACGAGCCTGCTGCCGCATCCCATCA	PHPIIVSIRSKVAFOFIELRD
			TTGTCAGTATCAGAAGCAAGGTGGCCTTCCAGTTCATTGAGCTCCGGGACCG	RUSLVEALLARLKQVHANH
			AGACAGCCTGGTGGAGGCGCTGCTTGCGAGGTTGAAGCAGGTCCACGCCA	FVHYUI SAUDUNIASLVFHS
			ACCACCCCGTGCACTACGACACCTCTGCGGATGATGACATGGCTTCACTCGT	I SIMICSUHRINGULEIMIMSSON
			GTTTCATTCAACAAGCAIGIGCAGIGACCACAGAIIIGGGGGAICIIGAAAIG	TAFOGSGSQSPDSRMSRE
			AIGIOILOI CAAAAA I AGOODAGAAAA GAAGAAAAAAAAAAAAAAAAAAAAAAA	

TTGTGGAATACGGCAGAAC GCTCGTAGCCATGGGCATC CTTCTCAGATGCGGTGACC CTGGTGGAGGAGTCCCTGC CGAGACTTGCTGCTCCCGGTTCCTCCCGGTTCCTCCCGGTTCCTCC	TTGTGGAATACGGCAGAACCGTGTGTGTTTCGCACAGAGAGATTCGGAA	
GCTCGTAGCCATGGGCATC CTTCTCAGATGCGGTGACC CTGGTGGAGGAGTCCCTG( CGAGACTCCCGCTCCCGGATTGCTTTGAGGAATTGCATTGGATACTGCAGTACTGCCAGTTCAAGAAGGAAG	CCCTGAATCTTTGCGAGGGAGACTCTGGCTTCT	GRLWLLFSDAVIDLASHPG
CTTCTCAGATGCGGTGACG CTGGTGGAGGAGTCCCTG( CGAGACCTGCACCGCTCCCGGATTGCTGCTTTGAGGAAGGA		YYGNLVEESLGKCCLVTEEI
CTGGTGGAGGAGTCCCTGC CGAGACCTGCACCGCTCCC GGAATTGCTGCTTTGAGGA AAGATTGGATACTTGCAGT ACACCAGGAGGAGGAAGG TGCTGCCCGATTACTTCAA TGCTGCCCGATTACTTCAA TGACGACCTCTCAGCCT TTCTATGATGGCATCAAAG CCAATGCTGAGGACCTGT TCTCATGATGGCATCAAAG CCAATGCTGAGGACCTGT AGTTGGCACCCCTGC	GGTGACGGATCTTGCCTCACACCCTGGTTACTACGGGAAT	ERDLHKSLPEHPAFQNE I G
CGAGACCTGCACCGCTCCC GGAATTGCTGCTTTGAGGA AAGATTGGATACTTGCAGT ACACCAAGGAGGAGGAAGT TGCTGCCCGATTACTTCAA CTGTCTTCGAGGAGCTCAT TGAACGACCTCTCAGCCT TTCTATGATGGCATCAAAG CCAATGCTGAGGACCTGT( TCCTCAGCAGCACCAAGGCCTGT( AGTTGGCACCACCTGC	CTGGTGGAGGAGTCCCTGGGGAAATGCTGCCTGGTAACCGAGGAGATAGAA	IAALKKVLIAYAHKNPKIGY
GGAATTGCTTTGAGGA AAGATTGCATACTGCCAGT ACACCAAGGAGGAAGGAGGAAGGATTCCAAGGAGGAAGGA	CGAGACCTGCACCGCTCCCTGCCAGAGCACCCCGCCTTCCAGAACGAAACG	COSMNILTSVLLLYTKEEEA
AAGATTGGATACTGCCAGT ACACCAAGGAGGAGGAGG ACACCAGGAGGAGGAGGAGGAGGAGGTTACTTCAA CTGTCTTCGAGGAGGTCAT TGAACGACCTCTCAGCCT TTCTATGATGGCATCAAGG CCAATGCTGAGGACCTGT( TCCTCAGCAGGACCTGT( AGTTGGCAGCACCATGAA	GGAATTGCTGCTTTGAGGAGAGTCTTGACGGCCTATGCCCACCGGAACCCC	FWLLVAVCERMLPDYFNH
ACACCAAGGAGGAAGGAAGGAAGGAAGGAAGGAAGGAAG	AAGATTGGATACTGCCAGTCCATGAACATCCTGACCTCCGTGCTGCTGCTGT	RVIGAQVDQSVFEELIKGHL
TGCTGCCCGATTACTTCAA CTGTCTTCGAGGAGCTCAT TGAACGACCTCTCAGCCT TGAACGACCTCATGCT GTTCCTCAGCATCAAGG TTCTATGATGGCATCAAAG CCAATGCTGAGGACCTGT TCCTCAGCAGGTTTCTAGA AGTTGGCAGCCTCTC GACTGATATTTCGGACCTGC	ACACCAAGGAGGAGGAAGCCTTCTGGCTGTTGGTTGCTGTGTGAGCGGA	PELAEHMNDLSALASVSLS
CTGTCTTCGAGGAGCTCAT TGAACGACCTCTCAGCCCT TGAACGACCTCTCAGCCCT GTTCCTCAGCATCATGCCT TTCTATGATGCCATCAAAG CCAATGCTGAGGACCTGTC TCCTCAGCAGGTTTCTAGA AGTTGGCAGCCATGCC GACTGCACCATGCC	ACTTCAACCACCGAGTGATCGGGGCACAAGTTGACCAGT	WFLTLFLSIMPLESAVNVVD
TGAACGACCTCTCAGCCT GTTCCTCAGCATCATGCCT TTCTATGATGCCATCAAAG CCAATGCTGAGGACCTGT( TCCTCAGCAGGTTTCTAGA AGTTGGCACCCATGC/ GACTGATATTTCGGACCTC	CTGTCTTCGAGGAGCTCATCAAGGGTCATCTCCCAGAGCTGGCAGAGCACA	CFFYDGIKAIFQLGLAVLEA
GTTCCTCAGCATCATGCCTCTTGCCTCTTGCCTTTTCTATGATGCCATCAAAGGCCTCTTTCTATGCAGGACCTGTCTCTAGAAGGTTTCTAGAAGTTTGGCAGCCACCTTGGACCTTCTAGAATTTTCGGACCTTC	CAGCCCTGGCGTCTGTCTCTCTCGTGGTTCCTGACCCT	NAEDLCSSKDDGQALMILS
TTCTATGATGCCATCAAGG CCAATGCTGAGGACCTGTC TCCTCAGCAGGTTTCTAGA AGTTGGCAGCCACCATGC/ GACTGATATTTCGGACCTC	CATGCCTCTAGAGAGTGCGGTGAATGTGGTAGACTGCTTC	RFLDHIKNEDSPGPPVGSH
CCATGCTGAGGACCTGTG TCCTCAGCAGGTTTCTAGA AGTTGGCAGCCACCATGCT GACTGATTCGGACCTG	TTCTATEATGCCATCAAAGCCATCTTCCAGCTGGGACTGGCTGTGCTTGAGG	HAFFSDDQEPYPVTDISDLI
TCCTCAGCAGGTTTCTAGA AGTTGGCAGCCACCATGCC GACTGATATTTCGGACCTG	CCAATGCTGAGGACCTGTGCAGCAGGATGATGGCCAGGCTTGATGA	RDSYEKFGDQSVEQIEHLR
AGTTGGCAGCCATGCC	TTCTAGATCACATTAAGAATGAGGACAGCCCAGGGCCCCC	YKHRIRVLQGHEDTTKQNV
GACTGATATTTCGGACCTG	A CTT G G C A C C C C C C C C C C C C C C C C	LRVVIPEVSILPEDLEELYDL
	GACTGATATTTCGGACCTGATCCGGGATTCCTATGAGAAATTTGGAGACCAG	FKREHMMSCYWEQPRPM
15A55TA5A5A56TSTCT	TOTET GARGEAGATE ACCIONATE ACAGE ACCAGGAT CAGGAT COMMENT OF THE CAGGAT CAGGAT COMMENT OF THE CAGGAT	ASRHDPSRPYAEQYRIDAR
CAAGGCCACGACGACACC	SACACCACAAAAGCAGAACGTGCTTCGAGTCGTTATCCCG	QFAHLFQLVSPWTCGAHT
GAAGTCTCAATTCTTCCTG	GAAGTCTCAATTCTTCCTGAAGACCTAGAGGAGCTCTACGACTTATTCAAGA	EILAERTFRLLDDNMDQLIE
GAGAACATATGATGAGCTG	GAGAACATATGATGAGCTGTTACTGGGAGCAGCCCAGGCCCATGGCCTCAC	FKAFVSCLDIMYNGEMNEK
GCCACGACCCAGCCGGC	A G C C G G C C C T A T G C T A G C C C C C C C C C C C C C C C C C C	IKLLYRLHIPPALTENDRDS
CAGTTTGCACACCTGTTTC	CTGTTTCAGCTAGTCTCGCCCTGGACCTGCGGGGCCCAC	QSPLRNPLLSTSRPLVFGK
ACGGAGATCCTCGCCGAA	ACGGAGATCCTCGCCGAAAGGACGTTCAGGCTCTTGGATGACAACATGGAC	PNGDAVDYQKQLKQMIKDL
CAGCTCATCGAGTTCAAAC	CAGCTCATCGAGTTCAAAGCGTTTGTGAGCTGCCTCGATATTATGTATAATG	AKEKDKTEKELPKMSQREF
GAGAAATGAATGAAAGAAT	AGAAGATTAAACTATTATACAGGCTTCATATCCCTCCAGCA	IQFCKTLYSMFHEDPEEND
CTCACTGAAAATGACCGAG	GACCGAGACAGCCAGTCGCCGTTGAGGAATCCTCTGTTGT	LYQAIATVTTLLLQIGEVGQ
	CCCTGGTTTTCGGGAAACCCAATGGTGATGCAGTTGATTA	RGSSSGSCSQECGEELHA
TCAGAAACAGCTGAAGCAC	GAAGCAGATGATTAAGGATTTAGCCAAAGAAAAAAAAAA	SAPSPEDSVFADTGKTPQD
ACTGAGAAATTGCCC	ACTGAGAAAGAATTGCCCAAAATGAGCCAGAGAGAATTTATCCAGTTCTGTA	SQALPEAAERDWTVSLEHI
TETATATATATATATATATATATATATATATATATATAT	**************************************	LASLLTEQSLVNFFEKPLD
COCATOGOCACAGICACO	AGTCACCACACTGCTGCTGCAGATCGGGGAGGTGGGGCA	MKSKLENAKINQYNLKTFE
GCGAGCAGCTCTGC	GCGAGGGAGCTCTGGAAGCTGCTCCCAGGAGTGTGGGGGAGGAGCTGC	MSHQSQSELKLSNL*
GGGCTTCAGCTCCTTCTC	GGGCTTCAGCTCCTTCTCCTGAGGACTCGGTTTTTGCAGACACTGGGAAGAC	
GCCCCAGGACTCCCAGGC	GCCCCAGGACTCCCAGGCACTTCCAGAGGCGCGCAGAAAGGGACTGGACTG	
TCTCCCTTGAACATATTT	TCTCCCTTGAACATATTTTAGCTTCACTTCTGACTGAACAGTCATTAG1CAAC1	

87 TCTCCCAGACC	
GGAGCTCAC GGAGCTTAA GGAGGTTTAA TCATTGATA ACGCCACAA CGGGACCC CTGCAGGGT	
SGTGTGGA( SCGCTGGCC SCAGCGCC	TGGTGTGGAGGACGTGCGAACCGTGCTGGAGCACTATGCCCTGGAGGATGA CCCGCTGGCGGCTTTCAAACAGCGGCAAAGCCGGCTAGAGCAGGAGGAGC AGCAGCGCCTGGCCGAGCTCTCCAAGTCCAACAGCAGAACCTCTTCCTTG GCTCCCTCACCAGCCGCTTGTGGCCTCGCTCCAAACAGCCCTGA
GGGGGGTGC TTCGCNNTTT TTNACTTGN AATTTTTCNC VTATTNGNC ATNCGGAT	88 TGGGGGGTGGGGATGGGGTTTGTTTNTNNNNCTTNTTTTTTTNTNNNTNCNN ATTGGNNTTTNNTTTTNCTACTATGGACNTGANTGATTTTTTTTTT
TCACAGO TCACAGO TCATTCCATO ACACGGCAC ACACGGCAC ACACGGCAC ACACGCAC ACACGCAC ACACATTA ACCATCAC CAACAATGC CAACAATGC CAACAATGC TCACCCC TCACCACCCC TCACCACCCCCCCCCC	NCALINCGGALICAMILONINIA  NCALINCGGALICAMILONINIA  CTCACACCACCTTTGAGAGGAGCTCGTCCTCAGGACCCCTCTGAGGAAGG  TCCCGGTGATTTTGGCTTCCTGCATGCCAGTAGTAGCATCGAGTCCGAGGCAAAA  AAACCAGCCCAGC

				GCAGAAGTGGGCATCTCGGAGCCAGCCTCCAGCAGGGGCTATTC FG* CCCCACACCCCTACCCACTGGAAAGGAGTGTTGTAAGACTAGGTTTTGGCTA	
Shigella ospC1	ю	prey67380	06	NINNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN	XXXXXXXXXXXXXXSLCIF F*M*VLCFIIFHIY*IKSEQ*LC AK*ILLSILAKKS*MSRMISP GHLYCSQVSNSFLGAKTSG FTLXLVNILKXYX
Shigella ospC1	m en	prey3296	5	IGCCCGACTGGAACACCTCTTTGAGTCTCG SAAGAAAGCTGGAACAAT ICGCACAAACACACACACAAAT ICGCACGAACGCCACCGCGGACAAT ATTAAGGCTGCTCTCAACTTTGATGAG ATTAAGGCTGCTCTGACCATCGGCCTAAC TTGAGAAGCTACTGACCATCGACATAC CCTGATGACACTTGACACTTTGACGG AGCACCAGCTGGCAACTTTGACGGC AGCCTCTCAAGCTTTGACAGCTTGGAACATAC TGCATCCTGGCTACCTCTTGACAGCTGGA ACCCGGCTTTGACGTTGGAACAGCT TGCATCCTGGCTACCTCTGTGGA ACCCGGCTTTGACGTTTGACACACCA ACCCGGCCTTTGACGCTCTTTCA TGCATCCTGGCTACCTGCTATTCA ACCCGGCCTTTTGACGTCTCTGCTATTCA ACCCGGCCTTTTGACCTCTGCTACTCA ACCCGGCCTTTTGACTTTTCACTGCTACCA ACCCGGCCTTTTGACTTTTCACTGCTACT ACCCGCGCTTTTGCCAGGCTACA ACCCGGCACCAGCCCGCGCACAC ACCCGGCACCAGCCCCAGCACC ACCCGCGCACAACACCACCACCAC ACCCGCAACAAGACCCCCAGCAAC ACCCGCGCAACAACACCACCACCAC ATCCCCAACAAGACCCCCAGCAAC ATCCCCAGAACAACACCCCAATCATGCC ATCCCCAGAACAACACCCCAACACCAC ATCCCCAGAACAACACCCCCAACACCAC ATCCCCAGAACAACACCCCCAATCATGCC ATCCCCAGAACAACACCCCCAACACACCAC ATCCCCAGAACAACACCCCCAACACACCACCACACACACA	DPVSVDTARLEHLFESRAK EVLPSKKAGEGRRTMTTVL DPKRTNAINIGLTTLPPVHVI KAALLNFDEFAVSKDGIEKL LTMMPTEERQKIEGAQLA NPDIPLGPAENFLMTLASIG GLAARLQLWAFKLDYDSM EREIAEPLFDLKVGMEQLV QNATFRCILATLLAVGNFLN GSQSSGFELSYLEKVSDVK DTVRRQSLLHHLCSLVLQT RPESSDLYSEIPALTRCAKV DFEQLTENLGQLERRSRAA EESLRSLAKHELAPALRAR LTHFLDQCARRVAMLRIVH RRVCNRFHRELLYLGYTPQ AAREVRIMQFCHTLREFAL EYRTCRERVLQQQQKQAT YRERNKTRGRMITETEKFS GVAGEAPSNPSVPVAVSS GPGRGDADSHASMKSLLT SRLEDTTHNRRSRGMVQS SSPIMPTVGPSTASPEEPP GSSLPSDTSDEIMDLLVQS VTKSSPRALAARERKRSRG NRKSLRRTLKSGLGDDLVQ ALGLSKGPGLEV*

Shigella ospC1	ဇာ	prey2108	<b>76</b>	293	QEAQSIDEIYKYDKKQQQEI LAAKPWTKDHHYFKYCKIS ALALLKMVMHARSGGNLEV MGLMLGKVDGETMIIMDSF ALPVEGTETRVNAQAAAYE YMAAYIENAKQVGRLENAI GWYHSHPGYGCWLSGIDV STQMLNQQFQEPFVAVVID PTRTISAGKVNLGAFRTYP KGYKPPDEGPSEYQTIPLN KIEDFGVHCKQYYALEVSY FKSSLDRKLLELLWNKYWV
					FDLSEKLEGSEAGLGRGSF MLGLETHDRKSEDKLAKAT RDSCKTTIEAIHGLMSQVIK DKLFNQINIS*
Shigella ospC1	ဇ	prey67403	93	TGGCAGGAGCTTTGGATTTCTTTAGGGAAATGGCAATCAGA TGGCAGGGAGCTTTGGATTCTTTTAGGGAAATGGCAATCAGAATCAGAATCAGAATCAGAATCAGAACAGCAC ATTCTCTGCTAAAGATGGTGCTTCCTCTACTTCCCCAGACC CCATTTCCATGAATTTTTCATCAGGGTCACAGGACAAAGGTT TTCTAATGAGACTCTGACTTGGCTCTGGATGACTATGAAAC TTTGTCTTTTCTGGAATCCN TTTGTCTTTTTCTGGAATCCN	GGSVFC*GNQNDPSNSTF DLYSLLKMVLPLLPQTPVSV PFP*IFHQGHRTKVLVFGSN ETSDLALDDYETSECICLF WNP
Shigella ospC1	က	prey67405	94	AGCTATTGATAGCTTACTATTGTATCANNNNNNNNNNNNN	XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
Shigella ospC1	м	prey14400	95	GGGCGAGAGGACTGAGTGTGCTGAGCCCCCGGGACGAACCCCGGGCTG 296 ATGGAGCTCTGAAGCGGGCAGGAGCTCAAGACTCAGGCCAATGACTACT TCAAAGCCAAGGACTACGAGAACGCCATCAAGTTCTACAGGCCAATGACTACG AGCTGAACCCCAGCAATGCCATCTACTATGGCAACCGCAGGCCTGGCTACC TGCGCACTGAGTGCTATGGCTACGCGCTGGGAGACGCCACGGGGCCATT GAGCTGGACAAGAAGTACATCAAGGGTTATTACCGCGGGCTGCCAGCATC ATGGCACTGGGCAAGTACATCAGGGCTGCCGCGGGCTGCCAGC ATGGCACTGGGCAAGTACATCAGGGCTGCCAGGGGCTGCCAGC CAAGGTGAAGAAGTACAAGGGTTATTACCGCGGGCTGCCAGCAAC ATGGCACTGGGCAAGTACCAAGGGTGCTACCAAAATGAAATACCAGGAGTGCAA	GEH I ECAEFT NDET FADO ALKRAEELKTQANDYFKAK DYENAIKFYSQAIELNPSNA IYYGNRSLAYLRTECYGYA LGDATRAIELDKKYIKGYYR RAASNMALGKFRAALRDYE TVVKVKPHDKDAKMKYQE CNKIVKQKAFERAIAGDEH

					VDC///DCI DIECMTIEDEVS
				GCAGAAGGCCIIIGAGCGGGCCAICGCGGCCACGACGAGCATGAGC	GPKLEDGKVTISFMKELMQ
					WYKDQKKLHRKCAYQILVQ
				GCAGTGGTACAAGGACCAGAAACTGCACCGGAAATG	VKEVLSKLSTLVETTLKETE
				TCTGGTACAGGTCAAAGAGGTCCTCTCCAAGCTGAGCACG	KITVCGDTHGQFYDLLNIFE
					LNGLPSETNPYIFNGDFVD
					RGSFSVEVILTLFGFKLLYP
					DHFHLLRGNHETDNMNOIY
					GFEGEVKAKYTAQMYELFS
					EVFEWLPLAQCINGKVLIM
					HGGLFSEDGVTLDDIRKIER
					NRQPPDSGPMCDLLWSDP
					QPQNGRSISKRGVSCQFG
					PDVTKAFLEENNLDYIIRSH
					EVKAEGYEVAHGGRCV I V
					FSAPNYCDQMGNKASYIHL
		-			QGSDLRPQFHQFTAVPHP
				()	NVKPMAYANTLLQLGMM*
				CCCAACTACTGCGACCAGATGGGGAACAAAGCCTCCTACATCCACCTCCAG	
				GGCTCTGACCTACGGCCTCAGTTCCACCAGTTCACAGCAGTGCCTCATCCCA	
				ACGTCAAGCCCATGGCCTATGCCAACACGCTGCTGCAGCTAGGAATGATGT	
					THE COLUMN TO TH
Shigella	ဗ	prey50029	96	297	LISEIPULNUWALSFIRSK HOOFBIKTSGOHEFSKOFF
ospC1					DOME TO BE FORDAVSAH
		-			AVICICACINECOS AVOIDA
					Y I L'ALLAFANINI I SAN SI OLL
				CATGCCTGCTGTAGGGACCATAGCCICIGICCCIGCAI	TOTAL TO SERVICE OF THE SERVICE OF T
					FELFIERENCE DAY FILLAR
					VLSLANVROIRLRAVF LLN
				-	MIND I MINOCENCERMII FIL
					KKKIMKF.YIHNI GINF.KRYA K*NICONIKONYOSTX/MS
					INTEGRAL DOLLARIO
					LK*TTT*RQKVDSGC*GLLE
					GQWHVSV*WVQCHSGCSV
					YGVGTLGSLYFSNKLAHT*
					KEKALEID
Olionida	_	250V67E63	07	A 298	AVLRGDAEAVKGIGSGKVL
Sriigelia	4	preyo/ 505	3/		

				TO SO SO SO A TO A TO TO A TOTA OF TO A CONTRACT OF A CONT	KSGPODHVFIYFTDHGSTG
ipaD					LVFPNEDLHVKDLNETIHY
					MYKHKMYRKMVFYIEACES
				()	GSMMNHLPDNINVYATTAA
				SCAACTACTGCTGCCAACCCCAGAGAGTCGTCCTACGCCT	NPRESSYACYYDEKRSTYL
					GDWYSVNWMEDSDVEDLT
					KETLHKQYHLVKSHTNTSH
					VMQYGNKTISTMKVMQFQ
					GMKRKASSPVPLPPVTHLD
					TPSPDVPLTIMKRKLMNT
					NDLEESRQLTEEIQRHLDA
					RHLIEKSVRKIVSLLAASEA
					EVEQLLSERAPLTGHSCYP
					EALLHFRTHCFNWHSPTYE
				(13	YALRHLYVLVNLCEKPYPL
				CTTCAACTGGCACTCCCCCACGTACGAGTATGCGTTGAGACATTTGTACGTG	HRIKLSMDHVCLGHY*
				CTGGTCAACCTTTGTGAGAAGCCGTATCCACTTCACAGGATAAAATTGTCCAT	
والمهزمي		prov0100	86	GACTAAGGATCACCATTACTTTAAGTACTGCAAAATCTCAGCATTGGCTCTTC 299	TKDHHYFKYCKISALALLKM
Singella	<b>t</b>	pieyzios	3	TGAAGATGGTGATGCCAGGTCGGGGAGGCAATTTGGAAGTGATGGGTC	VMHARSGGNLEVMGLMLG
Ipau				TGATGCTAGGAAAGGTGGATGGTGAAACCATGATCATTATGGACAGTTTTGC	KVDGETMIIMDSFALPVEGT
				TTTGCCTGTGGGGGGCACTGAAACCCGAGTAAATGCTCAGGCTGCTGCATAT	ETRVNAQAAAYEYMAAYIE
				GAATACATGGCTGCATACATAGAAAATGCAAAACAGGTTGGCCGCCTTGAAA	NAKQVGRLENAIGWYHSH
			_	ATRICA ATCREGET GETATION TARGET A GOOD AT THE CONTROL OF THE CANADA TO T	PGYGCWLSGIDVSTQMLN
				ATTGATGTTAGTACTCAGATGCTCAATCAGCAGTTCCAGGAACCATTTGTAG	QQFQEPFVAVVIDPTRTISA
				CASTESTEATTEATCOAACAATATCOGCAGGAAAGTATCOGCAGGGAAAGTGAATCTTGG	GKVNLGAFRTYPKGYKPPD
				CAGINATION CONTRACTOR AND CONTRACTOR	EGPSEYQTIPLNKIEDFGVH
				CACCOLLINGUACION CONTRACTOR CONTR	CKQYYALEVSYFKSSLDRK
				ACAATATTATGCCTTAGAAGTCTCATATTTCAAATCCTCTTTGGATCGCAAATT	LLELLWNKYWVNTLSSSSL
				GCTTGAGCTGTTGTGGAATAAATACTGGGTGAATACGTTGAGTTCTTCTAGCT	LTNADYTTGQVFDLSEKLE
				TGCTTACTAATGCAGACTATACCACTGGTCAGGTCTTTGATTTGTCTGAAAAG	QSEAQLGRGSFMLGLETH
				TTAGAGCAGTCAGAAGCCCAGCTGGGACGAGGGAGTTTCATGTTGGGTTTA	DRKSEDKLAKATRDSCKTT
				GAAACGCATGACCGAAAATCAGAAGACAAACTTGCCAAAGCTACAAGAGACA	IEAIHGLMSQVIKDKLFNQIN
				GCTGTAAAACTACCATAGAAGCTATCCATGGATTGATGTCTCAGGTTATTAAG	<u>*S</u>
				-	100000000000000000000000000000000000000
Shigella	4	prey25185	66	GGGCAATAAGGCCTGTAGCCCATGCTCCTCACAGTCCTCCAGCAGTGGCAT 300	GNKACSPCSSQSSSSGICT DEWDITYKLDNMNVSRKG
ipaD				GCACAGACI   CIGGGACI   AII   GG   AAAACI   GGACACA   GAATGCCACACACACACACACACACACACACACACACACA	KNSVKSVPVSAGGEGETS
-				CGGAAAAGGCAAGAACI CCG I GAAAG I CAG I GCCAG I GAGCAGCAG I GAGAAAAAAAAAA	PYSLEASPLGQLMNMLSHP

	GAACATGTCACACCCAGTCATCCGCCGGAGCTCTCTTAACTGAGAAA	VIRRSSLLTEKLLRLLSLISIA I PFNKVSFAQANSGSGAS
	CTCCTCAGACTCCTTTCTCTCTCTCTCCACAGAGACACCAC	STTTATSTTSTTTTAASTT
	CTCAACCACACACACCACCACCACCACCACCACCACACACAC	PTPPTAPTPVTSAPALVAAT
	CCCTACTGCACCCCTGTCACTTCTGCTCCAGCCCTGGTTGCTGCCAC	AISTIVVAASTTVTTPTTATT
	GGCTATTTCCACCATTGTCGTAGCTGCTTCGACCACAGTGACTACCCCCACG	TVSISPTTKGSKSPAKVSD
	ACTGCTACCACTACTGTTTCAATTTCTCCCACTACTAAGGGCAGCAAATCTCC	GGSSSTDFKMVSSGLIEN
	AGCGAAGGTGAGTGATGGGGGCAGCAGCAGTACAGACTTTAAGATGGTGTC	QLQLSVEVLISHSCSEEGL
	CTCTGGCCTCACTGAAAACCAGCTACAGCTCTCTGTAGAGGTGTTGACATCC	EDAANVLLQLSHGDSG1RD
	CACTCTTGTTCTGAGGAAGGCTTAGAGGATGCAGCCAACGTACTACTGCAGC	OCTI 1 AFI PEXNII EOOBB
	TCTCCCGGGGGGACTCTGGGACCCGGGACACTGTTCTCAAGCTGCTAC1GA	OIGILLAELHEYNLEGGRA
	ATGGAGCCCGCCATCTGGGTTATACCCTTTGTAAACAAATAGGTACCCTGCI	AQCETESPOGEPEGPQTT
	GGCCGAGCTGCGGGAATACAACCTCGAGCAGCAGCGGCGAGCCCAATGTG	ALKGRINGSHFDINAEIVVVIV
	AAACCCTCTCTCCTGATGGCCTGCCTGAGGAGCAGCCACAGAGC	ASQKRPLGGRELQLPSIMS
	TGAAGGGCAAAATGCAGAGCAGGTTTGACATGGCTGAGAATGTGGTAATTGT	MLISKISIQKFFLHVLQVII
	GGCATCTCAGAAGCGACCTTTGGGTGGCCGGGAGCTCCAGCTGCCTTCTAT	QLRDDI RRANKKAKU I GR
	GTCCATGTTGACATCCAAGACATCTACCCAGAAGTTCTTCTTGAGGGTACTA	LGSSGLGSASSIQAAVHQL
-	CAGGTCATCATCCAGCTCCGGGACGACGCGCGCCGGGCTAACAAGAAAGCC	EAEADAIIQMVREGORARH
	AAGCAGACAGGCAGGCTAGGTTCCTCCGGTTTAGGCTCAGCTAGCAGCATC	QQQAATSESSQSEASVRR
	CAGGCAGCTGTTCGGCAGCTGGAGGCTGAGGCTGATGCCATTATACAAATG	EESPMDVDQPSPSAQDTQ
		SIASDGTPQGEKEKEERPP
	GTCTAGCCAGTCAGAGGCGTCTGTCCGGAGGGAGGAATCACCCATGGATGT	ELPLLSEQLSLDELWDMLG
	GGACCAGCCATCTCCCAGTGCTCAAGATACTCAATCCATTGCCTCCGATGGA	ECLKELEESHDQHAVLVLQ
		PAVEAFFLVHATERESKPP
	CTCAGCGAGCAGCTGAGTTTGGACGAGCTGTGGGGACATGCTTGGGGAGTGT	VRDTRESQLAHIKDEPPPL
	CTAAAGGAACTAGAGGAATCCCATGACCAGCATGCGGTGCTAGTGCTACAG	SPAPLTPATPSSLDPFFSR
	CCTGCTGTCGAGGCCTTCTTTCTGGTCCATGCCACAGAGCGGGAGAGCAAG	EPSSMHISSSLPPDTQKFL
_		RFAETHRTVLNQILRQSTT
	CCTCCTCCACTCTCCCCTGCCCCCTTAACCCCAGCCACGCCTTCCTCCTTG	HLADGPFAVLVDYIRVLDFD
		VKRKYFRØELERLDEGLRK
	CCCTGACACACAGAAGTTCCTTCGCTTTGCAGAGACTCACCGCACTGTGTTA	EDMAVHVRRDHVFEDSYR
		ELHRKSPEEMKNRLYIVFE
		GEEGODAGGLLREWYMIIS
		REMFNPMYALFRTSPGDR
	GTGCATGTCCGTCGTGACCATGTGTTTGAAGACTCCTATCGTGAGCTGCATC	VTYTINPSSHCNPNHLSYF
	GCAAATCCCCCGAAGAAATGAAGAATCGATTGTATATAGATTGAAGGAGA	KFVGRIVAKAVYDNALLEC
	AGAAGGGCAGGATGCTGGCGGGCTCCTGCGGGAGTGGTATATGATCATCTC	YFTRSFYKHILGKSVRYID MTGTDXLEXOCIVXII END
	TCGAGAGATGTTTAACCCTATGTATGCCTTGTTCCGIACCICACCIGGIGAIC	MESEDINFIGGEVILLEND   VSTLGYDLTFSTEVQEFGV
	GAGICACCIACATOAAICAAICAAICAACAACAACAACAACAACAACAACAACA	

				CEVRDI KPNGANII VTEEN
				KKEYVHLVCQMRMTGAIRK
				QLAAFLEGFYEIIPKRLISIFI   EQELELLISGLPTIDIDDLKS
				NTEYHKYQSNSIQIQWFWR
				ALRSFDQADRAKFLQFVTG
				I SKVPLOGFAALEGMINGIO KEOIHRDDBSTDBI PSAHT
			TTAGAAGGC  C A GAGA CA  CCAAAGCGCC CA   CCA  CA	CFNQLDLPAYESFEKSATC
			· · · · · · · · · · · · · · · · · · ·	YCWLSRSALKALGWPNKA
			-	LPNSVGFFLPLLDLGRGEL
				KKEPERNCQKPINEIHQLIV CVPAAPSSPAHTCSSSHSL
-				PAACFLTFSPLSMPSMIPTP
			STTTGAGAAGTCCGCCACATGCTACTGTTGGCTATCCAGGA	CVLKRQ*
			GTGCTCTGAAGGCTTTGGGCTGGCCTAATAAGGCCCTGCCCAACTCCGTGG	
			GGTTTTTTTACCATTGTTGGACCTGGGGGGGGGGGGGGG	
			AGAAAGAAATTGTCAAAAACCAATAAATGAAATCCACCAACTCACGTGTGTG	
			CCCAGCIGCCCCA1CI	
	_		CCACCCATGTTTTAAAAAGGCAGTAG	
4 4	prev53990	100	CCACCTATACCCCGGGTGACTGTCCCAACTTTGCGGCTCCCCGCAGAGAGG 301	TYTPGDCPNFAAPRREVAP
inaD			TGGCACCACCCTATCAGGGGCTGACCCCATCCTTGCGACAGCCCTCGCCT	PYQGADPILA! ALASDPIPN
			CCGACCCCATCCCCAACCCCCTTCAGAAGTGGGAGGACAGCGCCCACAAGC	PLOKWEDSAHKPOSLD ID
			CACAGAGCCTAGACACTGATGACCCCGCGACGCTGTACGCCGTGGTGGAGA	DPATLYAVVENVPPLRWKE
			ACGTGCCCCGTTGCGCTGGAAGGAATTCGTGCGCCGCCTAGGGCTGAGC	FVRRLGLSDHEIDRLELON
			GACCACGAGATCGATCGGCTGGAGCTGCAGAACGGGCGCTGCCTGC	GRCLREAGYSMLA! WRRR
			GGCGCAATACAGCATGCTGGCGACCTGGAGGCGGCGCGCGC	TPRREATLELLGHVLHUMD
-			GAGGCCACGCTGGAGCTGCTGGGACGCGTGCTCCGCGACATGGACCTGCT	LLGCLEDIEEALCGPAALPF
			GGGCTGCCTGGAGGACATCGAGGGGGCGCTTTGCGGCCCCGCCGCCCCCCCC	AFSELK
Shinella 4	prev9120	101	GCCACGCGCTCTCTGCGTGCGCTGCGGAGCAGCGTGCCCGGGGTGCG 302	ATRSSAVRLRSSVPGVRLL
			GCTCCTGCAGGACTCGGTGGACTTCTCGCTGGCCGACGCCATCAACACGGA	QDSVDFSLADAINIEFKNI BTNEKVFI OFI NDBFANYI
			GIICAAGAACACCCGCACCAACAAGAAGAIGGACACCIGGAGCAGCAGCAGATAA	DKVRFLEGGNKILLAELEGL
-			GATOTTGCTGGCCGAGCTCGAGCTCAAGGGCCAAGGCAAGTCGCGCC	KGQGKSRLGDLYEEEMRE
			TAGGGGACCTCTACGAGGAGGAGATGCGGGAGCTGCGCCGGCAGGTGGAC	LRRQVDQLTNDKARVEVE
_			CAGCTAACCAACGACAAAGCCCGCG1CGAGG1GGAGCGCGACAACA1GGC	LOREEAENTLOSFRODVD
			CGAGGACATICALGOCOCOCOCOCOCOCOCOCOCOCOCOCOCOCOCOCOCOC	

2 4 0 1 1 1 0 2 0 1 1 1 1 1	303	304	AGGAAGA 305 AAATNHTTDNGVGPEEESV TCATCAG GEDPYPHKFHVDISLTDFIQ GEDPYPHKFHVDISLTDFIQ GEOPYPHKFHVDISLTDFIQ KYSHLQPGDHLTDITLKVA GRIHAKRASGGKLIFYDLR GEGVKLQVMANSRNYKSE ATATTAAT GEGVKLQVMANSRNYKSE EEFIHINNKLRRGDIIGVQG NPGKTKKGELSIIPYEITLLS SGAAACAA YRQRYLDLILNDFVRQKFII
AGAGGAAGCCGAAACCCCTGCAATCTTTCAGACAGGATGTTGACAATGCG TCTCTGGCACGTCTTGAACGCAAGTCGAAGTGTTTTTGAAGAAACCCTTGAAGAAGTCGAATTTTTTGAAGAAACTCCACGAAGGAAATCCAGGAGCTGCAGGACTCCAGGAACTCCAGGAACTCCAGGAACTCCAGGAACTCCAGGAACTTTTTCCAAGCCTGCAGGCTCCAGGAACCTCTGAACCTGCCAACGCTGCCAAGAACAATCCAAGTTTTTTTT		TCCTTTNAGGATGNTGAAAAGANGAATATATGCTTGGGAGCATGNNGTATCT TTNTGGTAGCATNACGCCATGNCCTACTTGTGCTTNNNNCACTTNGTTTNNN NGGACTACAACATGGAGGAANTNNACCNNATCTACCCTNTAGGCCTGCTCNT GGTCTCCTTGNTGTATCATGCCCTCGCTGGTNTGGAGCCNNNGCGGGNCCT CTTGANTATGCTTCANCCATACCAACACTGGTTGTATGTACGCGATCGCAAC ATCANATGCACGTATGTTNCTTGCTGTACAGACGCTACNAGAGANGGGCTTC	TGCTGCTGCCACCACCACCACTGATAATGGTGTGGGTCCTGAGGAAGA GAGCGTGGACCCAAATCCAAAATCCGCAGTCAAGCAATTCATCAG GAGCGTGGACCCAAATCAAAATCCGCAGTCAAGCAATTCATCAG CTGAAGGTCAATGGGGAAGACCCATACCCACACACAGTTCCATGTAGACATCT CACTCACTGACTTCATCCAAAAATATAGTCACCTGCAGCCTGGGGATCACCT GACTGACATCACCTTAAAGGTGGCAGGTAGGATCCATGCCAAAAGAGCTTCT GGGGAAAGCTCATCTTCTATGATCTTCGAGGAGGGGGTGAAGTTGCAA GTCATGGCCAATTCCAGAAATTATAAATCAGAAGAGAGATTTATTCATATTAAT AACAAACTGCGTCGGGGAGACATAATTGGAGTTCAGGGGAATCCTGGTAAAA CCAAGAAGGGTGAGCATCATTCCGTATGAGGCACCTGCTGCTCCC CTGTTTGCATATGTTACCTCATCTTCACTTTGGGGCAAAGGAAACAA
	102	103	104
	prey67571	prey67572	prey65696
	4	4	4
	Shigella ipaD	Shigella ipaD	Shigella ipaD

		ATTTATCATCCGCTCTAAGATCATCATCATATATAAGAAGTTTCTTAGATGAGCT	PMMNIIPGGAVAKPFITYHN
		GGGATTCCTAGAGATTGAAACTCCCATGATGAACATCATCCCAGGGGGGGG	ELDMNLYMRIAPELYHKML VVGGIDRVYEIGRQFRNEGI
		TGAGAATTGCTCCAGAACTCTATCATAAGATGCTTGTGGTTGGT	DLTHNPEFTTCEFYMAYAD
		CCGGGTTTATGAAATTGGACGCCAGTTCCGGAATGAGGGGGGTTTATGAAATTGACGCCTATGCAGATTCACCACCTGTGAGTTCTACATGGCCTATGCAGACTATC	TGSYKVTYHPDGPEGQAY
		ACGATCTCATGGAAATCACGGAGAGATGGTTTCAGGGATGGTGAAGCATAT	DVDF I PPFRRINMVEELEK ALGMKLPETNLFETEETRKI
		ACAGGAGI   ACAGGA   CACCO   ACCOCACO   CACCO   CACCO	LDDICVAKAVECPPPRTTA
		CTTGAGAAAGCCCTGGGGATGAAGCTGCCAGAAACGAACCTCTTTGAAACTG	RLLDKLVGEFLEVTCINPTFI
		AAGAAACTCGCAAAATTCTTGATGATATCTGTGTGGCAAAAGCTGTTGAATGC	CDHPQIMSPLAKWHRSKE GLTERFELFVMKKEICNAYT
		CC I CCACC I CGGACCACGAGGC COLL CACCAGGAT CATAGGAGGAGGTGAGGAT CATAGGAGGATGAT CATAGGAGATGCTACATTCATCTGTGATCACCACAGGATAAT	ELNDPMRQRQLFEEQAKA
		GAGCCCTTTGGCTAAATGGCACCGCTCTAAAGAGGGTCTGACTGA	KAAGDDEAMFIDENFCTAL
		GAGCTGTTTGTCATGAAGAAAGAGATATGCAATGCGTATACTGAGCTGAATG	EYGLPP I AGWGMGIDHVA
		ATCCCATGCGGCAGCGCAGCTTTTTGAAGAACAGGCCAAGGCCAAGGCIG	MITCH DONNINE VELFFAMINE
		CAGGTGATGATGAGGCCATGTTCATAGATGAAAACTTCTGTAC1GCCC1GGA	EURKENVALLUILESIIVG TSV*
		ATATGGGCTGCCCCCCACAGCTGGCTGGGCATGGGCATTGATCGGTTCCTGCTGCA	
		TGAAACCCGAAGACAAGAAGAAGAATGTAGCAACCACTGATACACTGGAAAG	
prey8889	105	GCTCAAGCCGGAGTTCATGCGGCGGCCGGACAAGTCCTTCGACCCCTTCAC 306	LKPEFMRRPDKSFUPF1EV
·		TGAGGTCATCGTGGCATCGTGGCCAATGCCTTGCGGGTCAAGGTGAI	IVDGIVAINALHVKVISGGFL SDBKVGIVVEVDMEGI PVD
		CTCAGGGCAGTTCCTGTCCGACGGAAGGIGGGCAICIACGIGGAGGIGGA	TERKYRTRISOGNSENDV
		CATGITTGGCCTCCCTGTTGATACGCGCGCGCAGIACCGCACCCGGACCIC	Wheepenepkyyi PTI ASI
		TCAGGGGAACTCGTTCAACCCCG1G1GGGACGAAGAGCCC11CGAC11CCC	WDEET DIT IN VEH TEASE BLADE BYS
		CAAGGTGGTGCTGCCCACGCTGGCTTCACTTCGCATTGCATCTGCTC	AIBSGYHYVCLBNEANOPL
		GGGGGG   AAAT   CG   AGGGCACCGGA   CC   GCC   GTGCCA   CCGCT   CCGCT	CLPALLIYTEASDYIPDDHQ
		COCAPTICATION OF ACCOCAME OF ACCUMENT OF	DYAEALINPIKHVSLMDQRA
		CCAGGACTATGCGGAGGCCCTGATCAACCCCATTAAGCACGTCAGCCTGAT	RQLAALIGESEAQAGQETC
		GGACCAGAGGCCCGGCAGCTGGCCCCCTCATTGGGGAGAGTGAGGCTC	QDTQSQQLGSQPSSNPTP
		AGGCTGGCCAAGAGACGTGCCAGGACACCCCAGTCTCAGCAGCTGGGGTCT	SPLDASPRRPPGPTTSPAS
		CAGCCGTCCTCAAACCCCCACCCCCAGCCCACTGGATGCCTCCCCCCGCCGG	TSLSSPGQRDDLIASILSEV
		CCCCCTGGCCCCACCACCTCCCCTGCCAGCACCTCCCTCAGCACCCAGG	ROFBUI BEI BKKHOBKAV
		GCAGCGTGATGATCTCATCGCCAGCATCTCTCAGAGGTGGCCCCCCACCCC	TLTRRLLDGLAQAQAEGRC
		A A GAGGA GACCT GCGGGAGCT GCGCAAGAAGCATCAGCGGAAGGCAGTC	RLRPGALGGAADVEDTKE

GGG GEDEAKRYQEFQNRQVQS 3AGG LLELREAQVDAEAQRRLEH LRQALQRLREVVLDANTTQ CAGG FKRLKEMNEREKKELQKIL DRKRHNSISEAKMRDKHKK FGAA AACT CQCQRARHITESVNSIR RLEEAQKQRHDRLVAGQQ QVLQQLAEEPKLLAQLAQ CAG EMPEGLGDGPLVACASNG FCG HAPGSSGHLSGADSESQE CTG GTC GTC	IGTT 307 MGIGLSAQGVNIMNRLPGW DKHSYGYHGDDGHSFCSS GTGQPYGPTFTTGDVIGCC VNLINNTCFYTKNGHSLGIA FTDLPPNLYPTVGLQTPGE VVDANFGQHPFVFDIEDYM REWRTKIQAQIDRFPIGDP GEEWQTMIQKMVSSYLVH HGYCATAEAFARSTDQTVL EELASIKNRQRIGKLVLAGR GAA MGEAIETTQQLYPSLLERN PNLLFTLKVRQFIEMVNGT DSEVRCLGGRSPKSQDSY PVSPRPFSSPSMSPSHGM NIHNLASGKGSTAHFSGFE SCSNGVISNKAHQSYCHSN KHQSSNLNVPELNSINMSR SQQVNNFTSNDVDMETDH YSNGVGETSSNGFLNGSS GGT QLRRQLCGGSQAAIERMIH FGRELQAMSEQLRRDCGK GAG
ACCCTCACCCGCCGCCGCGGGGGGGCGCGCGGGGGGGGGG	
	106
	prey700
	4
	Shigella ipaD

			AACOATOCATTOAOTTACTACTACTATTOAOTTATTOAOTTECAACTTOAOTTECAACTTC	CSAI NSAII ETHNI PKOPPI
			GAAATCAGCTTGACCCGATTCAGAGAACCTGTGTGCTCAGCTCTTAACAG	ALAMGQATQCLGLMARSGI
			TGCAATATTAGAAACCCACAATCTGCCAAAGCAACCTCCACTTGCCCTAGCA ATGGGACAGGCCACACAATGTCTAGGACTGATGGCTCGATCAGGAATTGGA TCCTGCGCATTTGCCACAGTGGAAGACTACCTACATTAG	GSCAFATVEDYLH*
Shigella 4	prey2694	107	125 🔀	MAHAMENSWTISKEYHIDE EVGFALPNPQENLPDFYND
			TATAATGACTGGATGTTCATTGCTAAACATCTGCCTGATCTCATAGAGTCTGG	WMFIAKHLPDLIESGQLRE
			CCAGCTTCGAGAAAGAGTTGAGAAGTTAAACATGCTCAGCATTGATCATCTC	RVEKLNMLSIDHLTDHKSQ
			ACAGACCACAGAGTCACAGGCGCCTTGCAGGTCTAGTTCTGGGATGCATCACCA	HGDVRKVLPRNIAVPYCOL
			GAAATATTGCTGTTCCTTACTGCCAACTCTCCAAGAAACTGGAACTGCCTCCT	SKKLELPPILVYADCVLANW
			ATTTTGGTTTATGCAGACTGTGTCTTGGCAAACTGGAAGAAAAAGGATCCTAA	KKKDPNKPLTYENMDVLFS
			TAAGCCCCTGACTTATGAGAACATGGACGTTTTGTTCTCATTTCGTGATGGAG	FRDGDCSKGFFLVSLLVEIA
			ACTGCAGTAAAGGATTCTTCCTGGTCTCTCTATTGGTGGAAATAGCAGCTGC	AASAIKVIPTVFKAMQMQE
				VELOUIDHYNIPKAFESYI BI
			GGGACACI  GC AAAGGCGC G  G  GGAAA AGC  C  GC  GGAGAAAGC	VFHGIHDHVINFKAFFSVENI VI SGWKGNPOI SDGI VYE
				GFWEDPKEFAGGSAGQSS
			CGGTCTGGTGTATGAAGGGTTCTGGGAAGACCCAAAGGAGTTTGCAGGGGG	VFQCFDVLLGIQQTAGGGH
			CAGTGCAGGCCAAAGCAGCGTCTTTCAGTGCTTTGACGTCCTGCTGGGCAT	AAQFLQDMRRYMPPAHRN
			CCAGCAGACTGCTGGTGGAGGACATGCTGCTCAGTTCCTCCAGGACATGAG	FLCSLESNPSVREFVLSKG
			AAGATATATGCCACCAGCTCACAGGAACTTCCTGTGCTCATTAGAGTCAAAT	DAGLREAYDACVKALVSLR
			CCCTCAGTCCGTGAGTTTGTCCTTTCAAAAGGTGATGCTGGCCTGCGGGAA	SYHLQIVTKYILIPASQQPKE
			GCTTATGACGCCTGTGAAAGCTCTGGTCTCCCTGAGGAGCTACCATCTGC	NKTSEDPSKLEAKGTGGTD
			AAATCGTGACTAAGTACATCCTGATTCCTGCAAGCCAGCAGCCAAAGGAGAAA	LMNFLKTVRSTTEKSLLKE
1.11			TAAGACCTCTGAAGACCCTTCAAAACTGGAAGCCAAAGGAACTGGAGGCACT	5
			GAAGGAAGGTTAA	
Shigella 4	prey53735	108	GGGTGAACCAGAAGGTTCCTTCGTGGATTACCAAACAACTATGGTGCGGACA 309	GEPEGSFVDYQTTMVRTA
ipaD			GCCAAGGCCATTGCAGTGACCGTTCAGGAGATGGTTACCAAGTCAAACACC	KAIAVTVQEMVIKSNISPE
			AGCCCAGAGGAGCTGGGCCCTCTTGCTAACCAGCTGACCAGTGACTATGGC	ELGPLANQLTSDYGRLASE
<del>,</del>			CG  C  GGCC  CGGAGGCCAAGCC  GCAGCGG  GGC  GC	VOELGHGCAALVTKAGALQ
			CGCTCTGGTCACCAAGGCAGGCGCCCTGCAGTGCAGCCCCAGTGATGCTA	CSPSDAYTKKELIECARRV
•			CACCAAGAAGGAGCTCATAGAGTGTGCCCGGAGAGTCTCTGAGAAGGTCTC	SEKVSHVLAALQAGNRGT
-			CCACGTCCTGGCTGCGCTCCAGGCTGGGAATCGTGGCACCCCAGGCCTGCAT	QACITAASAVSGIIADLDTTI
			CACAGCAGCAGCGCTGTGTCTGGTATCATTGCTGACCTCGACACCACCATC	MFATAGILNKEGIEIFADH BEGII KTAKVI VEDTKVI VO
	About the second			

				ACCACCAGAGAGACATCCTGAAGACTGCGAAGGTGCTGGTGGAGGACACC	NAAGSQEKLAQAAQSSVA
				AAGGTCCTGGTGCAAAACGCAGCTGGGAGCCAGGAGAAGTTGGCGCAGGC	TITRLADVVKLGAASLGAED
	-		•	TGCCCAGTCCTCCGTGGCGACCATCACCCGCCTCGCTGATGTGGGTCAAGCT	PETQVVLINAVKDVAKALG
			_	GGGTGCAGCCAGCCTGGGAGCTGAGGACCCTGAGACCCAGGTGGTACTAA	DLISATKAAAGKVGDDPAV
			•	TCAACGCAGTGAAAGATGTAGCCAAAGCCCTGGGAGACCTCATCAGTGCAA	WQLKNSAKVMVTNVTSLLK
				CGAAGGCTGCAGCTGGCAAAGTTGGAGATGACCCTGCTGTGTGGCAGCTAA	TVKAVEDEATKGTRALEAT
				AGAACTCTGCCAAGGTGATGGTGACCAATGTGACATCATTGCTTAAGACAGT	TEHIRGELAVFCSPEPPAKT
				AAAAGCCGTGGAAGATGAGGCCACCAAAGGCACTCGGGGCCCTGGAGGCAA	STPEDFIRMTKGITMATAKA
				CCACAGAACACATACGGCAGGAGCTGGCGGTTTTCTGTTCCCCAGAGCCAC	VAAGNSCRQEDVIATANLS
				CTGCCAAGACCTCTACCCCAGAAGACTTCATCCGAATGACCAAGGGTATCAC	RRAIADMLRACKEAAYHPE
				CATGGCAACCGCCAAGGCCGTTGCTGCTGGCAATTCCTGTCGCCAGGAAGA	VAPDVRLRALHYGRECAN
			•	TGTCATTGCCACAGCCAATCTGAGCCGCCGTGCTATTGCAGATATGCTTCGG	GYLELLDHVLLTLQKPSPEL
			_	GCTTGCAAGGAAGCAGCTTACCACCCAGAAGTGGCCCCTGATGTGCGGCTT	KQQLTGHSKRVAGSVTELI
			_	CGAGCCCTGCACTATGGCCGGGAGTGTGCCAATGGCTACCTGGAACTGCTG	QAAEAMKGTEWVDPEDPT
			_	GACCATGTACTGCTGACCCTGCAGAAGCCAAGCCCAGAACTGAAGCAGCAG	VIAENELLGAAAAIEAAAKK
			•	TTGACAGGACATTCAAAGCGTGTGGCTGGTTCCGTCACTGAGCTCATCCAGG	LEQLKPRAKPKEADESLNF
				CTGCTGAAGCCATGAAGGGAACAGAATGGGTAGACCCAGAGGACCCCACAG	<b>EEQILEAAKSIAAATSALVK</b>
				TCATTGCTGAGAATGAGCTCCTGGGAGCTGCAGCCGCCATTGAGGCTGCAG	AASAAQRELVAQGKVGAIP
				CCAAAAAGCTAGAGCAGCTGAAGCCCCGGGCCAAACCCAAGGAGGCAGATG	ANALDDGQWSQGLISAAR
				AGTCCTTGAACTTTGAGGAGCAGATACTAGAAGCTGCCAAGTCCATTGCAGC	MVAAATNNLCEAANAAVQ
				AGCCACCAGTGCACTGGTAAAGGCTGCGTCGGCTGCCCAGAGAGAACTAGT	GHASQEKLISSAKQVAAST
				GGCCCAAGGGAAGGTGGGTGCCATTCCAGCCAATGCACTGGACGATGGGC	AQLLVACKVKADQDSEAM
				AGTGGTCCCAGGGCCTCATTTCTGCTGCCGGATGGTGGCTGCGGCCACCA	KRLQAAGNAVKRASDNLVK
×				ACAATCTGTGTGAGGCAGCCAATGCAGCTGTACAAGGCCATGCCAGGCCAGG	AAQKAAAFEEQENETVVVK
				AGAAGCTCATCTCATCAGCCAAGCAGGTAGCTGCCTCCACAGCCCAGCTCC	EKMVGGIAQIIAAQEEMLRK
			•	TTGTGGCCTGCAAGGTCAAGGCTGACCAGGACTCGGAGGCAATGAAACGAC	ERELEEARKKLAQIRQQQY
			-	TTCAGGCTGCTGGCAACGCAGTGAAGCGAGCCTCAGATAATCTGGTGAAAG	KFLPSELRDEH*
				CAGCACAGAAGGCTGCAGCCTTTGAAGAGCAGGAGAATGAGACAGTGGTGG	
				TGAAAGAGAAGATGGTTGGCGGCATTGCCCAGATCATCGCAGCACAGGAAG	
				AAATGCTTCGGAAGGAACGAGAGCTGGAAGAGGCGCGGAAGAAACTGGCC	
				CAGATCCGGCAGCAGCAGTACAAGTTTCTGCCTTCAGAGCTTCGAGATGAG	
				CACTAA	
Shigella	4	prey67574	109	NNACAGGAGANTGAGTTGCAANCGGCGGGTGATGCNNNTCTACCNGNNCGT 310	XQEXELQXAGDAXLPXRXR
lpaD					VI DAXXVV VEGAGE   XXX   XXX
,				NCAINIACNI NGI CINI GI CAGANCANNOI GNAGINI GCACI NONNOGI CA	Mapi ITXXXIOXUXXX*EVEX
	_				MPRHFXXXIQYHXXX FXFX
				CNTGCNTGNGTGATTTNTTTTTTNGANNTGCCAATTNTGATGAAGGGAACATA TNTNTTTCATGGGAATTGGTCTTTCTGTTNANNGTNTNAACAC	XCQX***REHXXSWELVFLX
Objection	u	0.025	7	COTACTOR CONTOUT CONTOUR AND A STANDARD AND A STAND	STASYSPESPSYSPTS
oillyella	C	pleyor soa	$\neg$		

000				CANCATOTOTOAGOTACTCACCCACTTCCCCTAGCTATTCGCCCACTTCCCCT	PSYSPISPSYSPISPSYSP
2				AGCTACTCGCCAACGTCTCCCAGCTACTCGCCGACATCTCCCAGCTACTCGC	TSPSYSPTSPSYSPTSPSY
				CAACTTCACCCAGCTATTCTCCCACTTCTCCCAGCTACTCACCTACCT	SPTSPSYSPTSPSYSPTSP
				AGCTATTCACCCACCTCCCCCAGCTACTCACCCCACTTCCCCAAGTTACTCAC	SYSPTSPSYSPTSPNYSPT
				CCACCAGCCCGAACTATTCTCCAACCAGTCCCAATTACACCCCAACATCACC	SPNYTPTSPSYSPTSPSYS
				CAGCTACAGCCCGACATCACCCAGCTATTCCCCTACTAGTCCCAACTACACA	PTSPNYTPTSPNYSPTSPS
				CCTACCAGCCCTAACTACAGCCCAACCTCTCCAAGCTACTCTCCAACATCAC	YSPTSPSYSPTSPSYSPSS
				CCAGCTATTCCCCGACCTCACCAAGTTACTCCCCTTCCAGCCCACGATACAC	PRYTPQSPTYTPSSPSYSP
				ACCACAGTCTCCAACCTATACCCCAAGCTCACCCAGCTACAGCCCCAGTTCG	SSPSYSPTSPKYTPTSPSY
				CCCAGCTACAGCCCAACCTCACCCAAGTACACCCCAACCAGTCCTTGTATA	SPSSPEYTPTSPKYSPTSP
				GTCCCAGCTCCCCAGAGTATACCCCCAACCTCTCCCAAGTACTCACCTACCAG	KYSPTSPKYSPTSPTYSPT
				TCCCAAATATTCACCCACCTCTCCCAAGTACTCGCCTACCAGTCCCACCTATT	IPKYSPTSPTYSPTSPVYT
				CACCCACCACCCAAAATACTCCCCAACATCTCCTACTTATTCCCCAACCTCT	PTSPKYSPTSPTSPK
				CCAGTCTACACCCCAACCTCTCCCAAGTACTCACCTACTAGCCCCACTTACT	YSPTSPTYSPTSPKGSTYS
				CGCCCACTTCCCCCAAGTACTCGCCCACCAGCCCCACCTACTCGCCCACCT	PTSPGYSPTSPTYSLTSPAI
				CCCCCAAAGGCTCAACCTACTCTCCCACTTCCCCTGGTTACTCGCCCACCAG	SPDDSDEEN*
				CCCCACCTACAGTCTCACAAGCCCGGCTATCAGCCCGGATGACAGTGACGA	
				寸	
Shigella	5	prey67514	111	ATGCACAAGGAGGAACATGAGGTGGCTGTGCTGGGGGCACCCCCCAGCAC 312	MHKEEHEVAVLGAPPSTIL
ipaČ				CATCCTTCCAAGGTCCACCGTGATCAACATCCACAGGGAGACCTCCGTGCC	PRS I VINIHSEI SVPUHVV
				CGACCATGTCGTCTGGTCCCTGTTCAACACCCTCTTCTTGAACTGGTGCTGT	WSLFNTLFLNWCCLGFIAF
				CTGGGCTTCATAGCATTCGCCTACTCCGTGAAGTCTAGGGACAGGAAGATG	AYSVKSRDRKMVGDVTGA
				GTTGGCGACGTGACCGGGGCCCAGGCCTATGCCTCCACCGCCAAGTGCCT	QAYASTAKCLNIWALILGIL
				GAACATCTGGGCCCTGATTCTGGGCATCCTCATGACCATTGGATTCATCCTG	MTIGFILSLVFGSVTVYHIML
				TCACTGGTATTCGGCTCTGTGACAGTCTACCATATTATGTTACAGATAATACA	QIIQEKRGY*
				$\top$	
Shigella	2	prey2926	112	ATGGAGAAAACTTGTATAGATGCACTTCCTCTTACTATGAATTCTCAGAAAA 313	MEKTCIDALPLTMINSSEKU FTVCIFGTGDFGRSLGLKM
pac				TTGAAAATGCTCCAGTGGTTATTCTGTTGTTTTTGGAAGTCGAAACCCCCA	LOCGYSVVFGSRNPQKTTL
				GAAGACCACCTACTGCCCAGTGGTGCAGAAGTCTTGAGATCTACAGAAGCA	LPSGAEVLSYSEAAKKSDIII
				GCCAAGAAGTCTGACATCATAATCATAGCAATCCACAGAGAGCATTATGATTT	IAIHREHYDFLTELTEVLNG
				TCTCACAGAATTAACTGAGGTTCTCAATGGAAAAATATTGGTAGACATCAGCA	KILVDISNNLKINQYPESNA
				ACAACCTCAAAATCAATATCCAGAATCTAATGCAGAGTACCTTGCTCAT	<b>EYLAHLVPGAHVVKAFNTIS</b>
				TTGGTGCCAGGAGCCCACGTGGTAAAAGCATTTAACACCCATCTCAGCCTGG	AWALQSGALDASRQVFVC
				GCTCTCCAGTCAGGAGCACTGGATGCAAGTCGGCAGGTGTTTGTGTGTG	GNDSKAKQRVMDIVRNLGL
	-			AATGACAGCAAAGCCAAAGAGTGATGGATATTGTTCGTAATCTTGGAC	PMDQGSLMAAKEIEKYPL
				TTACTCCAATGGATCAAGGATCACICAIGGCAGCCAAAGAAAIIGAAAAGIA	QLFFMW RFFF 1 LSA 1 COVF
				CCCCCIGCAGCIAITICCAAIGIGGAGGIICCCCIICIAIIIGICIGCIGIG	NTERMAISIPNRIFPITAPYT

				GTTTATGAAAAGAAAAGATAATACATTTCGTATGGCTATTTCCATTCCAAATCGT	ACFGLPPWCYCCHSTTVP RHKIPSIPRI A*
Shigella 5 ipaC	5 prey4458		113	CCAGGACGTCCAGGCCAGCCAGGCGGAGGCTGACCAGCAGCAGACTCGCC 314 QD TCAAGGAGGCCATCGAGTCTGGAGAGGAGGCCATCGAG ELE ELE CTCAGGGAGGCCGTCGAGCAGCAGAAAGTGAAGAAACAAAGTGAAGAAACTGAAGAAACTGAAAAAAAA	QDVQASQAEADQQQTRLK ELESQVSGLEKEAIELREAV EQQKVKNNDLREKNWKAM
				AGGCCATGGAGGCACTGGCCACGGCCGAGCAGGCCTGCA CACTCCCTGACCCAGGCCAAGGAGGAATCGGAGAAGCAG GAGGCGCAGGCCAAGGAGGAGCCTGCTGCTCCCA CATGGCC	EALATAEQACKEKLHSLTQ AKEESEKQLCLIEAQTMEA LLALLPELSVL
Shigella 5 ipaC	5 prey4458		114	ACGCAGAGCACACTGCAGGCCGAGTGTGACCAGTACCGCA 315 IGAGACGGAGGCATGCTCAGAGACCTGCAGAAGAGGTG AGCAGGTGTGGAGGCCAAGGTGGGCGCCGCAGAGGAGG TCCCGGGTCACAGTGAAGCATCTCGAAGATTGTAG	AEETQSTLQAECDQYRSIL AETEGMLRDLQKSVEEEE QVWRAKVGAAEEELQKSR VTVKHLEEIV
Shigella 5	5 prey67522		115	TGG 316 CAT ATA TCC GNT 3GG	XEXXMPKGQGGIGXLXWL* IXXSVCDXLFLTPSGMVGX XHSXCHIYEAXAAYSPCLX TSXLXXXARXVPXDXVXXT AWCXTXRTAXTXTSWRTY HEXMLTLVGRLE
Shigella 5	5 prey527		116	CCTCCTAATGAACTCATTGAACTGCTGGAGAAATTGTC TATTCAGTGAACAGGAATCTGCAAAACCTCCTTATCCT GCTGACCGTACACGGAATCTGCAAAACCTCCTTATCCT GCTGACCGTACACGCATTATTAACCGCCTG CCCCAGATATTGCCAATATCGCCATCAGCAATGAGCTGTT GCCATTTTCCGGAAATTTGATGTCAATACTTCAGCAGTTC GCATATTGGAAACTTGGATCGGGCATATGAGTTTGCTGA AAGAAGCCATTGATTCTTATATCAAAGCCAGTTGCAG AAGAAGCCATTGATTCTTATATCAAAGCAGATGATCCTTC GTTGTTCAGGCTGCCAATACTAGTGGAAACTGGGAAAGAA TGCAGATGGCCCGTAAAACAAACCGC	MTADLPNELIELLEKIVLDN SVFSEHRNLQNLLILTAIKA DRTRVMEYINRLDNYDAPD IANIAISNELFEEAFAIFRKF DVNTSAVQVLIEHIGNLDRA YEFAERCNEPAVWSQLAK AQLQKGMVKEAIDSYIKAD DPSSYMEVVQAANTSGNW EELVKYLQMARKKARESYV
Shigella ipaC	5 prey5	prey53735	117	AGATCTCCCATCTCATTGAGCCGCTGGCCAATGCTGCCCG  TCCCAGCTGGGACACAAGGTGTCCCAGATGGCGCAGTACTT  ACCCTGGCTGCAGTGGGTGTCCCCAAGACCCTGAGCCA  ATGGCACTCCTGGACCAGACTAAACATTGGCAGAGTCTGC  TATACACTGCCAAGGACTGGTGGTGGTAACCAAAGCATGC  AGGAAGCCCTGGAGGCTGTGCAGATGATGACAAGCAAGC	AVQEISHLIEPLANAARAEA SQLGHKVSQMAQYFEPLTL AAVGAASKTLSHPQQMALL DQTKTLAESALQLLYTAKE AGGNPKQAAHTQEALEEA VQMMTEAVEDLTTTLNEAA

# and the first the same when the first train the same who will be same than

			CCGTAGAGGACCTGACCAACCATCAACGAGGCAGCCAGTGCTGGGGG	SAAGVVGGMVDSITQAINQ
			CG   GGG   GGCA   GG   GGAC   CCA   CACCAGGCCA   CAACCAGC   AGA   G   AAGGACCAATGGGTGAACCAGAAGGTTCCTTCGTGGATTACCAAACAACTAT	TMVRTAKAIAVTVQEMVTK
			GGTGCGGACAGCCAAGGCCATTGCAGTGACCGTTCAGGAGATGGTTACCAA	SNTSPEELGPLANQLTSDY
			GTCAAACACCAGCCCAGAGGAGCTGGCCCTCTTGCTAACCAGCTGACCAG	GRLASEAKPAAVAAENEEI
			TGACTATGGCCGTCTGGGCCTCGGAGGCCAAGCCTGCAGCGGTGGCTGCTG	GSHIKHRVQELGHGCAALV
			AAAATGAAGAGATAGGTTCCCATATCAAACACCGGGTACAGGAGCTGGGCC	TKAGALQCSPSDAYTKKELI
			ATGGCTGTGCCGCTCTGGTCACCAAGGCAGGCGCCCTGCAGTGCAGCCCC	ECARRVSEKVSHVLAALQA
			AGTGATGCCTACACCAAGAAGGAGCTCATAGAGTGTGCCCGGAGAGTCTCT	GNRGTQACITAASAVSGIIA
			GAGAAGGTCTCCCACGTCCTGGCTGCGCTCCAGGCTGGGAATCGTGGCACC	DLDTTIMFATAGTLNREGT
			CAGGCCTGCATCACAGCAGCGCTGTGTCTGGTATCATTGCTGACCTC	ETFADHREGILKTAKVLVED
			GACACCACCATCATGTTCGCCACTGCTGGCACGCTCAATCGTGAGGGTACT	TKVLVQNAAGSQEKLAQAA
			GAAACTTTCGCTGACCACCGGGAGGGCATCCTGAAGACTGCGAAGGTGCTG	OSSVAIII HLADVVKLGAAS
			GTGGAGGACACCAAGGTCCTGGTGCAAAACGCAGGTGGGAGCCAGGAAA	LGAEDPET QVVLINAVKDV
			GTTGGCGCAGGCTGCCCAGTCCTCCGTGGCGACCATCACCCGCCTCGCTGA	AKALGDLISATKAAAGKVG
			TGTGGTCAAGCTGCAGCCAGCCTGGGAAGCTGAGGACCCTGAGACCC	DDPAVWQLKNSAKVMV IN
			AGGTGGTACTAATCAACGCAGTGAAAGATGTAGCCAAAGCCCTGGGAGACC	VISLLKI VKAVEDEAI KGI
			TCATCAGTGCAACGAAGGCTGCAGCTGGCAAAGTTGGAGATGACCCTGCTG	HALEAI I EHIRGELAVFUSP
				EPPAKTSTPEDFIRMTKGIT
			GCTTAAGACAGTAAAAGCCGTGGAAGATGAGGCCACCAAAGGCACTCGGGGC	MATAKAVAAGNSCRQEDVI
			CCTGGAGGCAACCACAGAACACATACGGCAGGAGCTGGCGGTTTTCTGTTC	ATANLSRRAIADMLRACKE
			CCCAGAGCCACCTGCCAAGACCTCTACCCCAGAAGACTTCATCCGAATGAC	AAYHPEVAPDVRLKALHYG
			CAAGGGTATCACCATGGCAACCGCCAAGGCCGTTGCTGCTGGCAATTCCTG	RECANGYLELLD
			TCGCCAGGAAGATGTCATTGCCACAGCCAATCTGAGCCGCCGTGCTATTGC	
			AGATATGCTTCGGGCTTGCAAGGAAGCAGCTTACCACCCAGAAGTGGCCCC	
			TGATGTGCGGCTTCGAGCCCTGCACTATGGCCGGGAGTGTGCCAATGGCTA	
			-	
Shigella 5	prey53735	118	CAGTGATGTGCTGGACAAGGCCAGCGTCTCATTGAGGAGGCGAAAAAGGC 319	SDVLDRASSLIEEARRAAG
ipaC				TO A I NECVECT BOORDYD
			C AAAGCAG GACCAGGC C GAACCGC G GAGC GC GCC ACC GGCC  *******************************	NAI BAVGDASKBI SDSI P
	-		AGCGCGAI GI GGAI AAI GCCC I GAGGGGGGGGGG	DOTOTION OF A A A A A A A A A A A A A A A A A A
			TCCTGAGTGACTCGCTTCCTCCTAGCACTGGGACATTTCAAGAAGCTCAGAG	PSIGIFCEACSHINEAAAG
			CCGGTTGAATGAAGCTGCTGCTGGGCTGAATCAGGCAGCACAGAACIGGI	LNGAAIELVGASKGIPGDL
			GCAGGCCTCTCGGGGAACCCCTCAGGACCTGGCTCGAGCCTCAGGCCGAT	ARASGREGGDES FLEAGV
-			TTGGACAGGACTTCAGCACCTTCCTGGAAGCTGGTGTGAGGAGAIGGCAGGCC	EMAGGAPSCEDHACKVSN
			AGGCTCCGAGCCAGGACCGAGCCCAAGIIGIGICCAACIIGAAGGGCA	LKGISMSSSKLLLAAKALST
			TCTCCATGTCTTCAAGCAAACTTCTTCTGGCTGCCAAGGCCCTGTCCACGGA	DPAAPNLKSQLAAAAHAVI
			CCCTGCTGCCCCTAACCTCAAGAGTCAGCTGGCTGCAGCTGCCAGGGCAGI	DSINGLII MCI QQAPGQRE
			AACT GACAGCAT CAAL CAGC   CATCACCAGCAGGCACCCGG	CDIMALDELL I VITELLINI V

				CCAGAGAGGAGI GI GA LAACACCO GCGGGAGCCATCACTTTGGTTGCTGGCGTGGAGAACCCAGCCATCAATGACATGACATGACATGTCCTACTTTGGTTGCTGCCTGGACAGGTGTTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	CHINDMST FGCLDS WMENS KVLGEAMTGISQNAKNGNL PEFGDAISTASKALCGFTEA AAQAAYLVGVSDPNSQAG QQGLVEPTQFARANQAIQ MACQSLGEPGCTQAQVLS AATIVAKHTSALCNSCRLAS ARTTNPTAKRQFVQSAKEV ANSTANLVKTIKALDGAFTE ENRAQCRAATAPLLEAVDN LSAFASNPEFSSIPAQISPE GRAAMEPIVISAKTMLESA GGLIQTARALAVNPRD
Shigella 5 ipaC	10	prey67546	119	ATTGTGATCTCTGCCAGGACAATGTTAGAGAGTGCCGGGGGGACTCATCCAGA CAGCCCGGGCCTCGCAGTCAATCCCCGGGAGAC CAGCGCGGCTGACCTGGAAGAGCATCTTGGTGAAATCTGGAACCTGCG CCAGCGCCTGGAGGAGTCCATCTGCATCAATGACTGCCTACGGGAGCAACT GGAACACCGGC	TGADLLEEHLGEIWNLRQR LEESICINDCLREQLEHR
ipaC ipaC	0	prey46/1		AAATGGACTAGAGGAGGAGGAGCTGAGATCAGCCTCGTGGCC TGGAAATATGATCCCTGATTCAGGATCAGGCCTCGTGGCC TGGGAAATATGATTCCCTGATTCAGGATCAGGCCTCGTGGCC TGGGAAAAATACGAGGAGGAGCATCTCTTATCACCTGTGGCC CGGCAAAAAATACGAGAAGGGAGCATCTCTTATCACCCGGCATG CGAAAGGATACGAGAGCTTTTGAGGATCTCCTAAGGAGCCATGACATTGAC TACTACCTGGGACAACTCTCGGGAGCAACTCGCCCAGGGAAGCCAGCTG ACAGAGGACGCTTGAGCCTTCGGGACCCAAGGAGAAA GATCAAGCTGGACTTGAAGTCCTTGCAGGATCCTCCCAGGAAAA GAGAGGAGAAAGTCGTTGTTGAAGTCCTTGACTCCCAGCAGCTCGGTCC CTCACACCCTCCAGCAGCCATGCCTTGTCTGACTCCCAGCAGC GAGAAGGAGAAAGTCGAAGAAAAGTCTCTCAACAGCTCAGAT CCACCCTTTTCCTGTTGAAGAAAAGAA	EEKLAEELSSASWEGKYDS LIQDQARELSYLRQKIREGR GICYLITRHAKDTVKSFEDL LRSNDIDYYLGQSFREQLA QGSQLTERLTSKLSTKDHK SEKDQAGLEPLALRLSREL QEKEKVIEVLQAKLDARSLT PSSSHALSDSHRSPSSTSF LSDELEACSDMDIVSEYTH YEEKKASPSHSDSIHHSSH SAVLSSKPSSTSASQGAKA ESNSNPISLPTPQNTPKEA NQAHSGFHFHSIPKLASLP QAPLPSAPSSFLPFSPTGP LLLGCCETPVVSLAEAQQE LQMLQKQLGESASTVPPAS TATLLSNDLEADSSYYLNS AQPHSPPRGTIELGRILEPG

### The state of the s

5			AATCTAA ACCTA ACCT	
			GCCTCAGAAAGGGAGTGTATCTGGGGACCTATCCTCAGGCTCCTCTGTGTA CCAGCTTAACTCCAAACCCACAGGGCTGACCTGCTGGAAGAGCATCTTGG TGAAATCCGGAACCTGCGCGGCCTGGAGGAGTCCATCTGCATCAATGA	SICINDRLREQLEHR
	prey67550	121	ATGCTTACAGAGCTTCTCTTTGAATTACATGTGGCGGCCACACACA	MLTELLFELHVAATPDKLNK
		<u></u>	TCAATAAGGCCATGAAGAGGGC  CATGACTGGG  GGAAGAGGATCAAACCG    TGGTGTCAGTAGATGTGGCAAAAGTGTCCGAAGAAGAAGAACAAAGAAGAAGAAG	DVAKVSEEETKKEEKEEKS
			AAAAGGAAGAAATCTCAAGACCCTCAAGAAGACAAAAAGGAGAAAAGAA	QDPQEDKKEEKKTKTIEEV
		•	AACTAAGACCATAGAGGAAGTATACATGTCGTCCATTGAAAGTCTGGCGGAG	YMSSIESLAEVTARCIEGLH
· · · · ·		<u>- ·</u>	GTAACAGCGCGCTGTATTGAGCAGCTTCATAAAGTAGCAGAATTAATT	AKVLIKLTTAMCNEVASLSK
			TTAACTACTGCAATGTGCAATGAAGTGGCCTCTTTATCAAAGAAGTTTACGAA	KFTNSLTTVGSNKKAEVLN
****			TTCTTTAACCACTGTTGGGAGCAACAAGAAGGCCGAGGTCCTTAACCCCATG	PMISSVLLEGC
	prev8889	122	GTTCCAGAACAGACAGGTGCAGAGCCTGCTGGAGCTGCGGGAGGCCCAGG 323	FONROVOSLLELREAQVDA
			TGGACGCAGAGGCCCAGCGGAGGCTGGAACACCCTGAGACAGGCTCTGCAG	EAGRRLEHLROALORLREV
			CGGCTCAGGGAGGTCGTCCTTGATGCAAACACACTCAGTTCAAGAGGCTG	VLDAN I QFKKLKEMNEKE
	,		AAAGAGATGAACGAGAGAGAGAAGAAGGAGCTGCAGAAGATCCTGGACAGA	KKELQKILDKKHHNSISEAK
				MKDKHKKEAEL I EINKHHII ESVAISIBBI EEAOKOBHDB
			GAGGCGGAACTGACGAAGATTAACCGTCGGCACATAACTGAGTGACATGACGATGACGATGAGTAAGTGACGATGACGATGACGATGACGAAGTGACGATGACGAAGTGACGAAGTGAAGTAAGT	I VAGOGOVI GOLAEEEPKL
			COAT COAT COAC CACAGA	LAQLAGECGEGRARLPGEI
			GCTGGCCCAGCTGGCCCAGGAGTGTCAGGAGCAGCGGGGGGGG	RRSLLGEMPEGLGDGPLV
			AGGAGATCCGCCGGAGCCTGCTGGGCGAGATGCCGGAGGGGCTGGGGGA	ACASNGHAPGSSGHLSGA
			CGGGCCTCTGGTGGCCTGTGCCAGCAACGGTCACGCACCCGGGAGCAGCG GGCACCTGTCGGGGGGCGCTGACTCGGAGAGCCAGGAGAGAGA	DSESQEENI QL.
	prey11375	123	CTCCTCGGCTGGGGGCTCGGGCAATTCCCGGCCCCCCACGCAACCTCCAAG 324	LOMAITAGSEEPDPPPEPM
			CAGAACCGATGAGTGAGGAGGCGTCAGTGGCTGCAGGAGGCCATGTCG	SEERROWLOEAMSAAFRG
			GCTGCCTTCCGAGGCCAGCGGGAGGAGGTGGAGCAGATGAAGAGCTGCCT	MBBTAGEAEOAADOGEBE
			CCGAGTGCTGTCACAGCCCATGCCCCCACTGCTGGGGGGAGGTGCCAGGGGGGGG	GAL ELLADICENMONAADE
			TGTGAGAACATGGACATGCCGCAGACTTCTGCCAGCTGTCTGGCATGCAC	COLSGMHLLVGRYLEAGA
			CTGCTGGTGGGCCGGTACCTGGAGGCGGGGGCTGCGGGACTGCGGTGGC	AGLRWRAAQLIGTCSQNVA
			GGGCGGCACAGCTCATCGGCACGTGCAGTCAGAACGTGGCAGCCATCCAG	AIQEQVLGLGALRKLLRLLD

				CHOCHCH: COCCHECHCHC	
				CCGCGACGCCTGCGACACGGTGCGCGTCAAGGCCCTCTTCGCCATCTCTG TCTGGTCCGAGAGAGGCTGGGCTG	MEGEAGLLGFLALDGF3VL MRAMQQQVQKLKVKSAFL LQNLLVGHPEHKGT
Shigella ipaC	5	prey67473	124	SAAGGTGCTGGTAACAGGTGGGGCTGGCTACATTGGCAGCCAC SGAGCTGCTGGAGGCTGCTTGCCTGTGGTCATCGATAAC GCCTTCCGTGGAGGGGCTCCCTGCCTGTGGTCATCGATAAC GCCTTCCGTGGAGGCTCCCTGCCTGCGGCGGGGGGCTCTGTGGAGTTTGAGGAGATGGACATTTTG AGCCCTACAGGCCGTCTTCAAAAAGTTGAGGAGATGGACATTTTG AGCCTACAGGCCGTGGGGGGGGGG	MAEKVLVTGGAGYIGSHTV LELLEAGYLPVVIDNFHNAF RGGGSLPESLRRVQELTG RSVEFEEMDILDQGALQRL FKKYSFMAVIHFAGLKAVG ESVQKPLDYYRVNLTGTIQ LLEIMKAHGVKNLVFSSSAT VYGNPQYLPLDEA
Shigella ipaC	ഗ	prey8929	125	356	KVVQHLVERGRSLDDARK RAKQFHEAWSKLMEWLEE SEKSLDSELEIANDPDKIKT QLAQHKEFQKSLGAKHSVY DTTNRTGRSLKEKTSLADD NLKLDDMLSELRDKWDTIC GKSVERQNKLEEALLFSGQ FTDALQALIDWLYRVEPQL AEDQPVHGDIDLVMNLIDN HKAFQKELGKRTSSVQALK RSARELIEGSRDDSSWVKV QMQELSTRWETVCALSISK QTRLEAALRQAEEFHSVVH ALLEWLAEAEQTLRFHGVL PDDEDALRTLIDQHKE
Shigella ipaC	വ	prey3488	126	GCTGACTCATACCGAAGAGTTGTTAGATGCTCAGAGACCAATAAGTGGAGAC 327  CCAAAAGTCATTGAAGTTGAGCTCGCAAAGCACCATGTCCTAAAAATGATG  CCAAAAGTCATTGAAGTTGAGCTCGCAAAGCACCATGTCCTAAAAATGATG  TTTTGGCTCATCAAGCCACAGTGGAAACAGTCAACAAGCTGGCAATGATC  TCTTGAATCCAGTGCTGGAGATGATGCCAGCAGCTTAAGGAGCCGTTTGGAA  GCCATGAACCAATGCTGGAGTCAGTGTTACAGAAAAACAGAGGAGGGAG	LIHIELLDAGHFISGDFKV IEVELAKHHVLKNDVLAHQ ATVETVNKAGNELLESSAG DDASSLRSRLEAMNQCWE SVLQKTEEREQQLQSTLQQ AQGFHSEIEDFLLELTRME SQLSASKPTGGLPETAREQ LDTHMELYSQLKAKEETYN

			9		QLLDKGRLMLLSRDDSGS
	· · · · · · · · · · · · · · · · · · ·	_	0 0	CATGCTTCTAAGCCGTGACGACTCTGGGTCTGGCTCCAA	GSKTEGSVALLEGKWHVV
			⊢ د		EFQNSLQEFINWLTLAEQS
			- ن		LNIASPPSLILNTVLSQIEEH
			,		KVFANEVNAHRDQIIELDQT
	<del>-</del>		⋖	SACAAGGTTTTTGCTAATGAAGTAAATGCTCATCGAGACCA	GNOLKFLSOKODVVLIKNLL
		-	<u>.</u>		VSVQSRWEKVVQRSIERG
		•	<u> </u>		RSLDDARKRAKQFHEAWK
				SAGCGATCTATTGAAAGAGGGCGATCACTAGATGATGCCAG	KLIDWLEDAESHLDSELEIS
			<u> </u>		NDPDKIKLOLSKHKEFOKTL
		-	<u></u>	45	GGKQPVYDTIIRIGHALKE
			+		NILLPEDI GALDINFLGEVA
			<u></u>		
			٠, ١	AAAAGACIIIGCIICCCGAAGAIACICAGAAAACIIGAAAAIIICOIAGGAGAAAAIII	WI YKVEPOLAEDOPVHGD
		****		<u> </u>	DLVMNLMDAHKVFOKELG
		_	<u>ر ر</u>	AGCCCIGGIGITION CONTRACTOR CONTRA	KRTGTVQVLKRSGRELIEN
				GACCTTGACCTCGTCATGAACCTCATGGATGCACACAGG	SRDDTTWVKGQLQELSTR
					WDTVCKLSVSKQSRLEQAL
					KQAEVFRDTVHMLLEWLSE
					AEQTLRFRGALPDDTEALQ
	••••			AAAGCCGGCTTGAGCAGGCCTTAAAACAAGCGGAAGTGTT	SLIDT
				TCGAGACACAGTCCACATGCTGTTGGAGTGGCTTTCTGAAGCAGAGCAAAC	
				GCTTCGCTTTCGGGGAGCACTTCCTGATGACACAGAGGCCCTGCAGTCTCT	
		-			
Shigella	5 prey3514		127 (	328	EKEELPRAVGTQTLSGAGL
ipaC				(GA) GI I CAACAAAGCCACAGA GCCG I CAGCAAAA I GACC	ESDIWEFEKI OFVECEFOB
					BKLHAVVETLVNHBKELA
		_			LNTAGFAKSLAMLGSSEDN
				GAGCTCTGAGGACAACACGGCATTGTCACGGGCACTCTCC	TALSRALSQLAEVEEKIEQL
					HQEQANNDFFLLAELLSDYI
		*			RLLAIVRAAFDQRMKTWQR
					WQDAQATLQKKREAEARL
			_		LWANKPUKLQQAKUEILEW
			•		ESKV I QYEKDFEKISI VVK KEVIDEEKEKSKOEKNHVIK
				CGAG  GGGAG  C  CGGG  GAC  CAA  A  GAAAGGAAAC   CGAGAGAGA	YLETLLYSQQQLAKYWEAF

				CTTCAAGAACCACGTGATCAAGTACCTTGAGACACTCCTTTACTCACAGCAG CAGCTGGCAAAGTACTGGGAAGCCTTCCTTCCTGAGGCAAAGGCCATCTCC TAAA	LPEAKAIS*
Shigella	ιρ	prey5814	158	TGCCCCACCACCAGCTTGAAGATGAGGAACCTGCATTTCCACATACTGAC GCCAAGTTGATTGAACAGGCCTCGATGGGTGGTTCCACATT GCCAAGTTGCATTGAACAGGCCTTTTAGAACTCGATAGAAA GGCCTTGAACTGAAC	DAPPQLEDEEPAFPHTDLA KLDDMINRPRWVVPVLPKG ELEVLLEAAIDLSKKGLDVK SEACQRFFRDGLTISFTKIL TDEAVSGWKFEIHRCLVEL CVAKLSQDWFPLLELLAMA LNPHCKFHIYNGTRPCESV SSSVQLPEDELFARSPDPR SPKGWLVDLLNKFGTLNGF QILHDRFINGSALNVQIIAALI KPFGQCYEFLTLHTVKKYF LPIIEMVPQFLENLTDEELK KEAKNEAKNDALSMIIKSLK NLASRVPGQEETVKNLEIF RLKMILRLQISSFNGKMNA INEEEEWLTAERMAEWIQ ONNILSIVLRDSLHQPQYVE KLEKILRFVIKEKALTLQDLD NIWAAQAGKHEAIVKNVHD LLAKLAWDFSPEQLDHPFD CFKASRTNASKKQREKLLE LIRRLAEDDKDGVMAHRVL NLLWNLAHSDDVPVDIMDL ALSAHIKILDYSCSQDRDTQ KIQWIDRFIEELRTNDKWVI PALKQIREICSLFGEAPQNL SQTQRSPHVFYR
Shigella ipaC	ro	prey5814	129	TCTTGACTCACTTTTCT 330 AGGTAGTCTATGCCTTG TCTGATTTTCAGTTTCA TATGCTAACCAGAAAT GGTGCCTACCTCAATG	HAKLGESSLSPSLDSLFFG PSASQVLYLTEVVYALLMP AGAPLADDSSDFQFHFLKS GGLPLVLSMLTRNNFLPNA DMETRRGAYLNALKIAKLLL

	CTCTTAAAATAGCCAAGCTTTTGCTAACTGCCATTGGCTATGGTCATGTTCGA	TAIGYGHVRAVAEACQPGV
	GCTGTGGCAGAAGCTTGTCAGCCAGGTGTAGAAGGTGTGAATCCCATGACA	EGVNPMIQINQVIHDQAV
	CAGATCAACCAAGTTACCCATGATCAAGCAGIGGIGGIACAAAGIGCCIIC	NIVEVEI ACCIENTATION NIVERNITATION NIVERNITA
	AGAGCATTCCTAATCCATCATCCGAGTGCATGCTTAGAAATCTTTTTTTT	NVSVALACISCLEAGH INIT
	CTTGCTCAGCAGATATCTGATGAGGCTTCAAGATATATGCC1GA1A111G1G1	UCVIRAIQKIIWASGCGSLQ IVESDNIEETKIVEKTNADNI
	AATTAGAGCTATACAAAAAAI AICIGGGCA I CAGGA I GIGGGI ACAG	
	CTAGTATTTAGCCCAAATGAAGAAATCACTAAAATTTATGAGAAGACCAATGC	EFULEUE GVOCE ALE VIVI L
	· \	CFALIP I ALDALSKEKAWQI
	AGTGATGACCTTATGTTTTGCCTTGATTCCAACAGCCTTAGATGCTCTTAGTA	FIIDLLLHCHSKTVRQVAQE
	_	QFFLMCTRCCMGHRPLLFF
	AAAACTGTTCGTCAGGTGGCACAGGAGCAGTTCTTTTAATGTGCACCAGAT	ITLLFTVLGSTARERAKHSG
	GTTGCATGGGACACCGGCCTCTACTTTCTTCATTACTCTACTCTTTACTGTT	DYFTLLRHLLNYAYNSNINV
	TTGGGGAGCACAGCAAGAGAGAGCTAAACACTCAGGCGACTACTTTACT	PNAEVLFNNEIDWLKRIRD
	CTTTTAAGACACCTTCTTAATTACGCTTACAATAGTAATATTAATGTACCCAAT	DVKRTGETGIEETILEGHLG
	GCTGAAGTTCTTTCAATAATGAAATTGATTGGCTTAAAAGAATTAGGGATGA	VTKELLAFQTSEKKFHIGCE
		KGGANLIKELIDDFIFPASNV
	CTTGGAGTGACAAAGGAGTTACTGGCCTTTCAAACTTCTGAGAAAAAATTTCA	YLQYMRNGELPAEQAIPVC
	TATTGGTTGTGAAAAAGGAGGTGCTAATCTCATTAAAGAATTAATT	GSPPTINAGFELLVALAVGC
	TCATATTTCCTGCATCCAATGTTTACCTACAGTATATGAGAAATGGAGAGAGCTT	VRNLKQIVDSLTEMYYIGTA
	CCAGCTGAACAGGCTATTCCGGTCTGTGGTTCACCACCTACAATTAATGCTG	ITTCEALTEWEYLPPVGPR
	GTTTTGAATTACTTGTAGCATTAGCTGTTGGCTGTGTGAGGAATCTCAAACAA	PPKGFVGLKNAGATCYMN
	ATAGTAGATTCTTTGACTGAAATGTATTACATTGGCACAGCAATAACTTG	SVIQQLYMIPSIRNGILAIEG
	TGAAGCACTTACTGAGTGGGAATATCTGCCACCTGTTGGACCCCGCCCACC	TGSDVDDDMSGDEKQDNE
-	CAAAGGATTCGTGGGGCTGAAAATGCCGGTGCTACTTGTTACATGAATTCT	SNVDPRDDVFGYPQQFED
	GTGATTCAGCAACTCTACATGATTCCTTCCATTAGGAACGGTATTCTTGCCAT	KPALSKTEDRKEYNIGVLR
	TGAAGGCACAGGTAGTGATGTAGATGATGATGTCTGGGGATGAGAAGCA	HLQVIFGHLAASRLQYYVP
	GGACAATGAGAGCAATGTTGATCCCAGGGATGATGTATTTGGATATCCTCAA	RGFWKQFRLWGEPVNLRE
	CAATTTGAAGATAAACCAGCATTAAGTAAAACTGAAGATAGAAAAGAGTACAA	QHDALEFFNSLVDSLDEAL
	CATTGGTGTCCTAAGACACCTTCAGGTCATCTTTGGTCATTTAGCTGCTTCTC	KALGHPAMLSKVLGGSFAD
	GACTGCAATACTATGTGCCCAGAGGATTTTGGAAACAGTTCAGGCTTTGGGG	QKICQGCPHRYECEESFII
	TGAGCCTGTTAATCTGCGTGAACAACACGGTGCTTTAGAATTTTTTAATTCATT	LNVDIRNHONLLDSLEGYV
	GGTGGATAGTTTAGATGAAGCTTTAAAAGCTTTAGGACATCCAGCTATGCTAA	KGDLLEGANAYHCEKCNK
	GTAAAGTCTTAGGAGGTTCCTTTGCTGATCAGAAGATCTGCCAAGGCTGCCC	KVDTVKRLLIKKLPPVLAIQL
	ACATAGGTACGAATGTGAAGAATCTTTTACGACCCTAAACGTAGACATTAGAA	KRFDYDWERECAIKFNDYF
	ATCACCAAAATCTTCTTGATTCTTTGGAACAGTATGTCAAAGGAGATTTACTA	EFPRELDMEPYTVAGVAKL
	GAAGGTGCAAATGCATATCATTGTGAAAAATGCAATAAAAAGGTTGATACCGT	EGDNVNPESQLIQQSEQSE
	AAAGCGCTTGCTGATTAAAAATTACCTCCTGTTCTTGCTATACAACTAAAGC	SETAGSTKYRLVGVLVHSG
	GATTTGACTATGACTGGGAAAGAGAATGTGCAATCAAGTTCAATGATTATTT	QASGGHYYSYIIQRNGGDG
	GAATTTCCTCGAGAGCTGGACATGGAACCTTACACAGTTGCAGGTGTCGCAA	ERNRWYKFDDGDV1ECKM

	ACCTOCAACCCATAATGTAAACCCCAGAGTCAGTTGATACAACAGAGTGA	DDDEEMKNQCFGGEYMG
	ACCITATION AND TRANSPORTED AND	EVFDHMMKRMSYRRQKR
	GCTCGTACACAGTGGTCAAGCGAGTGGGGGGGCATTATTATTCTTACATCATC	WWNAYIPFYERMDTIDQDD
	CANAGGAATGGTGAGATGGTGAGAGAGAATCGCTGGTATAAATTTGATGATG	ELIRYISELAITTRPHQIIMPS
	CTCATGTAACAGAATGTAAAATGGATGATGATGACGAAGAAATGAAAAAACCAGTG	AIERSVRKQNVQFMHNRM
	TTTTGGTGGAGAGTACATGGGAGAAGTGTTTGATCACATGATGAAGCGTATG	QYSMEYFQFMKKLLTCNG
-	TCATACAGGCGCCAGAAAAGGTGGTGGAATGCTTATATACCTTTTTATGAAC	VYLNPPPGQDHLLPEAEEIT
	GAATGGACACAATAGACCCAAGATGATGATGATAAAGATATATAT	MISIQLAARFLFTTGFHTKK
	GCTATCACCAGACCTCATCAGATTATTATGCCATCAGCCATTGAGAGAA	VVRGSASDWYDALCILLRH
	GTGTACGGAAACAGAACGTACAATTCATGCATAACCGAATGCAGTACAGTAT	SKNVRFWFAHNVLFNVSN
	GGAGTATTTCAGTTTATGAAAAACTGCTTACATGTAATGGCGTTTACTTAAA	RFSEYLLECPSAEVRGAFA
	CCCTCCTCCCGGGCAAGATCACCTGTTGCCTGAAGCAGAAATCACTATG	KLIVFIAHFSLQDGPCPSPF
	ATCAGTATTCAACTTGCTGCTAGGTTCCTCTTTACTACAGGATTTCACACAAA	ASPGPSSQAYDNLSLSDHL
	GAAAGTAGTCCGTGGCTCTGCCAGTGATTGGTATGATGCATTGTATTCTC	LRAVLNLLRREVSEHGRHL
	CTTCGTCACAGCAAGAATGTACGTTTTTGGTTTGCTCATAACGTCCTTTTTAA	QQYFNLFVMYANLGVAEKT
-	TGTTTCAAATCGCTTCTCCGAATACCTTCTGGAGTGCCCTAGTGCAGAAGTG	QLLKLSVPATFMLVSLDEG
	AGGGGTGCGTTTGCAAAACTTATAGTCTTTATTGCACATTTTTCCTTGCAAGA	PGPPIKYQYAELGKLYSVV
	TGGGCCATGTCCTTCACCTTTTGCCTCTCGGACCTTCTAGTCAGGCTTAT	SQLIRCCNVSSRMQSSING
	GACAACTTAAGCTTGAGTGATCACTTACTAAGAGCAGTACTAAATCTCTTGAG	NPPLPNPFGDPNLSQPIMPI
	AAGGGAAGTTTCAGAGCATGGGCGTCATTTACAGCAGTATTTCAACCTGTTT	QQNVADILFVRTSYVKKIIE
		DCSNSEETVKLLRFCCWE
	GTGTACCTGCTACTTTTATGCTTGTGTCTTTAGATGAAGGTCCAGGTCCTCCA	NPQFSSTVLSELLWQVAYS
	ATCAAATACCAGTATGCTGAATTAGGCAAATTATACTCAGTAGTGTCACAGCT	YPYELRPYLDLLLQILLIEDS
	GATCCGCTGTTGCAATGTCTTCAAGAATGCAGTCTTCAATCAA	WQTHRIHNALKGIPDDRDG
	CTCCTCCCAATCCTTTGGTGATCCTAATTTATCACAACCTATAATGCCAA	LFDTIQHSKNHYQKHAYQC
	TTCAGCAGAATGTGGCAGACATTTTATTTGTGAGAACAAGTTATGTGAAGAAA	IKCMVALFSNCPVAYQILQG
-	ATCATTGAAGACTGCAGTAATTCAGAGGAAACCGTCAAATTGCTTCGTTTTTG	NGDLKHKW I WAVEWLGD
	CTGCTGGGAGAATCCTCAGTTCTCATCTACTGTCCTCAGTGAACTTCTCTGG	
_	CAGGTTGCATATTCCTATCCCTATGAACTGCGGCCCTATTTGGATCTGCTTTT	SPPVQSNETSNGYFLERSH
	GCAAATCTTACTGATTGAGGACTCCTGGCAAACTCACAGAATTCATAATGCAC	SAKMILAKACELCPEEVKK
	TGAAAGGAATTCCAGATGACCGAGATGGGCTGTTTGACACAATCCAGCGCTC	ATSVQQIEMEESKEPDDQD
	TAAGAATCACTATCAAAAAAAGAGCATACCAGTGTATAAAATGTATGGTAGCTC	APDEHESPPPEDAPLYPHS
	TATTTAGTAACTGTCCTGTTGCTTACCAAATCCTGCAGGCAATGGAGATCTT	PGSQYQQNNHVHGQPY1G
	AAAAGAAAGTGGACCTGGGCAGTGGAATGGCTTGGAGATGAAGA	PAAHHMNNPOHIGOHAUE
	AGACCATATACTGGCAATCCTCAGTACACTTACAACAATTGGTCTCCCCCAGT	NYEGSEEVSPPQ1 KDQ.
	GCAAAGCAATGAAACGTCCAATGGTTATTTCTTGGAGAGATCACATAGTGCT	
	AGGATGACACTTGCAAAAGCTTGTGAACTCTGTCCAGAGGAGGTAAAAAAAA	
	CCACCAGTGTGCAGCAGATAGAAATGGAAGAGAGCGAAAGAGCCAGAIGACC	
	AAGATGCTCCAGAIGAACAIGAGICGCCICCACCIGAAGAIGCCCCAIIGIA	

			CCCCCATTCACCTGGATCTCAGTATCAACAGAATAACCATGTGCATGGACAG CCATATACAGGCCAGCAGCACATCACAT	
Shigella 5 ipaC	prey67479	130	TGAGACATCAGCCCACCTTAAAACAGATGCAACGACTGCC TGAAGAAATCTTGGAAGGGACCCCAAATACAT CTTGAAGAAATCTTGGAAGGGACCCCAAATACAT CATCGATCCAGAAGGCACTGCCACTGCTCCTCC ATCATGCCGCAGAAGGCACTGCCACTGCTCCTCC ATCATGCCGCAGAAGGAAGCTTTAATTCTACCCAGCAAATGAAACT AGGCCATGCAGAAGTTTGTGAATCTATTCTGAGCAACAT TTAATGTGATGAAATTTGTGAATCTATTCTGAGCACAAT TGGGTTTCCCAGAAATTGTGAATCAGAAAGGACTGTTGCCTT TGGGTCTTCCCAATCTGCCATTGACTTTCCCACATCTGCT TGTTGCAGGTGTCTGCCATTGACTTTCCCACATCTGCT TGTTGCAGGTGTCTCCAATTGGAATCGATTTGGAAACCTCCTCCACATCTGCT TACAGAGGGTCTCCTTCAGTTGGACTCCATCTCCTCCTC TACACCGCCC	DELMRHQPTLKTDATTAIIK LLEEICNLGRDPKYICQKPS IQKADGTATAPPRSNHAA EEASSEDEEEEEVQAMQS FNSTQQNETEPNQQVVGT EERIPIPLMDYILNVMKFVE SILSNNTTDDHCQEFVNQK GLLPLVTILGLPNLPIDFPTS AACQAVAGVCKSILTLSHE PKVLQEGLLQLDSILSSLEP LHR
Shigella 5 ipaC	prey700	131	2388	MGIGLSAGGVNMNRLPGW DKHSYGYHGDDGHSFCSS GTGQPYGPTFTTGDVIGCC VNLINNTCFYTKNGHSLGIA FTDLPPNLYPTVGLQTPGE VVDANFGQHPFVFDIEDYM REWRTKIQAQIDRFPIGDR EGEWQTMIQKMVSSYLVH HGYCATAEAFARSTDQTVL EELASIKNRQRIQKLVLAGR MGEAIETTQQLYPSLLE
Shigella 5 ipaC	prey67481	132	333	KQDQKAPDKEAILRATANL PSYNMDRAAVQTNMRDFQ TELRKILVSLIEVAQKLLALN PDAVELFKKANAMLDEDED ERVDEAALRQLTEMGFPEN RATKALQLNHMSVPQAME WLIEHAEDP
Shigella 5 ipaC	prey67488	133	CTGTTCATGAAGAGTGAGGACACGCAGCCGAGGCACAGCTGGCCACAGCA 334 GAGCAGCAGCTACGGGCTACGGACCGAGGCGGAAAGGGCTCGCCAGG CCCAGAGCCGGGCCCAGGAGGCTCTGGACAAGGCCAAGGAGAAAGGACAAG	LFMKSERHAAEAQLATAEQ QLRGLRTEAERARQAQSR AQEALDKAKEKDKKITELSK

98 88 88 87 87 87 87 87 87 87 87 87 87 87				AAGATCACAGAACTCTCCAAAGAAGTCTTCAATCTTAAGGAAGCCTTGAAGG	EVFNLKEALKEOPAALATP
prey51967 194 TGACCAACTTGETTGATATTTGCTGGAAAATTTTGAAAGATTCAACTGAAACAGAACCTGAAACAGAACCTGAGAACAACAGAACCGAGAACAACAGAACCGAAACAGAACCGAGAACTAACT				AGCAGCCGCCCCTCGCCACCCCTGAGGTGGAGGCTCTCCGTGACCAG GTGAAGGATTTACAGCAGCAGCTGCAGGAAGCTGCCAGGGACCACTCCAGC	EVEALHUGVKDLGGGLGE AARDHSSVVALYRSHLLYAI Q
ATTITUTE CANACTECTANT AGTA ACTICIA CATCOGGT TO CAGGO ACTICA CAGGO ACTICA CAGGO ACTICA CAGGO ACTICA CAGGO ACTICA CAGGO ACTICA ACTICA CAGGO ACTICA ACTI		prey51967	134	GTTGATATTTGCTGGAAAAATTTTGAAAGATCAAGATACCT 3GAATTCATGATGGACTTACTGTTCACCTTGTCATTAAAACA	DQLVLIFAGKILKDQDTLSQ HGIHDGLTVHLVIKTQNRP QDHSAQQTNTAGSNVTTS
GGGTTTGATACTACCAGATCTCTGAATCACAGAGTCAGGAGTCAGGACAAA  CTTTTGTCTAACCCTGAATCAGTGAGCAATCATGAATAGTGACAAATCA  CAAATGCAGCAGTTGATCAGCAGATCATCAGTAATTAGTGATATTAGTGATAA  CAAATGCAGCAGTTGATCAGAGAAATCCAGAAATTAGTCATTAGTGATAATA  CAAATGCAGCAGTTGATCAGAGAAATCCAGTAATTAGTCATTAGTGATAA  CCAGGAGAATATAGAGACAAACGTTGGCAGGAATCAGAAACACAA  CCAGGAGAATAATGAGACAAACGTTGGCAGGAATCAGAAACACAA  CCAGGAGAATAATAAGACACAGACCAGTTTGCAGGAACCAACACAACAACAACAACACACAC				ATGTTACTACATCATCAACTCCTAATAGTAACTCTACATCTGGTTCTGCTACTA ACAACCCTTTTGGTTTAGGTGGCCTTGGGGGGACTTGCAGGTCTGAGTAGCTTT	STPNSNSTSGSATSNPFGL GGLGGLAGLSSLGLNTTNF
GAGGATGCTCAAATCCTGAGAGAAATCCAGGAATTAATTA				GGGTTTGAATACTACCAACTTCTCTGAACTACAGAGTCAGATGCAGCGACAA	SELQSQMQRQLLSNPEMM VQIMENPFVQSMLSNPDLM
TCCAGATATATATGAGACAMACGTTGGAGATTGACAGGATTCCAGCAATGATCACAGATTCCAGGAGATTCCAGGAGATTCCAGGAGATTCCAGGAGATTCCAGGAGATTCCAGGAGATTCCAGGAGATCCAGGAGATTCCAGGAATATCCAGAATATCCAGAATATCCAGAATATCCATTGACACAGAATATCCATTGATCACAGAATATCCATTGATCACAGAATATCCATTGATCACAGAATATCCATTGATCACAGAATATCCATTGATCACAGAATATCCATTGATCACAGAATATCCATTGATCACAGAATACATCCATGACACAGAATATCCATTGATCACAGAATATCCATTGATCACAGAATACATCCATTGATCACAGAATACATCCATTGATCACAGAATACATCCATTGATCACAGAATACATCCATTGATCACAGAATACATCCATTGATCACAGAATACATCCATTGATCACACACA				GAGCATGCTCTCAAATCCTGATGAGACAGTTAATTATGGCCAATCCA	ROLIMANPOMOOLIORNPE
CAGGAGATGATGACAGGACCAGAGCTTTGAGCAACCTAGAAAGCATC CAGGAGGAATAAATGCTTTAAGGCGCATTTACAGGAACCAA TGCTGAGTGGTGCAAGAGCAGTTGATCACAGAATTCAGGAACCAA TGCTGAGTGGTGCAAGAGGAGCAGTTGATGCAGTTTGCTTCCTTGGT GAGCAATACATCCTCTGGTGAGGTAGTCCCGTACAGAAATTGA GACCACTACCCCAATCCATGGGCTCCACAGGATTCCCGTACACACAC				TCCAGATATAAATGAGAACATTGGAAACTTGCCAGGAATCCAGCAATGATG	NPAMMQEMMRNQDRALS
CCAGGGGGATA AA I GCI II AAGGGATITIGGTGGTAATCCATTIGGTGGTAATCCATTIGGTGGTAATCCATTIGGTGGTAATCCATTIGGTGGTAATCCATTIGGTGGTAATCCATTIGGTGGTAATCCATTIGGTGGTAATCCATTIGGTGGTAATCCATTIGGTGGTAATCCATTIGGTGGTAATCCATTIGGTGGTAATCCATTIGGTGGTAATCCATTIGGTGGTAATCCATTIGGTGGTAATCCCTACAGAAATAGATCACATCCACACACAC				CAGGAGATGATGAGGAACCAGGACCGAGCTTTGAGCAACCTAGAAGCATC	NLESIPGGYNALRRMYTDI
GAGCAATACATCCTGGGTGAAGCTCCCCGTACAGAAATAGA     GAGCAATACATCCTGTGGTGAAGCTCCACAGACTTCCCAGAAAATAGA     GATCCACTACCCCAATCCATGGCTCCCAGACTTCCCAGAGTTCATCAGCTTC     CCAGCGGCAC     CCAGCGGCAC     AAGAAAGATTCACACACACACACTTGTACACACCACCACACACA				CCAGGGGGATATAATGCTTTAAGGCGCATGTACACAGATATTCAGAAACAA   TGCTGAGTGCTGCACAAGAGCAGTTTGGTGGTAATCCATTTGCTTGGT	SLVSNTSSGEGSQPSRTEN
SAGORGAGE CATCCATGGGCTCCAGGGCTTCCCAGGGTTCATCAGCTT  CCAGGGGGCAC  CCAGGGGGCAC  ACTICTACACCAGCACCACACTGTACACCACCACACACACACAC				GAGCAATACATCCTCTGGTGAAGGTAGTCAACCTTCCCGTACAGAAAATAGA	RDPLPNPWAPQTSQSSSA
5 prey67491 135 COCACCACCAGCAGAAGAACTCCCTCCCATCACCACCACCACACACCACCACCACCA				GATCCACTACCCAATCCATGGGCTCCACAGACTTCCCAGAGTTCATCAGCTT	SSG
ACTTCTACTACTACACCAGCTACCACTTGTACAGCGGGTTGCACCACCACCACCACCACCACCACCACCACCACCACCAC			135	t	KKDVKQPEELPPITTTTST
				ACTTCTACTACACCAGCTACCAACACCACIIGIACAGCCACGGIICCACCAC	YHDINVYSI AGI APHITI NP
				AGCCACAGI ACAGCI ACCACGACAI CAAI GI COOLI GCCCACGCI I GCC	TIPLFQAHPQLKQCVRQAIE
				TGAAGCAGTGTGTGTGCGTCAGGCAATTGAACGGGCTGTCCAGGAGCTGGTCC	RAVQELVHPVVDRSIKIAMT
				ATCCTGTGGTGGATCGATTAAGATTGCCATGACTACTTGTGAGCAAATA	TCEQIVRKDFALDSEESRM
				GTCAGGAAGGATTTTGCCCCTGGATTCGGAGGAATCTCGAATGCGAATAGCA	RIAAHHMMRNLTAGMAMII CDEDI I MSISTNII KNSEASA
	<del></del>		_	GCTCATCACATGATGCGTAACTTGACAAGTGGAATGGCTATGATTTGCTCATGAGACAGTTTTGCCTCA	LRTASPQQREMMDQAAAQ
		-		GCCCTTCGTACTGCTTCCCCACAACAAGAGAAATGATGGATCAGGCAGCTG	LAQDNCELACCFIQKTAVE
	-		_	CTCAATTAGCTCAGGACAATTGTGAGTTGGCTTGCTGTTTTATTCAGAAGACT	KAGPEMDKRLATEFELRKH
				GCAGTAGAAAAAGCAGGCCCTGAGATGGACAAGAGATTAGCAACTGAATTTG	ARQEGRRYCDPVVLTYQA
				AGCTGAGAAAACATGCTAGGCAAGAAGGACGCAGATACTGTGAICCIGIIGI	AVYEEFARNVPGFLPTNDL
				GGTGTGGACCCAAAGCAGTTGGCTGTTTACGAAGAGTTTGCACGCAATGTTC	SQPTGFLAQPMKQAWATD
	-			CTGGCTTCTTACCTACAAATGACTTAAGTCAGCCCACGGGATTTTTAGCCCA	DVAQIYDKCITELEQHLHAI
<u> </u>				GCCCATGAAGCAAGCTTGGGCAACAGATGATGTAGCTCAGATTTATGATAAG	PPTLAMNPQAQALRSLLEV
				TGTATTACAGAACTGGAGCAACATCTACATGCCATCCCACCAACTIIGGCCA	VVLSKINSKDAIAALGELUKA VEGLIDATSGADADLLLRY

				CGAAACTCTCGGGATGCCATAGCTGCTCTTGGATTGCTCCAAAAGGCTGTAG AGGGCTTACTAGATGCCACAAGTGGTGCTGATGCTGACCTTCTGCTGCGCTA	
Shigella ipaC	ro	prey323	136	CTCTATTCCGACACCCTCCAACATGGAGGAAACGCAACAGAAATCCAAT  SAGCTGCTCCGCATCTCCCTGCTGCTCATCGAGTCGTGGCTGGAGCCC  CGGTTCCTCAGGAGTATGTTCGCCAACACCTGGTGTATGACACCTCG  AGCGATGACTATCACCTCCTAAAGGACCTAGAGGAGGCATCCAAACG  ATGGGGAGGCTGGAAGGCAGCCGCGGACTGGGCAGTCCTCAA  SACCTACAGGAAGTTTGACAAACTCGCACAACGACGCACTGCTC  AACTACGGGCTGCTCTACTGCTTCAGGAAGGACATGGACAGGTCCTC  TCCTGCGCATGGTGCCGCTCTGTGGAGGCCACTGTC	DSIPTPSNMEETQQKSNLE LLRISLLLIESWLEPVRFLRS MFANNLVYDTSDSDDYHLL KDLEEGIQTLMGRLEDGSR RTGQILKQTYSKFDTNSHN HDALLKNYGLLYCFRKDMD KVETFLRMVQCRSVEGSC GF*
Shigella ipaC	2	prey67495	137	338	AAVSVLKPFSKGAPSTSSP AKALPQVRDRWKDLTHAISI LESAKARVTNTKTSKPIVHA RKKYRFHKTRSHVTHRTPK VKKSPKVRKKSYLS
Shigella	ဟ	prey67506	138	CCAATCAGGGGGAGATCCTGGTGATCCGCAGGGGCTGGC 339 AACATCAGCCTGATGAAAGGCGGCTCCAAGGAGTACTGGTT CCGAGTCACCTGTACAAGGCGGCTCCAAGGAGTACTGGTT CCGAGTCACTGTCCTCAAGGATGAGGAGAAAGA TGCTGCCTCTGGACACCTCAAGGATGAGGAGAGA TGCTGCCTCTGGACACCTCTCACACGGAGAAACGAGAAACGGGAGAAACGGGCTCTTCCCCAGGAAACGAGAAACGAGATCGGAGCTGGCTG	RAIPNQGEILVIRRGWLTIN NISLMKGGSKEYWFVLTAE SLSWYKDEEEKEKKYMLPL DNLKIRDVEKGFMSNKHVF AIFNTEQRNVYKDLRQIELA CDSQEDVDSWKASFLRAG VYPEKDQAENEDGAQENT FSMDPQLERQVETIRNLVD SYVAIINKSIRDLMPKTIMHL MINNTKAFIHHELLAYLYSS ADQSSLMEESADQAQRRD DMLRMYHALKEALNIIGDIS TSTVSTPVPP
Shigella ipaC	ιΩ	prey4578	139	CTGGAGTCCAATAAGATCCCAGAGCTGGACATGACTGAGGT 340 ITCATGGCCAACATCCTCTCCTCTTACCCTCAGGACGG AAGCCCCAGCCAAGGATAATGGGGACGTTTGCCAGGACTG BTGACTGACATCCAGACTGTTACGGACCACTCTT TGGTGGAACATGTCAAGGAGAGTGTGACCGCCTGGGCCCT	QKQLESNKIPELDMTEVVA PFMANIPLLLYPQDGPRSK PQPKDNGDVCQDCIQMVT DIQTAVRTNSTFVQALVEH VKEECDRLGPGMADICKNY ISQYSEIAIQMMIMHMQPKEI

CTGTGATGAGGTGAAAGGAGATGCCGTGGAACTGGTGAACTCGGTGAAGCCAAAGT  GGACGAGGTCCCAGCAAAGTGTGATTACTGTGAGGTGTGAACTCTGGGAGCCCATTAGAA  GGACGAGGTGCCAGCAAGTGTGTATGACTACAACAAGAAGATTCCTG  GTGACGGGTGTCAAATTTGCTCAAATTTTACTGTGAGGTGTTTGAAAAATTCCTG  TGACAGGAGG  TGCAGGAGG  TGCAGGAATTTGCTTGAAAATGTTCAATTGCAAAGAACCAAACACAA  AAACAGCAATTGCTCTTGAAACAATGCAGGAAAAAAACCAAAAAAACCAAAGA  ATTGGAAGGCATTTTCTTAATGCAAAATGCAGGAAAAAAAA					
GCACGAGGTCCCAGCAAGATCITGATE II NUT IG TANNI TO IG GCACGAGGTCCCAGAAGATCITGATE II NUT IG TANNI TO IG GCACGAGGTCCCAGAACAACAAGAACACAAGAACACAAGAACACACAC					VPAKVASKNVIPALELVEPI KKHEVPAKSDVYCEVCEFL VKEVTKI IDNNKTEKFII DA
GLCAGGARITATION   TOTO CONTINUE     CLCAGGARITATIGGGARICATION   TOTO CONTINUE     CLCAGGARITATIGGGARICATION   TOTO CONTINUE     CLCAGGARITATIGGGARICATION   TOTO CONTINUE     CLCAGGARITATIGGGARICATION   TOTO CONTINUE     CLCAGGARICATION   TOTO CONTINUE     CLCAGGARICATION   TOTO CONTINUE     AND CONTINUE   TOTO CONTINUE   TOTO CONTINUE     CONTINUE   TOTO CONTINUE   TOTO CONTINUE     CONTINUE   TOTO CONTINUE   TOTO CONTINUE     AND CONTINUE   TOTO CONTINUE   TOTO CONTINUE			· · · · · ·		FDKMCSKLPKSLSEECQE
TCTCTGAATATGCTCTTGGAGCAAATGCATTGATGAGCAATTGATGAGCAATTGAGCAATTGGAGCAAATTGCAGAAATGCATTTATAGCAAATTGAGAAATGCATTGATGAGCAAATTGAGCAAATTGCAGAATTGCAGAATTGCAGAATTGCAGAAATTGCAGAAATGCAGTTGATCACACAATTGACCAGAATTGCAGAATTGCAGAAATTGCAGAAATTGCAGAAATGCAGAAATGCAGAAATGCAGAATGCAGAAATGCAGAAATGCAGAAATGCAGAAATGCAGAAATGCAGAAATGCAGAAATGCAGAAATGCAGAAATGCAGAAATGCAGAAATGCAGAAATGCAGAATGCTTAGCAGAATGCTTAGAATGCAGAATGCAGAAATGCAGAAATGCAGAAATGCAGAATGCAGAAATGCAGAATGCAGAAATGCAGAATGCACAGAATGCAGAATGCAGAAATGCAGAATGCAGAAATGCAGAATGCAGAATGCAGAAATGCAGAAATGCAGAATGCAGAAATGCAGAAATGCAGAAATGCAGAATGCACAGAAATGCAGAATGCACAAATGCAGAATGCACTGAATGCAGAATGCATGAATTCCAGAATTCATCAGAATTCCAGAATTCCAGAATTCCATGAATTCCAGAATTCCAGAATCCACAGAATCCACAGAATCACAGAATGCACAGAATCCACAGAATCCACAGAATCACAGAATCACAGAATCACAGAATCACAGAATCACAGAATCACACAGAAAGAA	ည	prey1135		GGCATCTAAAGTATTTTATCACCTGGGGGCTTTTGAGGAG 341	AALVASKVFYHLGAFEESL
GTGTGGAAATIGCGAATTGCCTGAAGAAAAAACCAATTGACCAGGG ATTGAAAGGCATTGCCTGAAGGAGAAAAAACCAATTGAAATAAAT					ETIJAKCIDHYTKQCVENAD
ATTGGAAGGCATGCTTCGAGGAAGCTGAGGAGGTCTTGA ATAACAGGGTTTTTGGCATTGCTCGAGGAGATTGAGAGTCTTGA AAGGACCATACTGGAATGATGTCCCAGGAATGTTAGCTTTTGA AAGGACCATACTGGAATGATGCAATGATTGAGATTGCTAAG AAGGACCATACTGGAATGATGAACTTGGAGAATGTTAGGATTTTGTAAG AGTTCTGATTAAATCTTAGAACTTGAAGCAGCTTTGATTGA					LPEGEKKPIDQRLEGIVNK
A I AAACAGATCTTA I I GUCAT TO TO GAATA AACAGATGTTA GEGTTA TAGCCTTA AAGACCTTCTCGCATGCTTTA AT TOTA GAATA TOTA CAGAAT TA AACAGATTA AAGACTCTTA AACTGCTTA AACTGCTA AACTGCTA AACTGCTA AACTGCTA AACTGCTA AACTGCTA AACTGCTA AACTGCTA AACTGCA AACTGCTA AACTGCA AACTACA AACTACACA AACTACA AACT					MFQRCLDDHKYKQAIGIAL ETBRLDVFEKTILESNDVPG
AGGCTCTGCATGTTTAATGCAGAATAAACAGTTTCGGAATTAAGTACTAAGT AGTTCTAGTTAAAATCTACATGAACTTGGAGAAACCTGATTTCGTCAAGTGTTT AGTTCTAGTTAAATTTTCTTAGATGATCGATGGAGTTTTGTTTG					MLAYSLKLCMSLMQNKQF
AGTTCTAGTTAAAATCTACATGAACCTGATTAAAACCTGATGAGTGATTTCTTGAGAGGTGGGCTGTGAGAGTGTTTGATTTTGATTTTGTTTTGTTTTGTTTTGTTTTGTTTTGTTTTGTTTTGTTTT					SNKVLRVLVKIYMNLEKPU
GTICAGIGOTIANITITIOTICATICAGATICATION MANDER AAACTGGTAAAGGAAACCTCCTGATGGCATTTGTTTTGT					EKI VKEDNI LMAYQICEDLY
prey67465 prey67465 prey67465 prey67465 prey67465 prey67465 prey67485 prey67485 prey67485 prey67485 prey67485 prey67485 prey67486 prey67485 prey68880 prey28880 prey2880 prey28800 prey28800 prey28800 prey28800 prey28000 prey28000000000000000000000000000000000000					ESASQQFLSSVIQNLRTVG
TCCGGGATCAGAGAAGACGTGGATCCATATAGGGGTACTGT  TCCGGGATCAGAAAGACAGTGGACTCGATGGAAACAGAAAAGACAGG  CAGTGCATTTGTAGGAAAGACCGTGGCCGAGGAGACAGAACAAG  CAGTGCATTTGTAGGAAAGACCGTGGCCGAGGAGATCAAGCCCTA  CACTGCGCCGGTTCTGTTGTGTGCCCGGCGCGCGCATCGCCATCGCCGGTTGG  CAGTCAGCCGTTTCTCTCATCCCCACCTGCCGCGCGCGGAGTTTGTG  GATCGGATATTCCTTCCTCATCCCCACCGCGCGGCGGAGTTTGTG  CAGTCAGGATGTTCCTTCCTCATCCCCACCGCGCGGAGAGTTTGTG  GATCGGATGTTCCTTCCTCATCCCCACCGCGCGGAGAGTTTGTG  ATTCATCGATGTGTGCACGGCGGCGGCGGCGGCGGCGCGCGC					TPIASVPGSTNTGTVPGSE
TCCGGGATCAGAGAAGACAGTGACTCGATGGAAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGA					KDSDSMETEEKTSSAFVGK
prey67465  prey28880  prey2880  prey2880  prey28800  prey28880  prey28800  prey28800  prey28800  prey28800  prey28800  prey28800  prey28800  prey28800  pr				TCCGGGGATCAGAGAAAGACAGTGACTCGATGGAAACAGAAAAAAAA	
prey67465 141 CACTGCGCCGCTGCCCATGGCCCGAGGACGAGGACCATCGCCCTA 342 CATCAGCCGCTGTTCTGTGTGTGAGGCCCCGGCCATCGCCGTCCATCGCGGTCCA CAGTCAGCCGCTGTTCTGTGTGTGAGGCCCCGGCCATCGCCGTTTGTG CAGTCAGCATTCCTTCCTCCATCCCACTGCCCAGCTGGCGAGGTTTGTG GATCGGATATTCCTTCCTCATGCACGGCGGCGGAGACGAAGGCGTTGG GATCAGCATTCCTTCCTCATGCACGGCGGCAGCGCGCGCACAC ATTCATCGAATGCAATGGAGGCCGCCCCACCACCACCACACA ATTCATCGAATGCAATGGAGCCGGCCCCTCTCCGCGCCACCAC ATTCATCGAATGCAATGGAGCCGGCCCCCATCCGCGCCCCCCCC					
CATCAGCCGCIGITCIGIGIGIGIGIGIGIGIGIGIGIGIGIGIG	വ	prey67465	141	342	APLPMMPVAEDEIKPYISH   CSVCFAPAIAIAVHSODVSI
CAGICAGATATTCCTTCCTCATGCCGGCGGGGGGGGGGGG					PHCPAGWRSLWIGYSFLM
prey28880 142 AAGATCATGATGACAGGCCCCCACACACACACACACACAC				(5	HTAAGDEGGGQSLVSPGS
ATTCATCATGAATGCAATGGAGGCCGCGCACTACTACCACCACACAA GTACAGCTTCTGGCTGACCACCATTCCCGAGGCTTCCAGGGCTCGCC GTACAGCTTCTGGCTGACCACCACTTCCCGAGGCTTCCAGGGCTCGCC CTCCGCCGACACGCTCAAGGCCGGCCTCATCCGACACACAC				GTCACCGGCAGCTGTCTAGAGGACTTCCGCGCCACACC	CLEDFRATPFIECNGGRGT
prey28880 TTGCGCCGACACCCTCATCCCGAGCTTCCAGGGCTCGCC CTCCGCCGACACGCTCAAGGCCGGCCTCATCCGCACACCATCAGCCGCTG CCAGGTGTGCATGAAGAACCTGTGA  prey28880 TTGCTGACTGTAAAAGATGCCTATCCAACAAATGTACCCACCTTTTTGCAAC GTAATATTAAAAAGTGGCTGAAGATTGTGCAAGTAGTACTCGATGGAATCTTATA GAAGAATGTGGAGGGCTGGAAAATTGAACAATTCAAAATTGAAAATTGAAAATTGAAAATTGAAAATTGAAAATTGAATTCAAA					CHYYANKYSFWLTTIPEQS
CTCCGCCGACACGCTCAAGGCCGGCCTCATCCGCACATCAGCCGCTGGCCGCTGTGGCCGCTGTGA  CCAGGTGTGCATGAAGAACCTGTGA  CCAGGTGTGCATGAAGAACCTGTGA  TTGCTGACTTACCTTATCCAACAAATGTTATCCCACCTTTTTGCAAC  TTGCTGACTGTAAAAGGTGCACAAGTTGTGCAAGTAGTACTCGATGGACTAA  GTAATATTAAAAAGGCTGAAGATTGAAAAATTGAAAATCATGAAATCATGAACATTCAAAATG  AAGACATCTACAAATTGGCCTATGAGAACAGAAGGGTTCTTCTCTTCAGAT  GATATTGATGAAGACCCTAGCCTTGTTCCAAAGGGGTTCCAGGTTTTAG  TTGGTTTCAATTCATCACAATGCCCAATGACGAAATGAGGAAATGAGGAACTTCAATGCAATTAATAAAATGAAATAAAATGAAATAAAATGAAATAAAATGAAATAAAATGAAAATGAAATAAAATGAAATAAAATAAAATAAAATAAAATAAAATAAAATAAAATAAAA	-			GTACAGCTTCTGGCTGACCACCATTCCCGAGCAGAGCTTCCAGGGCTCGCC	FQGSPSADTLKAGLIRTHIS
prey28880 142 AAGATCAAGTGGCTTACCTTATCCAACAAATGTTATCCCACCTTTTTGCAAC 343 TTGCTGACTGTAAAAGATGCACAAGTTGTACCACAGTAGTACTCGATGGACTAA GTAATATTAAAAATGGCTGAAGATGAAGAACCATAGGCAATCTTATA GAAGAATGTGGAGGGCTGGAGAAATTGAACAATTCAAAATCTTCTTCTTCAGAAT GAAGAATTGATGAAATTGACCTTGTTCCAGAGGCAGTTTTAG TTGGTTTCAATTCATGCCAATGTACCAACGAAGGGTTCCAGAGAGAATAG				CTCCGCCGACACGCTCAAGGCCGGCCTCATCCGCACACATCAGCCGCIG	HOGVOMBINE
TTGCTGACTGTAAAGATGCACAAGTTGTGCAAGTAGTACTCGATGGACTAA  TTGCTGACTGTAAAAATGGCTGAAGATTGTGCAGAAACCATAGGCATTTAAAAATGGCTGAAGATTGAACAAATTGAACAATTCTAAAAATGGCTGGAGAAAATTGAACAACTTCAAAAATGAAAAATGAAATTGACAATTGAAAATTGAAAATGAACCTTGTTCCAGAATTCAGGAACATTCAATTC	L	000000	170	1	DQVAYLIQQNVIPPFCNLLT
GTAATATTAAAAATGGCTGAAGATGAGCAGAAACCATAGGCAATCTTATA GAAGAATGTGGAGGGCTGGAGAAAATTGAACAACTTCAAAAATGAAGACTTGAAAAATGAAGAAATTGACCTATGAGATCATTGATCATTCACTTCTCTCTC	Ω	preyzooou	747	TTGCTGACTGTAAAAGATGCACAAGTTGTGCAAGTAGTACTCGATGGACTAA	VKDAQVVQVVLDGLSNILK
GAAGAATGTGGAGGCTGGAGAAATTGAACATTCAAAATCATGAAAATG AAGACATCTACAAATTGGCCTATGAGATCATTGATCATTCTCTTCAGAT GATATTGATGAAGACCCTAGCCTTGTTCCAGAGGCCAATTCAGGAACATTCATT				GTAATATTAAAAATGGCTGAAGATGAGGCAGAAACCATAGGCAATCTTATA	MAEDEAETIGNLIEECGGLE
AAGACATCTACAAATTGGCCTATGAGATCATTGATCTTCTCTCTTCAGAT GATATTGATGAAGACCCTAGCCTTGTTCCAGAGGCAATTCAAGGAACAT TTGGTTTCAATTCATCTGCCAATGTACCAACAAAGGGTTCCAGTTTAG				GAAGAATGTGGAGGCTGGAGAAATTGAACAACTTCAAAAATCATGAAAATG	KIEOLONHENEDIYKLAYE!!
GATATTGATGAGACCCTAGCCTTGTTCCAGAGGCAATTCAAGGCGGAACA I TTGGTTTCAATTCATCTGCCAATGTACCAACAGGGGTTCCAGTTTTAG				AAGACATCTACAAATTGGCCTATGAGATCATTGATCAGTTCTTCTTCTGAT	DQFFSSUDIDEDFSLVFEAI
				_	QGG I FGFINSSAINVF I EGF QF*
		COL	,	GG       CAA     CAI   CI GCCAA   GACACAGAAA   CAA CATATA CTAA TAA TAA GAAAA TAA CTAA C	AVIEMCOLLVMGNEETLGG

DIMNHACRALTYMMEALPR SSAVVVDAIPVFLEKLQVIQ CIDVAEQALTALEMLSRRH SKAILQAGGLADCLLYLEFF SINAQRNALAIAANCCQSIT PDEFHFVADSLPLLTQRLT HQDKKSVESTCLCFARLVD NFQHEENLLQQVASKDLLT NVQQLLVVTPPILSSGMFIM VVRMFSLMCSNCPTLAVQL MKQNIAETLHFLLCGASNG SCQEQIDLVPRSPQELYEL TSLICELMPCLPKEGIFAVD TMLKKGNAQNTDGAIWQW RDDRGLWHPYNRIDSRIIE QINEDTGTARAIQRKPNPLA NSNTSGYSESKKDDARAQ LQMAELLMQKLKDVLKNHA VSSHIASMLSSQDLKIVVGA LQMAEILMQKLPDIFSVYFR REGVMHQVKHLAESESLLT SPPKACTNGSGSMGSTTS
SSAVVVDAIPVFLEKLGYN SSAVVVDAIPVFLEKLGYN CIDVAEQALTALEMLSRR SKAILQAGGLADCLLYLEI SINAQRNALAIAAANCCQS PDEFHFVADSLPLLTQRI HQDKKSVESTCLCFARL' NVQQLLVVTPPILSSGMF VVRMFSLMCSNCPTLAV MKQNIETLHFLLCGASV SCQEQIDLVPRSPQELYI TSLICELMPCLPKEGIFAY TSLICELMPCLPKEGIFAY TSLICELMPCLPKEGIFAY TSLICELMPCLPKEGIFAY TSLICELMPCLPKEGIFAY TSLICELMPCLPKEGIFAY IMKEDPELAKSFIKTLFG YEVYSSSAGPAVRHKCL ILRIIYFADAELLKDVLKNI VSSHIASMLSSQDLKIVV LQMAEILMQKKHLAESESI SPPKACTNGSGSMGST
SKAILQAGGLADCLLYLEI SKAILQAGGLADCLLYLEI SINAQRNALAIAANCCQS PDEFHFVADSLPLLTQRL HQDKKSVESTCLCFARL' NVQQLLVVTPPILSSGMF VVRMFSLMCSNCPTLAV MKQNIAETLHFLLCGASN SCQEQIDLVPRSPQELYI TSLICELMPCLPKEGIFAY TSLICELMPCLPKEGIFAY TSLICELMPCLPKEGIFAY TSLICELMPCLPKEGIFAY INKEDPELAKSFIKTLFG YEVYSSSAGPAVRHKCL ILRIIYFADAELLKDVLKNI VSSHIASMLSSQDLKIVV LQMAEILMQKLPDIFSVY REGVMHQVKHLAESESI SPPKACTNGSGSMGST
SKAILQAGGLADCLLYLE SINAQRNALAIAANCCQS PDEFHFVADSLPLLTQRL HQDKKSVESTCLCFARL' NVQQLLVVTPPILSGMF VVRMFSLMCSNCPTLAV MKQNIAETLHFLLCGASN SCQEQIDLVPRSPQELYI TSLICELMPCLPKEGIFAY TSLICELMPCLPKEGIFAY TSLICELMPCLPKEGIFAY MSNTSGYSESKKDDAR! CINKEDPELAKSFIKTLFG YEVYSSAGPAVRHKCL ILRIIYFADAELLKDVLKNI VSSHIASMLSSQDLKIVV LQMAEILMQKLPDIFSVY REGVMHQVKHLAESESI SPPKACTNGSGSMGST
SINAQHNALAIAANCCQS PDEFHFVADSLPLLTQRL HQDKKSVESTCLCFARL' NPQHEENLLQQVASKDL NVQQLLVVTPPILSGMF VVRMFSLMCSNCPTLAV MKQNIAETLHFLLCGASN SCQEQIDLVPRSPQELYI TSLICELMPCLPKEGIFAY TRLKKGNAQNTDGAIWC RDDRGLWHPYNRIDSRI QINEDTGTARAIQRKPNI NSNTSGYSESKKDDAR/ LMKEDPELAKSFIKTLFG YEVYSSAGPAVRHKCL ILRIIYFADAELLKDVLKNI VSSHIASMLSSQDLKIVV LQMAEILMQKLPDIFSVY REGVMHQVKHLAESESI SPPKACTNGSGSMGST
PDEFHYADSLPLL I GRE HQDKKSVESTCLCFARL NFQHEENLLQQVASKDL NVQQLLVVTPPILSSGMF VVRMFSLMCSNCPTLAV MKQNIAETLHFLLCGASN SCQEQIDLVPRSPQELYI TSLICELMPCLPKEGIFAY TMLKKGNAQNTDGAIWC RDDRGLWHPYNRIDSRI QINEDTGTARAIQRKPNIF NSNTSGYSESKKDDARZ LMKEDPELAKSFIKTLFG YEVYSSSAGPAVRHKCL ILRIIYFADAELLKDVLKNI VSSHIASMLSSQDLKIVV LQMAEILMQKLPDIFSVY REGVMHQVKHLAESESI SPPKACTNGSGSMGST
NECHENLLQQVASKDL NVQQLLVVTPPILSSGMF VVRMFSLMCSNCPTLAV MKQNIAETLHFLLCGASN SCQEQIDLVPRSPQELYF TSLICELMPCLPKEGIFAN TMLKKGNAQNTDGAIW( RDDRGLWHPYNRIDSRI QINEDTGTARAIQRKPNF NSNTSGYSESKKDDARF LMKEDPELAKSFIKTLFG YEVYSSSAGPAVRHKCL ILRIIYFADAELLKDVLKNV LQMAEILMQKLPDIFSVY REGVMHQVKHLAESESI SPPKACTNGSGSMGST
NVQQLLVVTPPILSSGMF NVQQLLVVTPPILSSGMF VVRMFSLMCSNCPTLAV MKQNIAETLHFLLCGASN SCQEQIDLVPRSPQELYF TSLICELMPCLPKEGIFAV TMLKKGNAQNTDGAIWC RDDRGLWHPYNRIDSRI QINEDTGTARAIQRKPNF NSNTSGYSESKKDDARF LMKEDPELAKSFIKTLFG YEVYSSSAGPAVRHKCL ILRIIYFADAELLKDVLKNV VSSHIASMLSSQDLKIVV LQMAEILMQKLPDIFSVY REGVMHQVKHLAESESI SPPKACTNGSGSMGST
NVGGLLVV I PPILSSGWING VVRMFSLMCSNCPTLAV MKQNIAETLHFLLCGASN SCQEQIDLVPRSPQELYI TSLICELMPCLPKEGIFAV TMLKKGNAQNTDGAIWC RDDRGLWHPYNRIDSRI QINEDTGTARAIQRKPNF NSNTSGYSESKKDDARY LMKEDPELAKSFIKTLFG YEVYSSSAGPAVRHKCL ILRIIYFADAELLKDVLKNV VSSHIASMLSSQDLKIVV LQMAEILMQKRPDIFSVY REGVMHQVKHLAESESI SPPKACTNGSGSMGST
WYNKINFSLINGSINGFILAY MKQNIAETLHFLLCGASIN SCQEQIDLVPRSPQELYE TSLICELMPCLPKEGIFAY TMLKKGNAQNTDGAIWC RDDRGLWHPYNRIDSRI QINEDTGTARAIQRKPNF NSNTSGYSESKKDDARF LMKEDPELAKSFIKTLFG YEVYSSSAGPAVRHKCL ILRIIYFADAELLKDVLKNI VSSHIASMLSSQDLKIVV LQMAEILMQKRPDIFSVY REGVMHQVKHLAESESI SPPKACTNGSGSMGST
MKQNIAE I LHFLLCGASN SCQEQIDLVPRSPQELYE TSLICELMPCLPKEGIFAN TMLKKGNAQNTDGAIWC RDDRGLWHPYNRIDSRI QINEDTGTARAIQRKPNF NSNTSGYSESKKDDARF LMKEDPELAKSFIKTLFG YEVYSSSAGPAVRHKCL ILRIIYFADAELLKDVLKNI VSSHIASMLSSQDLKIVV LQMAEILMQKLPDIFSVY REGVMHQVKHLAESESI SPPKACTNGSGSMGST
SCGEGIDL VPHSPGELYE TSLICELMPCLPKEGIFAN TMLKKGNAQNTDGAIWC RDDRGLWHPYNRIDSRI QINEDTGTARAIQRKPNF NSNTSGYSESKKDDAR/ LMKEDPELAKSFIKTLFG YEVYSSSAGPAVRHKCL ILRIIYFADAELLKDVLKNI VSSHIASMLSSQDLKIVV LQMAEILMQKLPDIFSVY REGVMHQVKHLAESESI SPPKACTNGSGSMGST
TSLICELMPCLPREGIFAN TMLKKGNAQNTDGAIWC RDDRGLWHPYNRIDSRI QINEDTGTARAIQRKPNF NSNTSGYSESKKDDARA LMKEDPELAKSFIKTLFG YEVYSSSAGPAVRHKCL ILRIIYFADAELLKDVLKNI VSSHIASMLSSQDLKIVV LQMAEILMQKLPDIFSVY REGVMHQVKHLAESESI SPPKACTNGSGSMGST
TMLKKGNAQN I DGAIWC RDDRGLWHPYNRIDSRI QINEDTGTARAIQRKPNF NSNTSGYSESKKDDARA LMKEDPELAKSFIKTLFG YEVYSSAGPAVRHKCL ILRIIYFADAELLKDVLKNI VSSHIASMLSSQDLKIVV LQMAEILMQKLPDIFSVY REGVMHQVKHLAESESI SPPKACTNGSGSMGST
RDDRGLWHPYNRIDSHI QINEDTGTARAIQRKPNF NSNTSGYSESKKDDARA LMKEDPELAKSFIKTLFG YEVYSSSAGPAVRHKCL ILRIIYFADAELLKDVLKNI VSSHIASMLSSQDLKIVV LQMAEILMQKLPDIFSVY REGVMHQVKHLAESESI SPPKACTNGSGSMGST
QINEDTGTARAIQHKPNF NSNTSGYSESKKDDARA LMKEDPELAKSFIKTLFG YEVYSSSAGPAVRHKCL ILRIIYFADAELLKDVLKNI VSSHIASMLSSQDLKIVV LQMAEILMQKLPDIFSVY REGVMHQVKHLAESESI SPPKACTNGSGSMGST
NSNTSGYSESKKUDAKA LMKEDPELAKSFIKTLFG YEVYSSSAGPAVRHKCL ILRIIYFADAELLKDVLKNI VSSHIASMLSSQDLKIVV LQMAEILMQKLPDIFSVY REGVMHQVKHLAESESI SPPKACTNGSGSMGST
LMKEDPELAKSFIKTLFG YEVYSSSAGPAVRHKCL ILRIIYFADAELLKDVLKNI VSSHIASMLSSQDLKIVV LQMAEILMQKLPDIFSVY REGVMHQVKHLAESESI SPPKACTNGSGSMGST
YEVYSSSAGPAVRHKCL ILRIIYFADAELLKDVLKNI VSSHIASMLSSQDLKIVV LQMAEILMQKLPDIFSVY REGVMHQVKHLAESESI SPPKACTNGSGSMGST
ILRIIYFADAELLKDVLKNV VSSHIASMLSSQDLKIVV LQMAEILMQKLPDIFSVY REGVMHQVKHLAESESI SPPKACTNGSGSMGST
VSSHIASMLSSQDLKIVV LQMAEILMQKLPDIFSVY REGVMHQVKHLAESESI SPPKACTNGSGSMGST
LQMAEILMQKLPDIFSVY REGVMHQVKHLAESESI SPPKACTNGSGSMGST
REGVMHQVKHLAESESI   SPPKACTNGSGSMGST
SPPKACTNGSGSMGST
C-C-V V J H V H V H V C C C C C C C C C C C C C C
VSSGIALAAIHAAADLGST
SLQHSRDDSLDLSPQGRLS
DVLKRKRLPKRGPRRPKYS
PPRDDDKVDNQAKSPTTT
QSPKSSFLASLNPKTWGRL
STOSNSNNIEPARTAGGSG
LARAASKDTISNNREKIKG
WIKEQAHKFVERYFSSENM
DGSNPALNVLQRLCAATEQ
LNLQVDGGAECLVEIRSIVS
ESDVSSFEIQHSGFVKQLLL
YLTSKSEKDAVSREIRLKRF
LHVEFSSPLPGEEPIGKVEP
ATGTCCTTCAGAGACTTTGTGCTGCAACCGAACACTCAACCTCCAGGTGGA TGGTGGAGCTGAGACTTGTAGAAATCCGTAGCATAGTCTCAGAGTCAGAT

	GTTTCATCATTTGAAATCCAACATAGTGGATTTGTGAAGCAGCIGIIGCIIIA	MEGFFVKVHDFFSGNG1G
	TTTGACATCTAAAAGIGAAAAGGAIGCIGIGAGCAGAGAGAGAGAICAGAIIAAAG	LKCOLORHPDCANVKOWK
	CGATTICTTCATGLATTCATGLACTTTGTTGGCATTAGTTCACCAGGTG	GGPVKIDPLALVQAIERYLV
	AACAACTGCCTCAGACGGAACAATTTCCAGTCAAAGTACATGATTTCC	VRGYGRVREDDEDSDDDG
	CTAGTGGAAATGGGACAGGAGGCAGCTTTTCTCTCAACAGAGGATCACAGG	SDEEIDESLAAQFLNSGNV
	CTTTAAAATTTTTCAACACACATCAATTAAAATGCCAGTTACAAAGGCATCCA	RHRLQFYIGEHLLPYNMTV
	GACTGTGCAAATGTGAAGCAGTGGAAGGGTGGACCTGTCAAGATTGACCCT	YQAVRQFSIQAEDERESTD
		DESNPLGRAGIWTKTHTIW
		YKPVREDEESNKDCVGGK
		RGRAQTAPTKI SPRNAKK
	GCTGCAGTTTTATATTGGAGAACATTTGCTGCCGTATAACATGACTGTGTATC	HDELWHDGVCPSVSNPLE
	AGGCAGTACGGCAGTTTAGTATACAGGCTGAAGATGAAAGAGAATCCACAGA	VYCIPIPPENII FEDPSCDVI
	TGATGAGAGCAATCCTCTAGGCAGAGCTGGTATTTGGACAAAGACTCATACA	LLLRVLHAISRYWYYLYDNA
	ATATGGTATAAACCTGTGAGAGGATGAAGAAGTAATAAAAGATTGTGTTG	MCKEIIPT SEFINSKLI AKAN
	GTGGTAAAAGAGGAAGAGCCCAAACAGCTCCAACGAAAACTTCCCCTAGAAA	RQLQDPLVIMTGNIPTWLI
	TGCAAAAAGCATGATGAGTTATGGCACGATGGAGTGTGCCCATCAGTATCA	ELGKTCPFFFPFDTRQMLF
	AATCCTTTAGAAGTTTACCTCATTCCCACACCACCTGAAAATATAACATTTGAA	YVTAFDRDRAMQRLLDTNP
	GACCGATCATTAGATGTGATCCTTTTTAAGAGTTTTACATGCTATCAGTCG	EINQSDSQDSRVAPRLDRK
	ATACTEGTATTACTTGTATGATATGCAATGCGAAGGAAATTATTCCAACTA	KRTVNREELLKQAESVMQ
	GTGAATTTATTAACAGTAAGTTAACAGCAAAAGCAAATAGGCAACTTCAAGAT	DLGSSRAMLEIQYENEVGT
	CCTTTAGTAATCATGAGGAAACATCCCAACATGGCTTACTGAGCTAGGAA	GLGPTLEFYALVSQELQRA
-	AAACCTGCCCATTTTCTTTCCTTTTGATACCCGGCAAATGCTTTTTATGTAA	DLGLWRGEEVTLSNPKGS
	• •	QEGTKYIQNLQGLFALPFG
	AATCAACCAGTCTGATTCTCAAGATAGCAGAGTTGCACCTAGATTGGATAGA	RTAKPAHIAKVKMKFRFLG
-		KLMAKAIMDFRLVDLPLGLP
	ATGCAGGACCTCGGCAGCTCACGGGCCATGTTAGAAATCCAGTATGAAAATG	FYKWMLRQETSLTSHDLFD
	AGGTTGGTACAGGTCTTGGGCCTACACTGGAGTTTTATGCGCTTGTATCTCA	IDPVVARSVYHLEDIVRQKK
	GGAACTACAGAGAGCTGACTTGGGTCTTTGGAGGGGGGAGAGGTAACTCTT	RLEQDKSQTKESLQYALET
	AGCAATCCAAAAGGGAGCCAAGAAGGGACCAAGTATTCAAAACCTCCAGG	LTMNGCSVEDLGLDFTLPG
	GCCTGTTTGCGCTTCCCTTTGGTAGGACAGCAAAGCCAGCTCATATCGCAAA	<b>FPNIELKKGGKDIPVTIHNLE</b>
	GGTTAAGATGAAGTTTCGCTTCTTAGGAAAATTAATGGCCAAGGCTATCATG	EYLRLVIFWALNEGVSRQF
	GATTTCAGATTGGTGGACCTTCCCCTTGGCTTACCCTTTTATAAATGGATGCT	DSFRDGFESVFPLSHLQYF
	ACGCAAGAAACTTCACTGACATCACACGATTTGTTTGACATCGACCCAGTT	YPEELDQLLCGSKADTWD
	GTAGCCAGATCAGTTTATCACCTAGAAGACATTGTCAGACAGA	AKTLMECCRPDHGYTHDS
	TTGAACAAGATAAATCCCAGACCAAAGAGAGTCTACAGTATGCATTAGAAAC	RAVKFLFEILSSFUNEQQRL
	CTTGACTATGAATGGCTGCTCAGTTGAAGATCTAGGACTGGATTTCACTCTG	FLOFVTGSPRLPVGGFRSL
	CCAGGGTTTCCCAATATCGAACTGAAAGGAGGGAAGGATATACCAGTCA	
	CTATCCACAATTTAGAGGAGTATCTAAGACIGGIIAIAIICIGGGCACIAAAI	LPOVINI CVINI ENEL DI SOIL

	GAAGGCGTTTCTAGGCAATTTGATTCGTTCAGAGATGGATTTGAATCAGTCTT CCCACTCAGTCATCTTCAGTACTTCTACCCGGAGGAACTGGATCAGCTCTT CCCACTCAGTCATCTTCAGTACTTCTACCCGGAGGAACTGGAACTGGCTCTT TGTGGCAGTAAAGCAGACACTTGGGATGCAAAGACACTGATGGAATGCTGTA GGCCTGATCATGGTTATACTCATGACAGGGCTGTGAAGTTTTTGTTTG		IMREKLIAAREGQQSFHLS	<u>n</u>
prey67717	44-	6 6 7 8 9	AGHPVLGSRA*DCPRQQH NHVQPSGVSDALVWQPRE CEPICSWEGLWASCGEGL LPGALRSLHRISRRAPSAA APLICANDWGPNSRVPARL PPIQTVGF*ELGAWGPLGW GGQGEQVGSVSLFPHALT HPNPWVRTELLKATEGGA AHSTWVAFRSSPPPGSSETE PGPLAAPRPRPFSDRGATT PGRGGKEGRPKSRGLSW WPWASLELWCHHLQKGG KNACVVQLRGYAVKTRMV GRLALNNGSIWPGAVAHAC NPSTLGGRGGRITRSGDQ DHPG*NGETPSLLKIQKISR A*WRAPVVPATWEAEAGE WCEPGRRSLQ*AEIPPLHS SLGDRARLKKKKNNGS IVFSAQEEGSWDRERATTP HPSLYNRRATFSSSEQDRL VAKSRK*GLVPARWLIPVIP VLWEAEAGAGWIT*GQGFE TSPTNMVKPRLY*EYKN*P GVVARACNLSCLGG*GRRI A*TDEAEAVAVGRDRATTVO	SSS SSS SSS SSS SSS SSS SSS SSS SSS SS
	TCTACTAGGAGGCTGAGGCGGGCGTGGTGGCGGGGGGGGG	) <del> </del> (5	PGGSVRLGL	

	MGIGLSAQGVNMNRLPGW DKHSYGYHGDDGHSFCSS GTGQPYGPTFTTGDVIGCC VNLINNTCFYTKNGHSLGIA FTDLPPNLYPTVGLQTPGE VVDANFGQHPFVFDIEDYM REWRTKIQAQIDRFPIGDR EGEWQTMIQKMVSSYLVH HGYCATAE	MGGLFSRWRTKPSTVEVL ESIDKEIQALEEFREKNORL QKLWVGRLILYSSVLYLFTC LIVYLWYLPDEFTARLAMTL PFFAFPLIIWSIRTVIIFFFSK RTERNNEALDDLKSQRKKI LEEVMEKETYKT	MGDKG I KVFKKASPNGKL TVYLGKRDFVDHIDLVDPV DGVVLVDPEYLKERRVYVT LTCAFRYGREDLDVLGLTF RKDLFVANVQSFPPAPEDK KPLTRLQERLIKKLGEHAYP FTFEIPPNLPCSVTLQPGPE DTGKACGVDYEVKAFCAE NLEEKIHKRNSVRLVIRKVQ YAPERPGPQPTAETTRQFL MSDKPLHLEASLDKEIYYH GEPISVNVHVTNNTNKTVK KIKISVRQYADICLFNTAQY KCPVAMEEADDTVAPSSTF CKVYTLTPFLANNREKRGL ALDGKLKHEDTNLASSTLL REGANREILGIIVSYKVKVK LVVSRGGLLGDLASSDVAV ELPFTLMHPKPKEEPPHRE
STACTGTCCAGCCGGCGGCAGT	COTTTCTGCTCAAGGTGTGAACATGAATAGACTACCAGGTT COTTTCTGCTCAAGGTGTGAACATGAACTACCAGGTT COATAGGTTACCATGGGGATGATGGACATTCGTTTTGTTCT ACAACCTTATGACCAACTTTCACTACTGGTGATGTCATTG ATCTTATCAACAATACCTGCTTTTACACCAGAATGGACAT GCTTTCACTGACCTACCGCCAATTTTGTATCCTACTGTGGG AGAGACTATTGCGAGAGGAACAACTTTC GAAGACTATTGGGAGAGGAACAACATCAGGCAC TTCCTATCGGAGATCGAGGAGAACGCAGGAT TTCATCTTATTTAGTCCACCATGGGTACTGTGCCACAGGAG		AGGGACCCGAGTGTTCAAGAAGGCCAGTCCAAATGGAAAG  AGGGACCCGAGTGTTTGTGGACCACTCGACCTCGTG  TGGTGTGGTCCTGGTGGACCTTTGTGGACCTCGTG  TGGTGTGGTCCTGGTGGATCCTGAGTATCTCAAAGAGCGG  TGGTGTGGTCCTGGTGGATCCTGAGTATCTCAAAGGCGG  CCTGACCTTTCGCAAGGACCTTTTGTGCCCAACGTACAGT  GCCCCCGAGGACCTGTTTTGTGGCCAACGTACAGT  GCCCCCGAGGACCTTTCGCCCTTTCACCTTTGAGATCC  CCTGACCTTTCTGTGCACCCTTTCACCTTTTGAGATCC  CCTGACCTTTCTGTGCACCTTCACCTTTGAGATCC  CCTGACCTTTCTGTGCCCCTTCTGCGCCGAACGC  CCTGACCTTGCAAGACCCTTCTGCGCCGAACGC  ATGTCGGACAACAGCCCTTGCACCTTCTGCGCCAACGC  ATGTCGGACAACAGCCCTTGCACCTTCTGGATAA  ATGTCGGACAAGACCCATCAGCGTCAAGCCTTTTCAACACACCC  ATGTCGGACAACAGCTCTGCACTTCTGCACTTTGGATAA  ACTGTGGCACCAGCTCGACGTCTTTGCACCACC  CTAGCCAATAACCGAGATCTTTCTGCAAGGTCTACACAC  CTAGCCAATAACCGAGATCTTTCTGCAAGGTCTACACAC  CTAGCCAATAACCGAGACCTTTTCTGCAAGTGAAAGT  ACTGTGGAACCCTTGGCCTTTTCTACACACCCTTGGACG  CCTAGCCAATAACCGAGATCTTTCTGCAAGGTGAAAGT  ACTGTGGAACCCCAGCTCTACAAGTGAAAGT  ACTGTGGAACCCTTGGACCTTTTCTGCAAGTGAAAGT  ACTGTGGAATCTTTCTTTCCTACAAAGTGAAAGT  CCTAGCCAATAACCGAGATCATTGTTTCCTACAAAAGTGAAAGT  CCTAGCAAAAAGCGGGATCATTGTTTCCTACAAAAGTGAAAGT  CCTAGCAAAAAGCCTTTTCCTACAAAGTGAAAGT  CCTAGCAAAAACCGAACATTGTTTCCTACAAAAGTGAAAGT  CCTAGCCAATAACCTTTGTTTCCTACAAAGTGAAAGT  CCTAGCAAAAAGCGGAACATTGTTTCCTACAAAAGTGAAAAGT  CCTAGCAAAAAACCTTTGTTTCCTACAAAAGTGAAAAGT  CCTAGCAAAAAACCTTTGTTTCCTACAAAAGTGAAAAGT  CCTAGCAAAAAACCTTTCTTCCTACAAAAGTAAAAGT  CCTAGCAAAAAACCTTTCTTCTTCTACAAAAGTGAAAAGT  CCTAGCAAAAAACAATTCTTCCTACAAAAGTGAAAATT  CCTAGCAAAAAACCTTTCTTCCTACAAAAACCCTTTCTACAAAAATT  CCTAGCAAAAAACCTTCTACAAACCCTTTTCTTCCTACAAAAATT  CCTAGCAAAAAACTTTCTTCTACAAACCCTTTTCTTCCTACAAAAAA
AGGTTGCAGTGAGCCGAGATCGAGCCACTACTGTCCAGCCCGGCGGCAGT		ATGGATT/ GTATAGA ATTACAA GTTTACA SACTTGC GAACAGI GAAACTT	ATGGGCGACAAAGGGACCCGAGTGTTCAAGAAGGCCAGTCCAAATGGAAAG CTCACCGTCTACCTGGGAAAGCGGGACTTTGTGGACCATCGACCTCGTG GACCCTGTGGATGGTGGTCCTGGTGGATCCTGAGTATCTCAAAGAGCGG GACCCTGTGGATGGTGGTCCTGGTGGACCTGTTCTCAAAGAGCGG AGAGTCTATGTGACCTGACC
	145	146	147
	prey700	prey67718	prey2530
	g	ω	Φ
	Shigella ipaH9.8	Shigella ipaH9.8	Shigella ipaH9.8

VPENETPVDTNLIELDTNDD DIVFEDFARQRLKGMKDDK EEEEDGTGSPQLNNR*		000
GAAGCTGGTGGTGTCTCGGGGCGGCCTGTTGGGAGATCTTGCATCCAGCGA CGTGGCCGTGGAACTGCCCTTCACCCTAATGCACCCAAGGCCAAAGGAA ACCCCGCATCGGGAAGTTCCAGAGAACGAGGCCAGTAGATACCAATCT CATAGAACTTGACACAAATGATGACGACATTGTATTTGAGGACTTTGCTCGCC AGAGACTGAAAGGCATGAAGGATGACAAGGAGGAGGAGGAGGTGCCG	ACTAGECAGAGGCGAGGCATTTTTAAATCGGGAAGAGCCATTAAAAACTG ACTGCAATAGCAGGCCAGGC	GCTCCCGGACGTCCCTGCTCCTGGCTTTTGCCCTGCTCTGCCTGC
	148	149
	prey67731	prey7155
	Ø	· Θ
	Shigella ipaH9.8	Shigella ipaH9.8

				CCCTTCTTTCTCCTCTTCTTCTTCTTCTTCTTCTTCTTC	I IUVOGOGOTOVI IIAIAA TAA
				GCTCATCGAGTCGTGGCTGGAGCCCGTGCGGTTCCTCAGGAGTATGTTCGC	KDLEEGIQTLMGVRVAPGV
					ANPGTPLA*
					EVDACEDED SKEPPIVE! BAA
Shigella	ၑ	prey1687	120	GGAGTATGATGCAGAGCCCCCCCAGCAAGCC	A DACTION OF THE STATE OF THE S
ipaH9.8		•		GGCTGCTGCCCTTCGTGCAGAGATCACAGATGCTGAAGGCCTGGGTTTGAA	ALRAEII DAEGLGLNLEUNE
-				GCTCGAAGATCGAGAGACAGTTATTAAGGAGTTGAAGAAGTCACTCAAGATT	I VINELANDLAINGEELSEA
				AAGGGAGAGGAGCTAAGTGAGGCCAATGTGCGGCTGAGCCTCCTGGAGAA	NVKLSLLERKLUSAAKUAU
				GAAGTTGGACAGTGCTGCCAAGGATGCAGATGAGCGCATCGAGAAAGTCCA	ERIEKVO I KLEE I QALLAKK
				GACTCGGCTGGAGGAGACCCAGGCACTGCTGCGAAAGAAGAAGAAGAAGAGTT	EKEFEE I MUALQADIUQLE
				TGAGGAGACAATGGATGCACTCCAGGCTGACATCGACCAGCTGGAGGCAGA	AEKAELKORLNSOSKRTIE
				GAAGGCAGAACTAAAGCAGCGTCTGAACAGCCAGTCCAAACGCACGATTGA	GLRGPPPSGIATLVSGIAGE
				GGGGGGGGCCTCCTTCAGGCATTGCTACTCTGGTCTCTGGCAT	EQQRGAIPGQAPGSVPGP
				TGCTGGTGAAGAACAGCAGCGAGGAGCCATCCCTGGGCAGGCTCCAGGGT	GLVKDSPLLLQQISAMRLHI
				CTGTGCCAGGCCCAGGGCTGGTGAAGGACTCACCACTGCTGCTTCAGCAGA	SQLQHENSILKGAQMKASL
				TCTCTGCCATGAGGCTGCACATCTCCCAGCTCCAGCATGAGAACAGCATCCT	ASL
				CAAGGGAGCCCAGATGAAGGCATCCTTGGCATCCCTGC	
Shinella	œ	prev67734	151	ATGAGCCAGAGGGACACGCTGGTGCATCTGTTTGCCGGAGGATGTGGTGGT 352	MSQRDTLVHLFAGGCGGT
a oHeri	)			ACAGTGGGAGCTATTCTGACATGTCCACTGGAAGTTGTAAAAACACGACTGC	VGAILTCPLEVVKTRLQSSS
pa 13.0				AGTCATCTTCTGTGACGCTTTATATTTCTGAAGTTCAGCTGAACACCATGGCT	VTLYISEVQLNTMAGASVN
				GGAGCCAGTGTCAACCGAGTAGTGTCTCCCGGACCTCTTCATTGCCTAAAG	RVVSPGPLHCLKVILEKEG
				GTGATCTTGGAAAAAGAAGGGCCTCGTTCCTTGTTTAGAGGACTAGGCCCCA	PRSLFRGLGPNLVGVAPSR
				ATTTAGTGGGGTAGCCCCTTCCAGAGCAATATACTTTGCTGCTTATTCAAAC	AIYFAAYSNCKEKLNDVFD
				TGCAAGGAAAAGTTGAATGATGTATTTGATCCTGATTCTACCCAAGTACATAT	PDSTQVHMISAAMAGFTAI
				GATTTCAGCTGCAATGGCAGGTTTTACTGCAATCACAGCAACCAAC	TATNPIWLIKTRLQLDARNR
				TGGCTTATAAAGACTCGGTTACAGCTTGATGCAAGGAACCGCGGGGAAAGG	GERRMGAFECVRKVYQTD
				CGAATGGGTGCTTTTGAATGTGTTCGTAAAGTGTATCAGACAGA	GLKGFYRGMSASYAGISET
	-			AAGGATTTTATAGGGGCATGTCTGCTTCATATGCTGGTATATCAGAGGACTGTT	VIHFVIYESIKQKLLEYKTAS
				ATCCATTTTGTTATTATGAAAGTATAAAACAAAAACTACTGGAATATAAAGACT	TMENGEESVKEASDFVGM
				GCTTCTACAATGGAAAATGGTGAAGAGTCTGTGAAAGAAGCATCAGATTTTG	MLAAATSKTCATTIAYPHVV
				TGGGAATGATGCTAGCTGCCACCTCAAAAACTTGTGCCACAACTATAGC	RTRLREEGIKYRSFFQILS
				ATATCCACATGTTGTAAGAACAAGACTACGTGAAGAGGGAACAAAATACAGA	LLVQEEGYGSLYRGLIIHL
				TCTTTTTTCAGACTCTATCTTTGCTTGTTCAAGAAGAAGGTTATGGGTCTCTT	VRQIPN I AIMIMA I YELVVYL
				TATCGTGGTCTGACAACTCATCTAGTGAGACAGATTCCAAAACACACAC	*SVI
				十	HOLHXUNGITIMONAL CONTRACTOR
Shigella	9	prey2694	152	ATGGCACACGCTATGGAAAACTCCTGGACAATCAGTAAAGAGTACCA1A11G 353	MAHAMENSW IISKETHIDE EVCEAL BNBOENI BDEVND
ipaH9.8				ATGAAGAAGTGGGCTTTGCTCTGCCAAATCCACAGGAAAATCTACTGACTTT	WMEIAKHI PDI IESGOI BE
				TATAATGACTGGATGT ICALTGCTAAACATCTGACCTGATCTCATAGATCTCG	BVEKLUMLSIDHLTDHKSQ
				UCAGO!!UGAGAAAGAGI!GAGAAG!!AAAGA!GA!GAGGAGGAGGAGGAGGAGGAGG	

					RLARLVLGCITMAYVWGKG
					HGDVRKVLPRNIAVPYCQL
				_	SKKLELFFILV YADOVLANWY KKKDPNKPLTYENMDVLFS
			- •		FRDGDCSKGFFLVSLLVEIA
					AASAIKVIPTVFKAMQMQE
			-		RDTLLKALLEIASCLEKALG
				GGGACACTTTGCTAAAGGCGCTGTTGGAAATAGCIICIIGCIIGGAGAAAGC	אואווסבוטבו
Shinella	9	prev67740	153	354	XXITCXXVEIGHXDKGMVH
	<b>o</b>	2		vr. (	VSCINCE   WXHXCYXVAT
2					NESDLSALAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
				TCNTTNTATGTGNGTGCAGCG111ACNC1AC1NCAN1C1GAN1G1AC11AN1G	GXGXRXFXLCTXXGG
					AITINI NITI DOMIDETD
	9	prey67703	154	GGCCATTGAGAAACTACTCGCTCTTCTCAACACGCTGGACAGGIGGAIIGAII 355	PVDQPSRFGNKAYRTWYA
ipaH9.8			_	GAGACTOCTATATACCAAACTTGATGAGGAAGCAGAAAACTTGGTGGCCACAGTG	KLDEEAENLVATVVPTHLA
				GTCCCTACCCATCTGGCAGCTGCTGTGCCTGAGGTGGCTGTTTACCTAAAG	AAVPEVAVYLKESVGNSTR
				GAGTCAGTGGGGAACTCCACGCGCATTGACTACGGCACAGGGCATGAGGCA	IDYGTGHEAAFAAFLCCLC
				GCCTTCGCTGCTTTCCTCTGCTGTCTCTGCAAGATTGGGGTGCTCCGGGGTG	KIGVLRVDDQIAIVFKVFING
				GATGACCAAATAGCTATTGTCTTCAAGGTGTTCAATCGGTACCTTGAGGTTAT	COCYMGI DDEDEI DEIWG
				GCGGAAACTCCAGAAACATACAGGATGGAGCCAGCCAGCC	
20.0				TGTGGGGTCTGGATGACTTCCAGIIICIGCCCIICAICIGGGGCAGIICGCA	מספבונים -
		7777	u u	GCIGALAGACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGA	DKLSQAKAYCNLGLAFKAL
-	<u>.                                    </u>	preyo//41	5	CTCTGCTGAATTTCAGTAAAGCTGAAGAGTGTCANGAAGTACCTACTGTCCC	LNFSKAEECXEVPTVPSPV
рану.8					SE*FPG*ISSPRKPGRYIHL*
				GGGCGATATATTCATCTGTAAAAAAAAAAATGATGGTGCAATAAAATTCTATG	KRYKWCNKIL*AAIGLSSP
				AGCAGCAACTGGGCTTAGCTCACCAGGTAAAGGACAGAAGATTAGAAGCCA	מאסמטאטאפעואסאפ
Shinella	(C	prev67742	156	AGGTAATGGAGCTGGTGGCAGCAGCCAGAAAACTCCACTCTTGAAACT 357	GNGAGGSSQKTPLFETY
ipaH9.8	)			TACTCGGATTGGGACAGAGAATCAAGAGGACAGGTGCTTCCGGGIGGAGA	SUWUKEIKH GASGWHVO
				GTTTGTTCTATTAACGAGGGIIACAIGAIAICCACIIGCCIICCAGAAIACAI	SLADODLKIFSHSFVGRRM
				TGTAGTGCCAAGTTCTTTAGCAGACCAAGATCTTTTCCCATTCTTTCCTAACGCAGTG	PLWCWSHSNGSALVRMAL
				CTCTTGTGCGAATGGCCCTCATCAAAGACGTGCTGCAGCAGGAAGATTG	KDVLQQRKIDQRICNAITKS
				ACCAGAGGATTTGTAATGCAATAACTAAAAGTCACCCACAGAGAAGTGATGT TTACAAATTTGGATAAGACCTTGCCTAATATCAAGAAGTACAAGAGCAG	HPGRSDV TRSDLDR I LF NI QEVQAAFVKLKQLCVNEPF
				I HOARATIOAGAILI CACATTA CACAT	

				GAAGCAGCTATGCGTTAATGAGCCTTTTGAAGAAACTGAA	EETEEKWLSSLENTRWLEY
				GAGAAATGGTTATCTTCACTGGAAAA ACTCGATGGTTAGAATATGTTAAGAGCAAACATCTC	LSVVLQEEEGRDLSCCVAS
					LVQVMLDPYFRTITGFQSLI
				-	QKEWVMAGYQFLDRCNHL
	-			A A G G G G G G G G G G G G G G G G G G	KRSEKESPLFLLFLDATWQ
					LLEQYPAAFEFSETYLAVLY
					DSTRISLFGTFLFNSPHQRV
				()	KOSTVSRIKSCTKODYFPS
					***************************************
Shinella	9	prev67339	157	358	EEEETELPIVPVPIEPSP
ipaH9.8	•			AGACCCTTGCAGTAGTGAACTGGATGCCATGATGC1GGG	MPDPCSSELDAMMEGENG   KTVAEKGDV/WT/VSDSGP
_					
	-			GGGCCCCTTGTTCCGAGTGTCTGCCC111GGGAGGGGC	GFLFRVSALWEGEFGINEDA AVXSBBTOWIHEEKGDKV
				1	
					EPNLDAALYWPLNGKVFLF
					KGSGYWQWDELARTDFSS
					YPKPIKGLFTGVPNQP
			_		
100	9	Drov67337	158	359	APLTFQEVQAGAADIRLSF
Snigella	0	pieyo/ 55/	3		HGRQSSYCSNTFDGPGRV
pans.o				()	LAHADIPELGSVHFDEDEF
					WTEGTYRGVNLRIIAAHEV
<del>,</del>				CATCATTGCAGCCCATGAGGGGCCATGCTCTGGGGCTTGGGCACTCCCG	GHALGLGHSRYSQALMAP
				ATTENDA OF COLOR AND A STATE OF COLOR AND A STATE OF A	VYEGYRPHFKLHPDDVAGI
				TAAACTGCACCCAGATGTGGCAGGGATCCAGGCTCTCTATGGCAAGAA	QALYGKKSPVIRDEEEEET
				AACOLOGICAL TATA A GAGA A GAA A GA	ELPTVPPVPTEPSPMPDPC
				GCCCCCAGTGCCCAGAGCCCAGTCCCATGCCAGACCCTTGCAGTAGTGA	SSELDAMMLGEAPPLQAV
				ACTEGATECCATGATGCTGGGTGAGGCCCCTCCCCTCCAGGCTGTTGGCAG	GRRWGQPADPEAWTNGS
				ACCEPTEGGGGCAGCCTGCTGATCCTGAGGCCTGGACAAATGGGAGTGACA	DMGLQHEQWRAPWEDLC
				TEGEACTICAGCATGAGCAATGGAGGCCCCGTGGGAAGACCTATGCTTTC	FAGGLCVDCIRFRTGPLVP
				A A G G G G G G T G T G T G T G T G T G	SVCPLGGAPRKPGCCCLLA
				CGAGTGTCTGCCCTTTGGGAGGGCTCCCCGGAAACCTGGATGCTGCTGTC	SNTMDSLL*
	_			TACTCGCCTCGAACACAATGGATTCACTTCTTAA	
Shigella	9_	prey67746	159		MEKYSIMKSMNMHRKKGK RTILEMTQILKRHGYCTLGE
lpang.o					AFNRLDFSSAIQDIRT FNYV

			CTTCATT ATT A CTTC COTTC A CA A CA A TTA CTTC A A CA TTA TA CA T CA A CA A TTA CTT CA A CA A TTA CA TA CA A CA	KNYFNILDKIVQKVLDDHHN
_			GITCANAGETTCTTGATGACCACACATCCTCGCTTAATCAAAGATCTTCT GTTCAAAAGGTTCTTGATGACCACCACAATCTTAGAGGAGTAGGGAAGTCT GCAAGACCTAAGCTCTACCTCTGCATTCTTATTAGAGGAGTAGGGAAGTCT	PRLIKDLLQDLSSTLCILIRG VGKSVLVGNINIWICRLETIL
			GTATTAGTGGGAAACATCAATATTTGGATTTGCCGATTAGAAACTATTCTCGC	AWQQQLQDLQMTKQVNN GLTLSDLPLHMLNNILYRFS
			CTGGCAACAACAGCTACAGGATCTTCAGATGAACAACATCCTATACGGGT	DGWDIITLGQVTPTLYMLSE
			TCTCAGACGGATGGGACATCATCACCTTAGGCCAGGTGACCCCCACG11G1 ATATGCTTAGTGAAGACAGACAGCTGTGGAAGAAGCTTTGTCAGTACCATTTT	CRHLILSEKGHIEWKLMYFA
			GCTGAAAAGCAGTTTTGTAGACATTTGATCCTTTCAGAAAAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG	LQKHYPAKEQYGD1LHFCH HCSILFWKDSGHPCTAADP
			TACGGAGACACACTGCATTTCTGTCGGCACTGCATTTTTTTT	DSCFTPVSPQHFIDLFKF*
			ACTCAGGACACCCCTGCACGGCGGCCGACCCTGACAGCTGCTTCACGCCTG	
1	prey54430	160	GCTGTCCAAAACCAACAGGACCCTCTTTATATTTGGTGTCACAAAGTATATTG 361	LSKTNRTLFIFGVTKYIAGP VFCFIRNPVSASRSDPVTL
			CAGGACCO	NLLHGPDLPSIYPSFTYYRS
			TTCATTCACCTATTACCGTTCAGGAGAAAACCTCTACTTGTCCTGCTTCGCCG	GENLYLSCFAESNPRAGYS
			AGTCTAACCCACGGGCACAATATTCCCCGAAATAACTACAAAGGAAGTTTCAGCTC	TKHSGLYACSVRNSATGKE
			TATECTTECTTECTTECTAACTCAGCCACTGGCAAGGAAAGCTCCAAATCCA	SSKSITVKVSDWILP*
- 1		3	CACAGE CAAAGE OF GEAUTING AND THE CONTRACT TAAAACT TGAAGTACTG 362	KKFKYIENLEKCVKLEVLNL
	prey67749	191		SYNLIGKIEKLDKLLKLRELN
			ATTACGTGAACTCAACTTATCATATAACAAAATCAGCAAAATTGAAGGCATAG	LSYNKISKIEGIENWCNLOK I NI AGNEJEHIPVWI GKKI K
			AAAATATGTGTAATCTGCAAAAGCTTAACCTTGCAGAAATGAAATTGATAGGGAAGAAGTTAAAATCTTTGCGAGTCCTCA	SLRVL
Ì	prey67751	162	GGAGGCAGAGACACACTGTCTCTTAAAAAAAGGAAAAAACTCGACAAG 363	GGRARHCLLKKGKKTRQE
	•		AATCCTAGTGGGAGAGGCAGGACCATCCTGTGATGGGTCAAI AATGACCCA	AO*CRKRGCECQEGQFRT
			GICAIGGAGCACAGGGCAAGGAAGCAGGCCTGTGAGAACGGGCCCTCTG	TWOGKQACENGPSEPELR
			AGCGGGAACTGAGGGAGGAGTTGAGCCTGGGGGCTCTCTGGGGGGTGCAGTG	EELSLGLSGGAVFXVG
	prev8739	163	GGCTGAGCCACCCGTCCCCTCTGCCACTGGCCTCATCCCCTGAATC 364	AEPPVPSPLPLASSPESAR
			AGCCCGACCCAAGCCCCGTGCCCGGCCCCTGAAGAAGGTGAAGATACCC	KKWKGVBWKBLBLLLTIOK
			G I CC I CG C C I CAAGAAA I GGAAAGGGCAG GCAC I GCAAGGGGAAA I TACTAACCATGAACGGGAAA I TACTAACCATGAAGGGCAGTGGACGGCAGGAGGGAAAAAAAA	GSGRQEDEREVAEFMEQL
			GTGGCAGAGTTTATGGAGCAGCTTGGCACAGCCTTGCGACCTGACAAGGTA	GTALRPDKVPRDMRRCCF

					WYHI NOA! WSTEVY
				ACTGATGGGCCTGCCCGTCTGCTGAACCTGGACCTGGACCTGTGACCTGTGACGGGGGGGG	ET GGGALMNVEVALHRGLL
			-		TKCSLCQRTGATSSCNRM
					RCPNVYHFGCAIRAKCMFF
					KDKTMLCPMHKIKGPCEGE
				ACAAGACCATGCTGTGTCCAATGCATAAGATCAAGGGGCCCTGTGAGCAAG	LSSFAVERR
					SDMMI NIINSSITTKAISBW
Shigella	9	prey18232	164	3	SSI ACNIAI DAVKMVOEFE
ipaH9.8				CTTTGGCTTGCAACATIGCCCTGGATGCTGTCAAGATGGT	NG BKEIDIKKYABVEKIPGG
				ACAGTTTGAGGAGAATGGTCGGAAAGAGAIIGACAIAAAAAAAIA	
				GTGGAAAAGATACCTGGAGGCATCATTGAAGACTCCTGTGTCTTGCGTGGAG	IEDSCVLFGVININKDV I DP
				TCATGATTAACAAGGATGTGACCCATCCACGTATGCGGCGCTATATCAAGAA	KMKKYIKNPKIVLLUSSLEY
				CCCTCGCATTGTGCTGCTGGATTCTTCTCTGGAATACAAGAAAGGAGGAAGC	KKGGSQ1DIEITREEDF1RI
				CAGACTGACATTGAGATTACACGAGAGGAGCTTCACCCGAATTCTCCAGA	LOMEEEYIQOLCEDIIQLKP
_				TEGAGGAAGAGTACATCCAGCAGCTCTGTGAGGACATTATCCAACTGAAGCC	DVVII EKGISDLAQHYLMKA
				COATGEGETCATCACTGAAAAGGGCATCTCAGATTTAGCTCAGCACTACCTT	NITAIRRVRKTDNNRIARAC
••				ATT TO THE TOTAL AND THE TOTAL	GARIVSRPEELREDDVGTG
				A I GOOD AND TO THE TOTAL OF TH	AGLLEIKKIGDEYFTFITDCK
				CGCATI GCT AGAGACT GT GGCGCCCCCCCCCCCCCCCCCCCC	DPK
				AGAGAAGA   GA   GI   GGAACAGGAGCAGCAGCC   GGAAAAA   CAAAAAA   CAAAAAAAAAA	
				GAGATGAATACITITATO ATTACATTA ACTUTO ACATE A AGA AGA TOC 366	MDDKFI IEYFKSOMKEDPD
Shigella	9	prey66739	165	`	MASAVAAIBTI I FEI KBDKG
ipaH9.8	_			TGACATGGCC   CAGCAG   GGC   GCCALCCAGGACG   CGCACACGGACGG   CGCACACGGACGG   CGCACACGGACGG   CGCACACGGACGG   CGCACACGGACGGACGG   CGCACACGGACGACGGACGGACGGACGACGACGACGACGA	VECTION TSAIFT OF V
! ! !				GAGAGATAAAGGGGAGACAATCCAGGGTCTGAGGGCGAATCTCACCAGTGC	
				CATAGAAACCCTGTGTGGTGTGGACTCCTCTGTGGCAGTGTCCTCTGGGCGG	USSVAVSSGGELFLRFISLA
			_	GGAGCTCTTCCTCCGCTTCATCAGTCTTGCCTCCCTGGAATACTCCGATTAC	SLEYSDYSKCKKIMIERGEL
		_		TCCAAATGTAAAAAGATCATGATTGAGCGGGGAAACTTTTTCTCAGGAAA	FLRRISLSRNKIADLCHIFIK
				TATCACTETCAAGAAACAAAATTGCAGATCTGTGCCATACTTTCATCAAAGAT	DGATILTHAYSRVVLRVLEA
				GEAGGGACAATATTGACTCAGGCCTACTCCAGAGTGGTCCTGAGAGTCCTG	AVAAKKRFSVYVTESQPDL
-	_			GAAGCAGCCGTGGCGGCCAAGAAGCGATTTAGTGTATACGTCACAGAGTCA	SGKKMAKALCHLNVPVTVV
				CAGCCTGATTTGTCAGGTAAGAAATGGCCAAAGCCCTCTGCCACCTCAACG	LDAAVGYIMEKADLVIVGAE
				TCCTGTCACTGTGGTGCTAGATGCTGCTGTCGGCTACATCATGGAGAAAGC	GVVENGGIINKIGTNQMAV
				AGATOTTGTCATAGTTGGTGCTGAAGGAGTTGTTGAAAACGGAGGAATTATT	CAKAQNKPFYVVAESFKFV
				AACAAGATTGGAACCAACCAGATGGCTGTGTGCCAAAGCACAGAACAAAC	RLFPLNQQDVPDKFKYKAD
-				CTTTCTATGTGGTTGCAGAAAGTTTCAAGTTTGTCCGGCTCTTTCCACTAAAC	TLKVAQTGQDLKEEHPWV
				CAGCAAGACGTCCCAGATAAGTTTAAGTATAAGGCAGACACTCTCAAGGTCG	DYTAPSLITLLFTDL
				CGCAGACTGGACAAGACCTCAAAGAGGAGCATCCGTGGGTCGACTACACTG	
				_	
Shigella	9	prey67769	166	GCAGCCTTCAA	AAFKVATPYSLYVCPEGQN VTI TCRLLGPVDKGHDVTF
ipaH9.8			_	CAGAACGTCACCCTCACCIGCAGGCICIIGGGCCCIGIGGACAAAGGGCAC	

			(AA   (AI (AA) (A   ACAAGACGI GGI ACCGCAGCI CCAGGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCA	
			ACCTGCTCAGAGCGCCGGCCCATCCGCAACCTCACGTTCCAGGACCTTCAC	RPIRNLTFQDLHLHHGGHQ AANTSHDLAQRHGLESASD
			CTGCACCATGGAGGCCACCAGGCTGCCAACACCAGCCACGACCTGCACCTCACCCTGGAGTCGGCCTCCGACCACGACCATGGCAACTTCTCCATCACC	HHGNFSITMRNLTLLDSGL
			ATGCGCAACCTGACCCTGCTGGATAGCGGCCTCTACTGCTGCTGGTGGTG	YCCLVVEIRHHHSEHRVHG
			GAGATCAGGCACCACCACTCGGAGCACAGGGTCCATGGTGCCATGGAGCTG	AMELQVQTGKDAPSNCVV
			CAGGTGCAGACAGGCAAAGATGCACCATCCAACTGTGTGTG	YPSSSQDSENII AAALA I G
•			TCCTCCCAGGATAGTGAAAACATCACGGCTGCAGCCCTGGCTACGGG1GCC	ACIVGILOLPLILLLY TRUPA
			TGCATCGTAGGAATCCTCTGCCTCCCCTCATCCTGCTCCTGGTCTACAAGC	AAS
	prov12613	167	CCTTGGAGCTGGTCCTTTCAGCCATATGATAAAATTAAAAACTAAGCCTCTCC 368	LGAGPFSHMIKLKTKPLPP
Snigelia o	pieyiooid	2	CTCCTGATCCACCTCGTCTGGAATGTGTTGCCTTTAGCCACCAGAACCTTAA	DPPRLECVAFSHQNLKLKW
0			GCTGAAATGGGGAGAAGGAACTCCAAAGACATTGTCAACCGATTCTATTCAG	GEGTPKTLSTDSIQYHLQM
			TACCACCTTCAGATGGAGGATAAGAATGGACGGTTTGTATCCCTATACAGAG	EDKNGRFVSLYRGFCHIY
			GACCATGTCATACATACAAAGTACAAAGACTTAATGAGTCAACATCCTATAAA	KVORLNESI SYRFCIQACIN
			TTCTGTATTCAAGCTTGTAATGAAGCTGGGGAAGGTCCCCTCTCCCAAGAAT	EAGEGPLSQEYIF11PKSV
······································			ATATTTTCACTACTCCAAAATCTGTCCCAGCTGCCTTGAAAGCCCCCAAAATA	PAALKAPKIEKVNUHICEII
			GAGAAAGTAAATGATCACATTTGTGAAATTACATGGGAGTGTTTACAGCCAAT	WECLGPMKGUPVIYSLUV
			GAAAGGTGATCCAGTTATTTACAGTCTTCAAGTTATGTTGGGAAAAGATTCAG	MLGKDSEFKQIYKGPDSSF
			AATTCAAACAGATTTACAAGGGTCCCGACTCTTCCTTCCGGTATTCCAGCCTT	RYSSLOLNCEYHFHVCAIR
			+	ATO IA ATOM LIAT ION IOA
Shinella	prev3337	168	GGCTCGGCTGAAGGACCTGGAGGCTCTGCTGAACTCCAAGGAGGCCGCAC	ARLKDLEALLINGNEAALS I A
			TGAGCACTGCTCTCAGTGAGAAGCGCACGCTGGAGGGCGAGCTGCATGATC	LSEKKI LEGELHULKGQVA
·			TGCGGGGCCAGGTGGCCAAGCTTGAGGCAGCCCTAGGTGAGGCCCAAGAAG	RLEAALGEARROLODEMEN
			CAACTTCAGGATGAGATGCTGCGGCGGGTGGATGCTGAGAACAGGCTGCAG	KVDAEIVRCA I WREELUFA
<del></del> .			ACCATGAAGGAGGAACTGGACTTCCAGAAGAACATCTACAGTGAGGAGCTG	KNIYSEELKEIKKKHEIKLV
			CGTGAGACCAAGCGCCGTCATGAGACCCGACTGGTGGAGATTGACAATGGG	EIDINGRÜREFESRLADALU
_			AAGCAGCGTGAGTTTGAGAGCCGGCTGGCGGATGCGCTGCAGGAACTGCG	ELRACHEDOVEO I RNELEN
			GGCCCAGCATGAGGACCAGGTGGAGCAGTATAAGAAGGAGGAGCTGGAAGA	YSAKLDINARGSAERINSINL
			CTTATTCTGCCAAGCTGGACAATGCCAGGCAGTCTGCTGAGAGGAACAGCA	VGAAHEELQQSAINIUSLSA
			ACCTGGTGGGGGCTGCCCACGAGGAGCTGCAGCAGTCGCGCATCCGCATC	CLSCLCACCAARCARCACTOC
			GACAGCCTCTCTGCCCAGCTCAGCCAGCTCCAGAAGCAGCTGACCAGCAGAGACAGC	REMAEMBARMOQQLDEY
			GAGGCGAAGCII CGAGAGACCI GGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG	QELLDIKLALDMEIHAYRKL
			CAGCCGGCGGC GC GGCGCGCGCGCGCGCGCGCGCCGCCGC	LEGEEERLRLSPSPTSQRS
			GCAAGGATGCACCACCACGCCTACCGCAAGCTCTTGGAGGCGAG	RGRASSHSSQTQGGGSVT
			GAGGAGGCTACGCCTGTCCCCCAGCCCTACCTCGCAGCGCAGCGTGG	KKRKLESTESRSSFSQHAR
			CCGTGCTTCCTCTCACTCATCCCAGACACAGGGTGGGGGGCAGCGTCACCAA	TSGRVAVEEVDEEGKFVRL
			A A A A A A A A A A A A A A A A A A A	RNASNEDOSMGNWOIKHO

					NGDDPLLTYRFPPKFTLKA
				TTGTCCGGCTGCGCAACAAGTCCAATGAGGACCAGTCCAIGGGCAAIIGGC	DLVWKAQNTWGCGNSLRT
					ALINSTGEEVAMPKLVRSV
					TVVEDDEDEDGDDLLHHH
				CCTGGGGCTGCGGGAACAGCTGCGTACGGCTCTCATCAACTCCACTGGGTGACG	
				ACCAGAGGATGAGATGACCTGCTCCATCACCACCATGTGGTA	
				010	CONSTRUCTION OF THE CONTROL OF THE C
Shigella	9	prey67774	169	CCCACCTCCTGGCCGGTCCTTGAAGTTTTCTGGGGICIAIGGGCCAAIAAIU 370	RPSTNELPLFDFPVKEVFEL
ipaH9.8					LGVENVFQLFTCALLEFQIL
				4	LYSQHYQRLMTVAETITAL
				CTGTGGGGGAGACGATTACAGCTCTCCATGTTTCCTTTCCAGTGGCAGCATGT	MFPFQWQHVYVPILPASLL
	_			CTATGTCCCTATTCTCCCAGCTTCTCTCTCCTGCATTTCTTAGATGCTCCTGTTC	HFLUAPVPYLMGLHSNGLD
				CATACCTGATGGGTTTGCATTCCAATGGCCTGGATGACCGGTCAAAGCTGGA	DRSKLELPGEANLCFVDID
				GCTGCCTCAAGAGGCTAACCTCTGCTTTGTGGACATTGACAACCACTTCATT	
				GAGTTGCCAGAGGACTTGCCACAGTTCCCCAACAAATTGGAGTTTGTCCAGG	QEVSEILMAFGIPPEGINLHO
				AAGTCTCTGAGATTCTCATGGCATTTGGAATTCCCCCTGAAGGGAATCTTCAT	SESASKLKALKASELVSDK
				TGCAGTGAGAGTGCCTCCAAGCTGAAGAGGCTGCGGGCCTCTGAGCTTGTC	RNGNIAGSPLHSYELLKEN
				TCGGACAAGAGGAATGGGAACATTGCTGGCTCCCCTTTGCATTCCTACGAGC	ETIARLOALVKRI GVSLEKL
				TTCTTAAGGAGAATGAAACTATTGCCCGGCTGCAAGCCTTGGTCAAGAAAC	EVREDPSSNKDLKVQCDE
				TGGGGTGAGCCTGGAAAAGTTGGAAGTGCGTGAAGACCCCAGCAGCAATAA	EELRIYOLNIQIREVFANKFI
				GGATCTCAAAGTTCAGTGTGATGAAGAAGAACTCAGGATTTACCAGCTAAAC	QMFADYEVFVIQPSQUKES
				ATTCAGATCCGGGAAGTTTTTGCAAATCGTTTCACTCAGATGTTTGCAGATTA	WFTNREQMONFDKASFLS
	_			TGAGGTGTTTGTCATCCAACCCAGGCAGGATAAGGAATCCTGGTTTACCAAC	DOPEPYLPFLSRFLETOMF
				AGGGAGCAAATGCAAAACTTTGATAAAGCATCTTTCTGTCAGATCAGCCTGA	ASFIDNKIMCHDDDDKDPV
				GCCCTACCTGCCCTTCCTCAAGATTCCTGGAGACCCAGATGTTTGCATCT	LRVFDSRVDKIRLLNVRTPI
				TTCATTGACAACAAAATAATGTGTCATGATGATGATGATAAAGACCCTGTACT	LRTSMYQKC11VDEAEKAI
				CCGGGTATTTGATTCCCGAGTTGACAAGATCAGGCTGTTGAATGTTCGGACA	ELRLAKIDHTAIHPHLLUMKI
				CCTACTCTCCGTACATCCATGTACCAGAAGTGTACCACTGTGGATGAAGCAG	GOGKYEPGFFPKLUSDVLS
				AGAAAGCAATTGAGCTGCGTCTGGCAAAAATTGACCATACTGCAATTCACCC	TGPASNKWTKRNAPACWH
				ACATTTACTTGACATGAAGATTGGACAAGGGAAATATGAGCCGGGCTTCTTC	RKDRQKQH I EHLHLDNDQ
				CCTAAGCTGCAGTCTGATGTACTTTCCACTGGCCCAGCCAG	REKYIQEAH I MGS I I HQ
- 11				CGAAAAGGAATGCCCCTGCCCAGTGGAGGCGGAAAGATCGGCAGAAGCAG	
				CACACAGAACACCTGCGTTTAGATAATGACCAGAGGGAGAAGIACAICCAGG	
				- 1	WDSTKISKAYYKAMVISTW
Shigella ina Ho 8	9	prey67776	170	TGGGATTCAACTAAAATTAGCAAAGCATTACAAAGCAATGAATTACACGTTTTGGTGTTACTGGCTAAGAAAAAAAGAGGCACTTGATGCATGAAAAAAAA	CYWLRKRHLMHETDSRVP
19al 13.0					

26				TTATTATTTGATACAAGTGCCATTTCAAATCAGCAAGGGAA	VSLLFDTSAISNQQGNWAN LLSILKTYXV*XLXDNVLXN
177 GCTCAGCTGCTGGAGTGCCTCCCAGCCAGCCAGCCAGGGGGGGG				NAAATGGGTGGAGGTGGATNGGNCATGTGGGTGTNANG	VEVDXXCGCXAVXA
GTTGCTGAGGGCAATGATGAAGAAGGACGAGGT GAAAA LAGI ISUCAAAA GATGGAAAACAATGAAGAAGAAAAATA GATGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAG			171	GGAGTCCACGGTGCCTCCCAGCCTCCACCTGTGGG 372 CCACATGAGCCTGCTTGAGATGAGGCGGAGCGTGGCGGA GCTCCAGCAGATGCGGCAGCTCCAGCTGCAGGA	LSALESTVPPSQPPPVG1S AIHMSLLEMRRSVAELRLQ LQQMRQLQLQNQELLRAM
AGIT GEORGA GEOR					EDPVQRQRVLVEQERQKY LHEEEKIVKKLCELEDFVED
TCGAAACAGGGGCCACCATGGCATAGAAGTGGAGGCCGTGCGGTT TCGAAGGAGGAGCCACCAGCTGGCGATGTCCTGAAGGGCCGTGCGGT TCTGAAGGAGGAGCCACCAGCTGGCGAGCATGTCACTGATGGGCTCCT CATGACGGAGCCACCACAGCTGCTGCGAGAGTGTCACTGATGGGCTCCT GAAGGCCGCAGAGCTCTGAAGAGTCAGGAGAAAAGGCCCCCCCC					LKKDSTAASRLVTLKDVED GAFLLRQVGEAVATLKGEF PTLQNKMRAILRIEVEAVRF
CATGACAGACGTCCTGACCATGCTGCGAGACATGTCACTGATGGGCTCCTCCG GAAAGGCACGGACGCCCACCTGCGACCCGACACCTCCG GAAAGGCACGGACGCCCACGCTCCGAGCCGCCACCTCCG GCAGCCCTTCCACGAGCTCCCAGGAGGCGCCCACCTCCG GCCAGCCCTTCCACGCAGGTCCCCAGGAGTTCCGAAGTTG GCCTTTGTCCCGACAGTTCCCCAGGCCCTGCTGAAGTTGC ATCCAGCCCTTCCAGCAGCCCTC ATCCAGCCCTTCCAGCAGCCCTC ATCCAGCCCTTCGAGCACTCCGTGGCCCTGCTGAAGACTTG CCTGAGGCCCTTGCAGTTGGGTGGGTGCCTTTCCCAGTGCTCTTG  CCTGAGCCCTTGAACACTCGAGCACCAGCAGCCTTTCCAATGAAGAAAA  172 CCTGAGGACCACACACACAGCAGCCTTTCCAATGAAGAAAA  CCCGTGCCCTGAACACCAGACACCAGCAGCACTTTCCAATGAAAAAA  CCCGTGCCCTGCAGCACCAGCACACGGGGCTTCCAATGAAAAAA  CAAGCCCCTGCAGCACCTGACACACGGGCTTCCAACTCAGCAAAAA  CAAGCCCCTGCAGCACCTGACACACAGCACCACACACGCAGC  GAAGCCCCTGCAGCACCTTTAAGTACTTTAAGTACTTCAACACATTGGCTCTTC  TGATGCTAAGGATCATGCTGAAAACCATGATTTGGAAGTTTTGC TTTGCCTGTGGAAAAATGCAAAACCATGATTTGGACTTTTGG TTTGCCTGTGGAAAAATGCAAAACCATGATTTGGACTTTTGG TTTGCCTGTGGGAAAAATGCAAAACCATGATTTTGC TTTGCCTGTGGGAAAAATGCAAAACCATGATTTTGC TTTGCCTGTGGGTGGTAAAAAAAACCATGATTTGGACTTTTTTGC TTTGCCTGTGGGTGGTTAAAAAAAAAA				GCGAGCCATCCTGCGCATAGAAGTGGAGGCCGTGCGGTT AGCCACACAGAGGGGCATGGAGGCGTGTGCGCAG	LKEEPHKLDSLLKRVRSMT DVLTMLRRHVTDGLLKGTD
CONTROLLE CONTRO				rcctgaccatgctgcggagaCatgtcactgatgggCTCCT	AAQAAQYMAMEKATAAEV LKSQEEAAHTSGQPFHSTG
GTGCCTTTGTCGGCATGATGGTTCGCCACGCGCAGACCTCGTGGTC ATCCAGCCCTCCCAGCCGTCGTGGCCTGCTGAACCTTGGTCCAGCCTCCCAGCCTTGGCCTCCCAGCCTCCAGCCTCCAGCCTTGGCCTCCCAGCCTTGGCCTCCCAGCCTTGGCCTCCCAGCCTTGTCCCCAGTGCTCTGTCCCCAGTGCTCTGTTGCCCAGTGCTCTGTTTGCCCAGTGCTCTGTTTGCCCAGTGCTCTGTTTTGCCCAGTGCTCTTTTGCCCAGTGCTCTTCCCCAGTGCTCTTTTGCCCTGGCCTTTGCCCAGTGCTCTTCCCCAGTGCTCTTCCCCAGTGCTCTTCCCCAGTGCTCTTCCCCAGTGCTCTTCCCCAGTGCTCTTCCCCAGTGCTCTTCCCCAGTGCTCTTCCCCAGTGCTCTTCCCCAGTGCTCTTCCCAGTGCTCTTCCCAGTGCTCTTCCCAGTGCTCTTCCCAGTGCTTTTTGCCTTTTGCCTTTTTGCTTTTGCTTTTTGCTTTTTGCTTTTTT					APGDAKSEVVPLSGMMVR HAQSSPVVIQPSQHSVALL
CCTCACGTGGCCAGCTCCCCAGCGTC  CCTGAGGACCAACCACTTGGGTGGGTGCAGGAGTTCCTCAATGAAGAGAA  172 CCTGAGGACCAACCACTTGGGTGGTGCTGCTTTGCCCAGTGCTCTGT  CCGTGCCCTGGAGCACCAGACAGGGGCTTTGCCCAGTGCTCTGT  CAAGCCCCTGGAGCACAGACAGGGGCTTCCAACTCAGAAAA  CAAGCCCCTGGAGCACAGACAGACAGGGCTTCCAACTCAGAAAA  CAAGCCCCTGGAGCACCTGACACAGACCTCAGCACTCCACCTCCTC  CGTGCCCAAAAGCCGCACTTTAGTACTTTAAGTACTCAGAAATCTCAGCACTTTGGACTCTTC  173 GACTAAGGATCACATTACTTTAAGTACTCGCAAATTTGGAAGTTTTGC  TGAAGATCGGAAAGGTGGATGGTGAAACCCAGGTTATTGGACTTTTGC  TTGCCTGTGGAAAGGTGGATGGTGAAAACCCGAGTTATTGGACTTTTGC  TTGCCTGTGGAGGGCACTGAAAACCCGAGTAAATTTTGGAACCTTTTGTAG  ATGCAATCGGGTGGTACATAGAAAATTCCAAAACCTCTGGAACCTTTTTTTGC  GAATTGATGTTAGTACCAAAAAAAAAA					PAGNLPHVASSPAV
172 CCTGAGGACCAGACACAGGAGCTTTGCCCAGTGCTGTGTCTGTC	- 1		!	373	LRTNHIGWVQEFLNEENRG
CAGCCCCTGGAGCAGTCTGTGGAAGACCTCAGCAAGGGTCCACCCTCCTC CAAGCCCCTGGAGCAGTCTGTGACCATCAAGCTGACCCCCACAGCAG GAAGGCCCTGCGG  173 GACTAAGGATCACCATTACTTTAAGTACTGCAAAATCTCAGCATTGGCTCTTC TGAAGATCACCATTACTTTAAGTACTGCAAAATCTCAGCATTGGCTCTTC TGATGCTAGGAAAGGTGGATGGTGAAACCATGATTATGGACAGTTTTGC TTTGCCTGTGGAGGCACTGAAACCGAGTAAATGCTCAGGCTGCTGCAAA GAATACATGGCTGCATACATAGAAAATGCAAAACAGGTTGGCTTTCTGG ATGCAATCGGGTGGTACCATAGAAAATGCAAAACAGGTTGGCTTTTGTAG GATTGATGTTAGTACCAAAAAAATAGCCTCTGAGGAAACTTTTGTAGGCTTTTGTAGGACCATTTTTGTAGGACCTTTTTTTT		prey67781	1/2		LDVLLEYLAFAQCSVTYDM ESTDNGASNSEKNKPLEQS
GAAGGCCCTGCGG  173 GACTAAGGATCACCATTACTTTAAGTACTGCAAAATCTCAGCATTGGCTCTTC TGAAGATGGTGATGCATGCAGATCGGGAGGCAATTTGGAAGTGGTC TGAAGATGGTGAAAGCCAGATCGGGAGGCAATTTGGAAGTTTTGC TGATGCTAGGAAAGGTGGTGAAACCATGATCATTATGGACAGTTTTGC TTTGCCTGTGGAGGGCACTGAAACCCAGGAAATTGCTCAGGCTGCTATAT GAATACATGGCTGCATACATAGAAAATGCTCAGGCTGCTTTGTAG ATGCAATCATGGTGTACTAGAAAATGCTCAGGAACCATTTGTAG GATTGATGTTAGTACTCAAAAATAGCAAAATTTTGGAAAATTGTTGG CGCCTTTAGGACATACCCAAAGGGCTACAAAATTTTTTTGGTGTACCAGAATTTCAAAAATTTTTTTT					EDLSKGPPSSVPKSHHLII LTPAHSRKALR
173 GACTAAGGATCACCATTACTTTAAGTACTGCAAAATCTCAGCALIGGCICIIC 3/4  TGAAGATGGTGATGCCAGATCGGGAGGCAATTTGGAAGTGATGGTC TGAAGATGGTGAAAGGTGGATGGTGAAACCATGATCATTATGGACAGTTTTGC TTGCCTGTGGAGGGCACTGAAACCCGAGTAAATGCTCAGGCTGCTGCATAT GAATACATGGCTGCATACATAGAAAATGCAAAACAGGTTGGCCTTTGTAG ATGCAATCGGGTGGTACATAGCACCCTGGCTATGGCTGCTTTGTAG GATTGATGTTAGTACCTAGAACAATTCCGCAGGGAAAGTGATTGTAG CAGTGGTGATTGATCCAACAAGGGCTACAAAATTGTGG CAGTGGTATCCAAAAATAGAAATAGAAATTTTTTGTAAAAATAGAAATTTTTT				01.7	ZELILYEKYOKISALALI KM
(5 (5		prey2109	173	3/4	VMHARSGGNLEVMGLMLG
					KVDGE I MIIINDSFALF VEG I ETRVNAQAAAYEYMAAYIE
					NAKQVGRLENAIGWYHSH PGYGCWI SGIDVSTOMLN
					QQFQEPFVAVVIDPTRTISA
					GKVNLGAFKI YFKG YRFED EGPSEYQTIPLNKIEDFGVH
					CKQYYALEVSYFKSSLDHK LLELLWNKYWVNTLSSSSL

				TGGAATAAATACTGGGTGAATACGTTGAGTTCTTCTAGCT	LTN
Shigella ipaH9.8	ω	prey4060	174	375 375 376 376 376 376	ANHFFKKDYSKVQHLALH AFHNTEVEAMQAESCYQL ARSFHVQEDYDQAFQYYY QATQFASSFVLPFFGLGQ MYIYRGDKENASQCFEKVL KAYPNNYETMKILGSLYAA SEDQEKRDIAKGHLKKVTE QYPDDVEAWIELAQILEQT DIQGALSAYGTATRILQEKV QADVPPEILNNVGALHFRL GNLGEAKKYFLASLDRAKA EAEHDEHYYNAISVTTSYN LARLYEAMCEFHEAEKLYK NILREHPNYVDCYLRLGAM ARDKGNFYEASDWFKEAL QINQDHPDAWSLIGNLHLA KQEWGPGQKKFERILKQP STQSDTYSMLAGNVWLQ TLHQPTRDREKEKRHQDR ALAIYKQVLRNDAKNLYAA NGIGAVLAHKGYFREARDV FAQVREATADISDVWLNLA HIYVEQKQYISAVQMYENC LRKFYK
Shigella ipaH9.8	<u>ه</u>	prey49284	175	0	INTERWKKPDIPRPIKINLLFPI IYLEWAFILVFSLWSEPVV GGIGLAIMLTGVPVYFLGVY WQHKPKCFSDFIELLTLVS QKMCVVYYPEVERGSGTE EANEDMEEQQQPMYQPTP TKDKDVAGQPQP*
Shigella ipaH9.8	9	prey67686	176	TTCTCAGCACCAT 377 TTTGTTGAAAATG	LGLQA*ATAPG*VFSAPFIE* TVLSLVYVIAFVENEFTIDV*I

YFWVLYPVLLVYMSVFMLV PCCFGYYGSVV*SEVR*CD SSXFVLSAX FTQEDIDRAIAYLFPSGLFE KRARPVMKHPEQIFPRQRA IQWGEDGRPFHYLFYTGK QSYYSLMITSFTSRSHRTE NS*	MEMRLPVARKPLSERLGR DTKKHLVVPGDTITTDTGF MRGHGTYMGEEKLIASVA GSVERVNKLICVKALKTRYI GEVGDIVVGRITERRRSAE DELAMRGFLQEGDLISAEV QAVFSDGAVSLHTRSLKYG KLGQGVLVQVSPSLVKRQK THFHDLPCGASVILGNNGFI WIYPTPEHKEEEAGGFIANL EPVSLADREVISRLRNCIISL VTQRMMLYDTSILYCYEAS LPHQIKDILKPEIMEEIVMET RQRLLEQEG*	KDLNMNVNSFQRKFVNEV RRCESLERILRFLEDEMQN EIVVQLLEKSPLTPLPREMI TLETVLEKLEGELQEANQN QQALKQSFLELTELKYLLKK TQDFFETETNLADDFFTED TSGLLELKAVPAYMTGKLG FIAGVINRERMASFERLLW RICRGNYYLKFSEMDAPLE DPVTKEEIQKNIFIIFYQGEQ LRQKIKKICDGFRATVYPCP EPAVERREMLESVNVRLED LITVITQTESHRQRLLQEAA ANWHSWLIKVQKMKAVYHI
AGTTCACCATAGATGTGTAGATTTATTTCTGGGTTCTCTATCCTGTTCTGTTG GTCTATATGTCTGTTTTCATGCTGGTACCATGCTGTTTTGGTTACTACGGCTC TGTAGTATAATCTGAAGTCAGGTAATGTGATTCCTCCTCCANITTTGTTCTTTCTG CTNANG TTTCACTCAAGAAGATATTGACAGAGCTATTGCTTACCTTTTCCCAAGTGGTT TGTTTGAGAAACGAGCCAGTAATGAAAGAAGGAATTTTTCC AAGACAAAGAGCAACCAGGAGAATATCATTAATGATTACCATTTCACTTACCAGCTATCCC AAGACAACAGACGAACAGTAATCATTAATGATTACTTCCCAGCTTTACTTCCCAGCTTTACTTCCCAGCTTTACTTCCCAGCTTTACTTCCCAGCTTTACTTCCCAGCTTTACTTCCCAGCTTTACTTCCCAGCTTTACTTCCCAGCTTTACTTCCCAGCTTTACTTCCCAGCTTTACTTCATTACTTCCCAGCTTTACTTCCCAGCTTTACTTCCCAGCTTTACTTCCCAGCTTTACTTCCCAGCTTTACTTCCATTACTTCCATTACTTCCATACTCCATACTCATACTCCATACTATACTCATACTATACTCATACTCATACTCATACTATACTATACTATACTATACTATACTATACT	CGATCACAGGACAGGAGCTCGCAAGCCTCTTAGCGAGAGACTGGGC 379  ATGGAGATGAGACATCTAGTGGTGCTCGCAAGCCATCACTACGGAC CGCGACACTAAGAAACATCTAGTGGTGCCGGGGGGATACAATCACTACGGAC CGCGACACTAAGAACATCTAGTGGAACGTATATGGGAGAAGAAGAGCTCATT ACAGGATTCATGCGGGGCCATGGAAGAGAAGA	CAAAGATTTAAATATGAATGTGAACAGCTTTCAAAGGAAATTTGTGAATGAA
177	178	179
prey66872	prey67690	prey67695
Ø	Φ	φ
Shigella ipaH9.8	Shigella ipaH9.8	Shigella ipaH9.8

				TCACCGCCAGCGCCTGCAGGAAGCCGCTGCCAACTGGCACTCCTGGCT CATCAAGGTGCAGAAGATGAAAGCTGTCTACCACACTGGCATGTGCAAC ATCGACGTCACCAGCAGTGTTCATCGCCGAGATCTGGTTCCCGGTGGCA GATGCCACACGTATCAAGAGGCACTGGAGCAAGGCATGGAACTAAGAGGCCCCATCATGACCACGTGCCACCATCATGACCAGGACAAACAGGCCCTCCCA	LNMCNIDVTQQCVIAEIWFP VADATRIKRALEQGMELSG SSMAPIMTTVQSKTAPPTF NR
Shigella ipaH9.8	ဖ	prey67336	180	TGGGACTTCAGCATGAGCAATGGAGGGCCCCGTGGGAA  SAAGGGGGACTTTGGGAGTGTATCAGATTCAGGACCG CGAGTGTCTGCCCTTGTATCAGATTCAGGACCG TACTCGCCTCGAACCTG TACTCGCCTCGAACCTG TACTCGCCTCGAACCTG TACTCGCCTCGAACCTG TACTCGCCTCGAACCTG TTCAGCTAACTTGGCATTCACTTCAACAAC TTCAGCAGCTACCCAAACCAATCAGATTTACGG TTCAGCAGCTACCCAAACCAATCAGAATTTACGG AGCCTCGGCTGCTATGAGTTGGCAGTGGAATACCACTCGCAGGACTA TCCAGCACTACTGGCAATCACAGCAGTAGA CCAGAAATATTTCCCACAACCACCAGCATTCAAAACAACCACACAATCAAAACAAAC	MGVTWDFSMSNGGPRGK TYAFKGDYVWTVSDSGPG PLFRVSALWEGLPGNLDAA VYSPRTQWIHFFKGDKVW RYINFKMSPGFPKKLNRVE PNLDAALYWPLNQKVFLFK GSGYWQWDELARTDFSSY PKPIKGLFTGVPNQPSAAM SWQDGRVYFFKGKVYWRL NQQLRVEKGYPRNISHNW MHCRPRTIDTTPSGGNTTP SGTGITLDTTLSATETTFEY*
Shigella ipaH9.8	Φ	prey6299	181		HCENNDKAPESESEKPTPL STGGGNRAEEGPNASSGF MKTAVLGPTLKNVMMKNN KLAVSPNYNATFMGFKMM DGKQHIVLKLVPIKGNVCSP GSQSGAAKDGTANLQPQT LDTNGFLTGVTTELNDTVY MKAATPFSCSSILSGKAS SEKEMTLISQRNNMLQTMD YEKSVSSLSATSELVTASV NLTTKFETRDNVDFWGNHL TQSHPEVLGTTIKSPDKVN CVAKPNAYNSGDMHNYCI NYGNCELPVESSNQGSLPF HNYSKVNNSNKRRFFSGT AVYENPQRESSSSKTVVQ QPISESFLSLVRQESSKPD SLLASISLLNDKDGTLKAKS EIEEQYVLEKGQNIDGQNL

				YSNENQNLECATEKSKWE
<del></del>				DFSNVDSPMMPRITSVFSL
			TGGGAAGACTTTTCTAATGTCGATTCACCTATGATGCCTAG	QSQQASEFLPPEVNQLLQD
				VLKIKPUVKQDSSNI PNKG
			AATTGCTTCAGGATGTATTGAAAATAAAACCTGATGTAAAA	LPLHCDQSFQKHEREGKIV
			<u>()</u>	ESSKDFKVQGIFPVPPGSV
			CGAGAGAGAGGCAAAATTGTTGAATCTTCGAAAGATTTCA	GINVPTNDLNLKFGKEKQV
			TCTTCCCAGTTCCACCTGGCAGTGTGGGTATTAATGTGCC	SSIPQDVRDSEKMPRISGF
			,	GTLLKTQSDAIITQQLVKDK
				LRATTQNLGSFYMQSPLLN
				SEQKKTIIVQTSKGFLIPLNI
				TNKPGLPVIPGNALPLVNS
<u>.</u>			TTAAATTCAGAACAAAAAAAAACTATAATTGTTCAGACTTCAAAAGGATTCTTA	QGIPASLFVNKKPGMVLTL
			ATACCATTGAACATTACTAACAAGCCTGGGCTACCAGTTATTCCTGGAAATGC	NNGKLEGVSAVKTEGAPA
			ACTTCCATTGGTTAATTCACAAGGTATCCCTGCTTCTCTTTTTGTAAACAAGAA	RGTVTKEPCKTPILKVEPN
_			ACCTGGGATGGTTTTAACACTTAATAATGGGAAACTTGAAGGTGTTTCCGCT	NNCLTPGLCSSIGSCLSMK
			GTCAAAACCGAGGGTGCCCCAGCTCGTGGAACTGTGACTAAGGAGCCTTGC	SSSENTLPLKGPYILKPTSS
			AAAACACCTATTTTGAAGGTAGAACCAAACAATAATTGTCTTACACCTGGACT	VKAVLIPNMLSEQQSTKLNI
			TTGTTCCAGCATTGGCAGTTGTTTGAGCATGAAAAGTAGCTCAGAAAATACTT	SDSVKQQNEIFPKPPLYTFL
			TGCCATTAAAAGGCCCTTACATTTTGAAACCAACGAGTTCTGTGAAAGCTGTT	PDGKQAVFLKCVMPNKIEL
			CTTATTCCTAACATGCTATCTGAGCAACAGAGCACTAAGTTGAATATCTCCGA	LKPKLVQNSTYQNIQPKKP
			TTCAGTAAAACAGCAGAATGAGATTTTTCCAAAACCACCTCTTTATACCTTCTT	EGTPORILLKIFNPVLNVIA
	_		GCCTGATGGCAAACAAGCTGTTTTTTAAAGTGTGTGATGCCAAATAAAACTG	ANNLSVSNSASSLOKDNVP
			AGCTGCTTAAGCCCAAATTAGTCCAAAATAGTACTTATCAAAATATACAGCCA	SNOIIGGEOKEPESHDALP
			AAGAAACCTGAAGGAACACCACAAAGAATATTGCTGAAAATTTTTAACCCTGT	FLLDDLMPANEIVII STATC
			TTTAAATGTGACTGCTGCTAATAATCTGTCAGTAAGCAACTCTGCATCCTCAT	PESSEEPICVSDCSESHVL
			TGCAAAAAGACAACGTACCATCTAATCAGATTATAGGAGGAGAGAAGA	HOKING MINISTER OF THE CONTROL OF TH
			GCCAGAATCTAGAGATGCCTTACCCTTCTTACTAGATGACTTAATGCCAGCAA	
	-			
			ATATGTGTCAGTGACTGTTCAGAGTCCAGGGIAIIAAGGIGIAIAAAACAAAIIG	
-			TAGAATTGAGGAACTICAATAGAAAAAAGACTICCAAAAAAAATTTTTCAA	
	9829	483	AAACAAAAACI CATGGAAGAACAGGAGAACACTTTCACGCGCTGGTGCAACGA 383	<b>APWKKIQQNTFTRWCNEH</b>
Snigeria lo	preyood	2	GCACCTGAAGTGCGTGAGCAAGCGCATCGCCAACCTGCAGACGGACCTGAG	LKCVSKRIANLQTDLSDGL
			CGACGGGCTGCGGCTTATCGCGCTGTTGGAGGTGCTCAGCCAGAAGAAGAT	RLIALLEVLSOKKMHRKHN
		_	GCACCGCAAGCACAACCAGCGGCCCACTTCCGCCAAATGCAGCT IGAGAA	ORFIFRONDCENVSVALER
			CGTGTCGGTGGCGCTCGAGTTCCTGGACCGCGAGAGCATCAAACTGGGCT	EDRESIALVSIDSKAIVDGIVE KI II GLIWTLILHYSISMPMW
-			CATCGACAGGAAGGCCA  CG   GGACGGGAACC   GAAGC   GAI CC   GGACCA   CATCTACTACTACTACTACTACTACTACTACTACTACTAC	DEEEDEEAKKOTPKORLLG
			CATCTGGACCCTGATCCTGCACCTCCTCCTCCTCCTCCTCCTCCTCCTCCTCCTCCTCC	

	GAGGAGGATGAGGAGGCCAAGAAGCAGACCCCCAAGCAGGAGGCTCCTGGG	WIQNKLPQLPITNFSRDWQ
	CTGGATCCAGAACAAGCTGCCTGGAGCGCGTGGTGGACAGCTGTGCCCG	WDSWDASKPVTNAREAM
		QQADDWLGIPQVITPEEIVD
	GCGCGAGAGGCCATGCAGCAGGCGGATGACTGGCTGGCCATCCCCCAGGT	PNVDEHSVMTYLSQFPKAK
	GATCACCCCGAGGAGATTGTGGACCCCAACGTGGACGAGCACTCTGTCAT	LKPGAPLRPKLNPKKARAY
	GACCTACCTGTCCCAGGTTCCCCAAGGCCAAGCTGAAGCCAGGGGCTCCCTT	GPGIEPTGNMVKKRAEFTV
-	GCGCCCCAAACTGAACCCGAAGAAAGCCCGTGCCTACGGGCCAGGCATCG	ETRSAGGEVLVYVEDPA
	AGCCCACAGGCAACATGGTGAAGAAGCGGGCAGAGTTCACTGTGGAGACCA	GHQEEAKVTANNDKNHIF
	GAAGTGCTGGCCAGGGAGAGGTGCTGGTGTACGTGGAGGACCCGGGCGGA	SVWYVPEVTG1HKV1VLFA
	CACCAGGAGGAGGCAAAAGTGACCGCCAATAACGACAAGAACCGCACCTTC	GOHIAKSPFEVYVDKSUGD
	TCCGTCTGGTACGTCCCCGAGGTGACGGGGACTCATAAGGTTACTGTGCTC	ASKVIAGGPGLEPSGNIAN
-	TTTGCTGGCCAGCACATCGCCAAGAGCCCCTTCGAGGTGTACGTGGATAAG	KIIYFEIFIAGAGIGEVEVV
	TCACAGGGTGACGCCAGCAAAGTGACAGCCCAAGGTCCCGGCCTGGAGCC	IQDPMGQKGI VEPQLEAR
	CAGTGGCAACATCGCCAACAAGACCACCTACTTTGAGATCTTTACGGCAGGA	GDSTYRCSYQPIMEGVHI
	GCTGGCACGGGCGAGGTCGAGGTTGTGATCCAGGACCCCATGGGACAGAA	VHV I FAGVPIPHSPY I V I V
	GGGCACGGTAGAGCCTCAGCTGGAGGCCCGGGGCGACAGCACATACCGCT	GOACNPSACHAVGRGLUP
	GCAGCTACCAGCCCACCATGGAGGGCGTCCACACCGTGCACGTCACGTTTG	KGVRVKETADFKVYIKGAG
	CCGGCGTGCCCATCCCTCGCAGCCCCTACACTGTCACTGTTGGCCAAGCCT	SGELKVTVKGPKGEERVK
	GTAACCCGAGTGCCTGCCGGGCGGTTGGCCGGGGCCTCCAGCCCAAGGGT	QKDLGDGVYGFEYYPMVP
	GTGCGGGTGAAGGAGACAGCTGACTTCAAGGTGTACACAAAGGGCGCTGGC	GTYIVTITWGGQNIGRSPFE
	AGTGGGGAGCTGAAGGTCACCGTGAAGGGCCCCCAAGGGAGAGAGGCGCGT	VKVGTECGNQKVRAWGPG
	GAAGCAGAAGGACCTGGGGGATGGCGTGTATGGCTTCGAGTATTACCCCAT	LEGGVVGKSADFVVEAIGD
	GGTCCCTGGAACCTATATCGTCACCATCACGTGGGTGGTCAGAACATCGG	DVGTLGFSVEGPSQAKIEC
	GCGCAGTCCCTTCGAAGTGAAGGTGGGCACCGAGTGTGGCAATCAGAAGGT	DDKGDGSCDVRYWPQEA
-	ACGGGCCTGGGGCCTGGGCTGGAGGGCGGCGTCGTTGGCAAGTCAGCAG	GEYAVHVLCNSEDIRLSPF
	ACTTTGTGGTGGAGGCTATCGGGGACGACGTGGGCACGCTGGGCTTCTCG	MADIRDAPODFHPDRVKAR
	GTGGAAGGGCCATCGCAGGCTAAGATCGAATGTGACGACAAGGGCGACGG	GPGLEKTGVAVNKPAEFTV
	CTCCTGTGATGTGCGCTACTGGCCGCAGGAGGCTGGCGAGTATGCCGTTCA	DAKHGGKAPLRVQVQDNE
	CGTGCTGTGCAACAGCGAAGACATCCGCCTCAGCCCCTTCATGGCTGACAT	GCPVEALVKDNGNGTYSC
	CCGTGACGCGCCCCAGGACTTCCACCCAGACAGGGTGAAGGCACGTGGGC	SYVPRKPVKHTAMVSWGG
	CTGGATTGGAGAGACAGGTGTGGCCGTCAACAAGCCAGCAGAGTTCACAG	VSIPNSPFRVNVGAGSHPN
	TGGATGCCAAGCACGGTGGCAAGGCCCCACTTCGGGTCCAAGTCCAGGACA	KVKVYGPGVAKTGLKAHEP
	ATGAAGGCTGCCCTGTGGAGGCGTTGGTCAAGGACAACGGCAATGGCACTT	TYFTVDCAEAGGGDVSIGI
	ACAGCTGCTCCTACGTGCCCAGGAAGCCGGTGAAGCACACACA	KCAPGVVGPAEADIDFDIIR
	CCTGGGGAGGCGTCAGCATCCCCAACAGCCCCTTCAGGGTGAATGTGGGA	NDNDTFTVKYTPRGAGSYI
	GCTGGCAGCCACCAACAAGGTCAAAGTATACGGCCCCGGAGTAGCCAAG	IMVLFADQATPTSPIRVKVE
	ACAGGGCTCAAGGCCCACGAGCCCACCTACTTCACTGTGGACTGCGCCGAG	PSHDASKVKAEGPGLSKI OVELOKPTHETVNAKAAGK
	GCTGGCCAGGGGGACGICAGCAICGGCAICAGGIGIGCCCCIGGAGIGGI	AVELGIN I I I VICTORIO

AGGCCCCGCGAAGCTGACATCGACTTCGACATCATCCGCAATGACAATGA	GKLDVQFSGLTKGDAVRD
CACCTTCACGGTCAAGTACACGCCCCGGGGGGCTGGCAGCTACACCATTAT	VDIIDHHDNI Y I VKY I FVQQ CBVCVNIVTVGGDBIBKSBE
GGTCCTCTTTGCTGACCAGGCCACGCCCAGGCCCCAICCGAGICAAGGI	SVAVSPS I DISKINSE GE
	KYDYGKDOFFTVKSKGAG
GTCGCACTGGTGTCGAGCLIGGCAAGCCCACCCACIICACAGIAAAIGCCA	GOGKVASKIVGPSGAAVPC
AAGCTGCTGCTAAAGGCAAAGCTGGAACGTCCAGTTCTAAGAAACACAAGAAGAAAAAAAA	KVFPGLGADNSVVRFLPRE
GGGA  GCAGIGCGAGA  G  GGACA  CA  CACCACCA  GACCACCA  CACCACACACA	FGPYEVEVTYDGVPVPGS
	PFPLEAVAPTKPSKVKAFG
IGGAGGGGAI CCCAI CCCI AAGAGCCCI I CI CAGI GGGGAGAGGGGGACGTT	PGLQGGSAGSPARFTIDTK
CIGGACCICAGCAAGAI CAAGGIGI CIGGAGGGIGCIGGIGGIGGIGGIGGIGGIGGIGGIGGIGGIGGI	GAGTGGLGLTVEGPCEAQ
AAAATGGGATCCAAGATTGTGGGCCCCTCGGGTGCAGCGGTGCCCTGCAAG	LECLDNGDGTCSVSYVPTE
 PARAPOCAGGCTGGGGCTGACAACAGTGTGGGGCTTCCTGCCCCG	PGDYNINILFADTHIPGSPF
 TO A COMMON TO A TO A COMMON T	KAHVVPCFDASKVKCSGP
OTO CONCOUNT TO TOTAL AND	GLERATAGEVGQFQVDCS
TO A A COLOR TITLE BOLD BE BOUNDED BY	SAGSAELTIEICSEAGLPAE
	VYIQDHGDGTHTITYIPLCP
	GAYTVTIKYGGQPVPNFPS
CAN A TETT CONTRIBUTION AND A TEST CONTRIBUTION OF A TEST CONTRIBUTI	KLQVEPAVDTSGVQCYGP
ACACATOTATOCATE ACACOTA CONTROLLA CO	GIEGGGVFREATTEFSVDA
 ACATOCIO TOGO GACACOCA AGATOCA	RALTQTGGPHVKARVANP
	SGNLTETYVQDRGDGMYK
CARACTER AGE TO A TOTAL A TOTA	VEYTPYEEGLHSVDVTYDG
GCCGAGGTGTACATCCAGGACCACGGTGATGGCACGCACACCATTACCTAC	SPVPSSPFQVPVTEGCDPS
 ATTOCCOTOTOGGGGGCCTACACCATCAAGTACGGCGGCCAG	RVRVHGPGIQSGTTNKPNK
CCGTGCCGAGCTTCCCCAGCAAGCTGCAGGTGGAACCTGCGGTGGACACT	FTVETRGAGTGGLGLAVEG
TCCGGTGTCCAGTGCTATGGGCCTGGTATTGAGGGCCAGGGTGTCTTCCGT	PSEAKMSCMDNKDGSCSV
 GAGGCCACCACTGAGTTCAGTGTGGACGCCCGGGCTCTGACACAGACCGG	EYIPYEAGTYSLNVTYGGH
AGGCCGCACGTCAAGGCCCCGTGTGGCCAACCCCTCAGGCAACCTGACGG	QVPGSPFKVPVHDVTDASK
 AGACCTACGTTCAGGACCGTGGCGATGGCATGTACAAAGTGGAGTACACGC	VKCSGPGLSPGMVRANLP
_	QSFQVDTSKAGVAPLQVKV
TECCCAGCAGCACCTTCCAGGTGCCCGTGACCGAGGGCTGCGACCCCTCC	QGPKGLVEPVDVVDNADG
   Ideocate   Ideocate	TQTVNYVPSREGPYSISVL
CAACAAGTTCACTGTGGAGACCAGGGGAGCTGGCACGGGCGGCCTGGGCC	YGDEEVPRSPFKVKVLPTH
TGGCTGTAGAGGGCCCCTCCGAGGCCAAGATGTCCTGCATGGATAACAAGG	DASKVKASGPGLNTTGVPA
ACGCCAGCTGCTCGGTCGAGTACATCCCTTATGAGGCTGGCACCTACAGCC	SLPVEFTIDAKDAGEGLLAV
 TCAACGTCACCTATGGTGGCCATCAAGTGCCAGGCAGTCCTTTCAAGGTCCC	QITDPEGKPK   HIQUNHU
TGTGCATGATGTGACAGATGCGTCCAAGGTCAAGTGCTCTGGGCCCGGCCT	GIYIVAYVPDVIGHTILIK VGGNEIPESPYBVBAVPTG
GAGCCCAGGCATGGTTCGTGCCAACCICCCICAGICCIICCAGGIGACAC	

		AAGCAAGGCTGGTGTGTGCCCATTGCAGGTCAAAGTGCAAGGGCCCAAAGG	DASKCTVTVSIGGHGLGAG
		CCI GGI GGAGCCAGI GGAGAGGGCCTACAGCATCTCAGITACTATATATATATATATATATATATATATATATATATA	KGKVTCTVCTPDGSEVDV
		GATGAAGAGAACCCCGGAGCCCTTCAAGGTCAAGGTGCTGCTACTCAT	DVVENEDGTFDIFYTAPQP
		GATGCCAGGAAGGCCAGTGGCCCCGGGCTCAACACCACTGGCGT	GKYVICVRFGGEHVPNSPF
		GCCTGCCAGCCTGCCGTGGAGTTCACCATCGATGCAAAGGACGCCGGGG	QVTALAGDQPSVQPPLRS
		AGGCCTGCTGGCTGTCCAGATCACGGATCCCGAAGGCAAGCCGAAGAAGA	QQLAPQYTYAQGGQQTWA
		CACACATCCAAGACAACCATGACGGCACGTATACAGTGGCCTACGTGCCAG	PERPLYGVNGLDVTSLRPF
		ACGTGACAGGTCGCTACACCATCCTCATCAAGTACGGTGGTGACGAGATCC	DLVIPFTIKKGEITGEVRMP
		CCTTCTCCCCGTACCGCGTGCCGTGCCCACCGGGGACGCCAGCAAG	SGKVAQPTITDNKDGTVTV
		TGCACTGTCACAGTGTCAATCGGAGGTCACGGGCTAGGTGCTGGCATCGGC	RYAPSEAGLHEMDIRYDNM
		CCCACCATTCAGATTGGGGAGGAGGGGGGTGATCACTGTGGACACTAAGGCG	HIPGSPLQFYVDYVNCGHV
		GCAGGCAAAGGCAAAGTGACGTGCACCGTGTGCACGCCTGATGGCTCAGAG	TAYGPGLTHGVVNKPATFI
		GTGGATGTGGACGTGGTGGAGAATGAGGACGGCACTTTCGACATCTTCTAC	VNTKDAGEGGLSLAIEGPS
		ACGGCCCCCAGCCGGGCAATACGTCATCTGTGCGCTTTGGTGGCGAG	KAEISCTDNQDGTCSVSYL
		CACGTGCCCAACAGCCCCTTCCAAGTGACGGCTCTGGCTGG	PVLPGDYSILVKYNEQHVP
	-	TCGGTGCAGCCCCTCTACGGTCTCAGCAGCTGGCCCCACAGTACACCTAC	GSPFTARVTGDDSMRMSH
		GCCAGGCCGCCAGCAGACTTGGGCCCCGGAGAGGCCCCTGGTGGGTG	LKVGSAADIPINISETDLSLL
		CAATGGGCTGGATGTGACCAGCCTGAGGCCCTTTGACCTTGTCATCCCCTTC	TATVVPPSGREEPCLLKRL
		ACCATCAAGAAGGCGAGATCACAGGGGAGGTTCGGATGCCCTCAGGCAAG	RNGHVGISFVPKETGEHLV
		GTGGCGCAGCCCACCATCACTGACAACAAGACGGCACCGTGACCGTGCG	HVKKNGQHVASSPIPVVIS
		GTATGCACCCAGCGAGGCTGGCCTGCACGAGATGGACATCCGCTATGACAA	QSEIGDASRVRVSGQGLHE
		CATGCACATCCCAGGAAGCCCCTTGCAGTTCTATGTGGATTACGTCAACTGT	GHTFEPAEFIIDTRDAGYG
		GGCCATGTCACTGCCTATGGGCCTGGCCTCACCCATGGAGTAGTGAACAAG	GLSLSIEGPSKVDINTEDLE
		CCTGCCACCTTCACCGTCAACACCAAGGATGCAGGAGAGGGGGGCCTGTCT	DGTCRVTYCPTEPGNYIINI
		CTGGCCATTGAGGGCCCGTCCAAAGCAGAAATCAGCTGCACTGACAACCAG	KFADQHVPGSPFSVKVTGE
		GATGGGACATGCAGCGTGTCCTACCTGCCTGTGCTGCCGGGGGACTACAGC	GRVKESITRRRAPSVANV
GACGACTCCATGCGTATGTCCCACCTAAAGGTCGGCTCTG  CCCATCAACATCTCAGAGAGCGGATCTCAGCCTGCTGACGG  CCCACCTCGGGCCGGGAGGAGCCCTGTTTGCTGAAGCGG  CCACGTGGGCCGGGAGGAGCCCTGTTTGCTGAAGCGG  CCACGTGGGGATTTCATTCGTGCCCAAGGAGACGGGGAG  TGTGAAGAAAATGGCCAGCACGTGGCCAGCAGCAGCAC  CCACCAGTCGAAAATTGGGGATGCCAGTGGTTTCGGGTC  CCTTCACGAAGCCACCTTTGAGCCTGTCCATGAGGCC  GACATCAACAAGGGACCTGGAGGACGGGACG		ATTCTAGTCAAGTACAATGAACAGCACGTCCCAGGCAGCCCCTTCACTGCTC	GSHCDLSLKIPEISIQDMIA
		GGGTCACAGGTGACGACTCCATGCGTATGTCCCACCTAAAGGTCGGCTCTG	QVTSPSGKIHEAEIVEGEN
		CTGCCGACATCCCCATCAACATCTCAGAGACGGATCTCAGCCTGCTGACGG	HTYCIREVPAEMGIHIVSV
		CCACTGTGGTCCCGCCTCGGGCCGGGAGGAGCCCTGTTTGCTGAAGCGG	KYKGQHVPGSPFQF1VGP
		CTGCGTAATGGCCACGTGGGGATTTCATTCGTGCCCAAGGAGACGGGGGGAG	LGEGGAHKVRAGGPGLER
		CACCTGGTGCATGTGAAAAAATGGCCAGCACGTGGCCAGCAGCCCCATC	AEAGVPAEFSIWTREAGAG
		CCGGTGGTGATCAGCCAGTCGGAAATTGGGGATGCCAGTCGTGTTCGGGTC	GLAIAVEGPSKAEISFEDRK
		TCTGGTCAGGGCCTTCACGAAGGCCACACCTTTGAGCCTGCAGAGTTTATCA	DGSCGVAYVVQEPGDYEV
		TTGATACCCGCGATGCAGGCTATGGTGGGCTCAGCCTGTCCATTGAGGGCC	SVKFNEEHIPUSPFVVFVA
		CCAGCAAGGTGGACATCAACACAGAGGACCTGGAGGACGGGACGTGCAGG	SPSGDARKLI VSSLQESGL
GTGCCTGGCAGCCCC  C C G GAAGG GACAGGCGAG		GTCACCTACTGCCCCACAGAGCCAGGCAACTACATCATCACATCAGGTTTG	NONCHAUTAVORINGANGAL
		CCGACCAGCACGTGCCTGGCAGCCCCTTCTGTGAAGGTGACAGGCGAG	DANVIIGE SCALECOLVIE

DQDKYAVRFIPRENGVYLID VKFNGTHIPGSPFKIRVGEP GHGGDPGLVSAYGAGLEG GVTGNPAEFVVNTSNAGA GALSVTIDGPSKVKMDCQE CPEGYRVTYTPMAPGSYLI SIKYGGPYHIGGSPFKAKVT GPRLVSNHSLHETSSVFVD SLTKATCAPQHGAPGPGP ADASKVVAKGLGLSKAYVG QKSSFTVDCSKAGNNMLLV GVHGPRTPCEEILVKHVGS RLYSVSYLLKDKGEYTLVV KWGHEHIPGSPYRVVVP*	384 PNIIQFVPADGFLFGDTVTS SEHLCGINFTGSVPTFKHL WKQVAQNLDRFHTFPRLA GECGGKNFHFVHRSADVE SVVSGTLRSAFEYGGQKC SACSRLYVPHSLWPQIKGR LLEEHSRIKVGDPAEDFGT FFSAVIDAKSFARIKKWLEH
AGAGAGCATCACCCGCAGGCGTCGGGCTCCTTCAGTGGC ITCATTGTGACCTCAGCCTGAAAATCCCTGAAAATTAGCATC GGCGAAGACCAGCCCATCGGGCAAGACCCATGAGGC GGGGGAGACCACGCCCATCGGGCAAGACCCATGAGGC GGGGGAGACCACCTACTGCATCCGCTTTGTTCCCGCT CCAGTTCACCGTGGGCCCTTTGTTCCCGCT CCAGTTCACCGTGGGGCCCTTTTGTTCCCGCT CGTTTCTGGACCCTGGAGGCCCTGGAGGCCCAAGG GGCCCCAGCAGCCTGGAGGCCCTGGAGCCCAAGG GGCCCAGCAGGCTGAGATCTCTTTTTGAGGCCTGGCCAAGG GGCCCAGCAGCCCCGCCCC	CCCCAACATCATCCAGTTTGTGCCAGCTGATGGGCCCCTATTTGGGGACACI GTCACCAGCTCAGAGCACCTCTGTGGCATCAACTTCACAGGCAGTGTGCCC ACCTTCAAACACCTGTGGAAGCAGGTGGCCCCAGAACCTGGACCGGTTCCAC ACCTTCCACGCCTGGCTGGAGAGTGCGGCGGAAAGAACTTCCACTTCGTG CACCGCTCGGCCGACGTGGAGAGTGCGGCGGAAAGAACTTCCACTTCGTG CACCGCTCGGCCGACGTGGAGAGCGTGGTGAGCGGGACCCTCCGCTCAGC CTTCGAGTACGGTGGCCAGAAGTGTTCCGCCTGCTCGCGTCCGCTCAGC GCACTCGCTGTGGCCGCAGATCAAAGGGCGGGCTGCTGCTGCAGTG GCACTCGCTGTGGCCGCAGATCAAAGGGCGGGCTCTCTTCTTCTTCTGCAGTT
	prey56789 183
	9
	Shigella ipaH9.8

Shigella	ω	prey67711	184	382	ARSSPSLTILAGGKCDDSV GYFVEPCIVESKDPQEPIM KEEIFGPVLSVYVYPDDKY KETLQLVDSTTSYGLTGAV FSQDKDVVQEATKVLRNAA GNFYINDKSTGSIVGQQPF GGARASGTNDKPGGPHYIL RWTSPQVIKETHKPLGDW SYAYMQ* NRAASWLFGSLGGEGAGR
ipaH9.8	, ,	C	100	ICGGGGAAGCCACCTGCGGATTCACTGGCTGCTGCTCCGC  AGCAAGCACGGAGGCTGCCAGACCTGGGGCTCCCTGCT  GTTGGGGAAACCACCGTCTGCCCCAGACCCTGACCCAGGA  GAAGCTGGG	GAAGKPPADSLAAAPPHTA SKHGGLPDLGLPAPCVRLG KPPSAPDPDPGPAWRKL MSQAVQTNGTQPLSKTWE
Shigella ipaH9.8	φ	preyz118	8 8	AGGACTCACACATAGAGAGAGAGAGAGAGAGAGAGAGAGA	LSLYELQRTPQEAITDGLEI VVSPRSLHSELMCPICLDM LKNTMTTKECLHRFCADCII TALRSGNKECPTCRKKLVS KRSLRPDPNFDALISKIYPS RDEYEAHQERVLARINKHN NQQALSHSIEEGLKIQAMN RLQRGKKQQIENGSGAED NGDSSHCSNASTHSNQEA GPSNKRTKTSDDSGLELDN NNAAMAIDPVMDGASEIEL VFRPHPTLMEKDDSAQTRY IKTSGNATVDHLSKYLAVRL ALEELRSKGESNQMNLDTA SEKQYTIYIATASGQFTVLN GSFSLELVSEKYWKVNKP MELYYAPTKEHK*
Shigella ipaH9.8	9	prey3596	186	ATGTCCAAGCGGCACCGGTTGGACCTAGGGGAGGATTACCCCTCTGGCAAG 387 AAGCGTGCGGGGACCGATGGGAAGGATCGAGATCGAGACCGGGATCGTGA AGATCGGTCTAAAGATCGAGACCGAGAACGTGATAGAGGAGATAGAGAGCG	MSKRHRLDLGED TPSGRR RAGTDGKDRDRDREDR SKDRDRERDRGDRERERE

() () () E = - () ()	388	SAGGC 389 MTTLYTAKKYAVPALEAHC TTCAT CTGTG CTGTG ARLFDEPQLASLCLENIDKN ACACT ACACT WSEACCARQQLQVTPENR SAAGG RKVLGKALGLIRFPLMTIEE SGAGG RKVLGKALGLIRFPLMTIEE FAAGPAQSGILVDREVVSL CCLRGKECSINRFQQVESR CCCGCT WGYSGTSDRIRFSVNKRIF CCGCT WGYSGTSDRIRFSVNKRIF CCGCT CCCGCT CCCCCCCC
AGAGAGGAGAAAAGGAAAGGAGTTGCGAGCTTCAACAAATGCTAT GCTTATCAGTGCTGGATTACCACCCTGAAAGCTTCCCATTCACCAATTGCTAT ACCCACTCAGCACTTCAACGCATTCTACCATTCAGCTCCATTCAGCTGC CGGACATGCAGGTCACTTCCACGTTCCAATTCAACGCTTCAGCATGC TTACCCCATACTCCTCGATACTTCTCACATTCTGGAAACGTTCAGCTTCAGCTTCTAGAAACATTCTGGGAATACCAAGGATACTGGTTACTGGTTGGGATACTGGTTTACAGAAACATTCTGGGTAGACATCAGTCCT TTGTACTGGTTGGTGGATAGGTTTACAGAAAACAACACAAATTCCACACCGGTTGGTGGATACATGCGATCATTACAGAAAACAACACAAAATTCCACGGAAAATTCCAAGCCAGAAAATTGCTGAATGCAATGGGATTTTTTTATGTATATGGTTACTCCATTCGATTTGAAGACTTTTTTTT	CATCACATCCCGGTTGGAATCTGTGCACATCATACTGAGAGATGGCCTGGAA GATCCCCTGGAGGATACGGGGCTGGTCCAGCAGCTTGGACCAGCTGTCC ACCATTGGGCGTTGTGAATATGAGAAGACGTGTGCACTTCGTGCAGTTGT TTGACCAGTCGGCCCAGTCGTACCAGGAGCTGCTACAGAGCGCCAGCGCAA GCCCAATGGACATTGCAGTGCAG	GATGACCACGCTATACACCGCCAAGAAGTACGCGGTGCCAGCGCTCGAGGC CCATTGCGTGGAGTTCCTGAAGAAGAACCTGCGAGCCGACAACGCCTTCAT GCTTGCGTGGAGTTCCTGAAGAAGAACCTGCGAGCCGACCAACGCCTTCAT GCTGCACGCAGGCGCGACTCTTCGATGAACCGCAGCTGGCCGCCTGTG CCTGGAGAACATCGACAAAAACACTGCAGACGCCATCACCGCGGAGGCCTT CACCGACATTGACCTGGACACGCTGGTGGCCGCTTGTCCGCGGAGGCCTT GGGCATCCGTGAGGCGCTGTTCAATGCCGTTGTCCGCTGGTCCGAGGC CGAGTGTCAGCGGCAGCTGCTGCAGTTCCCGCTGGTCCGAGGC TTCTGGGCAAGGCCCTGGCGCTCATTCGCTTCCCGCTGGTCGAGGC AGTTCGCTGCAGGCCCTCATTCGCTTCCTGGTGGACCGCGAGGTG AGTTCGCTGCAGGTCCCGCACGTCGGGGCATCCAAGCCGCTTCAACCGCT TTCAGCGGCCCCGCTGCTGCGGGGCTTCCAGGGGGTTCAACCGCT TCCAGCAGGTGGCACTGCTGCGGGGCTTCAACCGCTTTCAGCGCTTTCAGCGCTTTCGTGGGGATTTGGGGTTTTCAACCGCTTCAACCGCTTCAACCGCTTCAACCGCATCCAAGCGCATCAACCGCTTTCCAGGGGTTTTTCAACCGCATCACCGCATCCACGGATTATTCAACCGGATCCACGCACCACCCAACCCGATCCACCGCACCCACC
	187	88
	prey666	prey3917
	O	2
	Shigella ipaH9.8	Shigella ospG

	066 067 07 07 07 07 07 07 07 07 07 07 07 07 07	ATGGTC 391 IKDHHYFKYCKISALALLKW ATGGTC WHARSGGNLEVMGLMLG KVDGETMIIMDSFALPVEGT ETRVNAQAAAYEYMAAYIE NAKQVGRLENAIGWYHSH CTTTGAA PGYGCWLSGIDVSTQMLN QQFQEPFVAVVIDPTRTISA GKVNLGAFRTYPKGYKPPD GKVNLGAFRTYPKGYKPPD GGYNLGAFRTYPKGYKPPD GGYNLGAFRTYPKGYKPPD GGYNLGAFRTYPKGYKPPD GGYNLGAFRTYPKGYKPPD GGYNLGAATT LLE
TAGCAACACCGTCTTGGGCCAGAACGACAGGGGCTTCAGCTGCGACGGCTC AGCCAGCACCTTCCGCGTCATGTTCAAGGAGCCGGTGGAGGTGCTGCCCAA CGTCAACTACACGGCCTGTGCCACGCTCAAGGGCCCAGACTCCCACTACGG CACCAAAGGCCTGCGCAAGGTGACACACGAGTCGCCCACCACGGGCCCA AGACCTGCTTCACCTTTTGCTACGCGGCCGGGAACAAAGGCCACATCGGT	CTGTGGGAAAGCCTTCAGTTGGAAATCACACCTTATTGAGCATCAAAGAACT CACACTGGGAAAGCCTTATCACTGTACCAAATGTAAGAAGAGGCTTTAGTC CACACTGGTGAGAAACCTTATCACTGTACCAAATGTAAGAAGACCCTTATCACCTGGGGAAAGACCCCA TAAATGTGGTGAATGTGGGAAAGCCTTTCCATTAAACCCTTATACAAC TAAATGTGGTGAATTCACACTGGCAAAAGACTTTTCTTTGTATTGAAGTGTGGAAAA ACCAAAAAATTCACACTGGCGAAAGCCTTTTCTTTGTATTGAGTGTGGAAAA ACCAAAAATTCACACTGGCGAAAGCCTTTTCTTTCTTTTCAGTCGTGGAAAA ACCAAAAATTCAGTGCGAAAGAGTGTGGGAAAAGCTTTTCAGTCGGTGGAAAA ACCAAAATTCAGTGGAAAATTCACACAGGAAAAGCTTTTCAGTGGAAAA TTCACCAGGGAAAATTCACACAGGAAACTTTTCAGTCAGT	GACTAAGGATCACCATTACTITAAGTACTGCAAAATCTCAGCATTGGCTCTTC TGAAGATGGTGATGCCAGATCGGGAGGCAATTTGGAAGTGATGGTC TGAAGATGGTGAAGCCAGATCGGGAGGCAATTTGGAAGTGATGGTC TGATGCTAGGAAAGGTGGATGGTGAAACCATGATCATTATGGACAGTTTTGC TTTGCCTGTGGAGGCACTGAAACCCGAGTAAATGCTCAGGCTGCTGCATAT GAATACATGGGTGGTACATAGAAAATGCAAAACGGTTGGCTGCTGCTTGTAA ATGCAATGGGTGGTATCATAGAAAATGCAAAACGGTTGGCTGCTTTTGTAG CAGTGGTGATTGATCCAAAAGAAATACCGCAGGGAAAGTGAATTTTTGTAG CAGTGGTGATTGATCCAAAAGGGCTACAAACCTCCTGATGAAGGACCTTTTG GAGTACCAGACTATTCCAATAAAAATAGAAAGATTTTGGTGTTACGCAAATT ACAATATTATGCCTTAGAAAGTCTCATAATTCAAAATTTGGATCCTCTTTTGGATCGCAAATT
TAGA AGC CAC AGA	GAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	190 GA/C CA/C CA/C CA/C CA/C CA/C CA/C CA/C
	prey63632 18	prey2109 1
	7	2
	Shigella ospG	Shigella ospG

Shigella ospG	<b>~</b>	prey54201	191	ACGGATTAATAAGGAACTTAGTGATTTGGCCCGTGACCCTCCAGCACATGT  TCTGCAGGTCCAGTTGGGATGTTTTGTTT	RINKELSDLARDPPAQCSA GPVGDDMFHWQATIMGPN DSPYQGGVFELTIHFPTDY PFKPPKVAFTTRIYHPNINS NGSICLDILRSQWSPALTIS KVLLSICSLLCDPNPDDPLV PEIARIYKTDRDKYNRISRE WTQKYAM*
Shigella ospG		prey1922	192	CTCCTGCTAAGGCCAAGCCGGCTGAAGCTCCTGCTGCTGC CAGAACCTACAGCCAGCCGCTGAAGCTCCTCCCCTGCACCC CAGAACCTACAGCAGCGCCAGTTCCTCCCCCTGCAGCACC CACCACCACCGCTCCCCCCTCCTCTGG CTCCAGCTTCAGAACATGCCCCCCACCACTAGCTGAGCCA AGGTCTGCGTTCAGAACATCGGGAGAAATGAACATG TGCTCAGCGTTCAGAACATCGGGAGAAATGACATG TGCTCAGCGTTCAGAACATCAGGAAAATGAATGAATTTTTTTT	TGAAPAKAKPAEAPAAAAP KAEPTAAAVPPPAAPIPTQ MPPVPSPSQPPSGKPVSA VKPTVAPPLAEPGAGKGLR SEHREKMNRMRQRIAQRL KLGFMSAFVKASAFALQEQ PVNNAVIDDTTKEVVYRDYI DISVAVATPRGLVVPVIRNV EAMNFADIERTITELGEKAR KNELAIEDMDGGTFTISNG GVFGSLFGTPIINPPQSAIL GMHGIFDRPVAIGGKVEVR PMMYVALTYDHRLIDGREA VTFLRKIKAAVEDPRVLLLD L*
Shigella ospG	_	prey67418	193		AASHKLMKELEEIHKCGWK NFRNIQVDEANLLTWQGLI VPDNPPYDKGAFRIEINFPA EYPFKPPKITFKTKIYHPNID EKGQVCLPVISAENWKPAT KTDQVIQSLIALVNDPQPEH PLRADLAEEYSKDRKKFCK NAEEFTKKYGEKRPVD*
Shigella ospG	7	prey67314	194	ATGATGGCGAGCATGCGAGTGGTGAAGGAGCTGGAGGATCTTCAGAAGAAG 395 CCTCCCCCATACCTGCGGAACCTGTCCAGCGATGATGCCAATGTCCTGGTG TGGCACGCTCTCCTCCTACCGACCACCTCCCTACCACCTGAAAGCCTTCA	MIMASIMKV VRELEDLURKY PPYLRNLSSDDANVLVWHA LLLPDQPPYHLKAFNLRISF

				* COTTOCO ATTACOCOTTOCO ACTATOCO ATTACA AGAIN A AGAIN	PPEYPFKPPMIKFTTKIYHP
				ACCINCACACCAAGATCTACCACCCCAACGTGGACGAAACGGACAGATTTGC	NVDENGOICLPIISSENWKP
				CTGCCCATCATCAGCAGTGAGAACTGGAAGCCTTGCACCAAGACTTGCCAA	CTKTCQVLEALNVLVNRPNI
				GTCCTGGAGGCCCTCAATGTGCTGGTGAATAGACCGAATATCAGGGAGCCC	REPLAMDLADLLI QINPELF
				CTGCGGATGGACCTCGCTGACCTGCTGACACAGAATCCGGAGCTGTTCAGA	RKNAEEF I LAFGVUAPS.
		100	10	AAGAAI GCCGAAGAGI I CACCOI CCGAI I CGCAGATTCGATACAAAGCGAAT 396	MSVGHKAQESKIRYKTNEP
Shigella	7	prey67435	66 E	<u></u>	VWEENFTFFIHNPKRODLE
ospG				AGGACCIGIAI GAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGA	VEVRDEQHQCSLGNLKVPL
				ACCTGAAGGTCCCCTCAGCCAGCTGCTCACCAGTGAGGACATGACTGTGA	SQLLTSEDMTVSQRFQLSN
			,	ACCAGGGTTCCAGGTCAGTAACTCGGGTCCAAACAGCACCATCAAGATGA	SGPNSTIKMKIALRVLHLEK
				AGATTGCCTGCGGGTGCTCCATCTCGAAAAGCGAGAAAGGCCTCCAGACC	RERPPD
Chinolla	7	prev67443	196	CTGGGATGCCCTCAAGGCTGCCGCCTATGCTGCTGAAGCCAACGACCACGA 397	WDALKAAAYAAEANDHELA
Sulgalia September 1	_		)	GCTGGCCCAGGCCATCCTGGATGGAGCCAGCATCACCCTGCCTCATGGCAC	QAILDGASH LPHG I LCECY
) deo				CCTCTGTGAATGCTACGATGAGCTGGGCAATCGCTACCAGCTGCCCATCTAC	DELGNAYQLPIYCLSPPVN
				TGCCTGTCACCGCCGGTGAACCTGCTGGTGGAGCACACGGAGGAGAGAG	LLLEHI EEESLEPPEPPSV
	_			CCTGGAGCCCCCGAGCCTCCACCCAGCGTGCGCCGTGAGTTCCCGGCTGA	RREFPLKVRLSTGKDVRLS
				AGGIGCGCCTGTCCACGGGCAAGGACGTGAGGCTCAGCGCCAGCCTGCCC	ASLPDTVGQLKRQLHAQE
				GACACAGTGGGGCAGCTCAAGAGGCAGCTGCACGCCCAGGAGGGCATCGA	GIEPSWQRWFFSGKLLIDK
				GCCATCGTGGCAGCGGTGGTTCTTCTCCGGGAAGCTGCTCACAGACCGCAC	TRLOETKIOKDFVIOVIIN
				GCTCCAGG	
				AAC	STGANGGANGGVS
Shigella	7	prey67317	197		KROTGI PBRPWSSPVPST
ospG				CCACATCAAAGAGG GCACGGGGC GCCCAGGAGGCC	BASASWNLVGTSSKKLWG
	-			TTCCATCAACCAGAGCIICIGCCICCIGGAACCIGGIAGAGAAAACIGGAACATAGAAAAAAAAAA	TSYSWWKRSLPSRA*
				GAAGO I O I GGGGGAOOAGO I ACAGO I GGCGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG	
Shigolla	7	prev67393	198	GAGAATCCACAAGGAATTGAATGATCTGGCACGGGACCCTCCAGCACAGTG 399	RIHKELNDLARDPPAQCSA
Singella	<u> </u>	200	) } -	TTCAGCAGGTCCTGTTGGAGATGATATGTTCCATTGGCAAGCTACAATAATG	GPVGDDMFHWQAIIMGFN
2				GGGCCAAATGACAGTCCCTATCAGGGTGGAGTATTTTTCTTGACAATTCATTT	DSPYQGGVFFL I I HFF I DY
				CCCAACAGATTACCCCTTCAAACCACCTAAGGTTGCATTTACAACAAGAATTT	PFKPFKVAFII RIYHPNING
•••				ATCATCCAAATATTAACAGTAATGGCAGCATTTGTCTTGATATTCTACGATCA	NGSICLDILRSQWSPAL11S
				CAGTGGTCTCCAGCACTAACTATTCAAAAGTACTCTTGTCCATCTGTTCTCT	KVLLSICSLLCDPNPDDPLV
				GTTGTGTGTGTCCCAATCCAGATGATCCTTTAGTGCCTGAGATTGCTCGGATC	PEIARIYKTDREKYNRIARE
				TACAAAACAGATAGAGAAAAGTACAACAGAATAGCTCGGGAATGGACTCAGA	WTQKYAM*
				_	WOOLD CASCINGING BOW
Shigella	7	prey700	199	ATGGGAATTGGTCTTTCTGCTCAAGGTGTGAACATGAATAGACIACCAGGII	DKHSYGYHGDDGHSFCSS
osb@				GGGAIAAGCAIICAIAIGGIIACCAIGGGACTTTCACTACTGGTGATGTCATTG	GTGQPYGPTFTTGDVIGCC
			-		

				VI	VNLINNTCFYTKNGHSLGIA
					FTDLPPNLYPTVGLQTPGE
					VVDANFGQHPFVFDIEDYIM
					REWKI KIQAQIDAFI IGDA FGEWOTMIOKMVSSYI VH
				TTCCIAICGGAGAICGAGAAGGAGAAIGGCAGAACAAIGA	HGYCATAFAFABSTDQTVL
					EELASIKNRORIOKLVLAGR
	.,.			AGAAATTGGTATTAGCAGGAAGAATGGGAAGAA	MGEAIETTQ
				707	BEFOREBKBSATOOKKNT
Shigella	7	prey67411	200	104	KI SSKTTAKLSTSAKRIQKE
osbG					AEITLDPPPNCSAGPKGD
				T I CAGAAGGAGGCIAGCIGAAATAACCOTTGATCACCOCCOCCOCCACCCCACCACCACCACCACCACCACCA	NIYEWRSTILGPPGSVYEG
	-			()	GVFFLDITFSSDYPFKPPKV
					TFRTRIYHCNINSQGVICLDI
				AGTCAGGGAGTCATCTGTCTGGACATCCTTAAAGACAACTG	LKDNWSPALTISKVLLSICS
					LLTDCNPADPLVGSIATQYL
				CCTGCGGATCCTCTGGTTGGAAGCATAGCCACTCAGTATTT	TNRAEHDRIARQWTKRYAT
-				CACCAACAGAGGAGAGAGAGAGATAGCCAGACAGTGGACCAAGAGATA	
		-			
ollogido	7	prev67493	201	AACAGTTTCCTCGGTTAGGAGCCCCTTCTACCGGGCTGAGCC 402	MSSQQFPRLGAPSTGLSQ
Singella	_	2 2 2 2 2 2	!		APSCIANSGSAGLINFAA1 V
osba					NDESGRDSEVSAREHMSS
					SSSLOSREEKOEPVVVRPY
				<b>(</b> 5	POVOMLSTHHAVASATPVA
					VTAPPAHLTPAVPLSFSEG
				_	LMKPPPKPTMPSRPIAPAP
					PSTLSLPPKVPGQVTVTME
					SSIPQASAIPVATISGQQGH
				<u></u>	PSNLHHIMTTNVQMSIIRSN
					APGPPLHIGASHLPHGAAA
					AAVMSSSKVIIVLRFI SQL
				() [	PNAALAGPAVGHIIH
				CGACCTCACAGCTGCCAAATGCTGCTACTGCTCAGCCAGC	
				TITACITATION TO	SIJU GVBVI OSPGTVI VDEIS
Shigella	7	prey67298	202	GATATTCTAGGTGTTAGGGTGCTGCAATCCCCTGGAACIGIAIIAGIIGAIII 403	*VCIKHLLSMGLAWGLVLXT
osbG				TATTICALGAGIGIGCALAAAACACCIIOIAICIALGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG	YR*TRSLLARS*ELSEERVK
					SPQ*EHGGAHTWAAGTLP
				AUCT PALLANDAR STATE STA	

				VOTOVOTO VOCTO CONTOUR	YPDPVI TI KNIVXMIXBXG
				ATACCTGGGCTGCAGGCACACTGCCTNTGCCTGATCCAGTCCTGACACTGA	
Shigella		prey67464	203	NTTGNTGGGTGNGNTNGGGGTGATAAGGAAAGAGTGTGAGAAAATGGCATC 404 AAACAGGGAACAAGTAAGAGGTCTGGTGGCAAGGGACAAGAGATGAGTCC	XXGXXXGDKERV*ENGIKQ GTSKRSGGKRTRDESVNP
osbo				GTCACCCCCACAACTGAGACTTGAGAGGGATGAGTGGGTCCTGAGAACTC	HN*DLRGMSGS*ELRQS*V GGPTIN*KRDQLTCYXXSY
				CCTGCTACTANTANAGTTACCCTGGGCTCCGATGCANTGATGGCAGTGGGG	PGLRCXDGSGGRXPXPXG PGLXXXE
:	1	00000	5	GCCGGNAGCCGGNGCCCANGGGCCCTGGCCTNATINALINGTGCAGATACTTTGACAAGTTGGCTAGAACAGCGTTGTTCAGATACTTTGACAAGTTGGCTAGAACAGCGTTGTTCAGAT	SVPARYFDKLARTALFRWS
Shigella	<u>`</u>	preyo/320	404	GGAGCATAGAACATCGAGATTACTTTCTTCACCATGGCAATTGAGTACTGAT	IEHRDYFSSPWQLSTDLCL
osbe				CTTTGTCTTCCATCTTAGTACATTTACTTCTGAACTATGTATG	PSLKYIYF*TMYAI*FISVIVV
		_		TTCATATCTGTGATAGTAGTGGGTGACTTGATAGATATTATCTGGCTATGTGT	GDLIDIIWLCVLPC*QVIYVS
				ACTTCCATGTTAGCAAGTGATTTATGTGTCAAAGTTTCTACCCAGTGGGAATT	NTLY OGIN VOLIE
:	1	0000	200	CTETTE ACTATINCT CAGAINTNACGTTGCAATTGAAGINICTGGNTCAGGAAC 406	VLSXLRXXVAIEXLXQEP*K
Shigella	_	preyo/321	COZ	COTOAAAAAAAAGATGTTNCCAGCTANNGATNAAGCAAGNCCGCTGGTGGGNGTC	DVXSXXXSKXAGGXPXYH
osbei				CCTTNTACCATNTNGGGGCTTTTGNNNNNTTNCTATCAANGCGTGCTTTTCTT	XGAFXXXLSXRAFLFQLXX
				TTCCAACTACANANGCACATGGAAGTGGTCACTATCCGCTCTCTCCAGTATT	HMEVVTIRSLQYYXHQNXF
		_	_	ATANCCATCAGAATNNCTTCTTGCAGGANNNACTGGTTGTGNNGANGCNTNT	LQXXLVVXXXXWXLDXAEX
				GTGGGANTTAGACANNGCNGAGNNGGTNTNCGGGGGTTNNT	VXGGX
100:30	7	prov35777	900	ATGGGGCCCTCTCAGCCCTCCTGCACAGAGCACATCAAATGGAAGGGG 407	MGPLSAPPCTEHIKWKGLL
Snigella		heyson	2	CTCCTGGTCACAGCATCACTTTTAAACTTCTGGAACCTGCCCACCACTGCCC	VTASLLNFWNLPTTAQVIIE
osba				AAGTCACGATTGAAGCCCAGCCACCAAAAGTTTCCGAGGGGAAGGATGTTCT	AQPPKVSEGKDVLLLVHNL
			_	TCTACTTGTCCACAATTTGCCCCAGAATCTTACTGGCTACATCTGGTACAAAG	PONLTGYIWYKGQIRDLYH
				GGCAAATCAGGGACCTCTACCATTACATTACATCATGTAGTAGACGGTCA	YITSYVVDGQIIIYGPAYSGH
				AATAATTATATAGGGCCTGCATATAGTGGACGAGAAACAGCATATTCCAATG	ETAYSNASLLIQNVI REDA
				CATCCCTGCTGATCCAGAATGTCACCCGGGAGGACGCAGGATCCTACACCT	GSY I LHIIKKGDG I KGVI G
				TACACATCATAAAGCGAGGTGATGGGACTAGAGGAGTAACTGGATATTTCAC	YFIFICYCEIPRPSISSSINC
				CTTCACCTTATACCTGGAGACTCCCAAGCCCTCCATCTCCAGCAGCAACTTA	TEXONAMANGOSI PMTHB
				AACCCCAGGGAGGCCATGGAAACTGTGATCT   AACCTGTGATCT GAGACTC	FOI SETNRTLFLFGVTKYTA
				CGGACACGCIACCAGIGGIGGAIGAAIGGICAGAGCCICCCIAIGAGIGGICAGAGCCICCCIAIGAGIGGICAGAGCCIAGAGCAGAGCAGAGCAGAGCAGAGAGAG	GPYECEIRNSGSASRSDPV
				ATAGGT  CAGCTGTCCGAAAACCAACAGGAACTCTTTCTTTCAATACGGAACTCAGGGAGTGCCA	TLNLLHGPDLPRIHPSYTNY
				AAGIAIACIGCAGGACCCIAIGAAIGIGCAGGGGGGGGGG	RSGDNLYLSCFANSNPPAQ
				GCCGCAGIGACCCAGICACCCAGICACCCTTCAGGAGATAACCTTGTCT	YSWTINGKFQQSGQNLFIP
				GAATTCACCA ACTCTAACCCACCAGCACAGTATTCTTGGACAATTAATGGGA	QITTKHSGLYVCSVRNSAT
				AGTTTCAGCAATCAGGACAAAATCTGTTTATCCCCCAAATTACTACAAAAGCAT	GQESSTSLTVKVSASTRIGL
				AGCGGGCTCTATGTTTGCTCTGTTCGTAACTCAGCCACTGGGCAGGAAAGCT	
				CCACATOGITGACAGICAAAGICICAGIICAGAGAGAGAGAGAGAGAGAG	

					Vaccoda
Shigella ospG	_	prey67327	207	GCAGGCTTTGAACTTTACCCGTTTTCTTGACCAGTCAGGACCCCCATCTGGG 408 GGATGTGAATTCCCTTGATAAGAAGTTGGTGCTGGCATTCAGGACCCCCATCTGGG 408 TGCCCACGGAGTGGAATGTATTGGTGCTGGCATTCAGGCACCTGAAGC TGCCCACGGAGTGGAATGTATTGGTGCTGTGCGGTTTTGCATGATGCTG TGCCCACGGAGACATTGCAGAAGCCAGGTGGCCCCAGAGCTGCTGAGGT TGACGTGGTTCCTGTTGCAGAAGCCAGGTGGCCCCAGAGGCTAT ACAACCAGGAAGGGCGACGCTGTGAGCTTGGCAGAGCTGTATCC TGACGTGGTTCCTATGAAATACCGTTGGAGAATGCTGAGAGAACCATCATGAACTTCTGTGAGACTC TGAGAGTTTCCTGGAGACGGTTGCATTACATTTAACCTCTGAGTCTGATTTTAATGACATTATGAAACTTATGAAACTTATGAACATTTTAATGACACTGAAACCTCCAGGAGCCCCAGAGAGAG	CALINE I HELDUSGEPSGEDV NSLDKKLVLAFRHLKLPTE WNVLGTDQSLHDAGPRET LMHFAVRLGLLRLTWFLLQ KPGGRRALSIHNQEGATPV SLALERGYHKLHQLLTEEN AGEPDSWSSLSYEIPYGDC SVRHHRELDIYTLTSESDS HHEHPFPGDGCTGPIFKLM NIQQQLMKTNLKQMDSLM PLMMTAQDPSSAPETDGQ FLPCAPEPTDPQRLSSSEE TESTQCCPGS
Shigella ospG		prey412	508		ADSHQNFALFFQLVDMNT GAELTPHQTFVRLHNQKTG QEVVFVAEPDNKNVYKFEL DTSERKIEFDSASGTYTLYL IIGDATLKNPILWNVADVVIK FPEEEAPSTVLSQNLFTPK QEIQHLFREPEKRPPT
Shigella ospG	2	prey50598	509	0 1	LENGELLANDER OF THE CANSILLAL VISWELQUE OF THE CANSILLAL VISWELLE CANSILLA CANSENPLATION FOR THE CANSENPLANDER OF THE CANSENPLANDER OF THE CANSENPLANDER OF THE CANSENPLANDER OF THE CANSING OF THE CANSI
Shigella ospG	2	prey67364	210	ACAACAGIGGAAAIAIAGCCAGAACCIGACIAACCIGGAGGGGGGGG	AGENORHODL VEGPVCCL THTSRQVPRGRHHRPLR*G EALIEGETEAAHCLYLEVEN MXFCIYLC*LRXFTFXN SSKTAAKLSTSAKRIQKELA
Shigella	7	prey67367	211	ATCCAGCAAAACCGCIGCIAAAIIGICAACIAGIGCIAAAAAAAA	

osbG					EITLUPPPNCSAGPKGUNIY FWRSTII GPPGSVYEGGVF
-				AAGGAGACAACATTTATGAATGGAGGTCAACTTACCTTTTCACCCAGACTATC	FLDITESPDYPFKPPKVTFR
					TRIYHCNINSQGVICLDILKD
				(5	NWSPALTISKVLLSICSLL I
				TAAAGTTCTCCTCTCCATCTGCTCACTTCTTACAGATTGCA	DCNPADPLVGSIAIQYMIN
				CTCTGGTGGGCACACACACAGTACATGACCACA	KAEHUKWAKQW I KRTA I
				GAGCAGAGCATGACCGGATGGCCAGACAGIGGACCAAGCGGIACGCACACA	
=	1	03073,020	010	SCAATGAGCCGAGATGGTGCCACTCATGTATATGAAACTCATCCATGGT 413	VAMSRDGATHVYETHPWW
Snigella	_	preyor sos	7	AGATGTGTGAGCTCTGTAACCTTTTAAGGTCCTGGAAACAT	NFFQMCELCNLLRSWKHSI
D den				AGTACACTGTATCTCTATCAGGAAATTAAAATTGTTAGCT	FKS1LYISIRKLKLLAYIYISIK
					CCF VAINILAIVE INCE IN TELL IN
				TACGTACG I CAA I GAAC I GG I GAAAGGA	GWINNY INCINI CONTRA
				GARARAI I I A I GARACCA I ANCI CRAC	DKVMSEFNNNFRQQMENY
Shigella	7	prey67372	213		PKNNHTASILDRMQADFKC
osbG				COACCACACACACACACACACACACACACACACACACAC	CGAANYTDWEKIPSMSKN
				-	RVPDSCCINVTVGCGINFN
					EKAIHKEGCVEKIGGWLRK
					NVLVVAAAALGIAFVEVLGI
				TAGAATTGCTTTTGTCGAGGTTTTGGGAATTGTCTTTGCCTGCTGCTCGTG	VFACCLVKSIRSGYEVM*
			<u>.</u>	- 7	
-		01010	2	NA ANICHICATION TO A CONTACT TO TOTAL OF THE ANICHICATION TO A CONTACT TO TOTAL OF THE ANICHICATION TO THE ANICH TH	XXXLNRHXLLXXTCKTXLX
Shigella	_	preyo/3/9	7		XXATXGCXYXIXXXYWXLA
osbg				NAMINICAL AT STATE A A GRANNING A GATTTCT GNACT CTAGGAGANATTCT	HVKGXTVSXL*EXFLXC*XX
				TONICTETTAGNETNAAAGTACTTTTCACTNGATAAGCTATGNTGACGTTNCT	STFHXISYXDVXYXNXXXX*
				TATNAGAACNGNNNTTANTGNTGANTGCATGATNTCCATTCATNATGTATTTG	XHDXHSXCICHEXLIXXICH
			_	1	NEN THE STATE OF THE STATE OF T
Shinella	7	prev67381	215	+-	MIVQALVEEVPMEINVKVF
ospG				GTGTTCAGCAAGAACCAGAAAAGAACAAGIICAGCCCAAGAAAAAGAAG	PAKPI NCO VI KHEBBNI
_				GAAAAATATCCAGCAAAACCGCIGCIAAAIIGICAACIAGIGCIAAAAGAAII	QKSHWTLLPTVVLDPKETT
· · · · · ·				CAGAAGGAACIIGCAGAAAICACAIIGGACCCICOIOOTATATAGGGACCCCC	FMNGGQLYWDPQDLSMKE
				GACCCAAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG	GCSFLTLPFHQTIRLNPLRL
				ACTATCCGTTTAAACCCCCTAAGGTTACCTTCCGAACAAGAATCTATCACTGT	PSEQESITVILTAKV*
				AATATTAACAGCCAAGGTGTGA	